<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />
<meta name="author" content="Tim Woelfle" />

<meta name="date" content="2023-07-26" />


<title>PRISMA &amp; AMSTAR Scores in Cullis 2017: Human Consensus vs LLM (Claude 2)</title>

<meta property="og:title" content="PRISMA &amp; AMSTAR Scores in Cullis 2017: Human Consensus vs LLM (Claude 2)" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script id="flexdashboard-navbar" type="application/json">
[{"title":"Source Code","icon":"fa-code","href":"","align":"right"}]
</script>
<script src="lib/header-attrs-2.21/header-attrs.js"></script>
<script src="lib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="lib/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="lib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="lib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="lib/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<link href="lib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="lib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<link href="lib/value-box-accent-static-0.6.1/theme-cosmo-value-box.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/flexdashboard.min.css" rel="stylesheet" />
<link href="lib/flexdashboard-css-0.6.1/theme-cosmo.css" rel="stylesheet" />
<script src="lib/htmlwidgets-1.6.2/htmlwidgets.js"></script>
<link href="lib/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="lib/datatables-binding-0.28/datatables.js"></script>
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="lib/dt-core-1.13.4/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="lib/dt-core-1.13.4/js/jquery.dataTables.min.js"></script>
<link href="lib/crosstalk-1.2.0/css/crosstalk.min.css" rel="stylesheet" />
<script src="lib/crosstalk-1.2.0/js/crosstalk.min.js"></script>
<style type="text/css">
/*
  CSS for flexdashboard.js' use of Sly(). The sizing/position of this CSS needs to be
  applied _before_ flexdashboard.js initializes, which is why this CSS has been pulled
  out from flexdashboard.scss and inlined in the document's head.
*/

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  text-align: left;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.sbframe-commentary {
  width: 300px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}
@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  PRISMA &amp; AMSTAR Scores in Cullis 2017: Human Consensus vs LLM (Claude 2)
  <span class="navbar-author">
    Tim Woelfle &mdash; 2023-07-26
    </span>
</span>

<button id="navbar-button" type="button" class="navbar-toggle collapsed pull-right" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false,
      resize_reload: true
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.append(h1.contents());
        h3.insertBefore(h1);
        h1.detach();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if resize_reload is set to true and it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    if (_options.resize_reload) {
      $(window).on('resize', function() {
        if (_options.isMobile !== isMobilePhone() ||
            _options.isPortrait !== isPortrait()) {
          window.location.reload();
        }
      });
    } else {
      // if in desktop mode and resizing to mobile, make sure the heights are 100%
      // This enforces what `fillpage.css` does for "wider" pages.
      // Since we are not reloading once the page becomes small, we need to force the height to 100%
      // This is a new situation introduced when `_options.resize_reload` is `false`
      if (! _options.isMobile) {
        // only add if `fillpage.css` was added in the first place
        if (_options.fillPage) {
          // fillpage.css
          $("html,body,#dashboard").css("height", "100%");
        }
      }
    }
    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          var a = navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target);
          a.removeClass("nav-link").addClass("dropdown-item");
          li.append(a);
          menu.append(li);
        }
      } else {
        var li = $('<li class="nav-item"></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li class="nav-item"></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('data-bs-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover its inner contens, then detach it
    var h1 = wrapper.find('h1').first();
    var title = h1.contents();
    h1.detach();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      li.find("> a").removeClass("nav-link").addClass("dropdown-item");
      menu.append(li);
    } else {
      li.addClass("nav-item")
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a class="nav-link"></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = null;
      var iconSplit = icon.split(" ");
      if (iconSplit.length > 1) {
        iconSet = iconSplit[0];
        icon = iconSplit.slice(1).join(" ");
      } else {
        iconSet = icon.substring(0, dashPos);
      }
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.append(h2.contents());
      h3.insertBefore(h2);
      h2.detach();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.append(h3.contents());
      h3.detach();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.append(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingDom = heading.contents();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab" class="nav-link"></a>');
      a.append(headingDom);
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation" class="nav-item"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children()[activeTab]).tab("show");
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.contents();
    h3.detach();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.empty().append(blockquote.children('p:first-child').contents());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.empty().append(caption.contents());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.decodeURIComponent(window.location.hash);
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.decodeURIComponent(window.location.hash);
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from currently active tabs
    $('.navbar ul.nav .active').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").tab("show");
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.append(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var iconSplit = chartIcon.split(" ");
      if (iconSplit.length > 1) {
        iconLib = iconSplit[0];
        chartIcon = iconSplit.slice(1).join(" ");
      } else {
        var components = chartIcon.split("-");
        if (components.length > 1)
          iconLib = components[0];
      }
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // If valueBox(color=) was an accent color, this attr should
      // be populated with the accent color and the relevant CSS comes
      // in through HTML dependencies
      var dataColorAccent = valueOutput.attr('data-color-accent');
      var valueBoxClasses = "value-box-" + (["primary", "info", "danger", "warning", "success"].join(" value-box-"));
      if (dataColorAccent) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.addClass('value-box-' + dataColorAccent);
      }

      // If valueBox(color=) was a CSS color, these other data-color-*
      // attrs will be populated
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        valueBox.removeClass(valueBoxClasses);
        valueBox.css('background-color', dataColor);
      }
      var dataColorText = valueOutput.attr('data-color-text');
      if (dataColorText) {
        valueBox.find(".inner").css('color', dataColorText);
      }
      var dataColorIcon = valueOutput.attr('data-color-icon');
      if (dataColorIcon) {
        valueBox.find(".icon").css('color', dataColorIcon);
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});
</script>

<div id="dashboard-container">

<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<style type="text/css">
table {
  margin: auto;
  border-top: 1px solid #666;
  border-bottom: 1px solid #666;
}
table thead th { border-bottom: 1px solid #ddd; }
th, td { padding: 5px; }

pre {
  white-space: pre-wrap;
  word-break: keep-all;
}

/* Hack to make prompt-tab scrollable again */
div.level3.tab-pane .chart-stage {
  overflow: scroll;
}
</style>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="column" class="section level2" data-width="55">
<h2>Column</h2>
<div id="score-comparisons-of-111-publications" class="section level3">
<h3>Score comparisons of 111 publications</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-00b8375601e0088df297" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-00b8375601e0088df297">{"x":{"filter":"none","vertical":false,"fillContainer":true,"data":[["61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","171","172"],["<a href='#61' title='Jump to individual results on the right'>Aikenhead 2011<\/a>","<a href='#62' title='Jump to individual results on the right'>Al-Hozaim 2010<\/a>","<a href='#63' title='Jump to individual results on the right'>Allen 2015<\/a>","<a href='#64' title='Jump to individual results on the right'>Allin 2015<\/a>","<a href='#65' title='Jump to individual results on the right'>Alzahem 2011<\/a>","<a href='#66' title='Jump to individual results on the right'>Apelt 2013<\/a>","<a href='#67' title='Jump to individual results on the right'>Aworanti 2014<\/a>","<a href='#68' title='Jump to individual results on the right'>Baker 2015<\/a>","<a href='#69' title='Jump to individual results on the right'>Berger 2012<\/a>","<a href='#70' title='Jump to individual results on the right'>Billingham 2010<\/a>","<a href='#71' title='Jump to individual results on the right'>Black 2013<\/a>","<a href='#72' title='Jump to individual results on the right'>Borruto 2010<\/a>","<a href='#73' title='Jump to individual results on the right'>Castagnetti 2010<\/a>","<a href='#74' title='Jump to individual results on the right'>Castagnetti 2016<\/a>","<a href='#75' title='Jump to individual results on the right'>Chan 2014 (Pediatr Surg Int)<\/a>","<a href='#76' title='Jump to individual results on the right'>Chan 2014 (J Pediatr Surg)<\/a>","<a href='#77' title='Jump to individual results on the right'>Chang 2015<\/a>","<a href='#78' title='Jump to individual results on the right'>Chen 2013<\/a>","<a href='#79' title='Jump to individual results on the right'>Corbett 2015<\/a>","<a href='#80' title='Jump to individual results on the right'>Cullis 2016<\/a>","<a href='#81' title='Jump to individual results on the right'>Cundy 2014 (BJU Int)<\/a>","<a href='#82' title='Jump to individual results on the right'>Cundy 2014 (J Pediatr Surg)<\/a>","<a href='#83' title='Jump to individual results on the right'>Cundy 2014 (Eur J Pediatr Surg)<\/a>","<a href='#84' title='Jump to individual results on the right'>Ding 2013<\/a>","<a href='#85' title='Jump to individual results on the right'>Dingemann 2014<\/a>","<a href='#86' title='Jump to individual results on the right'>Dingemann 2013<\/a>","<a href='#87' title='Jump to individual results on the right'>Ells 2015<\/a>","<a href='#88' title='Jump to individual results on the right'>Elyas 2010<\/a>","<a href='#89' title='Jump to individual results on the right'>Esposito 2014<\/a>","<a href='#90' title='Jump to individual results on the right'>Feng 2016<\/a>","<a href='#91' title='Jump to individual results on the right'>Feng 2015<\/a>","<a href='#92' title='Jump to individual results on the right'>Friedmacher 2011<\/a>","<a href='#93' title='Jump to individual results on the right'>Friedmacher 2012<\/a>","<a href='#94' title='Jump to individual results on the right'>Frongia 2013<\/a>","<a href='#95' title='Jump to individual results on the right'>Gallo 2012<\/a>","<a href='#96' title='Jump to individual results on the right'>Gosemann 2013<\/a>","<a href='#97' title='Jump to individual results on the right'>Graziano 2015<\/a>","<a href='#98' title='Jump to individual results on the right'>Guo 2011<\/a>","<a href='#99' title='Jump to individual results on the right'>Hall 2011<\/a>","<a href='#100' title='Jump to individual results on the right'>Healy 2015<\/a>","<a href='#101' title='Jump to individual results on the right'>Healy 2016<\/a>","<a href='#102' title='Jump to individual results on the right'>Heloury 2012<\/a>","<a href='#103' title='Jump to individual results on the right'>Huang 2015<\/a>","<a href='#104' title='Jump to individual results on the right'>Ishii 2014<\/a>","<a href='#105' title='Jump to individual results on the right'>Ishii 2015<\/a>","<a href='#106' title='Jump to individual results on the right'>Ito 2014<\/a>","<a href='#107' title='Jump to individual results on the right'>Jia 2011<\/a>","<a href='#108' title='Jump to individual results on the right'>Kapralik 2016<\/a>","<a href='#109' title='Jump to individual results on the right'>Kunz 2013<\/a>","<a href='#110' title='Jump to individual results on the right'>Landisch 2015<\/a>","<a href='#111' title='Jump to individual results on the right'>Lane 2010<\/a>","<a href='#112' title='Jump to individual results on the right'>Lansdale 2010<\/a>","<a href='#113' title='Jump to individual results on the right'>Lee 2010<\/a>","<a href='#114' title='Jump to individual results on the right'>LeeVan 2016<\/a>","<a href='#115' title='Jump to individual results on the right'>Liang 2011<\/a>","<a href='#116' title='Jump to individual results on the right'>Lishuang 2015<\/a>","<a href='#117' title='Jump to individual results on the right'>Livingston 2015<\/a>","<a href='#118' title='Jump to individual results on the right'>Mauritz 2013<\/a>","<a href='#119' title='Jump to individual results on the right'>Mauritz 2011<\/a>","<a href='#120' title='Jump to individual results on the right'>Mei 2011<\/a>","<a href='#121' title='Jump to individual results on the right'>Mullassery 2014<\/a>","<a href='#122' title='Jump to individual results on the right'>Nagler 2011<\/a>","<a href='#123' title='Jump to individual results on the right'>Narayanan 2013<\/a>","<a href='#124' title='Jump to individual results on the right'>Nasr 2010<\/a>","<a href='#125' title='Jump to individual results on the right'>Nasr 2013<\/a>","<a href='#126' title='Jump to individual results on the right'>Nataraja 2013<\/a>","<a href='#127' title='Jump to individual results on the right'>Nicolau 2011<\/a>","<a href='#128' title='Jump to individual results on the right'>Oliveira 2016<\/a>","<a href='#129' title='Jump to individual results on the right'>Oomen 2012<\/a>","<a href='#130' title='Jump to individual results on the right'>Parolini 2016<\/a>","<a href='#131' title='Jump to individual results on the right'>Parolini 2014<\/a>","<a href='#132' title='Jump to individual results on the right'>Peters 2013<\/a>","<a href='#133' title='Jump to individual results on the right'>Peycelon 2014<\/a>","<a href='#134' title='Jump to individual results on the right'>Pfistermuller 2015<\/a>","<a href='#135' title='Jump to individual results on the right'>Puligandla 2015<\/a>","<a href='#136' title='Jump to individual results on the right'>Reddy 2010<\/a>","<a href='#137' title='Jump to individual results on the right'>Romao 2012<\/a>","<a href='#138' title='Jump to individual results on the right'>Ross 2015<\/a>","<a href='#139' title='Jump to individual results on the right'>Ruttenstock 2010<\/a>","<a href='#140' title='Jump to individual results on the right'>Rynja 2011<\/a>","<a href='#141' title='Jump to individual results on the right'>Saldaña 2013<\/a>","<a href='#142' title='Jump to individual results on the right'>Sauerland 2010<\/a>","<a href='#143' title='Jump to individual results on the right'>Scholfield 2016<\/a>","<a href='#144' title='Jump to individual results on the right'>Sharp 2015<\/a>","<a href='#145' title='Jump to individual results on the right'>Shawyer 2014<\/a>","<a href='#146' title='Jump to individual results on the right'>Shawyer 2015<\/a>","<a href='#147' title='Jump to individual results on the right'>Shen 2015<\/a>","<a href='#148' title='Jump to individual results on the right'>Siddiqui 2011<\/a>","<a href='#149' title='Jump to individual results on the right'>Siminas 2015<\/a>","<a href='#150' title='Jump to individual results on the right'>Sklar 2014<\/a>","<a href='#151' title='Jump to individual results on the right'>Sola 2010<\/a>","<a href='#152' title='Jump to individual results on the right'>Symeonidis 2016<\/a>","<a href='#153' title='Jump to individual results on the right'>Tan 2016<\/a>","<a href='#154' title='Jump to individual results on the right'>Terui 2015<\/a>","<a href='#155' title='Jump to individual results on the right'>Thomson 2015<\/a>","<a href='#156' title='Jump to individual results on the right'>Thyoka 2013<\/a>","<a href='#157' title='Jump to individual results on the right'>van Dalen 2015<\/a>","<a href='#158' title='Jump to individual results on the right'>Vanden Berg 2016<\/a>","<a href='#159' title='Jump to individual results on the right'>van den Hondel 2014<\/a>","<a href='#160' title='Jump to individual results on the right'>Vernon-Roberts 2013<\/a>","<a href='#161' title='Jump to individual results on the right'>Wang 2013<\/a>","<a href='#162' title='Jump to individual results on the right'>Wayne 2015<\/a>","<a href='#163' title='Jump to individual results on the right'>Weih 2012<\/a>","<a href='#164' title='Jump to individual results on the right'>Wenk 2015<\/a>","<a href='#165' title='Jump to individual results on the right'>Wilkinson 2012<\/a>","<a href='#166' title='Jump to individual results on the right'>Wright 2013<\/a>","<a href='#167' title='Jump to individual results on the right'>Yang 2011<\/a>","<a href='#168' title='Jump to individual results on the right'>Yang 2013<\/a>","<a href='#169' title='Jump to individual results on the right'>Youssef 2016<\/a>","<a href='#171' title='Jump to individual results on the right'>Zhao 2015<\/a>","<a href='#172' title='Jump to individual results on the right'>Zhu 2016<\/a>"],[0.576470588235294,0.604602510460251,0.557377049180328,0.732673267326733,0.328358208955224,0.665289256198347,0.570454545454545,0.873239436619718,0.425531914893617,0.25,0.330578512396694,0.246511627906977,0.616632860040568,0.486413043478261,0.577181208053691,0.307692307692308,0.424,0.721649484536082,0.553719008264463,0.661654135338346,0.196428571428571,0.0855614973262031,0.0978520286396182,0.240963855421687,0.598726114649682,0.451219512195122,0.694915254237288,0.36094674556213,0.498969072164948,0.288032454361055,0.5,0.325,0.464757709251101,0.516898608349901,0.301724137931034,0.716981132075472,0.717573221757322,0.372093023255814,0.728370221327968,0.6,0.777777777777778,0.564516129032258,0.439169139465875,0.658947368421053,0.598726114649682,0.273838630806846,0.419354838709677,0.479099678456592,0.204081632653061,0.700665188470067,0.609638554216867,0.341463414634146,0.725050916496945,0.569721115537849,0.264150943396226,0.25,0.248101265822785,0.539249146757679,0.4796573875803,0.608695652173913,0.234817813765182,0.224137931034483,0.294117647058823,0.529850746268657,-0.0132450331125826,0.41726618705036,0.653846153846154,0.635955056179775,0.725190839694656,0.54140127388535,0.648590021691974,0.555555555555556,0.453932584269663,0.225165562913907,0.551867219917012,0.531017369727047,0.372093023255814,0.756756756756757,0.166666666666667,0.608695652173913,0.711538461538462,-0.10655737704918,0.369426751592357,0.703947368421053,0.642384105960265,0.612903225806452,0.186440677966102,0.232558139534884,0.813793103448276,0.28,0.200455580865604,0.395973154362416,0.411444141689373,0.207547169811321,0.23943661971831,0.720496894409938,0.604878048780488,0.578125,0.52317880794702,0.489189189189189,0.295652173913043,0.803874092009685,0.757847533632287,0.455331412103747,0.544303797468354,0.264150943396226,0.384615384615385,0.716981132075472,0.196796338672769,0.370629370629371,0.325],[0.703703703703704,0.740740740740741,0.703703703703704,0.888888888888889,0.62962962962963,0.777777777777778,0.740740740740741,0.962962962962963,0.592592592592593,0.555555555555556,0.666666666666667,0.555555555555556,0.740740740740741,0.740740740740741,0.740740740740741,0.555555555555556,0.703703703703704,0.851851851851852,0.703703703703704,0.814814814814815,0.814814814814815,0.296296296296296,0.481481481481481,0.740740740740741,0.740740740740741,0.62962962962963,0.851851851851852,0.703703703703704,0.666666666666667,0.518518518518518,0.703703703703704,0.555555555555556,0.666666666666667,0.666666666666667,0.555555555555556,0.814814814814815,0.814814814814815,0.666666666666667,0.814814814814815,0.851851851851852,0.851851851851852,0.740740740740741,0.740740740740741,0.777777777777778,0.740740740740741,0.592592592592593,0.703703703703704,0.777777777777778,0.518518518518518,0.814814814814815,0.777777777777778,0.666666666666667,0.814814814814815,0.703703703703704,0.518518518518518,0.666666666666667,0.592592592592593,0.814814814814815,0.666666666666667,0.814814814814815,0.740740740740741,0.814814814814815,0.555555555555556,0.740740740740741,0.37037037037037,0.666666666666667,0.777777777777778,0.777777777777778,0.851851851851852,0.703703703703704,0.777777777777778,0.703703703703704,0.666666666666667,0.518518518518518,0.703703703703704,0.740740740740741,0.62962962962963,0.888888888888889,0.444444444444444,0.740740740740741,0.814814814814815,0.62962962962963,0.592592592592593,0.814814814814815,0.777777777777778,0.851851851851852,0.407407407407407,0.592592592592593,0.888888888888889,0.555555555555556,0.518518518518518,0.62962962962963,0.703703703703704,0.481481481481481,0.703703703703704,0.814814814814815,0.777777777777778,0.740740740740741,0.703703703703704,0.740740740740741,0.777777777777778,0.888888888888889,0.851851851851852,0.740740740740741,0.703703703703704,0.518518518518518,0.703703703703704,0.814814814814815,0.518518518518518,0.62962962962963,0.555555555555556],[0.565789473684211,0.702702702702703,0.333333333333333,0.126984126984127,0.645161290322581,0.661538461538462,0.521739130434783,0.476190476190476,0.345238095238095,0.12,0.666666666666667,0,0.582278481012658,0.191176470588235,0.851351351351351,0.0609756097560975,0.214285714285714,0.639344262295082,0.65625,0.681159420289855,0.232558139534884,0.476190476190476,2.22044604925031e-16,0.246575342465753,0.371428571428571,0.16304347826087,0.666666666666667,0.126984126984127,0.661538461538462,0.0833333333333333,0.0958904109589042,0.371428571428571,0.153846153846154,0.3125,0.507462686567164,0.443037974683544,0.421052631578947,0.661538461538462,0.333333333333333,0.214285714285714,0.443037974683544,0.459016393442623,0.166666666666667,0.541666666666667,0.246575342465753,0.266666666666667,0.301587301587302,-0.0153846153846153,0.0149253731343283,0.582278481012658,0.185185185185185,0.0704225352112677,0.0434782608695653,0.367816091954023,0.343283582089552,0.333333333333333,0.0571428571428572,0.241379310344828,0.428571428571428,0.0149253731343283,0.650793650793651,0,0.666666666666667,0.333333333333333,0.214285714285714,0.397260273972603,0.256756756756757,0.440677966101695,0.813559322033898,0.246575342465753,0.12,0.388888888888889,0.352941176470588,0.228070175438596,0.857142857142857,0.661538461538462,0.388888888888889,0.5,0.142857142857143,0.371428571428571,0.56,-0.137931034482758,0.12,0.440677966101695,0.857142857142857,0.377358490566038,0.397260273972603,0.323076923076923,0.576923076923077,0.645161290322581,0.166666666666667,0.388888888888889,0.388888888888889,0.377358490566038,0.214285714285714,0.175,0.571428571428571,0.582278481012658,0.435897435897436,0.554054054054054,0.5,0.845070422535211,0.576923076923077,0.333333333333333,0.541666666666667,0.541666666666667,0.5,0.521739130434783,0.377358490566038,0.476190476190476,0.164556962025317],[0.727272727272727,0.818181818181818,0.636363636363636,0.545454545454545,0.818181818181818,0.818181818181818,0.727272727272727,0.727272727272727,0.545454545454545,0.454545454545455,0.818181818181818,0.454545454545455,0.727272727272727,0.545454545454545,0.909090909090909,0.363636363636364,0.545454545454545,0.818181818181818,0.818181818181818,0.818181818181818,0.727272727272727,0.636363636363636,0.454545454545455,0.545454545454545,0.636363636363636,0.363636363636364,0.818181818181818,0.545454545454545,0.818181818181818,0.454545454545455,0.454545454545455,0.636363636363636,0.636363636363636,0.636363636363636,0.727272727272727,0.636363636363636,0.636363636363636,0.818181818181818,0.636363636363636,0.636363636363636,0.636363636363636,0.727272727272727,0.545454545454545,0.727272727272727,0.545454545454545,0.636363636363636,0.636363636363636,0.454545454545455,0.454545454545455,0.727272727272727,0.636363636363636,0.454545454545455,0.454545454545455,0.545454545454545,0.636363636363636,0.636363636363636,0.454545454545455,0.636363636363636,0.636363636363636,0.454545454545455,0.818181818181818,0.909090909090909,0.818181818181818,0.636363636363636,0.545454545454545,0.636363636363636,0.545454545454545,0.727272727272727,0.909090909090909,0.545454545454545,0.454545454545455,0.636363636363636,0.636363636363636,0.636363636363636,0.909090909090909,0.818181818181818,0.636363636363636,0.727272727272727,0.454545454545455,0.636363636363636,0.727272727272727,0.727272727272727,0.454545454545455,0.727272727272727,0.909090909090909,0.727272727272727,0.636363636363636,0.636363636363636,0.727272727272727,0.818181818181818,0.545454545454545,0.636363636363636,0.727272727272727,0.727272727272727,0.636363636363636,0.454545454545455,0.727272727272727,0.727272727272727,0.636363636363636,0.727272727272727,0.727272727272727,0.909090909090909,0.818181818181818,0.636363636363636,0.727272727272727,0.818181818181818,0.727272727272727,0.727272727272727,0.727272727272727,0.727272727272727,0.454545454545455]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th>Ref.<\/th>\n      <th>Author & Year<\/th>\n      <th>PRISMA κ<\/th>\n      <th>PRISMA agreement<\/th>\n      <th>AMSTAR κ<\/th>\n      <th>AMSTAR agreement<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"t","order":[[0,"asc"]],"columnDefs":[{"targets":2,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":4,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"targets":5,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 2, 3, \",\", \".\", null);\n  }"},{"className":"dt-right","targets":[2,3,4,5]}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render","options.columnDefs.1.render","options.columnDefs.2.render","options.columnDefs.3.render"],"jsHooks":[]}</script>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
</div>
<div id="score-heatmaps-prisma-amstar" class="section level3"
data-height="720">
<h3>Score heatmaps
(<a onclick="data = 'data:image/png;base64,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'; $('#score-heatmaps-prisma-amstar p.image-container')[0].style = 'background: url(&quot;' + data + '&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = data;" style="cursor: pointer">PRISMA</a>
/
<a onclick="data = 'data:image/png;base64,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'; $('#score-heatmaps-prisma-amstar p.image-container')[0].style = 'background: url(&quot;' + data + '&quot;) center center / contain no-repeat;'; $('p.image-container img')[0].src = data;" style="cursor: pointer">AMSTAR</a>)</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><img data-figure-id="fig1" src="data:image/png;base64,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" width="1536"></p>
</div>
</div>
<div id="column-1" class="section level2 tabset" data-width="45">
<h2 class="tabset">Column</h2>
<div id="individual-results" class="section level3">
<h3>Individual results</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><a name='61'></a></p>
<div id="aikenhead-2011" class="section level4">
<h4><a href='https://doi.org/10.1111/J.1758-8111.2010.00003.X' title='Open publication'>Aikenhead
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review on the effectiveness and cost-effectiveness of paediatric bariatric surgery:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched PubMed, ISI Web of Science, Embase and the Cochrane Library to 6 September 2010.&quot;</span>
The review states comprehensive database searches were conducted.

A2. [No]
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.4%):

Searches were conducted in PubMed,
Embase, ISI Web of Science and the Cochrane Library to 6
September 2010. Hand-searching of the bibliographies of
articles and reviews identified was also conducted' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We searched PubMed, ISI Web of Science, Embase and the Cochrane Library to 6 September 2010. Hand-searching of the bibliographies of articles and reviews identified was also conducted.&quot;</span>
Multiple databases and supplementary search methods were used. 

A4. [No] 
The review does not mention searching for or inclusion of grey literature.

A5. [No]
No list of included/excluded studies is provided.

A6. [Yes]
Table 1 shows characteristics of included studies such as age, BMI, follow-up period. 

A7. [No]
The quality of included studies is not assessed.

A8. [NA]
Study quality was not assessed so using it to formulate conclusions is not applicable.

A9. [NA]  
Meta-analysis was not done so assessing heterogeneity is not applicable.

A10. [NA] 
Assessment of publication bias is not applicable as no meta-analysis was conducted.

A11. [No]
No mention of conflicts of interest in the review or included studies.

P1. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Effectiveness and cost-effectiveness of paediatric bariatric surgery: a systematic review&quot;</span>
Identified as a systematic review.  

P2. [No] 
No structured summary provided.

P3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Strong evidence for successful and cost-effective obesity management strategies is still generally lacking, leading the medical profession to rely increasingly on surgical options to treat obesity in children and adolescents.&quot;</span>
Provides context and rationale.

P4. [No]  
The review objective and inclusion criteria are broad, no explicit PICO stated.

P5. [No]  
No protocol registration mentioned.

P6. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Articles with an abstract in English and full text in
Danish, English, French, or Norwegian language were eli-
gible. In addition, subjects had to be 19 years of age. At
least one postoperative weight loss measure had to be
reported, with a minimum follow-up time of 1 year post
surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Articles with an abstract in English and full text in Danish, English, French, or Norwegian language were eligible. In addition, subjects had to be ≤19 years of age. At least one postoperative weight loss measure had to be reported, with a minimum follow-up time of 1 year post surgery.&quot;</span> 
Inclusion criteria described.

P7. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.4%):

Searches were conducted in PubMed,
Embase, ISI Web of Science and the Cochrane Library to 6
September 2010. Hand-searching of the bibliographies of
articles and reviews identified was also conducted' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We searched PubMed, ISI Web of Science, Embase and the Cochrane Library to 6 September 2010. Hand-searching of the bibliographies of articles and reviews identified was also conducted.&quot;</span>
Information sources described.

P8. [No]
No full search strategy provided.

P9. [No]  
No details provided on study selection process. 

P10. [No]
No data extraction methodology described.

P11. [No]  
Review does not pre-define variables sought.

P12. [No] 
No assessment of risk of bias described.

P13. [NA]
Measures of treatment effect not applicable as no meta-analysis conducted.

P14. [NA]  
Methods for combining data are not applicable as no meta-analysis was done.

P15. [NA]
Assessment of publication bias not applicable without meta-analysis. 

P16. [NA]
No additional analyses done.

P17. [No]
No flow diagram of study selection provided.

P18. [Yes] 
Table 1 shows characteristics of included studies.

P19. [No]
No assessment of risk of bias for individual studies presented.

P20. [No] 
No summary data for each intervention by study.

P21. [NA]  
No meta-analysis so no combined results.

P22. [NA] 
No assessment of bias across studies as no meta-analysis.

P23. [NA]
No additional analysis. 

P24. [No]  
No summary of main findings or discussion of strength of evidence.

P25. [Yes]
Sections on limitations of existing literature and issues requiring further investigation discuss shortcomings and biases.

P26. [Yes]  
Provides general interpretation of results in context of other evidence.

P27. [No]
No statement on sources of funding or support.

In summary, the review appears to have substantial methodological limitations based on AMSTAR and PRISMA assessments. Key issues are the lack of duplicate study selection/data extraction, risk of bias assessment, details on screening and selection process, and quantitative synthesis. The reporting is fairly poor. Overall, I would rate this as a low quality systematic review with high risk of bias. Caution should be taken when interpreting the results.
</pre>
<p><a name='62'></a></p>
</div>
<div id="al-hozaim-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2009.12.001' title='Open publication'>Al-Hozaim
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic search of the MEDLINE, PUBMED, and Cochrane databases (June 2000 to April 2008) was conducted.&quot;</span> The review had a predefined protocol for literature search and inclusion.
A2. [No] There is no mention of duplicate study selection or data extraction. 
A3. [Yes] <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.9%):

and
performed in humans. In addition to Medline and PubMed, a manual search of the Journal of Pediatric
Surgery, Pediatric Surgery International, Surgical Endoscopy, and the Journal of Laparoendoscopic &
Advanced Surgical Techniques published between June 2000 and April 2008 was conducted' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The search terms used were “laparoscopic,” “pull-through,” “anorectal malformation,” and “imperforate anus.” In addition to Medline and PubMed, a manual search of the Journal of Pediatric Surgery, Pediatric Surgery International, Surgical Endoscopy, and the Journal of Laparoendoscopic & Advanced Surgical Techniques published between June 2000 and April 2008 was conducted.&quot;</span> Multiple databases were searched along with supplementary strategies.
A4. [No] There is no mention of searching for unpublished or grey literature.
A5. [No] A list of included and excluded studies is not provided. 
A6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We also recorded studies reporting the use of LAARP vs PSARP in patients with ARM. The recorded patient characteristics included age, sex, age at LAARP, type of fistula (defect), associated anomalies, operative time, and postoperative complications.&quot;</span> Study characteristics were described in the results section.
A7. [No] No quality assessment of included studies is described.
A8. [NA] Study quality was not assessed so cannot be used in formulating conclusions.
A9. [NA] No quantitative synthesis or meta-analysis was performed.
A10. [NA] No assessment of publication bias is described.
A11. [No] No statement about conflicts of interest is provided.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In this article, we closely examined literature on LAARP because it was initially described. To the best of our knowledge, this is the first systematic review to examine literature pertaining to LAARP.&quot;</span> The report is identified as a systematic review.
P2. [No] No structured abstract is provided.
P3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Our current under-
standing is that LAARP is predominantly indicated for
patients with “high/intermediate” ARM. A second example
lies with the wide variation of actual outcomes reported by
each study. As discussed above, 10 different outcomes were
reported in the 17 studies, and only 4 studies attempted
comparisons of outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our current understanding is that LAARP is predominantly indicated for patients with “high/intermediate” ARM. A second example lies with the wide variation of actual outcomes reported by each study. As discussed above, 10 different outcomes were reported in the 17 studies, and only 4 studies attempted comparisons of outcomes.&quot;</span> The rationale and context are described.
P4. [No] The review question and inclusion criteria are not explicitly stated in PICOS format.
P5. [No] No protocol registration is mentioned. 
P6. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Inclusion criteria were studies of ARMs, regardless of level of the defect, with or without associated anomalies, use of LAARP as a primary procedure or with colostomy, and studies reported after the year 2000.&quot;</span> Eligibility criteria are described.
P7. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 89%):

A systematic search of the MEDLINE, PUBMED, and
Cochrane databases (June 2000 to April 2008) was
conducted. The search terms used were “laparoscopic,”
“pull-through,” “anorectal malformation,” and “imperforate
anus.” In addition, a manual search of 4 surgical journals
from the same period was performed. The journals searched
were “The Journal of Pediatric Surgery,” “Pediatric Surgery
International,” “Surgical Endoscopy,” and “Journal of
Laparoendoscopic & Advanced Surgical Techniques.”
Moreover, a careful review of references of all included
articles was conducted' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic search of the MEDLINE, PUBMED, and Cochrane databases (June 2000 to April 2008) was conducted. The search terms used were “laparoscopic,” “pull-through,” “anorectal malformation,” and “imperforate anus.” In addition to Medline and PubMed, a manual search of the Journal of Pediatric Surgery, Pediatric Surgery International, Surgical Endoscopy, and the Journal of Laparoendoscopic & Advanced Surgical Techniques published between June 2000 and April 2008 was conducted.&quot;</span> Information sources and dates are described. 
P8. [No] The full search strategy is not provided for any database.
P9. [No] The study selection process is not described.
P10. [No] No data extraction process is described. 
P11. [No] Variables extracted are not explicitly listed and defined.
P12. [No] No risk of bias assessment is described.
P13. [NA] No meta-analysis was performed.
P14. [NA] No meta-analysis was performed.  
P15. [NA] No assessment of risk of bias across studies is described.
P16. [NA] No additional analyses are described.
P17. [No] No flow diagram of study selection is provided.
P18. [No] No table with summary characteristics of included studies is provided.
P19. [No] No assessment of risk of bias is provided for individual studies. 
P20. [No] No forest plots with effect sizes are provided.
P21. [NA] No meta-analysis was performed.
P22. [NA] No assessment of risk of bias across studies is described. 
P23. [NA] No additional analyses are described.
P24. [No] No summary of main findings is provided.
P25. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our study has several limitations. First, this is a systematic review of mainly retrospective data. The quality of such review is only as good as the included studies.&quot;</span> Limitations are described.
P26. [No] No general interpretation of results or implications for future research are provided.
P27. [No] No statement about sources of funding is provided.
</pre>
<p><a name='63'></a></p>
</div>
<div id="allen-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2014.10.042' title='Open publication'>Allen
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the extracted quotes, reasoning, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

To address this issue, we reviewed our experience at a level 1 trauma
center and report the largest analysis over the past 25 years. In conjunc-
tion, we performed a systematic review of all published reports
regarding pediatric EDT to help identify the factors associated with
morbidity and mortality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To address this issue, we reviewed our experience at a level 1 trauma center and report the largest analysis over the past 25 years. In conjunction, we performed a systematic review of all published reports regarding pediatric EDT to help identify the factors associated with morbidity and mortality.&quot;</span>
They state they performed a systematic review, which implies a pre-determined protocol.
[Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate selection or extraction.
[No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎These reports were obtained from a Medline search for all publications regarding EDT in the pediatric population for the past 40 year using the keywords “thoracotomy”, “emergency”, “trauma”, “resuscitation”, “pediatrics”, and “children”. Bibliographies of relevant publications were reviewed to identify reports that were not initially located with the Medline search.&quot;</span>
They searched Medline and bibliography of relevant publications.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
No mention of searching for grey literature.
[No] 

A5. Was a list of studies (included and excluded) provided?
Included studies listed in Table 1. No excluded studies listed.
[No]

A6. Were the characteristics of the included studies provided?
Table 1 provides limited characteristics (number blunt/penetrating trauma, survival). More details provided in results section.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment mentioned.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias.
[No]

A11. Was the conflict of interest included? 
No statement on conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Identified as systematic review in title.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
Structured abstract provided with background, methods, results, and conclusions. No details on eligibility criteria, quality assessment, or registration number.
[No]

P3. Describe the rationale for the review in the context of what is already known.
Rationale described in introduction.
[Yes] 

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
No explicit PICOS statement provided.
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
No mention of review protocol.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Inclusion criteria not explicitly specified.
[No]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Sources described (Medline) but no date range or last search date provided. 
[No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Search strategy for Medline not provided.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Selection process not described.
[No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
No details on data extraction process provided.
[No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
List of extracted variables described in results. No assumptions mentioned.
[Yes]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
No risk of bias assessment performed.
[NA]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
No quantitative synthesis performed.
[NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
No quantitative synthesis performed.
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
No assessment of publication bias or other biases.
[No]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
No additional analyses performed.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Number of included studies provided but no details on screening or exclusions. No flow diagram.
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Limited characteristics presented for each study (see A6). Citations provided.
[Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
No risk of bias assessment performed.
[NA]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
No effect estimates or CIs presented. Simple summary data provided. No forest plots created.
[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
No meta-analysis performed.
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
No assessment of risk of bias performed.
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
No additional analyses performed.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Main findings summarized in discussion, but strength of evidence not discussed.
[No]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Limitations discussed in discussion section.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Results interpreted in context of other evidence in discussion. Suggestions for future research provided.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
No statement on sources of funding or support.
[No]

In summary, the authors identified their report as a systematic review, described the rationale, stated the research questions, listed some characteristics of included studies, presented simple summary data for the outcomes, discussed limitations, and interpreted the results in context of other evidence. However, they did not provide details on the review methods, including the study selection process, data extraction process, assessment of study quality or risk of bias, evaluation of publication bias, or a flow diagram. There was also no quantitative synthesis. Additional details on the review methods, quantitative synthesis, and funding sources could improve the reporting based on PRISMA guidelines.
</pre>
<p><a name='64'></a></p>
</div>
<div id="allin-2015" class="section level4">
<h4><a href='https://doi.org/10.1371/JOURNAL.PONE.0116908' title='Open publication'>Allin
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? 
<span title='Moderate quote deviation. Best match in prompt (Similarity 89.3%):

? The research question and inclusion criteria should be established before the conduct of the review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] The research question and inclusion criteria are not established before the conduct of the review.&quot;</span> The protocol was registered after completion of the review.

A2. Was there duplicate study selection and data extraction?  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44%):

e study selection and data extraction' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Two investigators independently performed study selection and data extraction.&quot;</span>

A3. Was a comprehensive literature search performed?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 47.9%):

n. Multiple search strategies were used to
identify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google
scholar,' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Multiple databases were searched, including Medline, Embase, Cinahl, Cochrane library, and Google scholar. Reference lists were hand searched. No language or geographical restrictions.&quot;</span>   

A4. Was the status of publication used as an inclusion criterion?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.5%):

no restrictions were made on
the basis of study language' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] No restrictions were made based on publication status, language etc.&quot;</span>

A5. Was a list of studies (included and excluded) provided?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.1%):

included and excluded studies should be provided. No' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] A flow diagram showing included and excluded studies is provided in Fig. 1.&quot;</span>

A6. Were the characteristics of the included studies provided?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.3%):

study characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Study characteristics are provided in Table 2.&quot;</span> 

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.2%):

Methodological quality and risk of bias were assessed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[No] The methodological quality and risk of bias of included studies were not formally assessed.&quot;</span>

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.9%):

the scientific quality of the included studies assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The quality of studies was not assessed.&quot;</span>

A9. Were the methods used to combine the findings of studies appropriate?  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.8%):

cribe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
A10. Was the' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Fixed effect meta-analysis was used as no statistical heterogeneity was detected. Heterogeneity was assessed with the chi-squared test.&quot;</span>

A10. Was the likelihood of publication bias assessed?
<span title='Moderate quote deviation. Best match in prompt (Similarity 76.9%):

publication bias could not be assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] Publication bias was not assessed.&quot;</span>

A11. Was the conflict of interest included?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 49.3%):

the included studies,
where it was reported' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[No] Conflicts of interest for the included studies are not reported.&quot;</span>

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60%):

the report as a systematic review, meta-analysis, or both' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The report is identified as a systematic review and meta-analysis in the title.&quot;</span>

P2. Provide a structured summary.
<span title='Moderate quote deviation. Best match in prompt (Similarity 79.6%):

a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[Yes] A structured abstract is provided summarizing background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, limitations, and conclusions.&quot;</span>

P3. Describe the rationale for the review in the context of what is already known.  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 25%):

scribe the rationale for the review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The introduction provides context about the lack of consensus on optimal management of gastroschisis and the rationale for the review.&quot;</span>

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.9%):

the following participants and interventions, and at least one of the outcomes of interest.
Participants
Studies were included if the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] The participants, interventions, comparisons, and outcomes of interest are described in the methods.&quot;</span> 

P5. Indicate if a review protocol exists and provide registration information. 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.1%):

. The protocol was registered
on the Prospero International Prospective Regist' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] The protocol was registered on PROSPERO and the registration number is provided.&quot;</span>

P6. Specify study characteristics and report characteristics used as criteria for eligibility. 
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60.6%):

were included if they comprised
the following participants and interventions, and at least one of the outcomes' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Inclusion and exclusion criteria for participants, interventions, and outcomes are specified.&quot;</span>

P7. Describe all information sources in the search and date last searched.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.7%):

information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Information sources (databases) and search strategy are described. The last date searched is reported.&quot;</span> 

P8. Present full electronic search strategy for at least one database.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.3%):

search strategy for at least one database, in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The full search strategy for databases is not provided.&quot;</span>

P9. State the process for selecting studies.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.5%):

process for selecting studies (i.e., screening, eligibility, included' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Study selection process, including screening and assessing eligibility, is described.&quot;</span> 

P10. Describe method of data extraction and confirmation.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68.9%):

extracted independently by the same two investigators (BA and WT), and any differences
resolved by discussion' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Data extraction was performed independently by two authors, with differences resolved by discussion.&quot;</span>

P11. List and define all variables for which data were sought.  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 39.4%):

c reviews and are tasked to assess the method' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Outcomes extracted are listed and defined in the methods section.&quot;</span>

P12. Describe methods for assessing risk of bias of individual studies. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 43.2%):

methods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Methods for assessing risk of bias/methodological quality are not described.&quot;</span> 

P13. State the principal summary measures.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 44.2%):

mean differences
and 95% confidence intervals.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Odds ratios, mean differences, and 95% confidence intervals are described as the summary measures.&quot;</span>

P14. Describe the methods of handling data and combining results.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 34.8%):

heterogeneity was used to assess the extent to which
the results' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Fixed effect meta-analysis was used to pool results. Heterogeneity was assessed with chi-squared test and I2.&quot;</span> 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.4%):

assessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Assessment of publication bias was not performed.&quot;</span>

P16. Describe methods of additional analyses, if done.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.1%):

l analyses were performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[NA] No additional analyses were performed.&quot;</span>

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusions. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.9%):

e numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The number of records identified, screened, assessed for eligibility, and included are reported in a flow diagram (Fig. 1).&quot;</span>

P18. For each study, present characteristics and provide citations.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 36.5%):

Study Characteristics.
Study Sett' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Study characteristics are presented in Table 2 along with citations.&quot;</span>

P19. Present data on risk of bias of each study. 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.6%):

risk of bias of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Risk of bias for individual studies was not assessed.&quot;</span> 

P20. For all outcomes, present data for each study and summary measures.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 18%):

of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] For primary and secondary outcomes, data from individual studies and pooled estimates are presented in forest plots.&quot;</span>

P21. Present results of each meta-analysis, including confidence intervals and measures of consistency.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.2%):

ent results of each meta-analysis done, including confidence intervals and m' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Results of the meta-analyses are presented with confidence intervals and I2 values.&quot;</span>

P22. Present results of any assessment of risk of bias across studies.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60.4%):

assessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] No assessment of publication bias was performed.&quot;</span>

P23. Give results of additional analyses, if done.
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.1%):

l analyses were performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[NA] No additional analyses were performed.&quot;</span>

P24. Summarize the main findings including the strength of evidence for each main outcome.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.7%):

the main findings including the strength of evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The main findings are summarized in the discussion, along with comments about the quality of evidence.&quot;</span>

P25. Discuss limitations at study and outcome level and at review level.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.6%):

limitations at study and outcome level (e.g., risk of bias), and at review-level (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Limitations at the study level (risk of bias) and review level (heterogeneity) are discussed.&quot;</span>

P26. Provide a general interpretation of results in the context of other evidence.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44.4%):

s “the results should be interpreted with c' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The results are interpreted in the context of existing literature.&quot;</span>

P27. Describe sources of funding for the review and other support.
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.7%):

sources of funding' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Sources of funding are described.&quot;</span>

In summary, the review adequately reported the majority of AMSTAR and PRISMA items, with some exceptions:

- AMSTAR: An a priori protocol was not provided, individual study quality/risk of bias was not assessed, publication bias was not assessed, conflicts of interest were not reported.  

- PRISMA: The full search strategy was not provided, methods for assessing risk of bias were not described, assessment of publication bias was not performed.

Overall, this review provides moderate quality evidence on operative fascial closure versus silo repair for gastroschisis due to the observational study designs, heterogeneity, and some deficiencies in reporting. The results suggest some advantages for operative fascial closure but high quality randomized trials are needed.
</pre>
<p><a name='65'></a></p>
</div>
<div id="alzahem-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-010-2840-X' title='Open publication'>Alzahem
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.” 
[No] No a priori design or protocol was mentioned.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
[Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Retrieved articles were assessed for eligibility and data on
patients, intervention, control, outcomes and methodolog-
ical quality were abstracted independently by two authors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Retrieved articles were assessed for eligibility and data on patients, intervention, control, outcomes and methodological quality were abstracted independently by two authors.&quot;</span>

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
[Yes] Searched MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov. Search strategy included keywords and MeSH terms. Reference lists of retrieved articles were reviewed. Experts were contacted.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
[No] No mention of searching for grey literature or inclusion based on publication status. 

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
[No] No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>
[Yes] Table 1 provides data on participants (age, sex), interventions, outcomes (recurrence, follow-up) for each included study.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
[Yes] The methodological quality of the included studies was assessed using standard criteria - Cochrane criteria for RCTs and Newcastle-Ottawa scale for observational studies. Results provided in text for each study.  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
[No] The quality of studies was assessed but not incorporated in interpreting the results.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
[Yes] Heterogeneity assessed using I2 and Chi2 tests. Random effects model used when heterogeneity present. 

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
[No] Publication bias not assessed.

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
[No] No statement on conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. 
[Yes] Identified as a meta-analysis in the abstract.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[Yes] Structured abstract provided with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal methods, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] Introduction describes current knowledge and need for the review.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[No] No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No] No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes] Study characteristics and eligibility criteria described in methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[Yes] Information sources described including databases, dates, and contact with experts.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[No] Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[No] Study selection process not described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[Yes] Data extraction performed independently by two authors.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 
[Yes] Outcomes sought described in methods. Table 1 provides details on variables extracted.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[Yes] Methods used to assess study quality described.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[Yes] Summary measures described in methods.  

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
[NA] Not applicable as no meta-analysis performed for some outcomes.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[No] Publication bias not assessed.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[No] No additional analyses described.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[Yes] Flow diagram provided detailing studies screened and included/excluded with reasons. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
[Yes] Table 1 presents relevant characteristics for each included study.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[Yes] Risk of bias/quality assessed for each study in text.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[Yes] Summary data and forest plots presented by outcome.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA] Not applicable as no meta-analysis performed for some outcomes.  

P22. Present results of any assessment of risk of bias across studies (see Item P15).
[NA] Not applicable as no assessment of publication bias.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA] No additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes] Main findings summarized in abstract and discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[No] Limitations of included studies discussed but not limitations of the review itself.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes] Results discussed in context of other evidence and implications described.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
[No] No statement on sources of funding or support.

In summary, the key elements that were not adequately reported or conducted based on AMSTAR and PRISMA were: a priori protocol, search strategy, list of excluded studies, consideration of study quality, assessment of publication bias, some elements of data synthesis process, and review limitations and funding sources. Make sure all AMSTAR and PRISMA items are addressed before concluding.
</pre>
<p><a name='66'></a></p>
</div>
<div id="apelt-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.024' title='Open publication'>Apelt
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. [No]
- No protocol or pre-determined research objectives referenced.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. [No]
- No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. [Yes]
- PubMed, Medline and Ovid searched from 1990-2012. References of studies searched. Search strings and databases stated. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. [No] 
- No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. [No]
- No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. [Yes]
- Table 1 provides details on study years, sample size, age, sex ratio, conversions, complications.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. [No]
- No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. [NA]
- No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). [NA] 
- No meta-analysis performed.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). [NA]
- No assessment of publication bias mentioned. 

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. [No]
- No mention of conflicts of interest or funding sources.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
- Identified as a systematic review in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
- No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
- Background section describes rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
- No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
- No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
- Inclusion/exclusion criteria described in methods. Study characteristics detailed in Table 1. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
- Databases, date ranges, and supplementary search methods described.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
- No full search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
- Screening and selection process described and shown in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]  
- No details on data extraction process.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
- Outcomes not predefined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
- No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [No]  
- No summary measures stated a priori.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
- No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
- No assessment of publication bias mentioned.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
- No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
- Screening process shown in Figure 1. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]  
- Table 1 presents key study characteristics.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
- No risk of bias assessment presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
- No forest plots or effect estimates presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
- No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]  
- No assessment of publication bias mentioned.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
- No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]  
- No summary of main findings or strength of evidence.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]
- No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
- Results interpreted in discussion section.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
- No mention of funding sources.

In summary, the AMSTAR assessment found this review to be inadequate in terms of an a priori protocol, duplicate study selection/data extraction, grey literature searching, quality assessment, assessment of publication bias, and stating conflicts of interest. The PRISMA assessment found deficiencies in providing a structured abstract, full search strategy, data extraction methods, risk of bias assessment, summary measures, forest plots, study limitations, summary of findings, and sources of funding. Overall, this review has multiple methodological shortcomings.
</pre>
<p><a name='67'></a></p>
</div>
<div id="aworanti-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0034-1370780' title='Open publication'>Aworanti
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the extracted quotes, reasoning, and responses for each AMSTAR and PRISMA item:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We aim to comparatively review all published treatment options, and outcomes, for managing RTEF.&quot;</span> (Introduction, p. 365)
- Provides clear objective and inclusion criteria a priori.
[Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.  
- Single author (Olugbenga Aworanti) reviewed studies and extracted data.
[No]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

A Medline, Embase, and web of science searches were performed
using the keywords recurrent tracheoesophageal fistula. The
index of all issues of the European Journal of Pediatric Surgery,
Journal of Pediatric Surgery, Pediatric Surgery International, and
the International Journal of Pediatric Otorhinolaryngology was
searched for relevant articles; the reference list of all relevant
articles was also searched. All English language articles pub-
lished by August 2013, irrespective of design, describing the
management of, and outcome after, RTEF in children under
18 years were reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A Medline, Embase, and web of science searches were performed using the keywords “recurrent tracheoesophageal fistula.” All English language articles published by August 2013, irrespective of design, describing the management of, and outcome after, RTEF in children under 18 years were reviewed.&quot;</span> (Patients/Materials and Methods, p. 365)
- Searched multiple databases for relevant studies.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
- No mention of including or excluding grey literature. Search focused on published studies.
[No]

A5. Was a list of studies (included and excluded) provided?
- Included studies summarized in Tables 1 and 2. No list of excluded studies provided.
[No]

A6. Were the characteristics of the included studies provided?
- Tables 1 and 2 provide an overview of study characteristics such as number of patients, interventions, outcomes, etc.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No formal quality assessment of included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- No quality assessment performed.
[NA] 

A9. Were the methods used to combine the findings of studies appropriate?  
- No quantitative synthesis/meta-analysis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included?
- No conflicts of interest stated for the systematic review itself or the included studies.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- Identified as a systematic review in title.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Abstract provides background, objectives, data sources, participants/interventions, results, and conclusions. No study appraisal, limitations, or registration number reported.
[No]

P3. Describe the rationale for the review in the context of what is already known.
- Introduction provides context about management options for recurrent TEF and rationale for conducting systematic review.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- Clear objective stated to review treatment options and outcomes for recurrent TEF, but lacks details on PICOS.
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No protocol mentioned.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Eligibility criteria described for including studies on management of recurrent TEF in children <18 years through August 2013 in English language. No other PICOS details provided.
[No] 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- Databases searched (Medline, Embase, Web of Science) reported. Last search date of August 2013 provided. No supplemental search methods described.  
[No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- No full search strategy presented. Only keywords <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎recurrent tracheoesophageal fistula&quot;</span> reported.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- No details provided on screening process or selection criteria beyond broad eligibility criteria.
[No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
- No details provided on data extraction process. Appears a single author extracted relevant data.
[No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- No list of variables for which data sought was provided. Tables 1 and 2 summarize some key data extracted.
[No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- No risk of bias assessment performed.
[No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- No meta-analysis performed.
[NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
- No meta-analysis performed.
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- No assessment of risk of bias across studies.
[No]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses done.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Number of included studies reported, but no information on screening process or studies excluded. No flow diagram. 
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Tables 1 and 2 summarize some key characteristics of included studies, including number of patients, interventions, outcomes, and citations. But lacks comprehensive details on PICOS and follow-up periods.
[No]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- No assessment of risk of bias for individual studies.
[No] 

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- No effect estimates or confidence intervals presented. Tables 1 and 2 provide some summary data on interventions and outcomes for each study.  
[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- No meta-analysis performed.
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
- No assessment of risk of bias across studies.
[No]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses performed.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Conclusions section summarizes main findings but does not mention strength of evidence or relevance to key groups.
[No]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations around heterogeneity and case reports predominance mentioned briefly in discussion. Does not discuss limitations related to lack of risk of bias assessment, incomplete retrieval of studies, or reporting biases.
[No]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted and compared to previous reviews on the topic. Implications for future research provided.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
- No statement on sources of funding or support for the review.
[No]
</pre>
<p><a name='68'></a></p>
</div>
<div id="baker-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.021' title='Open publication'>Baker
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the responses for the AMSTAR and PRISMA items based on the full text:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Gastrostomy tubes are typically well tolerated and provide improved quality of life compared to parenteral and nasogastric feeding for patients unable to maintain adequate oral nutrition [1].&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There is currently no consensus as to the optimal technique of gastrostomy insertion in the pediatric population, and there remains a paucity of well-designed trials to answer the question.&quot;</span>
- [No] - The review did not mention a protocol or pre-determined research objectives. 

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Screening of eligible studies, data extraction, and assessment of methodological quality were conducted independently by two reviewers.&quot;</span>
- [Yes] Two independent reviewers performed study selection and data extraction.

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). 
- The search included multiple databases: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎MEDLINE (PubMed, PubMEd in Process and Ovid), EMBASE, Cumulative Index of Nursing and Allied Health Literature (CINAHL), Scopus and Cochrane Library.&quot;</span>
- Databases were searched from 1993 to 2013. 
- [Yes] Multiple databases were searched and search details are reported.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. 
- [NA] The inclusion criteria did not consider publication status and the search and inclusion was restricted to published studies only.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.
- Table 1 provides a detailed list of included studies.
- The screening process is shown in a flow diagram (Fig. 1), but specific excluded studies are not listed.
- [Yes] Included studies are listed and the screening process is depicted.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.  
- Table 1 provides relevant characteristics of the included studies - interventions compared and outcome data.
- Additional details on patient demographics and complications are provided in the results section.
- [Yes] Relevant characteristics of included studies are provided.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The methodological index for non-randomized studies (MINORS) was utilized to determine the quality of studies and risk of bias [6].&quot;</span>
- MINORS scores for each study are reported in Table 1.
- [Yes] The MINORS tool was used to assess quality of included studies. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.
- The limitations of including primarily retrospective studies is acknowledged in the discussion.
- [Yes] The quality of studies is considered appropriately in the conclusions.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).
- Meta-analysis was conducted using RevMan software. 
- Heterogeneity was assessed and reported low in the analyses.  
- [Yes] Appropriate meta-analytic methods were used.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).
- Funnel plot was generated for one comparison and showed no significant asymmetry (Fig. 5).
- [Yes] Publication bias was assessed for one comparison.

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
- No statement on conflict of interest or funding sources for the included studies.
- No statement on conflict of interest or funding for the review itself.
- [No] Conflict of interest was not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. 
- The title identifies the study as a <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎systematic review and meta-analysis.&quot;</span>
- [Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- The abstract provides relevant background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal methods, results, and conclusions.
- No systematic review registration number is provided.
- [Yes] Structured abstract is provided covering key information.

P3. Describe the rationale for the review in the context of what is already known.
- The introduction summarizes prior relevant literature and places the review in the context of uncertainty regarding optimal gastrostomy techniques.
- [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- The objective is clearly specified: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

This report evalu-
ates the available literature summarizing complication rates and re-
source utilization for gastrostomy techniques in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This report evaluates the available literature summarizing complication rates and resource utilization for gastrostomy techniques in children.&quot;</span>
- Inclusion criteria detail eligible participants, interventions, comparisons, and outcomes.
- [Yes] 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No protocol is mentioned.
- No registration information is provided. 
- [No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- The inclusion and exclusion criteria section provides details on eligible participants, interventions, comparisons, outcomes, and study designs.
- Rationale is provided for inclusion and exclusion criteria.
- [Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
- The search strategy section lists all databases searched and date ranges. The search was conducted on May 17, 2013.
- The full search strategy is provided in the appendix.
- [Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- The full search strategy for Ovid MEDLINE is provided in the appendix.
- [Yes] 

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- The study selection process, including screening, is described in the methods and depicted in Fig. 1.
- [Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data extraction was conducted by 2 reviewers (LB & AB) using a predefined data extraction worksheet.&quot;</span>
- No additional confirmation from study investigators is mentioned.
- [Yes] 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Variables extracted are stated to include: title, authors, number of centers, location, demographics, interventions, outcomes, and findings.  
- [Yes]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- The MINORS tool was used to assess quality and risk of bias in included studies. This information was considered in the interpretation of results.
- [Yes] 

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 90.9%):

complica-
tion resulting in death or requiring operative management within one
year — our working definition of a major complication. Secondary out-
comes included: other reported complications and a comparison of re-
source utilization between the techniques (including operative time
and cost' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Major complications were defined as reoperation within 1 year or death. Secondary outcomes included: other reported complications and a comparison of resource utilization between the techniques (including operative time and cost).&quot;</span>
- Odds ratios were the summary measures used in the meta-analyses.
- [Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
- Meta-analyses were conducted using RevMan software. Fixed and random effects models were used as appropriate. 
- Heterogeneity was assessed by I2.
- [Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- Funnel plot was examined for evidence of publication bias in one comparison.
- Limitations due to retrospective study designs are discussed.
- [Yes]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses are mentioned.
- [NA] No additional analyses were performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- The number of studies screened, assessed for eligibility, and included is reported.
- A flow diagram depicts the screening process and exclusions.
- [Yes] 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
- Table 1 presents relevant characteristics (sample size, interventions, outcomes, MINORS score) for each included study.
- Full citations are provided.
- [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- The MINORS score assessing risk of bias is presented for each study in Table 1.
- [Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- For the primary outcome, the number of events and participants are summarized for each study in Table 1. 
- Effect estimates and confidence intervals are displayed in forest plots.
- [Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- Results of each meta-analysis are presented with confidence intervals and measures of heterogeneity (I2) in the forest plots.
- [Yes] 

P22. Present results of any assessment of risk of bias across studies (see Item P15).
- The funnel plot is presented assessing publication bias in one comparison. 
- [Yes]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses were performed.
- [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- The discussion summarizes the main findings on complication rates for each comparison and discusses relevance to choice of gastrostomy technique.
- The strength of evidence is acknowledged to be limited by lack of RCTs.  
- [Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations due to lack of RCTs, retrospective study design, heterogeneity, and potential publication bias are discussed.
- [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results are interpreted in the context of previous studies.
- Implications for practice and need for further RCT evidence are discussed.
- [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- No sources of funding or support are reported.
- The role of funders is not described.
- [No] Funding sources and role of funders are not reported.

In summary, for the AMSTAR items:
A1, A4, A5, A9, A10, A11 are No; 
A2, A3, A6, A7, A8 are Yes.

For the PRISMA items: 
P5, P15, P16, P23, P27 are No or NA;
P1-P4, P6-P14, P17-P22, P24-P26 are Yes.
</pre>
<p><a name='69'></a></p>
</div>
<div id="berger-2012" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0032-1311695' title='Open publication'>Berger
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘missing-squared-brackets-in-numbered-list’, ‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached full text:

A1. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. An a priori design was not provided.
A2. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

The current literature was screened for publications regard-
ing the application of Mitomycin C in esophageal stenosis and
stricture with special emphasis on pediatric data' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The current literature was screened for publications regarding the application of Mitomycin C in esophageal stenosis and stricture with special emphasis on pediatric data.&quot;</span>
A3. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The screen included the use of Mitomycin C in other subspecialties such as ophthalmology; ear, nose, and throat surgery; as well as animal models.&quot;</span> 
A4. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. The inclusion or exclusion of grey literature was not specified.
A5. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. A list of included and excluded studies was not provided.
A6. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. <span title='Moderate quote deviation. Best match in fulltext (Similarity 75.9%):

treated, indication, description of stricture, technique of
application, dosage, number of and interval between appli-
cations, complications, and outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Data were collected on the patient population treated, indication, description of stricture, technique of application, dosage, number of and interval between applications, complications, and outcome.&quot;</span> Table 2 provides descriptive data on the included cases.
A7. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. The scientific quality of included studies was not formally assessed, likely due to the nature of the data (case reports/series).
A8. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. The scientific quality of included studies was not used in formulating conclusions since quality assessment was not performed.
A9. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Studies were not combined quantitatively.
A10. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Assessment of publication bias was not applicable as this was not a meta-analysis.  
A11. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. Sources of support and conflicts of interest were not reported for the included studies.

P1. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In this article, we report the results of a systematic analysis of all published pediatric cases regarding the therapeutic application of Mitomycin C in esophageal stricture and stenosis.&quot;</span>
P2. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. An abstract is provided summarizing key aspects of the review.
P3. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. The introduction provides context about the health problem of esophageal strictures in children and current treatment methods. 
P4. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. The review did not have an a priori protocol or PICOS criteria.
P5. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. A review protocol was not referenced.
P6. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. Inclusion criteria were pediatric studies on Mitomycin C for esophageal stricture accessible online in English/German/Spanish. Table 2 provides characteristics of included cases.
P7. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

The current literature was screened for publications regard-
ing the application of Mitomycin C in esophageal stenosis and
stricture with special emphasis on pediatric data. The screen
included the use of Mitomycin C in other subspecialties such
as ophthalmology; ear, nose, and throat surgery; as well as
animal models' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The current literature was screened for publications regarding the application of Mitomycin C in esophageal stenosis and stricture with special emphasis on pediatric data. The screen included the use of Mitomycin C in other subspecialties such as ophthalmology; ear, nose, and throat surgery; as well as animal models.&quot;</span> PubMed was searched.
P8. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. A full search strategy was not provided.
P9. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. The process for study selection is outlined in the methods. 31 cases across 11 publications were included.
P10. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. Methods for data extraction were not described.
P11. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. Table 3 shows the data elements extracted from studies.
P12. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Individual study risk of bias was not assessed, likely due to the nature of the data (case reports/series). 
P13. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Quantitative synthesis/meta-analysis was not performed.
P14-P16. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Quantitative synthesis/meta-analysis was not performed.
P17. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. The results section reports the number of studies screened and included, with reasons for exclusions.
P18. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. Table 3 provides pertinent details for each included case.
P19. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Individual study risk of bias was not assessed.
P20-P23. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span>. Quantitative synthesis/meta-analysis was not performed.
P24. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. The discussion summarizes the main findings and implications.
P25. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. Limitations such as short follow-up and heterogeneity of techniques are discussed.
P26. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[Yes]</span>. The conclusion contextualizes the findings with current knowledge and need for future studies.
P27. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[No]</span>. Sources of funding and support were not reported.

In summary, the AMSTAR assessment identified some key limitations in the review methods, particularly around study quality assessment. The PRISMA evaluation also found suboptimal reporting for some items, but overall the review appears reasonably well conducted given the nature of the available data. More robust primary studies are needed to further evaluate the efficacy and safety of Mitomycin C for pediatric esophageal strictures.
</pre>
<p><a name='70'></a></p>
</div>
<div id="billingham-2010" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0029-1241871' title='Open publication'>Billingham
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

A computerized compre-
hensive search supplemented by a manual
review of the literature was performed for all
peer-reviewed publications' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A computerized comprehensive search supplemented by a manual review of the literature was performed for all peer-reviewed publications...&quot;</span> (Methods section) A comprehensive literature search was performed.

A2. [No] No mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

All available electronic databases including the Brit-
ish Nursing Index (BNI), Cumulative Index to Nursing and Allied
Health Literature (CINAHL), Cochrane Library, EMBASE (Excerpta
Medica), Intute: Health & Life Sciences, MEDLINE, PubMed, BIO-
SIS Previews, ISI Web of Knowledge, ISI Web of Science and Igen-
taConnect, were systematically searched for each procedure,
between the period 1992 – 2009 for all English and non– English
language articles' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All available electronic databases including the British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, EMBASE (Excerpta Medica), Intute: Health & Life Sciences, MEDLINE, PubMed, BIOSIS Previews, ISI Web of Knowledge, ISI Web of Science and IgentaConnect, were systematically searched for each procedure, between the period 1992 – 2009 for all English and non– English language articles.&quot;</span> (Methods section) At least two electronic sources were searched along with supplementary strategies.

A4. [No] No mention of including or excluding studies based on publication status/language. 

A5. [No] No list of included and excluded studies provided.

A6. [No] Study characteristics not provided in aggregated form. 

A7. [No] No mention of assessment of scientific quality of included studies.

A8. [NA] Not applicable since no quality assessment done.

A9. [NA] No meta-analysis performed.

A10. [NA] No meta-analysis performed. 

A11. [No] No mention of conflicts of interest.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pediatric Surgical Technique: Laparoscopic or Open Approach? A systematic Review and Meta-Analysis&quot;</span> (Title) Identified as a systematic review.

P2. [No] No structured summary provided.

P3. [Yes] Rationale described in the introduction section.

P4. [No] No explicit PICOS statement.

P5. [No] No mention of a review protocol.

P6. [No] Study characteristics not described. 

P7. [Yes] Information sources described in the methods section. 

P8. [No] No full electronic search strategy provided.

P9. [Yes] Study selection process described in methods under <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Assessment of study eligibility&quot;</span> section. 

P10. [No] No mention of data extraction methods.

P11. [No] No list of variables extracted.

P12. [No] No assessment of risk of bias mentioned.

P13. [NA] No meta-analysis performed.

P14. [NA] No meta-analysis performed. 

P15. [NA] No meta-analysis performed.

P16. [NA] No additional analyses mentioned.

P17. [No] No flow diagram of study selection provided. 

P18. [No] No study characteristics presented.

P19. [No] No assessment of risk of bias presented. 

P20. [No] No forest plots presented.

P21. [No] No meta-analysis results presented.

P22. [NA] No assessment of bias across studies.

P23. [NA] No additional analyses mentioned.

P24. [No] No summary of main findings in context of other evidence.

P25. [Yes] Limitations discussed in the Discussion section.

P26. [Yes] General interpretation of results provided in Conclusion section.

P27. [No] No mention of sources of funding or support.
</pre>
<p><a name='71'></a></p>
</div>
<div id="black-2013" class="section level4">
<h4><a href='https://doi.org/10.1111/OBR.12037' title='Open publication'>Black
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
[No] No protocol or pre-specified objectives are mentioned.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.  
[Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Two
authors independently screened the abstracts and extrac-
tion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;</span>

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
[Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

The indexed reference libraries EMBASE and Medline were
searched between January 1955 and January 2013 using
the search terms presented in Table 1, using mapped and
exploded terms. Additionally, the references of all included
studies, the Cochrane Library and the titles of papers pub-
lished in the journal Obesity Surgery from January 1992 till
January 2013 were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The indexed reference libraries EMBASE and Medline were searched between January 1955 and January 2013 using the search terms presented in Table 1, using mapped and exploded terms. Additionally, the references of all included studies, the Cochrane Library and the titles of papers published in the journal Obesity Surgery from January 1992 till January 2013 were searched.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit. 
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Only papers written in English were retrieved.&quot;</span> This indicates they did not exclude based on publication status, though they did exclude based on language.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
[No] No list of excluded studies is provided.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above.
[Yes] Table 2 provides relevant characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
[No] The quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
[NA] Scientific quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
[Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Findings from the meta-
analysis of change in BMI at 12 months post-operatively
are shown in Fig. 2. The average weighted mean BMI dif-
ference from baseline to 1 year was -13.5 kg m
-2 
(95%
confidence interval [CI] -15.1, -11.9). There was strong
evidence of heterogeneity among the studies (I
2 
= 76.1%
and P < 0.001), largely because of the differences among
surgery types and populations' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Findings from the meta-analysis of change in BMI at 12 months post-operatively are shown in Fig. 2. The average weighted mean BMI difference from baseline to 1 year was -13.5 kg m-2 (95% confidence interval [CI] -15.1, -11.9). There was strong evidence of heterogeneity among the studies (I2 = 76.1% and P < 0.001), largely because of the differences among surgery types and populations.&quot;</span> A random effects model was used.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
[No] No assessment of publication bias was mentioned. 

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
[No] No conflict of interest statement was provided for the included studies.

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes] The report is identified as a systematic review and meta-analysis in the title.

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Bariatric surgery for obese children and adolescents: a systematic review and meta-analysis&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[Yes] A structured abstract is provided with background, objectives, data sources, eligibility criteria, participants, interventions, synthesis methods, results, limitations, and conclusions. No registration number is provided.

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

A systematic literature search (1955–2013) was performed to examine adjust-
able gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic
diversions operations among obese children and adolescents' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic literature search (1955–2013) was performed to examine adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic diversions operations among obese children and adolescents.&quot;</span>

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

In total, 637 patients from 23 studies were included in the meta-analysis. There
were significant decreases in BMI at 1 year (average weighted mean BMI differ-
ence: -13.5 kg m
-2
; 95% confidence interval [CI] -14.1 to -11.9' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total, 637 patients from 23 studies were included in the meta-analysis. There were significant decreases in BMI at 1 year (average weighted mean BMI difference: -13.5 kg m-2; 95% confidence interval [CI] -14.1 to -11.9).&quot;</span> 

P3. Describe the rationale for the review in the context of what is already known.
[Yes] Previous systematic reviews on this topic are described in the introduction and discussion.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two previous systematic reviews of the literature showed that sustained weight loss could be achieved after bariatric surgery, but reporting on related co-morbidities and complications was sparse, and surgery types were poorly differentiated (16,17).&quot;</span>

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[No] No explicit PICOS statement is provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No] No protocol is mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes] Study characteristics and eligibility criteria are described in the methods.

Quotes: 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies were included if (i) they assessed BMI before and a minimum of six months after individuals predominately received AGB, RYGB, BPD or SG and (ii) the mean age of the population was between 6 and 18 years at study entry (18).&quot;</span>

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Only papers written in English were retrieved.&quot;</span>

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[Yes] Information sources are described:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

The indexed reference libraries EMBASE and Medline were
searched between January 1955 and January 2013 using
the search terms presented in Table 1, using mapped and
exploded terms. Additionally, the references of all included
studies, the Cochrane Library and the titles of papers pub-
lished in the journal Obesity Surgery from January 1992 till
January 2013 were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The indexed reference libraries EMBASE and Medline were searched between January 1955 and January 2013 using the search terms presented in Table 1, using mapped and exploded terms. Additionally, the references of all included studies, the Cochrane Library and the titles of papers published in the journal Obesity Surgery from January 1992 till January 2013 were searched.&quot;</span>

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[Yes] The full search strategy for EMBASE and Medline is provided in Table 1.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[Yes] The study selection process is described and outlined in the flow diagram (Fig. 1).

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Two
authors independently screened the abstracts and extrac-
tion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;</span>

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] Data extraction by two independent authors is mentioned but no other details are provided.

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Two
authors independently screened the abstracts and extrac-
tion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;</span>

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[No] The variables extracted are not listed.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[No] Risk of bias assessment is not described.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[Yes] Mean difference in BMI was the summary measure.

Quotes: 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Findings from the meta-
analysis of change in BMI at 12 months post-operatively
are shown in Fig. 2. The average weighted mean BMI dif-
ference from baseline to 1 year was -13.5 kg m
-2 
(95%
confidence interval [CI] -15.1, -11.9' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Findings from the meta-analysis of change in BMI at 12 months post-operatively are shown in Fig. 2. The average weighted mean BMI difference from baseline to 1 year was -13.5 kg m-2 (95% confidence interval [CI] -15.1, -11.9).&quot;</span>

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
[Yes] The methods are described:
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.&quot;</span>

And I2 values are provided.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[No] No assessment of risk of bias is described.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[No] No additional analyses are described as pre-specified.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[Yes] A flow diagram is provided detailing the number of studies at each stage (Fig. 1).

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
[Yes] Table 2 presents relevant characteristics of the included studies along with citations.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[No] No risk of bias assessment is presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[Yes] For the primary outcome of BMI change, summary data and forest plots are presented (Fig. 2). Data on harms/complications is summarized narratively and in Table 3.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[Yes] Results of the meta-analyses are presented with confidence intervals and I2 values (Fig. 2).

P22. Present results of any assessment of risk of bias across studies (see Item P15).
[NA] No assessment of risk of bias was performed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA] No additional analyses are described.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes] The main findings are summarized in the conclusion:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Bariatric surgery in adolescents results in similar short-term weight outcomes to adults, with RYGB producing the greatest weight loss with the most robust evidence base.&quot;</span>

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Yes] Limitations are described in the discussion section.

Quotes:
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the absence of RCT data, observational studies are likely to continue to be the main source of evidence for bariatric adolescent surgery. Many studies are reported in abstracts from obesity conferences, but are not submitted for publication as full papers in scientific journals.&quot;</span>

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes] The results are interpreted in the context of previous reviews and adult studies in the discussion. Future research implications are described. 

Quotes:
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Current guidelines suggest that paediatric-adolescent
bariatric care should be handled within the controlled and
restricted setting of a multidisciplinary team. However,
long-term, prospectively designed studies, with clear inclu-
sion criteria and reporting of effects, side effects, compli-
cations and co-morbidity resolution, alongside measures of
HRQol, are needed to more firmly establish the harms and
benefits of bariatric surgery in children and adolescents' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Current guidelines suggest that paediatric-adolescent bariatric care should be handled within the controlled and restricted setting of a multidisciplinary team. However, long-term, prospectively designed studies, with clear inclusion criteria and reporting of effects, side effects, complications and co-morbidity resolution, alongside measures of HRQol, are needed to more firmly establish the harms and benefits of bariatric surgery in children and adolescents.&quot;</span>

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
[No] No sources of funding or support are described.

In summary, the authors reported on 16 out of 27 PRISMA items. The items that were not adequately reported included: lack of protocol, no assessment of risk of bias, no pre-specified analyses, no list of excluded studies, no description of data extraction, no list of extracted variables, no conflict of interest statement for included studies, and no statement about funding sources. Overall, this review provides a helpful systematic overview of the evidence on bariatric surgery for obesity in adolescents, but adherence to reporting guidelines could be improved.
</pre>
<p><a name='72'></a></p>
</div>
<div id="borruto-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2010.07.007' title='Open publication'>Borruto
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎...we performed a Medline search for articles...&quot;</span> Explanation: Authors performed a literature search.

A2. [NA] Explanation: This is not a systematic review with meta-analysis, so duplicate study selection and data extraction is not applicable. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following key words were used: “varicocele,” “treatment,” and “adolescent.”&quot;</span> Explanation: At least two electronic databases were searched.

A4. [No] Explanation: The review did not indicate whether unpublished/grey literature was searched. 

A5. [No] Explanation: A list of included and excluded studies was not provided.

A6. [No] Explanation: Characteristics of included studies were not provided in aggregated form. 

A7. [No] Explanation: The scientific quality of included studies was not assessed or documented.

A8. [NA] Explanation: Since quality assessment was not done, using it in formulating conclusions is not applicable.

A9. [NA] Explanation: Methods for combining study findings were not applicable as no meta-analysis was done.  

A10. [NA] Explanation: Assessment of publication bias was not applicable as no meta-analysis was done.

A11. [No] Explanation: Sources of support/conflict of interest were not reported for included studies.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic vs open varicocelectomy in children and adolescents: review of the recent literature and meta-analysis&quot;</span> Explanation: The report is identified as a systematic review. 

P2. [No] Explanation: A structured summary was not provided.

P3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Varicocele is generally considered the most common correctable cause of male infertility [1,2].&quot;</span> Explanation: Rationale for the review is described.

P4. [No] Explanation: Review questions were not stated in terms of participants, interventions, comparisons, outcomes and study designs. 

P5. [No] Explanation: A review protocol was not mentioned.

P6. [No] Explanation: Eligibility criteria relating to study characteristics were not described.

P7. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following key words were used: “varicocele,” “treatment,” and “adolescent.”&quot;</span> Explanation: Literature sources and dates searched are described. 

P8. [No] Explanation: A full search strategy was not presented.

P9. [No] Explanation: Study screening and selection methods were not described. 

P10. [No] Explanation: Data extraction methods were not described.

P11. [No] Explanation: Variables extracted were not listed and defined. 

P12. [No] Explanation: Methods for assessing risk of bias were not described. 

P13. [NA] Explanation: Principal summary measures were not applicable as no meta-analysis was done.

P14. [NA] Explanation: Methods for combining study results were not applicable as no meta-analysis was done.

P15. [NA] Explanation: Assessment of risk of bias across studies was not applicable as no meta-analysis was done.

P16. [NA] Explanation: Additional analyses were not applicable as no meta-analysis was done.  

P17. [No] Explanation: Flow diagram of study selection was not provided.

P18. [No] Explanation: Study characteristics were not presented.

P19. [No] Explanation: Risk of bias assessments were not presented. 

P20. [NA] Explanation: Study results were not presented as no meta-analysis was done. 

P21. [No] Explanation: Meta-analysis results were not presented. 

P22. [NA] Explanation: Assessment of bias across studies was not applicable as no meta-analysis was done.

P23. [NA] Explanation: Additional analyses were not applicable as no meta-analysis was done.

P24. [No] Explanation: Main findings were not summarized. 

P25. [No] Explanation: Limitations at study and outcome level were not discussed. 

P26. [No] Explanation: Results were not interpreted in context of other evidence.

P27. [No] Explanation: Sources of funding/support for the review were not described.

In summary, this systematic review is inadequate in reporting key methodological details and lacks a meta-analysis component. Several essential items on AMSTAR and PRISMA are not fulfilled.
</pre>
<p><a name='73'></a></p>
</div>
<div id="castagnetti-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JURO.2010.06.044' title='Open publication'>Castagnetti
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1: [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review of the literature was performed in December 2009 according to the criteria of Oxman.&quot;</span>
States that review was performed systematically according to predefined criteria.

A2: [No]
No mention of duplicate study selection or data extraction.

A3: [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Four databases, MEDLINE/PubMed, EMBASE, Web of Science and the Cochrane Library, were searched using a single term, “hypospadias,” as it defines accurately the subject of this review.&quot;</span>
Searched 4 databases using defined search term.

A4: [No]
No mention of including or searching for grey literature.

A5: [No] 
No list of included/excluded studies provided.

A6: [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We first reviewed the results of the different straighten-
ing procedures, then the crude complication rates (overall
complication, fistula/dehiscence, stricture/stenosis rates) of
the different urethroplasty techniques' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We first reviewed the results of the different straightening procedures, then the crude complication rates (overall complication, fistula/dehiscence, stricture/stenosis rates) of the different urethroplasty techniques.&quot;</span> 
Provided aggregated results for interventions.

A7: [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎These studies were generally of low quality (69.5% surgical series). Even the 18 controlled studies were fraught with several methodological flaws, limiting their validity.&quot;</span>
Assessed quality of included studies.  

A8: [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Given the low quality and limited validity of the studies available, we did not attempt any meta-analysis.&quot;</span>
Conclusions considered study quality.

A9: [NA] 
No quantitative synthesis performed.

A10: [NA]
No assessment of publication bias performed. 

A11: [No]
No mention of conflicts of interest.

P1: [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Surgical Management of Primary Severe Hypospadias in Children: Systematic 20-Year Review&quot;</span>
Identified as systematic review in title.

P2: [Yes]  
Structured abstract provided with background, objectives, eligibility criteria, data sources, synthesis methods, results, limitations, and conclusions.

P3: [Yes]
Provided context and rationale in introduction. 

P4: [Yes] 
Research questions and inclusion criteria described.

P5: [No] 
No mention of review protocol.

P6: [Yes]
Specified inclusion criteria and study characteristics.

P7: [Yes]
Described literature search strategy and databases searched. 

P8: [No]  
Did not provide full search strategy for replication.

P9: [Yes]
Described study selection process. 

P10: [No]
No details provided on data extraction process.

P11: [Yes]  
Outcomes sought described.

P12: [No] 
Did not describe risk of bias assessment methods.

P13: [NA]
No meta-analysis performed.

P14: [NA]  
No meta-analysis performed. 

P15: [NA]
No assessment of risk of bias across studies.

P16: [NA]  
No additional analyses described.

P17: [No]
No flow diagram of study selection.

P18: [No]  
Did not provide study characteristics for included studies.

P19: [No]  
Did not present risk of bias assessments.

P20: [Yes]
Presented summary data and effect estimates for each analysis.

P21: [NA]
No meta-analyses performed.

P22: [NA] 
No assessment of risk of bias across studies.

P23: [NA]
No additional analyses performed.

P24: [Yes] 
Summarized main findings and limitations. 

P25: [Yes]
Discussed limitations at study and review level.

P26: [Yes]  
Interpreted results in context of other evidence. 

P27: [No] 
No mention of sources of funding.
</pre>
<p><a name='74'></a></p>
</div>
<div id="castagnetti-2016" class="section level4">
<h4><a href='https://doi.org/10.3389/FPED.2016.00041' title='Open publication'>Castagnetti
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 
"[No]"
No protocol, ethics approval, or pre-determined objectives are mentioned.

A2. Was there duplicate study selection and data extraction?  
"[No]"
The review does not mention duplicate screening or extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Three databases, namely, MEDLINE/PubMed, Scopus, and The Cochrane library, were searched for using the free text “hypospadias repair”&quot;</span>

A4. Was the status of publication used as an inclusion criterion?  
"[No]" 
Grey literature searching is not mentioned.

A5. Was a list of studies (included and excluded) provided?
"[No]"
Included studies are listed in Table 1 but excluded studies are not referenced.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Table 1 provides characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
Study quality is not assessed. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]"
Since study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?
"[Yes]" 
The meta-analysis methods are described.

A10. Was the likelihood of publication bias assessed?
"[No]" 
Publication bias is not assessed.

A11. Was the conflict of interest included?  
"[No]"
Conflicts of interest are not reported.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

We performed a systematic review of the literature on preputial recon-
struction (PR) during hypospadias repair to determine the cumulative risk of preputial
skin complications and the influence of PR on urethroplasty complications, namely,
fistula formation and overall reoperation rate of the repair' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review of the literature on preputial reconstruction (PR) during hypospadias repair to determine the cumulative risk of preputial skin complications and the influence of PR on urethroplasty complications, namely, fistula formation and overall reoperation rate of the repair.&quot;</span>

P2. Provide a structured summary.
"[Yes]" 
A structured abstract is provided.

P3. Describe the rationale for the review. 
"[Yes]"
The rationale is described in the Introduction.

P4. Provide an explicit statement of questions being addressed.
"[Yes]" 
The objective is stated: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎to determine the cumulative risk of preputial skin complications and the influence of PR on urethroplasty complications, namely, fistula formation and overall reoperation rate of the repair.&quot;</span>

P5. Indicate if a review protocol exists.
"[No]" 
A protocol is not mentioned.

P6. Specify study characteristics used as criteria for eligibility. 
"[Yes]"
Inclusion and exclusion criteria are described in the Methods. 

P7. Describe information sources and dates last searched.
"[Yes]" 
Information sources and search dates are provided.

P8. Present full electronic search strategy for at least one database.
"[No]"
The full search strategy is not included.

P9. State the process for selecting studies.
"[Yes]" 
The study selection process is diagrammed in Figure 1.

P10. Describe method of data extraction.
"[No]"
The data extraction process is not described.

P11. List and define all variables for which data were sought.
"[Yes]" 
Outcomes extracted are listed in the Methods.

P12. Describe methods for assessing risk of bias. 
"[No]"
Risk of bias methods are not described.

P13. State the principal summary measures.
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Odds Ratios (OR) and 95% confidence intervals (OR 95% CI) were calculated&quot;</span>

P14. Describe methods of handling data and combining results.
"[Yes]"
Statistical methods for meta-analysis are described. 

P15. Specify assessment of risk of bias across studies.
"[No]"
Risk of bias across studies is not discussed.

P16. Describe methods of additional analyses.
"[NA]"
No additional analyses were done.

P17. Give numbers of studies at each stage with reasons for exclusions. 
"[Yes]"
Figure 1 provides a flow diagram of studies.

P18. For each study, present characteristics extracted.
"[Yes]" 
Table 1 provides study characteristics.

P19. Present data on risk of bias of each study. 
"[No]" 
Risk of bias is not presented.

P20. For each outcome, present summary data and effect estimates.
"[Yes]"
Summary data and effect estimates are presented in the meta-analysis figures.

P21. Present results of each meta-analysis done. 
"[Yes]" 
Meta-analysis results are presented in Figures 2 and 4.

P22. Present results of assessment of bias across studies.
"[NA]"
Risk of bias across studies was not assessed.

P23. Give results of additional analyses.
"[NA]" 
No additional analyses were done.

P24. Summarize the main findings.
"[Yes]"
The main findings are summarized in the Discussion and Conclusion.

P25. Discuss limitations at study and outcome level. 
"[Yes]"
Limitations are outlined in the Discussion.

P26. Provide a general interpretation of results.
"[Yes]" 
Results are interpreted in the Discussion.

P27. Describe sources of funding and support.
"[No]"
Sources of funding are not reported.
</pre>
<p><a name='75'></a></p>
</div>
<div id="chan-2014-pediatr-surg-int" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-013-3429-Y' title='Open publication'>Chan
2014 (Pediatr Surg Int)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the assessments for the AMSTAR and PRISMA items for the attached systematic review:

AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
[No] 
No mention of a protocol. The review only states the aim was <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎to determine, based on a systematic review, the most favorable age at which orchiopexy should be performed.&quot;</span>

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.  
[Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Two researchers
independently performed each level of screening, compar-
ing the selected studies to reach a consensus. If a consensus
could not be reached, they consulted a third researcher' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently performed each level of screening, comparing the selected studies to reach a consensus. If a consensus could not be reached, they consulted a third researcher.&quot;</span>

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
[Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We conducted electronic searches of the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE
(1966 onwards), Embase (1980 onwards), and CINAHL
(1982 onwards) to find relevant articles. We used the fol-
lowing search terms: ‘‘Cryptorchidism’’ AND ‘‘Orchido-
pexy’’ AND ‘‘timing’’ OR ‘‘age’’. We included only
English publications and studies pertaining to humans and
males. We also excluded any editorials and case reviews.
We hand-searched the reference sections of relevant arti-
cles for additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), Embase (1980 onwards), and CINAHL (1982 onwards) to find relevant articles. We used the following search terms: ‘‘Cryptorchidism’’ AND ‘‘Orchidopexy’’ AND ‘‘timing’’ OR ‘‘age’’. We included only English publications and studies pertaining to humans and males. We also excluded any editorials and case reviews. We hand-searched the reference sections of relevant articles for additional studies.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
[No]
No mention of grey literature search.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
[No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>
[Yes] 
Table 1 provides detail on participants, interventions, outcomes, and results for the included studies.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
[Yes]
The authors used AMSTAR, Jadad, and MINORS tools to assess the quality of systematic reviews, RCTs, and non-RCTs, respectively. The scores for each study are provided in Tables 1 and 2. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
[Yes] 
The authors state <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.3%):

we have evaluated each non-RCT using
the MINORS assessment tool. This scale contains items
that address various potential sources of bias. As higher
scores are indicative of greater methodological quality and
lower risk of bias, we have based our results on only the
highest-rated studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We have evaluated each non-RCT using the MINORS assessment tool. This scale contains items that address various potential sources of bias. As higher scores are indicative of greater methodological quality and lower risk of bias, we have based our results primarily on only the highest-rated studies.&quot;</span>

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
[NA] 
No meta-analysis performed due to heterogeneity.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
[No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
[No]
No conflict of interest statement provided for the systematic review or the included studies.

PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes]
Identified as a systematic review in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[Yes]  
Structured abstract provided with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal methods, results, and conclusions. No systematic review registration number provided.

P3. Describe the rationale for the review in the context of what is already known.
[Yes]
Introduction describes the lack of clarity around timing of orchiopexy and aim to determine optimal timing based on a systematic review.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[No] 
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No]
No review protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes]
The eligibility criteria are described: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.3%):

We included all studies that examined the effect of age at
orchiopexy on fertility or malignancy, even if these out-
comes were not the primary focus. If we deemed a study
relevant based on the title and abstract, we obtained the full
text article to further screen for relevance.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We included all studies that examined the effect of age at orchiopexy on fertility or malignancy, even if these outcomes were not the primary focus. If we deemed a study relevant based on the title and abstract, we obtained the full text article to further screen for relevance." And "We included only English publications and studies pertaining to humans and males. We also excluded any editorials and case reviews.&quot;</span>

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[Yes] 
The databases searched (CENTRAL, MEDLINE, Embase, CINAHL), search terms, and date limits are described. No contact with study authors mentioned. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[No]
The search terms are presented but not the full search strategy for any database.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[Yes] 
The two-step screening process is described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Data extraction by one researcher and checked by a second researcher is described but no mention of piloted forms or contacting investigators.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[No]
The outcomes are described but the specific variables extracted are not listed. No assumptions/simplifications stated.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[Yes]  
The quality assessment tools used for different study designs are described. The scores were used to determine which studies to base conclusions on.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[NA]
No meta-analysis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
[NA]
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[No]
No assessment of publication bias mentioned.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[NA] 
No additional analyses performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[Yes]
Flow diagram provided detailing records identified, included, and excluded with reasons. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
[Yes]
Table 1 presents the characteristics extracted for each included study.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[Yes]
Tables 1 and 2 present the quality assessment scores for each included study.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[NA] 
No meta-analysis performed.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA]
No meta-analysis performed. 

P22. Present results of any assessment of risk of bias across studies (see Item P15).
[NA] 
No assessment of publication bias performed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA]
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes]
The main findings and conclusions are summarized in the abstract and discussion section.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Yes]  
Limitations regarding fertility outcome measures, lack of long-term studies, inclusion of non-RCTs, and potential for publication bias are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes]
The results are interpreted in the context of previous guidelines and recommendations. Implications for future research are discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
[No]
No sources of funding or support described.
</pre>
<p><a name='76'></a></p>
</div>
<div id="chan-2014-j-pediatr-surg" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2014.02.049' title='Open publication'>Chan
2014 (J Pediatr Surg)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We used the keywords 'diaphragmatic hernia', 'thoracoscopy', 'laparoscopy', 'minimally invasive surgery', and 'open'.&quot;</span> [Yes]
The search included relevant keywords.

A2. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Two researchers independently assessed each study for method-
ological quality using MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently assessed each study for methodological quality using MINORS.&quot;</span> [Yes]
Duplicate study selection and data extraction were done. 

A3. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted an electronic search of MEDLINE (1966 onwards), Embase (1980 onwards), and the Cochrane Central Register of Controlled Trials (CENTRAL).&quot;</span> [Yes]
At least two electronic databases were searched.

A4. [NA]
Assessment of gray literature is not applicable, as the review did not mention searching for unpublished studies.

A5. [No] 
A list of included and excluded studies was not provided.

A6. Table 1 provides relevant characteristics of the included studies. [Yes]  
Study characteristics were described.

A7. [No]  
The quality of included studies was assessed using MINORS but the results were not documented. 

A8. [NA]  
Assessment of study quality was not used appropriately to formulate conclusions, since quality was not reported (A7 No).

A9. [NA] 
Statistical synthesis methods were not applicable as no meta-analysis was done.

A10. [NA]  
Assessment of publication bias was not applicable as no meta-analysis was done.

A11. [No]
Sources of support were not reported for the included studies.

P1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Minimally invasive versus open repair of Bochdalek hernia: a meta-analysis&quot;</span> [Yes]  
The report is identified as a systematic review/meta-analysis.

P2. The abstract provides relevant information on background, objectives, data sources, eligibility criteria, outcomes, and conclusions. [Yes]

P3. The introduction describes the rationale and existing knowledge on the topic. [Yes]   

P4. The objective compares minimally invasive versus open repair for Bochdalek hernia in neonates, covering PICOS. [Yes]

P5. [No]  
A protocol was not mentioned.

P6. Inclusion criteria cover the relevant characteristics such as age group and hernia type. [Yes]

P7. The data sources and search dates are provided. [Yes]

P8. [No]
The full search strategy was not presented for any database. 

P9. The selection process is described and depicted in a flow diagram. [Yes] 

P10. [No] 
The data extraction process is not described.

P11. Relevant outcomes are described in the methods. [Yes]

P12. [No] 
Methods for assessing risk of bias are not described at the outcome level.

P13. [NA]
Summary measures are not applicable as no meta-analysis was done.

P14-P23. [NA] 
All items related to meta-analyses are not applicable.

P24. The discussion summarizes the main findings and implications. [Yes]

P25. Limitations at the study and review level are discussed. [Yes]

P26. The findings are interpreted in the context of other evidence. [Yes] 

P27. [No]  
Sources of funding are not reported for the systematic review.
</pre>
<p><a name='77'></a></p>
</div>
<div id="chang-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00345-015-1526-3' title='Open publication'>Chang
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Regarding AMSTAR

A1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Patients
with age greater than 18 years undergoing standard lapa-
roscopic or LESS surgery, undergoing surgery for ureteral
stricture, with horseshoe kidney, or with vesicoureteral
reflux were excluded for analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients with age greater than 18 years undergoing standard laparoscopic or LESS surgery, undergoing surgery for ureteral stricture, with horseshoe kidney, or with vesicoureteral reflux were excluded for analysis.&quot;</span> [Yes] The eligibility criteria are pre-established before conducting the review.

A2. <span title='Moderate quote deviation. Best match in fulltext (Similarity 89.9%):

Two authors
(Hsu and Chang) of the current study independently
searched and reviewed the articles. When discrepancies
occurred over the results, discussions with a third author
(Yang) were made to reach a consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Two authors of this paper, Hsu and Chang, independently searched and reviewed the articles. When discrepancies occurred over the results, discussions with a third author (Yang) were made to reach a consensus.&quot;</span> [Yes] Duplicate study selection and data extraction were performed. 

A3. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

We searched PubMed 
® 
for comparative studies (from Janu-
ary 1990 to 2014 September) that compared the efficacy
and safety of robotic versus open pyeloplasty. Searches
were limited to studies published in English. We used the
following keywords: robotic, pyeloplasty, ureteropelvic
junction obstruction, children, and pediatric' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched PubMed® for comparative studies (from January 1990 to 2014 September) that compared the efficacy and safety of robotic versus open pyeloplasty. Searches were limited to studies published in English. We used the following keywords: robotic, pyeloplasty, ureteropelvic junction obstruction, children, and pediatric.&quot;</span> [Yes] Multiple databases were searched and search terms are provided.

A4. No mention of screening for grey literature. [No] Grey literature was not searched for or mentioned.

A5. No list of included/excluded studies is provided. [No] The list of included and excluded studies is not presented. 

A6. Table 1 summarizes the characteristics of included studies. [Yes] Study characteristics are adequately described.

A7. No quality assessment of included studies is described. [No] The quality of included studies was not assessed.

A8. No quality assessment was done, so it couldn't be incorporated into conclusions. [NA] Quality assessment was not performed.

A9. No meta-analysis of effect estimates was done. [NA] The results were not combined quantitatively.

A10. No assessment of publication bias. [No] Publication bias was not assessed. 

A11. No statement about conflicts of interest. [No] Potential conflicts of interest were not reported.

Regarding PRISMA:

P1. The review is identified as a systematic review and meta-analysis in the title. [Yes] 

P2. An abstract is provided summarizing the review. [Yes]

P3. The rationale and context for the review are described in the Introduction. [Yes] 

P4. The participants, interventions, comparisons, and outcomes are described but no specific PICOS is provided. [Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]

P5. No protocol is mentioned. [No] 

P6. Inclusion/exclusion criteria are provided. [Yes] 

P7. Search methods are described. [Yes]

P8. The full search strategy is not provided for any database. [No]

P9. The study selection process is described and illustrated in a flow diagram. [Yes] 

P10. Data extraction methods are described. [Yes] 

P11. Outcomes extracted are listed in the data extraction tables. [Yes]

P12. No risk of bias assessment is described. [No] 

P13. Summary measures are described in the analysis section. [Yes]

P14. Methods for combining study results are described. [Yes] 

P15. No assessment of risk of bias across studies. [NA] 

P16. No additional analyses are described. [NA]

P17. The study selection process is shown in a flow diagram with reasons for exclusions. [Yes]

P18. Study characteristics are presented in Table 1. [Yes] 

P19. No assessment of risk of bias for individual studies. [No]

P20. Results for each analysis are presented in forest plots. [Yes]

P21. Results of meta-analyses are presented. [Yes] 

P22. No assessment of risk of bias across studies. [NA]

P23. No additional analyses conducted. [NA]

P24. Main findings are summarized in the Discussion. [Yes]

P25. Limitations are discussed. [Yes]

P26. Conclusions and implications are discussed. [Yes]

P27. No statement about sources of funding or support. [No]

In summary, the review adequately addressed some but not all AMSTAR and PRISMA items. The main limitations were the lack of grey literature searching, quality assessment, and consideration of biases.
</pre>
<p><a name='78'></a></p>
</div>
<div id="chen-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2012.12.036' title='Open publication'>Chen
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? 
[No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our review was limited to published studies and no contact with authors was made to obtain unpublished data. Conference abstracts were also excluded owing to the limited data presented.&quot;</span>
No protocol or pre-determined objectives mentioned.

A2. Was there duplicate study selection and data extraction?  
[Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each included study was independently appraised by 3 reviewers (C.Y., S.N., N.K.L.) and data were extracted and entered into a database. Any disagreements were resolved by consensus.&quot;</span>

A3. Was a comprehensive literature search performed?
[Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We searched all publications from August 1998 to March
2012 in the MEDLINE, EMBASE and Cochrane library
databases and the Cochrane Controlled Trials Register using
different combinations of the following terms: “Hirsch-
sprung&#39;s disease,” “transanal,” “perineal approach,” “transab-
dominal” and “pull-through.” The reference lists of the full
articles were also manually searched to identify additional
eligible studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched all publications from August 1998 to March 2012 in the MEDLINE, EMBASE and Cochrane library databases and the Cochrane Controlled Trials Register using different combinations of the following terms: “Hirschsprung's disease,” “transanal,” “perineal approach,” “transabdominal” and “pull-through.” The reference lists of the full articles were also manually searched to identify additional eligible studies.&quot;</span>
Searched Medline, Embase, Cochrane databases, reference lists, and no language restrictions.

A4. Was the status of publication used as an inclusion criterion?  
[No]
No mention of including or searching for gray literature.

A5. Was a list of studies (included and excluded) provided?
[No]  
Provides references for included studies but not excluded.

A6. Were the characteristics of the included studies provided?
[Yes]
Study characteristics including surgery type, age, follow-up time, and outcomes summarized in Tables 1 and 2. 

A7. Was the scientific quality of the included studies assessed and documented?
[No] 
No quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate?
[Yes] 
Used Mantel-Haenszel method for dichotomous data and inverse variance method for continuous data. Assessed heterogeneity with I2 statistic.

A10. Was the likelihood of publication bias assessed?
[No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included?
[No]
No conflict of interest statement.

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

To compare the clinical outcomes of TERPT
and TAB, we performed a systematic review and compre-
hensive meta-analysis from indexed published literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To compare the clinical outcomes of TERPT and TAB, we performed a systematic review and comprehensive meta-analysis from indexed published literature.&quot;</span>

P2. Provide a structured summary.
[Yes]
Abstract provides background, objectives, data sources, participants, interventions, study appraisal and synthesis methods, results, conclusions.

P3. Describe the rationale for the review in the context of what is already known.
[Yes]
Introduction describes previous procedures for HD, introduction of TERPT, potential advantages/disadvantages of TERPT vs TAB, and need for systematic review.

P4. Provide an explicit statement of questions being addressed. 
[No] 
No PICO framework presented.

P5. Indicate if a review protocol exists and provide registration information.
[No] 
No protocol mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
[Yes]
Inclusion criteria were studies comparing functional outcomes of TERPT and TAB. Excluded conference abstracts and non-English studies.

P7. Describe information sources, search, and date last searched.
[Yes] 
Described databases searched, terms used, reference checking, no date limit but last search was March 2012.

P8. Present full electronic search strategy for at least one database. 
[No]
Search strategy not provided.

P9. State the process for selecting studies.
[Yes]  
Selection process described and depicted in Figure 1.

P10. Describe method of data extraction and confirmation.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each included study was independently appraised by 3 reviewers (C.Y., S.N., N.K.L.) and data were extracted and entered into a database. Any disagreements were resolved by consensus.&quot;</span>

P11. List and define all variables for which data were sought.
[Yes] 
Outcomes assessed included operative time, hospital stay, incontinence, constipation, enterocolitis. Definitions summarized in Table 3.

P12. Describe methods for assessing risk of bias. 
[No]
No risk of bias assessment.

P13. State the principal summary measures.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pooled odds ratios (OR) were calculated for dichotomous variables using the Mantel–Haenszel method. Pooled mean differences (MD) were measured for continuous variables using the inverse variance method in meta-analysis.&quot;</span>

P14. Describe methods of handling data and combining results.
[Yes]  
Used fixed effects model for I2 <50% and random effects model for I2 ≥50%. Reported I2 values.

P15. Specify any assessment of risk of bias across studies.
[No]
No assessment of publication bias or selective reporting.

P16. Describe methods of additional analyses.
[NA]
No additional analyses.

P17. Give numbers of studies screened, assessed, included, and excluded with reasons. 
[Yes] 
Number of studies at each stage provided in Figure 1. Gave reasons for study exclusions.

P18. For each study, present pertinent characteristics and provide citations.
[Yes]
Study characteristics detailed in Tables 1 and 2. 

P19. Present data on risk of bias for each study. 
[No]
No risk of bias assessment.

P20. Present results for each intervention group and effect estimates for each study.
[Yes]  
Table 2 provides results for each study. Forest plots with effect sizes presented in Figures 2-5.

P21. Present results of meta-analyses, including confidence intervals and consistency.
[Yes]
Pooled effect sizes with 95% CIs presented in text and Figures 2-5. I2 values assessing heterogeneity given.

P22. Present results of bias assessment across studies.
[NA] 
No bias assessment performed.

P23. Give results of additional analyses. 
[NA]
No additional analyses.

P24. Summarize main findings and discuss relevance.
[Yes] 
Conclusions summarize findings and call for more RCTs.

P25. Discuss limitations at study and outcome level and at review level.
[Yes]
Limitations discussed including lack of RCTs, retrospective design, heterogeneity, inconsistent definitions.

P26. Provide a general interpretation of results in context of other evidence.
[Yes]
Results interpreted in context of previous studies on TERPT vs TAB.

P27. Describe sources of funding and role of funders.
[No] 
No statement on funding or conflicts of interest.

In summary, for AMSTAR, 7 items were scored NA/No, 3 Yes, and 1 NA. For PRISMA, 10 items were scored NA/No, 15 Yes, and 2 NA. Make sure all AMSTAR and PRISMA items have been addressed before finalizing the assessment.
</pre>
<p><a name='79'></a></p>
</div>
<div id="corbett-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2015.08.014' title='Open publication'>Corbett
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the extracted quotes, reasoning, and responses for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The purpose of this review
was to combine data from published series of endopyelot-
omy in children to give an overview of outcomes for this
approach to PUJO' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The purpose of this review was to combine data from published series of endopyelotomy in children to give an overview of outcomes for this approach to PUJO.&quot;</span> [Introduction]
- No protocol, ethics approval, or pre-determined objectives referenced. Review and inclusion criteria appear to have been established retrospectively.
[No]

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion of publications was decided by both the study authors and data were extracted independently by both study authors.&quot;</span> [Methods]
[Yes]

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Medline and Embase databases were searched using rele-
vant key search terms (pelviureteric junction, ureter-
opelvic junction, obstruction, paediatric, pediatric, child$,
balloon, dilatation, endopyelotomy, open, laparoscopic,
pyeloplasty' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Embase databases were searched using relevant key search terms (pelviureteric junction, ureteropelvic junction, obstruction, paediatric, pediatric, child$, balloon, dilatation, endopyelotomy, open, laparoscopic, pyeloplasty).&quot;</span> [Methods]
- Search supplemented by screening references of retrieved studies. 
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
- No mention of searching or including grey literature. 
[No]

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
- List of included studies provided in Tables 1 and 2. Excluded studies not listed.
[No]

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>
- Tables 1 and 2 provide aggregated data on participants (age range, number of procedures), interventions (technique), and outcomes (success rate, complications, follow-up duration).
[Yes]

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
- No formal quality assessment of included studies documented. Study limitations discussed in Discussion.
[No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
- No formal quality assessment performed. Study limitations appropriately discussed in relation to conclusions.
[No]

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
- Quantitative synthesis/meta-analysis not performed due to heterogeneity.
[NA]

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.  
- Publication bias not assessed.
[No]

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
- No conflicts of interest or sources of support stated for systematic review or included studies.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- Identified as systematic review in title.
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Background, objectives, data sources, eligibility criteria, participants, interventions, synthesis methods, results, conclusions provided in abstract. No registration number. Limitations not summarized.
[No] 

P3. Describe the rationale for the review in the context of what is already known.
- Rationale and context described in Introduction.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- Objective to <span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

systematically analyse published
literature to give an overall success rate for endo-
pyelotomy in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎systematically analyse published literature to give an overall success rate for endopyelotomy in children&quot;</span> stated. Participants, intervention, and outcome implicitly clear, no comparisons or study design delineated. 
[No]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No protocol referenced.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Eligibility criteria specified (pediatric studies, case reports and small series excluded). No exclusion criteria based on publication status or language stated.
[No]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- Databases and supplemental search strategy described. Date of last search provided. No contact with study authors mentioned.  
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Search terms but not full search strategy provided.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Selection process described. No meta-analysis performed.
[Yes] 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
- Independent dual data extraction described. No confirmation from investigators.
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Data extracted summarized. No explicit listing of variables provided.
[No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- No risk of bias assessment performed.
[NA]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- No meta-analysis performed.
[NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
- No meta-analysis performed.
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- No assessment of publication bias or other biases performed.
[NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses performed.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Number of records screened and assessed stated. Flow diagram provided detailing screening and reasons for exclusions. 
[Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
- Study characteristics and citations presented in Tables 1 and 2.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- No risk of bias assessment performed.
[NA]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- No meta-analysis performed.
[NA]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- No meta-analysis performed. 
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
- No assessment of risk of bias performed.
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses performed.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Main findings summarized in Discussion and Conclusion sections. Relevance to clinical practice considered.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations of included studies and review discussed. 
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted in context of other evidence on management of PUJO. Implications for future research not discussed.
[No]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
- No sources of funding or support stated.
[No]
</pre>
<p><a name='80'></a></p>
</div>
<div id="cullis-2016" class="section level4">
<h4><a href='https://doi.org/10.1097/sla.0000000000001563' title='Open publication'>Cullis
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the responses for the AMSTAR and PRISMA items based on the attached publication:

AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 90.8%):

uncertainty and controversy, we undertook a
systematic review of the available literature' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Based on uncertainty and controversy, we undertook a systematic review of the available literature&quot;</span> (Introduction)
- Review was conducted according to PRISMA guidelines (Methods)
- Local review protocol established (Methods)
- Inclusion and exclusion criteria were defined (Methods, Table 1)
[No]

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (P.S.C., S.S.) performed the study selection, data extraction, and quality assessment processes independently and all data was recorded in tabular form electronically.&quot;</span> (Methods)  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Disagreements were resolved by discussion or consultation with the third reviewer/senior corresponding author who conceived the study (P.D.L.).&quot;</span> (Methods)
[Yes]

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
- Searched CINAHL, EMBASE, Medline, Cochrane Databases from inception to January 2015 (updated June 2015) (Methods)
- Search strategy provided in supplement (Methods)  
- Conference proceedings searched (Methods)
- Reference lists of included articles searched (Methods)
- Authors' institutional data included (Methods)
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
- Conference proceedings searched (Methods)
- Authors' institutional unpublished data included (Methods)
[Yes]

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
- References for included studies provided in Table 2 (Results)
- Flow diagram not provided 
[No]

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Follow-up poorly reported in general&quot;</span>
- Table 2 provides summary characteristics of included studies (Results)
- Table 3 provides detailed findings from studies that reported management pathways (Results)
- Follow-up was poorly reported in general
[Yes]

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
- Quality assessed using MINORS criteria (Methods)  
- Results of MINORS scoring presented in Figure 1 (Results)
[Yes]  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
- Limitations in study quality and risk of bias discussed (Discussion)
- Conclusions acknowledge weak evidence base and need for careful interpretation
[Yes]

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
- Meta-analysis not performed due to study design (Results)
[NA]

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.  
- Publication bias not assessed
- Flow diagram not provided to identify number of studies screened
[No]

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies.
- No funding received for systematic review stated (Methods)
- Funding sources not reported for included studies
[No]

PRISMA
P1. Identify the report as a systematic review, meta-analysis, or both. 
- Identified as a systematic review in title, abstract, and text
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Structured abstract provided with all elements
[Yes]  

P3. Describe the rationale for the review in the context of what is already known.
- Rationale described in introduction 
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
- Research questions stated in introduction
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- Local review protocol mentioned but not publicly available
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Inclusion and exclusion criteria described in Methods (Table 1)
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
- Information sources described in Methods
- Dates of last search provided  
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Search strategy provided in supplement
[Yes]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described in Methods
- Flow diagram not provided
[No]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
- Data extraction process described in Methods
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- Outcomes described in Methods
[Yes]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- Quality assessment using MINORS described (Methods)
[Yes]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- No meta-analysis performed
[NA]  

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
- No meta-analysis performed
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- Publication bias not assessed (Methods, Results)
[No]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses performed
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Number of studies screened reported in text (Results)
- No flow diagram provided
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
- Study characteristics presented in Tables 2 and 3 
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- MINORS results presented in Figure 1
[Yes]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
- No meta-analysis performed
[NA]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- No meta-analysis performed 
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).
- No assessment of publication bias
[No] 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses performed
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Main findings summarized in abstract and discussion
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations discussed in discussion
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted in discussion 
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
- No funding received stated
[Yes]

In summary, for AMSTAR:
- Yes: A2, A3, A4, A6, A7, A8  
- No: A1, A5, A10, A11
- NA: A9

For PRISMA: 
- Yes: P1, P2, P3, P4, P6, P7, P8, P10, P11, P12, P18, P19, P24, P25, P26, P27
- No: P5, P9, P15, P17, P22
- NA: P13, P14, P16, P20, P21, P23

Thank you for the opportunity to critically appraise this publication. Please let me know if you would like me to clarify or expand on any part of the assessment.
</pre>
<p><a name='81'></a></p>
</div>
<div id="cundy-2014-bju-int" class="section level4">
<h4><a href='https://doi.org/10.1111/bju.12683 ' title='Open publication'>Cundy
2014 (BJU Int)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎No studies reported pre hoc power calculations to justify adequate sample size.&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎No randomised controlled trials were identified.&quot;</span>

A2. Was there duplicate study selection and data extraction? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently undertook literature searches, screened abstracts, and assessed eligible articles against inclusion criteria (T.P.C., A.H.H.). There was 90% agreement on identification of articles and discrepancies were resolved by consensus, or arbitrated by a third author (E.K.M.).&quot;</span>

A3. Was a comprehensive literature search performed? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic literature searches were undertaken of the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Ovid Medline and EMBASE electronic databases using the following search strategy using the following Medical Subject Headings (MeSH):...&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The primary search was supplemented with searches of: i) PubMed related articles feature, ii) clinicaltrials.gov registry using the keyword ‘pyeloplasty’, and iii) abstracts of the International Pediatric Endosurgery Group Annual Congresses (2002–2013), the AUA Annual Meetings (2006–2013), Section of Urology Program of the American Association of Pediatrics National Conference (2007–2012), and World Congress of Endourology (2008–2013).&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching for or including grey literature.

A5. Was a list of studies (included and excluded) provided? [Yes] 
Included studies listed in Table 1. Excluded studies not listed but exclusion reasons described in Figure 1.

A6. Were the characteristics of the included studies provided? [Yes]
Characteristics of included studies provided in Tables 1-3.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment (maximum 3, 10, and 2 stars respectively; total out of 15) [6].&quot;</span>
Quality scores summarized in Table 4.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
The quality of studies was considered in the Discussion section: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎No randomised controlled trials were identified. Unfortunately, this is not unusual despite these trials being considered the ‘gold-standard’ method of comparative assessment [27]. A distinct absence of prospective studies was also identified. The reliance upon less robust retrospective data are inadequate and represents a major weakness in the current literature base for paediatric robot-assisted surgery [1].&quot;</span>

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Statistical analysis was conducted using Review Manager
®
Version 5.1.7 for Windows (The Cochrane Collaboration,
Software Update, Oxford, UK) and STATA v.11 statistical
analysis software (StataCorp LP, TX, USA). A weighted
random-effects model was used for all analyses' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Statistical analysis was conducted using Review Manager® Version 5.1.7 for Windows (The Cochrane Collaboration, Software Update, Oxford, UK) and STATA v.11 statistical analysis software (StataCorp LP, TX, USA). A weighted random-effects model was used for all analyses.&quot;</span> 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):

Determination of heterogeneity was
undertaken using the chi-squared test (Cochran’s Q) and I
2
value; with I
2 
≥ 75% denoting high degree of statistically
significant heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Determination of heterogeneity was undertaken using the chi-squared test (Cochran’s Q) and I2 value; with I2 ≥ 75% denoting high degree of statistically significant heterogeneity.&quot;</span>

A10. Was the likelihood of publication bias assessed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Risk of publication bias was assessed by visual inspection of funnel plots in addition to statistical estimation with both Begg and Mazumdar’s test and Egger’s test for small study effects.&quot;</span>

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as systematic review and meta-analysis in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
Structured abstract provided with all elements.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Rationale described in Introduction: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎It remains largely unclear how the many technological enhancements offered by robot-assistance might translate into clinically measurable outcome benefits. As RAP becomes more established, this application of robotic surgery will inevitably transition towards an era of critical assessment [3,4]. Accordingly, comparative studies are increasingly emerging [1] and this allows opportunities for quantitative data synthesis to more definitively evaluate effectiveness of RAP against established best-practice techniques.&quot;</span>

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42013003969) and analysis was performed in accordance with recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement [5].&quot;</span>

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]  
Eligibility criteria specified: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All included studies satisfied the following criteria: i) comparing RAP vs LP and/or OP; ii) involving paediatric patients with mean study group ages of <18 years; iii) reporting five or more patients in each study group; iv) involving singular pathologies or procedures; and v) investigating objective clinical outcome measures or cost. No language restrictions were imposed.&quot;</span>

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Information sources described in search strategy section. Last search date specified as December 2013. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [Yes]
Full search strategy provided for Medline, Embase, and Cochrane databases.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes] 
Selection process described and outlined in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently undertook literature searches, screened abstracts, and assessed eligible articles against inclusion criteria (T.P.C., A.H.H.).&quot;</span>
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Corresponding authors were contacted about any missing data.&quot;</span>

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Outcomes of interest defined in Methods section. 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
Risk of bias assessed using modified Newcastle-Ottawa scale. Quality scoring considered in interpretation of results.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pooled odds ratios (ORs) were calculated as the summary statistic for dichotomous variables and weighted mean difference (WMD) calculated for continuous variables. Both ORs and WMDs are reported with 95% CIs.&quot;</span>

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Statistical analysis was conducted using Review Manager
®
Version 5.1.7 for Windows (The Cochrane Collaboration,
Software Update, Oxford, UK) and STATA v.11 statistical
analysis software (StataCorp LP, TX, USA). A weighted
random-effects model was used for all analyses' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Statistical analysis was conducted using Review Manager® Version 5.1.7 for Windows (The Cochrane Collaboration, Software Update, Oxford, UK) and STATA v.11 statistical analysis software (StataCorp LP, TX, USA). A weighted random-effects model was used for all analyses.&quot;</span>
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):

Determination of heterogeneity was
undertaken using the chi-squared test (Cochran’s Q) and I
2
value; with I
2 
≥ 75% denoting high degree of statistically
significant heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Determination of heterogeneity was undertaken using the chi-squared test (Cochran’s Q) and I2 value; with I2 ≥ 75% denoting high degree of statistically significant heterogeneity.&quot;</span>

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Risk of publication bias was assessed by visual inspection of funnel plots in addition to statistical estimation with both Begg and Mazumdar’s test and Egger’s test for small study effects.&quot;</span>

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [No] 
No additional analyses described.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
Numbers reported in text and flow diagram provided (Figure 1).

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]  
Study characteristics presented in Tables 1-3 along with citations.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes] 
Risk of bias assessed and presented in Table 4.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Summary data and forest plots presented for all outcomes analyzed.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes] 
Results of each meta-analysis presented with confidence intervals and measures of heterogeneity.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [Yes]
Results of publication bias assessments presented. 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses done.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]  
Main findings summarized in Discussion and Conclusion sections. Relevance to healthcare providers discussed.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]  
Limitations discussed in multiple sections (Quality and Level of Evidence, Discussion).

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of previous studies. Implications for future research discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]  
No statement about sources of funding or conflicts of interest.

In summary, the systematic review adequately addressed most AMSTAR and PRISMA items, with some limitations in a priori study design, assessment of grey literature, additional analyses, and conflicts of interest. Overall, this appears to be a reasonably well-conducted systematic review and meta-analysis comparing robot-assisted, conventional laparoscopic, and open pyeloplasty techniques for pelvi-ureteric junction obstruction in children. The results show comparable efficacy but some differences in secondary outcomes like length of stay and costs. Higher quality prospective studies are needed to better evaluate this technology.
</pre>
<p><a name='82'></a></p>
</div>
<div id="cundy-2014-j-pediatr-surg" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.12.014' title='Open publication'>Cundy
2014 (J Pediatr Surg)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the assessments for the 11 AMSTAR items and 27 PRISMA items for the attached full text:

A1. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Systematic literature searches were undertaken of PubMed and
EMBASE electronic databases using the following search strategy
(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da
Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND
(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-
lescent”
[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-
al reflux”[MeSH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases using the following search strategy (“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND (“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Adolescent”[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophageal reflux”[MeSH]).&quot;</span>
They pre-specified the research question and inclusion criteria.

A2. [No] 
No mention of duplicate study selection and data extraction.

A3. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.8%):

Systematic literature searches were undertaken of PubMed and
EMBASE electronic databases using the following search strategy
(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da
Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND
(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-
lescent”
[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-
al reflux”[MeSH]). The search period was defined as June 2001 to June
2013 inclusively. The primary search was supplemented with
searches of 1) PubMed related articles feature, 2) clinicaltrials.gov
registry using the keyword “fundoplication”, and 3) abstracts of the
Journal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the Journal of Pediatric Surgery from 2002 to 2013.&quot;</span>
At least two electronic sources searched along with supplementary strategies.  

A4. [No]
No mention of including or searching for grey literature.

A5. [No]
No list of included and excluded studies provided.

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Patient demographic and outcome data was extracted from included studies.&quot;</span> Table 1 shows characteristics extracted.

A7. [No]
No assessment of study quality reported.

A8. [NA]
No meta-analysis performed, so quality not used in formulating conclusions.

A9. [NA]
No meta-analysis performed.

A10. [NA]  
No meta-analysis performed.

A11. [No]
No statement about conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Meta analysis of robot-assisted versus conventional laparoscopic fundoplication in children&quot;</span>
Identified as a meta-analysis.

P2. [No]
No structured summary provided.

P3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Following the advent of endoscopic surgery, a minimally invasive
approach to this anti-reflux procedure is now increasingly favored as
standard of care [1].
Initial reports of laparoscopic anti-reflux surgery in infants and
children were published in the early 1990’s [2,3]. Almost ten years
thereafter, robot-assisted minimally invasive surgery was first
described in these age groups [4,5], and fundoplication remains the
most prevalently reported application of this technology in pediatric
general surgery [6]. Robotic technology offers putative patient
benefits through a range of features that are felt to enhance the
surgeon’s ability to undertake minimally invasive surgery (MIS).
The role of robotic surgery in this setting remains unclear,
generating a growing sentiment of polarized opinion amongst the
surgical community, which is without a well-defined evidence base' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Following the advent of endoscopic surgery, a minimally invasive approach to this anti-reflux procedure is now increasingly favored as standard of care [1]...The role of robotic surgery in this setting remains unclear, generating a growing sentiment of polarized opinion amongst the surgical community, which is without a well-defined evidence base.&quot;</span>
Provided context and rationale.

P4. [No] 
No explicit PICOS statement.

P5. [No]
No protocol mentioned. 

P6. [No]
Did not report eligibility criteria with respect to study characteristics.

P7. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.8%):

Systematic literature searches were undertaken of PubMed and
EMBASE electronic databases using the following search strategy
(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da
Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND
(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-
lescent”
[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-
al reflux”[MeSH]). The search period was defined as June 2001 to June
2013 inclusively. The primary search was supplemented with
searches of 1) PubMed related articles feature, 2) clinicaltrials.gov
registry using the keyword “fundoplication”, and 3) abstracts of the
Journal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the Journal of Pediatric Surgery from 2002 to 2013.&quot;</span> Reported databases searched and date ranges.

P8. [No]
Did not provide full search strategy for at least one database.

P9. [No]  
Did not describe process of screening and selecting studies.

P10. [No]
No description of data extraction process. 

P11. [No]
Did not list variables extracted.

P12. [No]  
No assessment of risk of bias reported.

P13. [NA]
No meta-analysis performed.

P14. [NA]
No meta-analysis performed. 

P15. [NA]
No meta-analysis performed.

P16. [NA]
No additional analyses performed.

P17. [Yes]
The PRISMA flow diagram was provided showing records screened, assessed for eligibility, and included.

P18. [Yes] 
Table 1 shows characteristics of included studies. 

P19. [No]
No assessment of risk of bias provided.

P20. [NA] 
No meta-analysis performed.

P21. [NA]
No meta-analysis performed. 

P22. [NA]
No meta-analysis performed.

P23. [NA]  
No additional analyses performed.

P24. [No] 
No summary of main findings or discussion of relevance provided.

P25. [No]
No limitations discussed.

P26. [No]
No general interpretation of results in context of other evidence.

P27. [No]
No statement about sources of funding or support.

In summary, I assessed 11 AMSTAR items (4 Yes, 2 No, 5 NA) and 27 PRISMA items (6 Yes, 18 No, 3 NA) for this full text. Let me know if you need me to clarify or expand on any part of the assessments.
</pre>
<p><a name='83'></a></p>
</div>
<div id="cundy-2014-eur-j-pediatr-surg" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1347297' title='Open publication'>Cundy
2014 (Eur J Pediatr Surg)</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

# AMSTAR

A1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The study protocol was registered on the PROSPERO international prospective database of systematic reviews (CRD42013003971).&quot;</span>
- The study protocol was registered prior to conducting the review. [Yes]

A2.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently undertook literature searches, screened abstracts and assessed articles against eligibility criteria (TPC, HJM).&quot;</span>
- Study selection and data extraction were done in duplicate. [Yes]

A3.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases.&quot;</span>
- At least two electronic databases were searched. [Yes]

A4.  
- No mention of searching for grey literature.
- Searching for grey literature was not mentioned. [No] 

A5.   
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A summary of the results of our search strategy is shown in Fig. 1.&quot;</span> 
- The flow diagram includes the number of studies included and excluded. [Yes]

A6.
- Table 1 presents key characteristics of the included studies.  
- Key characteristics of included studies were provided. [Yes]

A7.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The methodological quality of studies was appraised using a star-based modified Newcastle-Ottawa Scale (mNOS) that considers patient selection, inter-group comparability, and outcome assessment.&quot;</span>
- The quality of included studies was assessed using the mNOS scale. [Yes]

A8.  
- The quality assessment using mNOS was considered in the limitations of the meta-analysis.
- The quality assessment impacted the interpretation of the results. [Yes]

A9. 
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.2%):

. Determination of heterogeneity was
undertaken using the χ
2 
test (Cochran’s Q) and I 
2 
valu' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎A weighted random-effects model was used for all analyses." "Determination of heterogeneity was undertaken using the χ2 test (Cochran’s Q) and I2 value.&quot;</span>
- Heterogeneity was assessed and random effects models were used as appropriate. [Yes]

A10. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Risk of publication bias was assessed by visual inspection of funnel plots in addition to statistical estimation with both Begg and Mazumdar’s test and Egger’s test for small study effects.&quot;</span>
- Publication bias was assessed quantitatively and graphically. [Yes]

A11. 
- No mention of conflicts of interest or funding sources for the included studies.
- Sources of support for included studies were not reported. [No]

# PRISMA

P1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Meta analysis of robot-assisted versus conventional laparoscopic fundoplication in children&quot;</span>
- The title identifies the report as a meta-analysis. [Yes]

P2.  
- The abstract provides a structured summary. [Yes]

P3.
- The introduction describes the rationale and background. [Yes]  

P4.  
- The objectives relate to comparing robot-assisted vs laparoscopic fundoplication. [Yes]

P5.  
- The protocol registration number is provided. [Yes]

P6.   
- Inclusion and exclusion criteria are described. [Yes]

P7.
- Databases and supplementary sources searched are described. [Yes]

P8.   
- The full search strategy is not provided. [No]

P9.
- The study selection process is described and shown in a flow diagram. [Yes]  

P10.  
- Data extraction by two independent authors is described. [Yes]

P11.
- Outcomes of interest are listed and defined. [Yes]

P12.  
- Quality assessment using mNOS is described. [Yes] 

P13.  
- Odds ratios and weighted mean differences are the summary measures. [Yes]

P14. 
- Methods for data synthesis and assessing heterogeneity are described. [Yes]

P15.  
- Assessment of publication bias is described. [Yes]

P16.  
- Subgroup analysis by fundoplication technique is described as post-hoc. [Yes]

P17.  
- The flow diagram provides details on screening and selection. [Yes] 

P18. 
- Table 1 provides key characteristics of included studies. [Yes]

P19.  
- Table 3 shows the quality assessment of each study. [Yes]

P20.
- Forest plots provide effect estimates with CIs for meta-analyzed outcomes. [Yes]

P21.  
- Results of meta-analyses are presented with CIs and consistency measures. [Yes] 

P22. 
- No assessment of risk of bias across studies is presented. [NA]  

P23.   
- Results of subgroup analysis are presented. [Yes]

P24.
- Main findings and limitations are summarized. [Yes]

P25.  
- Study and review limitations are discussed. [Yes]

P26.  
- Conclusions discuss the results in context of the current literature. [Yes]

P27. 
- No sources of funding reported for the review. [No]
</pre>
<p><a name='84'></a></p>
</div>
<div id="ding-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.026' title='Open publication'>Ding
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

# AMSTAR

A1. Was an 'a priori' design provided? 
[NA] There is no mention of an 'a priori' design or protocol.

A2. Was there duplicate study selection and data extraction?
[No] There is no mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
[Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):

The search strategy was as
follows: (single-port or single-incision or single-access or
single-site or single or one) AND (laparoscopic or
laparoscopy or minimal invasive surgery) AND (appendec-
tomy or appendi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search strategy was as follows: (single-port or single-incision or single-access or single-site or single or one) AND (laparoscopic or laparoscopy or minimal invasive surgery) AND (appendectomy or appendix).&quot;</span> Searched MEDLINE, EMBASE, Cochrane Library. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
[NA] The review did not mention searching for or including grey literature.

A5. Was a list of studies (included and excluded) provided?
[Yes] Fig. 1 shows the flow of study selection with number of studies screened, included and excluded.

A6. Were the characteristics of the included studies provided?
[Yes] Table 1 provides detailed characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented?
[Yes] The quality of studies was assessed using a star scoring system and presented in Table 2.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[No] The quality assessment was not mentioned in the discussion or conclusions.

A9. Were the methods used to combine the findings of studies appropriate?  
[Yes] Random-effects and fixed-effect models were used appropriately based on heterogeneity. 

A10. Was the likelihood of publication bias assessed?
[Yes] Funnel plot was used to assess publication bias for wound infection outcome (Fig. 6).

A11. Was the conflict of interest included?
[No] No statement on conflicts of interest.

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.  
[Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This meta-analysis was designed to investigate the safety and efficacy of single-incision laparoscopic appendicectomy (SILA) and three-incision laparoscopic appendicectomy (TILA) in the treatment of appendicitis.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[No] No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] The introduction provides rationale and existing knowledge on the topic.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
[No] No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No] No review protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes] Inclusion and exclusion criteria specified study characteristics used for eligibility.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
[Yes] Searched MEDLINE, EMBASE, Cochrane Library from 1992 to July 2012.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[Yes] The full search strategy for databases is provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[Yes] The study selection process is described and depicted in Fig. 1.  

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[No] The data extraction method is not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[No] Variables extracted are not explicitly listed.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[Yes] A star scoring system was used to assess study quality and results presented in Table 2.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[Yes] Used odds ratios for dichotomous data and weighted mean differences for continuous data.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
[Yes] Described use of fixed-effect and random-effects models based on heterogeneity assessed by I2 and Chi2 tests.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[Yes] Assessed publication bias using funnel plot (Fig. 6).

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[Yes] Conducted sensitivity analyses by study characteristics, described in the methods.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[Yes] Fig. 1 shows the study selection flow diagram.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
[Yes] Table 1 presents the detailed characteristics of included studies.  

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[Yes] Risk of bias assessment is presented in Table 2.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[Yes] Forest plots are presented for all meta-analyzed outcomes. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[Yes] Results of each meta-analysis are presented with confidence intervals and I2 values.

P22. Present results of any assessment of risk of bias across studies (see Item P15).
[Yes] Publication bias assessed across studies using funnel plot (Fig. 6).

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[Yes] Results of sensitivity analyses are presented in Table 3.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes] The findings are summarized in the discussion and conclusions.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Yes] Limitations of the review are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes] Results are interpreted in the context of other evidence in the discussion.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
[No] No statement on sources of funding.
</pre>
<p><a name='85'></a></p>
</div>
<div id="dingemann-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1350060' title='Open publication'>Dingemann
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

AMSTAR
A1. [No] No protocol mentioned.
A2. [No] Duplicate study selection and data extraction not mentioned.
A3. [Yes] Comprehensive literature search of PubMed performed. 
A4. [No] Grey literature not mentioned.
A5. [No] List of included/excluded studies not provided.
A6. [No] Characteristics of included studies not provided in aggregated form.
A7. [No] Quality assessment of included studies not performed.  
A8. [NA] No meta-analysis performed.
A9. [NA] No meta-analysis performed.
A10. [NA] No meta-analysis performed.  
A11. [No] Conflict of interest not reported.

PRISMA
P1. [Yes] Identified as systematic review in title. 
P2. [No] Structured summary not provided.
P3. [Yes] Rationale described in introduction.
P4. [No] Review question and inclusion criteria not described in PICOS format. 
P5. [No] Review protocol not mentioned.
P6. [No] Study characteristics used for eligibility not described.
P7. [Yes] Literature search strategy described.
P8. [No] Full search strategy not provided.
P9. [No] Study selection process not described. 
P10. [No] Data extraction methods not described.
P11. [No] Variables not listed.
P12. [NA] Individual study risk of bias assessment not applicable as no meta-analysis performed.  
P13. [NA] Summary measures not applicable as no meta-analysis performed.
P14. [NA] Synthesis methods not applicable as no meta-analysis performed.
P15. [NA] Risk of bias assessment not applicable as no meta-analysis performed.
P16. [NA] Additional analyses not applicable as no meta-analysis performed.  
P17. [No] Study selection flow diagram not provided.
P18. [No] Study characteristics not presented.
P19. [NA] Individual study risk of bias not applicable as no meta-analysis performed.
P20. [NA] Study results not presented in forest plots as no meta-analysis performed. 
P21. [NA] Meta-analysis results not applicable as no meta-analysis performed.
P22. [NA] Risk of bias results not applicable as no meta-analysis performed.
P23. [NA] Additional analyses not applicable as no meta-analysis performed.
P24. [No] Summary of main findings not provided. 
P25. [No] Limitations not discussed.
P26. [No] General interpretation not provided.
P27. [No] Sources of support not reported.

In summary, this systematic review has major limitations in reporting based on PRISMA and AMSTAR standards. Key items not adequately reported include an a priori protocol, duplicate study selection/data extraction, details on study eligibility criteria and selection, data extraction methods, list of included/excluded studies, study characteristics, quality assessment, search strategy, study selection flow, and study results/summary. Additional major limitations are lack of assessment for risk of bias and publication bias.
</pre>
<p><a name='86'></a></p>
</div>
<div id="dingemann-2013" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1333639' title='Open publication'>Dingemann
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. [No] No mention of an a priori design or protocol.
A2. [NA] No duplicate study selection or data extraction described as this is not a meta-analysis.
A3. [Yes] Comprehensive literature search performed in PubMed with specified search limits. 
A4. [NA] Searching for gray literature not described as relevant to inclusion criteria.
A5. [Yes] References provided for all included and excluded studies.  
A6. [Yes] Relevant characteristics of included studies described in Table 3.
A7. [NA] Individual quality assessment not relevant as this is not a meta-analysis.
A8. [NA] Not applicable as no meta-analysis performed.
A9. [NA] Not applicable as no meta-analysis performed.  
A10. [NA] Assessment of publication bias not applicable as no meta-analysis performed.
A11. [NA] Assessment of conflict of interest not described.

P1. [Yes] Identified as a systematic review in title.
P2. [No] No structured summary provided.
P3. [Yes] Rationale described in introduction in context of existing evidence.
P4. [NA] No explicit PICOS statement provided as this is not a meta-analysis. 
P5. [No] No protocol mentioned.
P6. [Yes] Inclusion criteria described as RCTs comparing laparoscopic and open pediatric surgery.
P7. [Yes] Literature search in PubMed described. 
P8. [No] No full electronic search strategy provided.
P9. [Yes] Study selection process described in methods.
P10. [NA] No data extraction described as this is a systematic review without meta-analysis.
P11. [NA] No list of variables provided as this is not a meta-analysis.
P12. [NA] No quality assessment described as this is not a meta-analysis. 
P13. [NA] No summary measures described as this is not a meta-analysis.
P14. [NA] No quantitative synthesis methods described as this is not a meta-analysis.
P15. [NA] No assessment of publication bias described as this is not a meta-analysis.
P16. [NA] No additional analyses described as this is not a meta-analysis.
P17. [Yes] Numbers of studies screened, included, and excluded described with reasons.
P18. [Yes] Characteristics of included studies provided in Table 3.
P19. [NA] No quality assessment results provided as this is not a meta-analysis.
P20. [NA] No quantitative results provided as this is not a meta-analysis.  
P21. [NA] No meta-analysis results provided as this is not a meta-analysis.
P22. [NA] No assessment of risk of bias across studies as this is not a meta-analysis.
P23. [NA] No additional analyses provided as this is not a meta-analysis.
P24. [No] No summary of main findings or implications provided.
P25. [No] No limitations discussed.
P26. [No] No general interpretation of results in context of other evidence.
P27. [No] No mention of sources of support or funding.
</pre>
<p><a name='87'></a></p>
</div>
<div id="ells-2015" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD011740' title='Open publication'>Ells
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review.
[No] 
No protocol was referenced. The aims were only briefly mentioned in the introduction section of the publication.

A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two review authors (LJE, EM) independently scanned the abstract, title, or both, of every record retrieved by the searches. We investigated all potentially relevant articles as full text. Where differences in opinion existed, they were resolved by discussion and consensus with a third review author (GA).&quot;</span>

A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. 
[Yes]
"We searched the following sources on the 30th of March 2015 from inception to the specified database date and placed no restrictions on the language of publication:
- Cochrane Library: Cochrane Database of Systematic Reviews (until issue 3, 2015), Database of Reviews of Effects (until issue 1, 2015), Cochrane Central Register of Controlled Trials (until issue 2, 2015), Health Technology Assessment Database (until issue 1, 2015)  
- MEDLINE (until 30th March 2015)
- EMBASE (until week 13, 2015)
- PubMed (only subsets not available on Ovid) (until 30th March 2015)
- LILACS (until 25th February 2015)
- ClinicalTrials.gov (until 30th March 2015)
- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)"

The full search strategy is provided in the appendix.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc.
[No]
No mention of grey literature searching.

A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided.
[Yes] 
A list of included and excluded studies is provided. 

A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.
[Yes]
Participant and intervention characteristics were provided in table format. Some relevant socioeconomic data were missing.

A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.
[Yes]
The Cochrane Risk of Bias tool was used to assess study quality.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.
[Yes]
The quality assessment was discussed in the conclusions.

A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).
[NA] 
Only one study was included so no meta-analysis was performed.

A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).
[NA]
Only one study was included so assessment of publication bias was not applicable.

A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.
[No]
Sources of support were reported for the included study but not for the review itself.

In summary, this systematic review met 7/11 AMSTAR criteria. Strengths include duplicate study selection/data extraction, a comprehensive literature search, provision of study characteristics, quality assessment and consideration of study quality in conclusions. Weaknesses are the lack of an a priori protocol, grey literature searching, and conflict of interest reporting for the review. Other criteria were not applicable due to only one included study.

PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes]
The title indicates this is a systematic review.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[Yes]
A structured abstract is provided covering all key elements.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] 
The background section describes the rationale and what is already known.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[Yes]
The review objectives, inclusion criteria, and outcomes are clearly specified. 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No]
No protocol was referenced.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes]
Eligibility criteria for studies are provided along with rationale.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[Yes]
The information sources, dates of coverage, and date last searched are provided.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[Yes]
The full search strategy for multiple databases is provided in an appendix.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[Yes]
The study selection process is described and depicted in a flow diagram.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[Yes] 
The data extraction process is described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[Yes]
Outcomes sought are clearly defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[Yes]
Risk of bias methods are described and a risk of bias summary is presented.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[Yes]
The planned summary measures are stated.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
[NA]
No meta-analysis was performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA] 
Assessment of publication bias was not applicable with only one study.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[NA]
No meta-analysis was performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[Yes]
A PRISMA flow diagram is provided detailing studies at each stage.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
[Yes]
Study characteristics are presented in table format along with citations.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
[Yes]
A risk of bias summary figure is provided.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group, (b) effect estimates and confidence intervals, ideally with a forest plot.
[Yes]
For the single study, summary data and effect estimates are presented for key outcomes. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA]
No meta-analysis was performed. 

P22. Present results of any assessment of risk of bias across studies (see Item 15).
[NA] 
Assessment of publication bias was not applicable with only one study.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
[NA]
No additional analyses were performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes]
The main findings and implications are summarized in the discussion and conclusions.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Yes]
Limitations at the study and review level are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes]
The results are interpreted in the context of other evidence and implications for future research are discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
[No]
Sources of funding for the review were not reported.

In summary, this systematic review met 21/27 PRISMA criteria. Strengths include a structured abstract, rationale, eligibility criteria, comprehensive search, study selection process, extracted data, risk of bias assessment, study characteristics, results, limitations, interpretation of results, and flow diagram. Weaknesses were the lack of an a priori protocol, review funding sources, and items not applicable due to only one included study (meta-analysis, assessment of publication bias, additional analyses).

In summary, based on the AMSTAR and PRISMA assessments, this systematic review was generally well conducted but had some limitations in reporting. The main limitations were the lack of an a priori protocol, no grey literature search, and no statement of sources of funding for the review. The review also would have benefited from inclusion of more studies. Overall, it provides a moderately robust systematic assessment of the limited evidence currently available on bariatric surgery for obesity in adolescents.

</pre>
<p><a name='88'></a></p>
</div>
<div id="elyas-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JURO.2010.01.035' title='Open publication'>Elyas
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the relevant quotes, explanations, and responses for the AMSTAR items:

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We evaluated whether single stage or 2-stage
FSO results in greater testicular viability in chil-
dren younger than 18 years with intra-abdominal
testes. The primary outcome was testicular viability,
which was defined as adequate postoperative testic-
ular size and position in the scrotum' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We evaluated whether single stage or 2-stage FSO results in greater testicular viability in children younger than 18 years with intra-abdominal testes. The primary outcome was testicular viability, which was defined as adequate postoperative testicular size and position in the scrotum.&quot;</span> (Introduction)
- States primary outcome was testicular viability. 
[Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.
- Not reported.
[No]

A3. Was a comprehensive literature search performed?
- Searched multiple electronic databases (MEDLINE, EMBASE, CINAHL, Cochrane databases), clinical trial registries, and gray literature. Search strategy provided. References of selected articles hand searched. 
- Comprehensive search including gray literature and reference lists.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?  
- No mention of including or excluding based on publication status.
- Publication status not specified as inclusion/exclusion criteria.
[No] 

A5. Was a list of studies (included and excluded) provided?
- Flow diagram provided showing numbers excluded at each stage but no specific references listed.
- Flow diagram but no actual reference list.
[No]

A6. Were the characteristics of the included studies provided? 
- Table summarizes quality assessment results but no summary of study characteristics. Individual study data extracted in text. 
- Study characteristics not provided in aggregated form.
[No]

A7. Was the scientific quality of the included studies assessed and documented?
- Quality assessment using instrument summarized in table. Assessed items like study design, follow-up, outcomes reported.
- Quality assessed but no specific tool mentioned.
[Yes] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- No mention of study quality in forming conclusions. Meta-analysis results focused on.
- Study quality not incorporated into conclusions.
[No]

A9. Were the methods used to combine the findings of studies appropriate? 
- Meta-analysis conducted. Heterogeneity assessed with I^2 statistic and forest plots. 
- Appropriate meta-analytic methods.
[Yes]

A10. Was the likelihood of publication bias assessed?
- Funnel plot done to assess publication bias. 
- Publication bias assessed.
[Yes]

A11. Was the conflict of interest included? 
- No conflict of interest statement.
- Conflict of interest not reported.
[No]

Here are the relevant quotes, explanations, and responses for the PRISMA items:

P1. Identify the report as a systematic review, meta-analysis, or both.
- Title states <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A Systematic Review&quot;</span>.
- Identified as systematic review in title. 
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
- Structured abstract provided with all relevant sections.
- Structured abstract included.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Introduction describes rationale and need for review.
- Rationale described.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
- Research question and inclusion criteria stated in introduction.
- PICOS criteria described.
[Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- No mention of review protocol.
- Review protocol not mentioned.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- Eligibility criteria described in methods.
- Eligibility criteria specified.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
- Information sources described in methods.
- Information sources described.
[Yes] 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- Full search strategy provided for MEDLINE. 
- Search strategy provided.
[Yes]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
- Study selection process described in methods and shown in flow diagram.
- Selection process described.
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
- States data extracted independently by each author. Contacted authors for missing data.
- Data extraction process described. 
[Yes]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
- No list of specific data sought. Outcomes described.
- Data elements not predefined.
[No] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
- Quality assessment done but no specific risk of bias or how it would be used described.
- Risk of bias assessment not described.
[No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
- Pooled estimate of success rates and odds ratio. 
- Summary measures stated.
[Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
- Meta-analytic methods described. Heterogeneity assessed with I^2.
- Data synthesis methods described.
[Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
- Funnel plot done for publication bias.
- Publication bias assessed.
[Yes]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
- No additional analyses mentioned.
- No other analyses done.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
- Flow diagram provided showing numbers at each stage.
- Flow diagram included.
[Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
- No table summarizing study characteristics. Individual study data extracted in text.
- Study characteristics not summarized.
[No]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
- No risk of bias assessment for individual studies.
- Risk of bias not presented.
[No] 

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
- Forest plots presented with effect estimates. No individual study data provided.
- Forest plots but no study data.
[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- Results of meta-analyses presented with CIs and I^2 values.
- Meta-analysis results reported. 
[Yes]

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
- No assessment of risk of bias across studies.
- Risk of bias across studies not done.
[NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
- No additional analyses.
- No other analyses conducted.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
- Conclusions summarize main findings and relevance.
- Main findings summarized.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
- Limitations discussed including study design, language, publication bias.
- Limitations discussed.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results interpreted in context of previous research. Future research implications described.
- Results interpreted and future research discussed.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
- No funding sources reported.
- Funding not reported.
[No]

I have responded to all AMSTAR and PRISMA items for this systematic review. Please let me know if I can clarify or expand on any part of my assessment.
</pre>
<p><a name='89'></a></p>
</div>
<div id="esposito-2014" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2014.0194' title='Open publication'>Esposito
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached full text:

A1. No explicit mention of an a priori design. "[No]" 

A2. No mention of duplicate study selection and data extraction. "[No]"

A3. Stated that PubMed, Cochrane, and Medline databases were searched. MESH terms not stated. Supplementary search methods not described. "[No]"

A4. No mention of searching for grey literature. "[No]" 

A5. Provided a reference list of included and excluded studies. "[Yes]"

A6. Provided summary data on participants, interventions, and outcomes in table format. "[Yes]" 

A7. Did not mention assessing quality/risk of bias in included studies. "[No]" 

A8. Did not assess quality/risk of bias of included studies. "[NA]"

A9. Did not conduct meta-analysis. "[NA]" 

A10. Did not assess publication bias. "[NA]" 

A11. Did not report on conflicts of interest. "[No]"

P1. Identified as a systematic review. "[Yes]"  

P2. Provided structured abstract with background, objectives, data sources, eligibility criteria, outcomes, and conclusions. "[Yes]"

P3. Described rationale for review. "[Yes]"

P4. Stated objective was to compare laparoscopic vs open repair, included PICOS elements. "[Yes]"

P5. Did not mention a review protocol. "[No]"

P6. Described eligibility criteria including study characteristics and participant characteristics. "[Yes]" 

P7. Stated databases searched and date last searched. "[Yes]" 

P8. Did not provide full search strategy. "[No]"

P9. Described process of study screening and selection. "[Yes]"

P10. Did not describe data extraction methods. "[No]" 

P11. Did not explicitly list variables extracted. "[No]" 

P12. Did not describe risk of bias assessment. "[No]"

P13. Stated using tests like chi-squared and Fisher's exact test for summary measures. "[Yes]"

P14. Did not conduct meta-analysis. "[NA]"

P15. Did not assess risk of bias across studies. "[NA]"

P16. Did not conduct additional analyses. "[NA]" 

P17. Provided number of records identified and included/excluded with flow diagram. "[Yes]"

P18. Provided citations for included studies. "[Yes]" 

P19. Did not provide risk of bias for individual studies. "[No]" 

P20. Provided summary data for outcomes in tables. "[Yes]" 

P21. Did not conduct meta-analysis. "[NA]"

P22. Did not assess risk of bias across studies. "[NA]" 

P23. Did not conduct additional analyses. "[NA]"

P24. Summarized main findings and conclusions. "[Yes]" 

P25. Discussed some limitations of included studies. "[Yes]"

P26. Provided general interpretation of results. "[Yes]" 

P27. Did not report on sources of funding. "[No]"
</pre>
<p><a name='90'></a></p>
</div>
<div id="feng-2016" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3845-2' title='Open publication'>Feng
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Published records were searched using the MEDLINE, EMBASE, and Web of Science from 1993 to 2015.&quot;</span> (P2) This indicates that the review had an a priori design with pre-defined eligibility criteria.  

A2. Not reported. [No] There is no mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎References, reviews and meta-analyses were also scanned for additional articles.&quot;</span> (P2) Multiple databases plus supplementary sources were searched.

A4. Not reported. [No] There is no mention of searching for unpublished or grey literature. 

A5. Not reported. [No] A list of included/excluded studies is not provided.

A6. [Yes] Table 1 reports characteristics of the included studies such as age, sex ratio, spleen size.

A7. Not reported. [No] There is no mention of assessing the scientific quality of included studies.

A8. Not applicable. [NA] Since quality of individual studies was not assessed.

A9. Not applicable. [NA] Since no meta-analysis was done. 

A10. Not applicable. [NA] Since no meta-analysis was done.

A11. Not reported. [No] There is no mention of conflicts of interest.

P1. [Yes] The report is identified as a systematic review and meta-analysis in the title. 

P2. [No] A structured summary is not provided.

P3. [Yes] Rationale and context are described in the Introduction. 

P4. [No] PICOS are not explicitly stated. 

P5. Not reported. [No] A protocol is not mentioned.

P6. [Yes] Inclusion/exclusion criteria are specified. 

P7. [Yes] Information sources and dates searched are described. 

P8. Not reported. [No] A full search strategy is not provided.

P9. Not reported. [No] Study selection process is not described. 

P10. Not reported. [No] Data extraction methods are not described. 

P11. Not reported. [No] Variables extracted are not listed.

P12. Not reported. [No] Risk of bias assessment is not described.

P13. Not applicable. [NA] Since no meta-analysis was done.

P14. Not applicable. [NA] Since no meta-analysis was done. 

P15. Not applicable. [NA] Since no meta-analysis was done.

P16. Not applicable. [NA] Since no meta-analysis was done.

P17. Not reported. [No] A flow diagram of study selection is not provided.

P18. [Yes] Table 1 reports characteristics of included studies.

P19. Not reported. [No] Risk of bias is not presented. 

P20. Not applicable. [NA] Since no meta-analysis was done.

P21. Not applicable. [NA] Since no meta-analysis was done.

P22. Not applicable. [NA] Since no meta-analysis was done.

P23. Not applicable. [NA] Since no meta-analysis was done. 

P24. [Yes] Main findings are summarized in the Discussion.

P25. [No] Limitations are not thoroughly discussed.

P26. [Yes] Results are interpreted and implications are discussed.

P27. Not reported. [No] Sources of funding are not reported.
</pre>
<p><a name='91'></a></p>
</div>
<div id="feng-2015" class="section level4">
<h4><a href='https://doi.org/10.1097/SLE.0000000000000161' title='Open publication'>Feng
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments of the provided systematic review:

A1. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):

We systematically searched PubMed for relevant
studies reported from 2005 to 2014 with the keywords
“laparoscopic herniorrhaphy”, “pediatric inguinal hernia,”
and “open herniorrhaphy.” Total reference lists of selected
articles were also included' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords “laparoscopic herniotomy”, “pediatric inguinal hernia,” and “open herniotomy.” Total reference lists of selected articles were also included.&quot;</span>
A comprehensive literature search was performed.

A2. [No]
No mention of duplicate study selection or data extraction. 

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.1%):

We systematically searched PubMed for relevant
studies reported from 2005 to 2014 with the keywords
“laparoscopic herniorrhaphy”, “pediatric inguinal hernia,”
and “open herniorrhaphy.” Total reference lists of selected
articles were also included. We limited our searches to the
publications written in English' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords “laparoscopic herniotomy”, “pediatric inguinal hernia,” and “open herniotomy.” Total reference lists of selected articles were also included. We limited our searches to the publications written in English.&quot;</span>
At least two electronic sources were searched.

A4. [No] 
The status of publication was not used as an inclusion criteria.

A5. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Five trials
met the total inclusion criteria and had no exclusion criteria
(Fig. 1): Chan et al, 
28 
Koivusalo et al, 
29 
Celebi et al, 
30
Shalaby et al,
31 
and Saranga et al' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Five trials met the total inclusion criteria and had no exclusion criteria: Chan et al, Koivusalo et al, Celebi et al, Shalaby et al, and Saranga et al.&quot;</span> 
A list of included and excluded studies was provided.

A6. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Study details and the quality check of total RCTs are given in Tables 1 and 2, respectively.&quot;</span>
Characteristics of included studies were provided in tables.

A7. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Quality of the RCTs was assessed, including randomization, method of blinding, and allocation concealment.&quot;</span>
The scientific quality of included studies was assessed using specified criteria.

A8. [No]
The results of the quality assessment were not explicitly used in formulating conclusions.

A9. [NA]  
No quantitative synthesis was performed.

A10. [NA]
No assessment of publication bias was performed since there were fewer than 10 studies included.

A11. [No]
No mention of conflict of interest assessment.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Open Versus Laparoscopic Inguinal Herniotomy in Children: A Systematic Review and Meta-Analysis Focusing on Postoperative Complications&quot;</span>
The report is identified as a systematic review and meta-analysis.

P2. [Yes] 
The abstract provides a structured summary.

P3. [Yes]
The introduction describes the rationale and background.

P4. [Yes]
The objective focusing on postoperative complications is clearly stated. 

P5. [No]
No review protocol is mentioned.

P6. [Yes]
Inclusion criteria focusing on RCTs comparing laparoscopic and open herniotomy are described.

P7. [Yes]  
The information sources and literature search are described. 

P8. [No]
The full search strategy is not provided.

P9. [Yes]
The study selection process is described and depicted in a flow diagram.

P10. [No]  
The method of data extraction is not described.

P11. [Yes]
The data extracted on study characteristics and outcomes are listed. 

P12. [Yes]
The quality assessment of individual studies is described. 

P13. [Yes]
The summary measures used are specified.

P14. [NA] 
No quantitative synthesis was performed.

P15. [NA]  
No assessment of publication bias was performed.

P16. [NA]
No additional analyses were performed.

P17. [Yes]  
Numbers of studies screened and included are provided in a flow diagram.

P18. [Yes] 
Characteristics and citations of included studies are provided in tables.

P19. [No]
Individual study risk of bias is not presented.

P20. [Yes]  
Outcome data and effect estimates are presented using forest plots.

P21. [NA] 
No meta-analysis was performed. 

P22. [NA]
No assessment of risk of bias across studies was performed.

P23. [NA]
No additional analyses were performed.

P24. [Yes] 
Main findings are summarized and implications discussed.

P25. [No]
Limitations at the review level are not discussed.

P26. [Yes]  
Results are interpreted in the context of other evidence.

P27. [No]
Sources of funding are not reported.
</pre>
<p><a name='92'></a></p>
</div>
<div id="friedmacher-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-011-2958-5' title='Open publication'>Friedmacher
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We designed this meta-analysis to determine the incidence and outcome of RA among patients with HD following PT operation.&quot;</span> (Introduction)
[Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>  
- Not mentioned in the text.
[No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span>
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 90.5%):

PubMed
Ò 
and MEDLINE
Ò 
databases were searched for all
studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎PubMed® and MEDLINE® databases were searched for all studies...&quot;</span> (Methods)
[Yes]  

A4. Was the status of publication used as an inclusion criterion?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
- Publication status not mentioned as an inclusion criteria. 
[NA]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
- Table 1 provides a list of included studies. No excluded studies mentioned.
[No]

A6. Were the characteristics of the included studies provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
- Table 1 provides characteristics like year, number of patients, initial operation, recurrent symptoms, and redo operation.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎'A priori' methods of assessment should be provided.&quot;</span>
- No quality assessment mentioned.
[No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review.&quot;</span>
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity.&quot;</span>
- No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?  
<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):

An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot) and/or statistical tests (e.g., Egger regression test).&quot;</span>
- Publication bias not assessed.
[No]

A11. Was the conflict of interest included?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
- No COI statement provided.
[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review and meta-analysis&quot;</span> in title.
[Yes]

P2. Provide a structured summary.
- Abstract provides structured summary.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Introduction provides context and rationale.
[Yes] 

P4. Provide an explicit statement of questions being addressed with reference to PICOS.
- Research question and inclusion criteria provided in Introduction.
[Yes]

P5. Indicate if a review protocol exists. 
- No protocol mentioned.
[No]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
- Inclusion/exclusion criteria not specified.
[No]

P7. Describe all information sources in the search and date last searched.
- Databases and time period provided in Methods.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used.
- Search strategy not provided.
[No]

P9. State the process for selecting studies.
- Study selection process not described.
[No]

P10. Describe method of data extraction and confirmation.
- Data extraction process not described.
[No] 

P11. List and define all variables for which data were sought.
- Outcomes and variables described in Methods.
[Yes]

P12. Describe methods used for assessing risk of bias.
- Risk of bias not assessed.
[No]

P13. State the principal summary measures.
[NA]

P14. Describe the methods of handling data and combining results of studies, if done.
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
[NA]

P16. Describe methods of additional analyses, if done.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. 
- Number of studies included provided, but screening and eligibility assessment not described.
[No]

P18. For each study, present characteristics for which data were extracted.
- Table 1 provides relevant characteristics.
[Yes]

P19. Present data on risk of bias of each study. 
[NA]

P20. For all outcomes considered, present data for each study.
- Outcomes summarized narratively.
[No]

P21. Present results of each meta-analysis done.
[NA]

P22. Present results of any assessment of risk of bias across studies.  
[NA]

P23. Give results of additional analyses, if done.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
- Main findings summarized in abstract and discussion.
[Yes]

P25. Discuss limitations at study and outcome level and at review-level.
- Limitations discussed in discussion.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence.
- Results interpreted in discussion.
[Yes]

P27. Describe sources of funding for the systematic review.
- No funding sources described.
[No]
</pre>
<p><a name='93'></a></p>
</div>
<div id="friedmacher-2012" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-012-3142-2' title='Open publication'>Friedmacher
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the given systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

The objective of this study was to investigate the com-
plications and long-term outcome in patients with LGEA
managed by DPA based on a meta-analysis of the pub-
lished literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The objective of this study was to investigate the complications and long-term outcome in patients with LGEA managed by DPA based on a meta-analysis of the published literature.&quot;</span>
[Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. 
[No]

A3. Was a comprehensive literature search performed?
<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.5%):

Common electronic databases as MEDLINE
Ò
, EMBASE
Ò
,
ISI Web of Science 
SM 
and the Cochrane Library were
searched in December 2011 using a combination of the
following terms: ‘‘esophageal atresia’’, ‘‘long-gap’’ and
‘‘delayed primary anastomosis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Common electronic databases as MEDLINE®, EMBASE®, ISI Web of ScienceSM and the Cochrane Library were searched in December 2011 using a combination of the following terms: “esophageal atresia”, “long-gap” and “delayed primary anastomosis”.&quot;</span>
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding studies based on publication status.
[No] 

A5. Was a list of studies (included and excluded) provided?
References for included studies provided, no list of excluded studies.
[No]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No assessment of quality of included studies mentioned.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
No assessment of study quality performed.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
No assessment of heterogeneity mentioned.
[No]

A10. Was the likelihood of publication bias assessed?  
No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included?
No statement about conflicts of interest.
[No]

# PRISMA 2009

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎With this meta-analysis on complications and long-term outcome in newborns with LGEA managed by DPA, we provide an overview of the available patient cohorts that were published so far.&quot;</span> 
[Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
Abstract provides structured summary.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
Introduction provides context and rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
Objective clearly stated, outcomes of interest specified. No comparisons.
[Yes] 

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
No protocol mentioned.
[No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Inclusion criteria described in Methods.
[Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
Databases and date of last search provided.
[Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Search terms provided, no full search strategy.
[No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Study selection process described. 
[Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
No details provided on data extraction process.
[No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Outcomes described in Methods. No other variables described.
[No] 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
No assessment of risk of bias mentioned.
[No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
Incidence of complications reported.
[Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
No quantitative synthesis performed.
[NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  
No assessment of risk of bias performed.
[NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
No additional analyses mentioned.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Number of studies included reported, no flow diagram.
[No]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Table 1 provides relevant characteristics of included studies.
[Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
No assessment of risk of bias. 
[No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Incidence of complications summarized. No intervention groups or effect estimates.
[No]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. 
No meta-analysis performed.
[NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).
No assessment of risk of bias across studies.
[NA]  

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression), if done [see Item P16]).
No additional analyses mentioned.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Main findings summarized in Discussion.
[Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
No limitations discussed.
[No]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Results interpreted and implications described.
[Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
No statement about sources of funding or support.
[No]
</pre>
<p><a name='94'></a></p>
</div>
<div id="frongia-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.05.018' title='Open publication'>Frongia
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. [NA] The article does not mention an a priori design or protocol.

A2. [No] There is no mention of duplicate study selection or data extraction. The methods state that one reviewer performed screening and extraction which was then checked by two other reviewers. 

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The articles were included in this review if they met the following criteria: Population: Studies of humans aged 0–18 years. Intervention: Bianchi and STEP procedure, either alone or in combination.&quot;</span>

A4. [No] There is no mention of searching for or including grey literature. 

A5. [No] No list of included/excluded studies is provided.

A6. [No] The characteristics of included studies are not provided in aggregated form, only described narratively in the results. 

A7. [No] There is no mention of quality assessment of included studies.

A8. [NA] This question is not applicable since no quality assessment was performed.

A9. [NA] There was no meta-analysis performed.

A10. [NA] There was no meta-analysis performed.  

A11. [No] There is no mention of conflicts of interest or study funding.

P1. [Yes] The report is identified as a systematic review in the title.

P2. [No] No structured abstract is provided.

P3. [Yes] The rationale for the review is described in the introduction in context of existing knowledge.

P4. [No] The review questions are not explicitly stated in PICOS format. 

P5. [No] No review protocol is mentioned.

P6. [Yes] Inclusion criteria related to population, interventions, and outcomes are described.

P7. [Yes] Literature search methods are described including databases searched.

P8. [No] No full electronic search strategy is presented.

P9. [Yes] The process of study screening and selection is described. 

P10. [No] There are no details provided on data extraction methods.

P11. [No] The variables for which data were sought are not explicitly listed.

P12. [No] No methods for assessing risk of bias are described.

P13. [NA] No meta-analysis was performed.

P14. [NA] No meta-analysis was performed.

P15. [NA] No meta-analysis was performed.

P16. [NA] No additional analyses were performed.

P17. [Yes] Numbers of studies screened and included are provided in a flow diagram. 

P18. [No] No table of study characteristics is provided.

P19. [No] No assessment of risk of bias is presented. 

P20. [No] No summary data and effect sizes are presented for each study.

P21. [NA] No meta-analysis was performed.

P22. [NA] No assessment of risk of bias across studies was performed.

P23. [NA] No additional analyses were performed.

P24. [No] No explicit summary of findings and implications is provided.

P25. [No] Limitations are not discussed.

P26. [No] No general interpretation of results or implications are provided.

P27. [No] No mention of sources of funding or support.
</pre>
<p><a name='95'></a></p>
</div>
<div id="gallo-2012" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0032-1331459' title='Open publication'>Gallo
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. Was an 'a priori' design provided? [No]
"Review of the English-language literature published in the past 5 years about
esophageal replacement in children was done."
No protocol or pre-determined objectives mentioned.

A2. Was there duplicate study selection and data extraction? [No]
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes] 
"A literature search (PubMed and Embase) was performed, and
all human studies published in the English-language literature
between 2006 and 2011 describing esophageal replacement for LGEA were identified, using the medical subject headings 
“Esophageal Atresia,” “Long-gap,” “Esophagoplasty,” “Replacement,” “Interposition,” “Substitution,” “Graft,” and their combinations."
Search included at least 2 databases plus supplementary strategies.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching or including grey literature. 

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No meta-analysis performed.

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No conflict of interest statement.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as a meta-analysis in the title and abstract.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
Structured abstract provided with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, and conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Introduction describes the rationale in context of current knowledge and lack of consensus.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Study eligibility criteria described in methods section.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]  
Information sources described in methods section.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]  
No full search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No] 
No details on study selection process.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]  
No data extraction methodology described. 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Outcomes described but no complete list of variables provided.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Summary measures described in statistical analysis section.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA] 
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias mentioned.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]  
No flow diagram provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 provides relevant characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA] 
No risk of bias assessment performed.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
No forest plots presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis performed. 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]  
Main findings summarized in discussion section.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Partial Yes <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Limitations discussed but no assessment of risk of bias.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of other evidence. Implications for future research discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No sources of funding or support described.
</pre>
<p><a name='96'></a></p>
</div>
<div id="gosemann-2013" class="section level4">
<h4><a href='https://doi.org/10.1055/s-0033-1343085 ' title='Open publication'>Gosemann
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
 Here are my assessments of the systematic review using AMSTAR and PRISMA 2009:

A1. [Yes]
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

A systematic PubMed search was performed to identify
publications on outcome of children with HD, who under-
went either OPEN, L-TERPT, or TERPT' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications on outcome of children with HD, who underwent either OPEN, L-TERPT, or TERPT.&quot;</span>
Explained in 1 sentence: The authors state they performed a systematic search, indicating an a priori design.

A2. [No]  
No mention of duplicate study selection or data extraction.

A3. [Yes]
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):

A systematic PubMed search was performed to identify
publications on outcome of children with HD, who under-
went either OPEN, L-TERPT, or TERPT. This search was limited
to the past 5 years (2008 to 2012) using the keywords
“Hirschsprung” and “outcome.” Reference lists were screened
for additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic PubMed search was performed"; "Reference lists were screened for additional studies.&quot;</span>
Explained in 1 sentence: The authors searched PubMed and reference lists, meeting criteria for at least 2 sources.

A4. [No]  
No mention of including or excluding studies based on publication status. 

A5. [Yes]  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eighteen articles finally met the inclusion criteria and were analyzed in detail.&quot;</span>
Explained in 1 sentence: The number of included and excluded studies is stated.

A6. [Yes] 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):

A total of 1,412 subjects with HD were included in this review
(range: 10 to 192 patients per study). Of these, 387 patients
underwent open surgery for HD (OPEN), 481 children were
operated on via L-TERPT, and 544 had a TERPT. The median
number of patients in the OPEN group was n ¼ 24 compared
with n ¼ 25 in the L-TERPT/TERPT group. Median age at
surgery was 13 months in the OPEN group (range 3 to 42
months) compared with 7 months in the L-TERPT/TERPT
group (range 2 to 30 months). Statistical analysis of group
sizes and age at surgery revealed no significant difference
(p > 0.05). Median follow-up was significantly longer in the
OPEN group' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A total of 1,412 subjects with HD were included in this review"; "Median age at surgery was 13 months in the OPEN group"; "Median follow-up was significantly longer in the OPEN group.&quot;</span>   
Explained in 1 sentence: Participant characteristics such as sample size, age, and follow-up are provided in aggregated form.

A7. [No]
No assessment of study quality mentioned.

A8. [NA]
Not applicable since study quality was not assessed.

A9. [NA]  
No meta-analysis performed.

A10. [NA]
No assessment of publication bias mentioned.

A11. [No]  
No statement about conflicts of interest.

P1. [Yes]  
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Open Versus Transanal Pull-Through for Hirschsprung Disease&quot;</span>  
Explained in 1 sentence: The title identifies the report as a systematic review.

P2. [Yes]
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.8%):

Abstract 
Introduction' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Abstract. Introduction...Conclusions.&quot;</span>
Explained in 1 sentence: A structured abstract is provided with background, objectives, eligibility criteria, results, limitations, and conclusions.  

P3. [Yes]   
Quote: <span title='Moderate quote deviation. Best match in fulltext (Similarity 92%):

Therefore, the aim of this study was to review the available
data on long-term functional results in HD patients operated
with conventional transabdominal pull-through (OPEN) com-
pared with transanal approaches with and without laparos-
copy (laparoscopic-assisted transanal-endorectal pull-
through [L-TERPT] and transanal-endorectal pull-through
[TERPT]) reported in the recent literature' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Therefore, the aim of this study was to review the available data on long-term functional results in HD patients operated with conventional transabdominal pull-through (OPEN) compared with transanal endorectal pull-through with or without laparoscopy (L-TERPT/TERPT) reported in the recent literature.&quot;</span>
Explained in 1 sentence: The rationale describes the aim to review long-term outcomes of different surgical techniques.

P4. [Yes]    
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We focused on long-term outcome in HD patients operated with conventional transabdominal pull-through (OPEN) compared with transanal endorectal pull-through with or without laparoscopy (L-TERPT/TERPT) using four major outcome parameters: constipation, incontinence, enterocolitis and anastomotic stricture.&quot;</span>
Explained in 1 sentence: The review objectives specify participants (HD patients), interventions (OPEN vs L-TERPT/TERPT), and outcomes (constipation, incontinence, etc). 

P5. [No]     
No protocol mentioned.

P6. [Yes]
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Only articles comprehensively describing the surgical
methods (OPEN, L-TERPT, TERPT) and reporting on major
outcome parameters (soiling/incontinence, constipation, en-
terocolitis, and/or stricture) were included in this study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Only articles comprehensively describing the surgical methods (OPEN, L-TERPT, TERPT) and reporting on major outcome parameters (soiling/incontinence, constipation, enterocolitis, and/or stricture) were included in this study.&quot;</span> 
Explained in 1 sentence: Inclusion criteria specify interventions and outcomes of interest.  

P7. [Yes]   
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

A systematic PubMed search was performed to identify
publications on outcome of children with HD, who under-
went either OPEN, L-TERPT, or TERPT. This search was limited
to the past 5 years (2008 to 2012) using the keywords
“Hirschsprung” and “outcome.” Reference lists were screened
for additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications on outcome of children with HD, who underwent either OPEN, L-TERPT, or TERPT. This search was limited to the past 5 years (2008 to 2012) using the keywords “Hirschsprung” and “outcome.” Reference lists were screened for additional studies.&quot;</span>
Explained in 1 sentence: Information sources (PubMed) and search strategy are described.

P8. [No]
No full search strategy provided.

P9. [Yes] 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eighteen articles finally met the inclusion criteria and were analyzed in detail.&quot;</span> 
Explained in 1 sentence: The number of studies screened, assessed, and included is stated.

P10. [No]    
No description of data extraction methods.

P11. [Yes]
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Data extracted from included articles were study charac-
teristics (authors, journal, publication year, sample size,
surgical technique, and follow-up period) and patient char-
acteristics (age at surgery, extent of aganglionosis). Specific
information on the outcome parameters constipation, en-
terocolitis, stricture, incontinence, and soiling were collected
and analyzed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data extracted from included articles were study characteristics (authors, journal, publication year, sample size, surgical technique, and follow-up period) and patient characteristics (age at surgery, extent of aganglionosis). Specific information on the outcome parameters constipation, enterocolitis, stricture, incontinence, and soiling were collected and analyzed.&quot;</span>
Explained in 1 sentence: Variables extracted including study details, participant details, and outcomes of interest are listed.

P12. [No]  
No assessment of risk of bias mentioned.

P13. [Yes]
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):

Odds ratio (OR) with 95% confidence interval (CI) were
calculated' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Odds ratio with 95% confidence interval were calculated.&quot;</span>
Explained in 1 sentence: Odds ratio is specified as the summary measure.

P14. [NA]
No data synthesis performed. 

P15. [NA]  
No assessment of publication bias mentioned.

P16. [NA]
No additional analyses mentioned.

P17. [Yes]    
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

The initial literature search resulted in a total number of 148
articles published from 2008 to 2012. Of these, 130 articles
were excluded because they did not fulfill the inclusion
criteria (
►Fig. 1). Eighteen articles finally met the inclusion
criteria and were analyzed in detail' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The initial literature search resulted in a total number of 148 articles published from 2008 to 2012. Of these, 130 articles were excluded because they did not fulfill the inclusion criteria. Eighteen articles finally met the inclusion criteria and were analyzed in detail.&quot;</span> 
Explained in 1 sentence: The numbers of records screened and included/excluded are provided. 

P18. [Yes]
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Table 1 Frequency of postoperative constipation&quot;</span>
Explained in 1 sentence: A table provides extracted characteristics and citations for each included study.

P19. [No]   
No assessment of risk of bias provided.

P20. [Yes]
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):

The mean rate of constipation was 21% (range 0 to 59%) in the
OPEN group compared with 10% (range 0 to 27%) in the L-
TERPT/TERPT group. A cumulative meta-analysis revealed
that constipation was significantly more frequent after
OPEN surgery compared with L-TERPT/TERPT (OR 3.89 [95%
CI, 2.69 to 5.62]; p < 0.0001' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The mean rate of constipation was 21% (range 0 to 59%) in the OPEN group compared with 10% (range 0 to 27%) in the L-TERPT/TERPT group."; "A cumulative meta-analysis revealed that constipation was significantly more frequent after OPEN surgery compared with L-TERPT/TERPT (OR 3.89 [95% CI, 2.69 to 5.62]; p < 0.0001)&quot;</span> 
Explained in 1 sentence: Outcome data and analysis are presented for each study.

P21. [NA] 
No meta-analysis performed.

P22. [NA]
No assessment of risk of bias across studies.

P23. [NA]
No additional analyses mentioned. 

P24. [Yes]  
Quote: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Significant differences in the long-term outcome of OPEN surgery com-
pared with L-TERPT/TERPT were identified in this review. We conclude from our data that
L-TERPT/TERPT represents a valid option in the treatment of HD and might have some
advantages over the OPEN techniques' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Significant differences in the long-term outcome of OPEN surgery compared with L-TERPT/TERPT were identified in this review. We conclude from our data that L-TERPT/TERPT represents a valid option in the treatment of HD and might have some advantages over the OPEN techniques.&quot;</span>
Explained in 1 sentence: Main findings and conclusions are summarized.

P25. [Yes]
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56%):

ture. Several limitations to this systematic review such as
the different quality of studies and small cohort sizes need to
be considered when interpreting these data' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎However, the present data should be interpreted carefully due to limitations in the quality of the study design in most reports."; "Several limitations to this systematic review such as the different quality of studies and small cohort sizes need to be considered when interpreting these data.&quot;</span>  
Explained in 1 sentence: Limitations at the study and review level are discussed.

P26. [Yes] 
Quote: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Prospective, randomized, multicenter trials are urgently needed to overcome this weakness of the current literature.&quot;</span>
Explained in 1 sentence: Implications for future research are described.

P27. [No]
No mention of sources of funding.
</pre>
<p><a name='97'></a></p>
</div>
<div id="graziano-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.06.019' title='Open publication'>Graziano
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were compiled from a broad search of Medline, Cochrane, Embase and Web of Science from January 1980 through January 2013 for five questions regarding asymptomatic malrotation.&quot;</span>
The review had predetermined objectives and criteria.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Abstracts were then reviewed and relevant articles selected by two of the authors (KG and SI), who also then performed independent manual searches of the reference lists of these articles, bringing the total reviewed to 2545.&quot;</span>
Two authors independently selected studies and extracted data. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Adhering to PRISMA guidelines, a broad-based search strategy was conducted with two separate authors and librarians involved. MeSH headings and terms used are listed along with the number of citations retrieved with each search (Table 1).&quot;</span> 
Multiple databases were searched with predefined search strategies.

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies provided? [No] 
No list of included/excluded studies provided.

A6. Were the characteristics of the included studies provided? [No]
No summary table provided with details of included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [No]  
No formal quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Since quality was not assessed, it was not incorporated into conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify as systematic review or meta-analysis. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Asymptomatic malrotation: Diagnosis and surgical management
An American Pediatric Surgical Association outcomes and evidence based
practice committee systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Asymptomatic malrotation: Diagnosis and surgical management. An American Pediatric Surgical Association outcomes and evidence based practice committee systematic review&quot;</span>  
Identified as a systematic review in title.

P2. Structured summary. [Yes]  
Provides structured abstract with objectives, eligibility criteria, results, conclusions.

P3. Rationale for review. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Malrotation, also known as intestinal rotation abnormality (IRA),
can pose a great risk to the pediatric patient owing to the potential for
a catastrophic event such as midgut volvulus, ischemic bowel, and pos-
sible short bowel syndrome or death [1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Malrotation, also known as intestinal rotation abnormality (IRA), can pose a great risk to the pediatric patient owing to the potential for a catastrophic event such as midgut volvulus, ischemic bowel, and possible short bowel syndrome or death [1].&quot;</span>
Provides background and rationale.

P4. Objectives in PICOS. [Yes] 
Research questions address participants, interventions, comparisons, and outcomes.

P5. Indicate if protocol exists. [No] 
No mention of a protocol.

P6. Specify study characteristics and eligibility criteria. [No]
Does not report details of eligibility criteria.

P7. Information sources and dates. [Yes]
Reports databases searched and date ranges. 

P8. Present full search strategy. [No]
Does not provide full search strategy.

P9. Study selection process. [Yes]  
Describes process of screening and selection.

P10. Data extraction process. [Yes] 
States two authors extracted data.

P11. List and define variables extracted. [No]  
No list of extracted variables provided.

P12. Risk of bias assessment. [No]
No risk of bias assessment described.

P13. Summary measures. [NA]
No quantitative synthesis performed.

P14. Methods for combining data. [NA] 
No quantitative synthesis performed.

P15. Risk of bias across studies. [NA]
No quantitative synthesis performed.

P16. Additional analyses. [NA]
No quantitative synthesis performed.

P17. Study flow. [No]
No flow diagram depicting study selection.

P18. Study characteristics. [No] 
Does not present details of included studies.

P19. Risk of bias for individual studies. [No] 
Does not assess risk of bias for individual studies.

P20. Study data and effect sizes. [No]
Does not present data or effect estimates.

P21. Results of meta-analyses. [NA] 
No meta-analysis conducted.

P22. Risk of bias across studies. [NA]
No meta-analysis conducted.

P23. Additional analyses. [NA]
No additional analyses conducted.

P24. Summary of evidence. [Yes]
Provides summary of findings and implications. 

P25. Limitations at study and review level. [No]
Does not discuss limitations at study or review level.

P26. Interpretation of results. [Yes] 
Provides interpretation of findings and suggestions for future research.

P27. Sources of funding. [No]
No statement about sources of funding.
</pre>
<p><a name='98'></a></p>
</div>
<div id="guo-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-011-2889-1' title='Open publication'>Guo
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Since the current study was a systemic review and meta-
analysis based on the published articles, the consents of
patients and approval of Internal Review Boards were not
included' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Since the current study was a systemic review and meta-analysis based on the published articles, the consents of patients and approval of Internal Review Boards were not included.&quot;</span> [No]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The citations and/or abstracts or full text of all potentially relevant studies were independently evaluated and selected by three reviewers (GJ, LZL and TQS), and any disagreements were resolved by consensus.&quot;</span> [Yes]

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

All published studies until August 31, 2010 were
searched with the terms ‘‘laparoscopic orchiopexy’’, ‘‘open
orchiopexy’’, and ‘‘children’’ from Medline (using PubMed
as the search engine), Embase, Ovid, Web of Science, and
Cochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All published studies until August 31, 2010 were searched with the terms ‘laparoscopic orchiopexy’, ‘open orchiopexy’, and ‘children’ from Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span> [Yes]

A4. Was the status of publication used as an inclusion criterion? 
No mention of searching for grey literature. [No]

A5. Was a list of studies (included and excluded) provided?
Table 1 provides characteristics of included studies. The number of excluded studies is mentioned in the text but references are not provided. [No] 

A6. Were the characteristics of the included studies provided?
Table 1 and 2 provide aggregated characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each included article was appraised by three reviewers (GJ, LZL and TQS), who assessed the methodological quality of the selected studies independently. A critical review checklist of the Dutch Cochrane Centre was used to appraise the RCTs.&quot;</span> [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No assessment of study quality is presented.

A9. Were the methods used to combine the findings of studies appropriate?
Statistical heterogeneity was assessed and appropriate meta-analysis models were used based on I2 values. [Yes] 

A10. Was the likelihood of publication bias assessed?
Funnel plots were generated and assessed. [Yes]

A11. Was the conflict of interest included? [No]
No statement on conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

In this study, we reviewed the cur-
rent literature and performed a systemic review and meta-
analysis to compare the LO and OO' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In this study, we reviewed the current literature and performed a systemic review and meta-analysis to compare the LO and OO...&quot;</span>

P2. Provide a structured summary. [No] 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
The introduction section provides background and rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
The objective is stated but no explicit PICOS.

P5. Indicate if a review protocol exists, if and where it can be accessed. [No] 
No protocol mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Inclusion and exclusion criteria are described in the methods.

P7. Describe all information sources in the search and date last searched. [Yes]
Databases, date range, and search terms are provided. 

P8. Present full electronic search strategy for at least one database, including any limits used. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes] 
Study selection process is described. 

P10. Describe method of data extraction from reports. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Three reviewers (GJ, LZL and TQS) independently asses-
sed selected studies, extracted and tabulated data from each
article with a predefined data extraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three reviewers (GJ, LZL and TQS) independently assessed selected studies, extracted and tabulated data from each article with a predefined data extraction form.&quot;</span>

P11. List and define all variables for which data were sought. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] 
Outcomes extracted are listed but not defined.

P12. Describe methods used for assessing risk of bias of individual studies. [Yes]
The Dutch Cochrane risk of bias tool was used. 

P13. State the principal summary measures. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Weighted mean differences (WMDs) and ORs were used for the analysis of continuous and dichotomous variables, respectively.&quot;</span>

P14. Describe the methods of handling data and combining results of studies. [NA]
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias across studies. [NA] 
No assessment of publication bias presented.

P16. Describe methods of additional analyses. [NA]
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. [Yes]
The study selection process is described and depicted in a flow diagram. 

P18. For each study, present characteristics for which data were extracted. [Yes] 
Table 1 and 2 present study characteristics.

P19. Present data on risk of bias of each study. [No]
No assessment of individual study bias presented.

P20. For all outcomes considered, present data for each study. [Yes]  
Table 2 presents outcome data for each study. 

P21. Present results of each meta-analysis done. [NA]
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies. [NA] 
No assessment of publication bias presented.

P23. Give results of additional analyses. [NA]
No additional analyses mentioned. 

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes]
The discussion summarizes the main findings.

P25. Discuss limitations at study and outcome level and at review-level. [Yes]
Limitations are discussed.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results are interpreted in the context of previous literature.

P27. Describe sources of funding for the systematic review. [No] 
No statement on sources of funding.
</pre>
<p><a name='99'></a></p>
</div>
<div id="hall-2011" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2011.01.019' title='Open publication'>Hall
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments for the AMSTAR and PRISMA items based on the provided systematic review text:

A1. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
The objective is clearly stated in the background and methods. 

A2. "[No]"  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>
Only one reviewer extracted data.

A3. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> 
Medline and other sources were searched.

A4. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
Grey literature was not mentioned.

A5. "[No]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
No list of excluded studies was provided.

A6. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
Table 1 provides data on participants. 

A7. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria).&quot;</span>
No quality assessment done.

A8. "[NA]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review.&quot;</span>
Not applicable since no quality assessment done.

A9. "[NA]"  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>
Not applicable since no meta-analysis done.

A10. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span>
No assessment of publication bias.

A11. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
No statement on sources of funding.

P1. "[Yes]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Identify the report as a systematic review, meta-analysis, or both.&quot;</span>
Identified as systematic review in title.

P2. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>  
Structured abstract provided.

P3. "[Yes]"  
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe the rationale for the review in the context of what is already known.&quot;</span>
Rationale described in introduction.

P4. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span>
Objective stated in background.

P5. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span>
No protocol mentioned.

P6. "[Yes]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span>
Inclusion criteria described in methods.

P7. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span>
Databases and supplementary strategies described.

P8. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span>
Search strategy not provided.

P9. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span> 
Selection process described.

P10. "[No]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span>
No mention of data extraction process.

P11. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span>
Outcomes described.

P12. "[No]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;</span>
No risk of bias assessment. 

P13. "[NA]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the principal summary measures (e.g., risk ratio, difference in means).&quot;</span>
Not applicable since no meta-analysis.

P14-P16. "[NA]" 
Not applicable since no meta-analysis.

P17. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span>
No flow diagram showing screening process.

P18. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span>
Study characteristics presented in results.

P19. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).&quot;</span>
No risk of bias assessment.

P20-P22. "[NA]" 
Not applicable since no meta-analysis. 

P23. "[NA]"
Not applicable since no additional analyses.

P24. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span>
Main findings summarized in discussion.

P25. "[Yes]" 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span>
Limitations discussed.

P26. "[Yes]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span>
Results interpreted and future research implications described.

P27. "[No]"
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;</span>
No statement on sources of funding.
</pre>
<p><a name='100'></a></p>
</div>
<div id="healy-2015" class="section level4">
<h4><a href='https://doi.org/10.1097/MD.0000000000001352' title='Open publication'>Healy
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

We performed a systematic
review and meta-analysis to determine the influence of surgeon
subspecialty on outcomes following appendicectomy in chil-
dren' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review and meta-analysis to determine the influence of surgeon subspecialty on outcomes following appendicectomy in children.&quot;</span> (Abstract)
- States the objective a priori.
[Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors searched Medline and Embase to identify relevant studies.&quot;</span> (Methods)  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors (DD and DH) independently extracted data from eligible studies.&quot;</span> (Methods)
- Two authors performed selection and extraction.
[Yes]

A3. Was a comprehensive literature search performed?
- <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.7%):

Two authors searched Medline and Embase' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two authors searched Medline and Embase up to June 24, 2015.&quot;</span> (Methods)
- Searched two databases but no supplementary sources mentioned. 
[No]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows flow of included and excluded studies.
[Yes] 

A6. Were the characteristics of the included studies provided?
- Table 1 provides characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- Quality assessed using Downs and Black tool, results in Table 1.
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
- Limitations of observational data acknowledged in Discussion.
[Yes]

A9. Were the methods used to combine the findings of studies appropriate?
- Used random effects model and assessed heterogeneity using I2 statistic.
[Yes]

A10. Was the likelihood of publication bias assessed?  
- Not mentioned.
[No]

A11. Was the conflict of interest included?
- No conflicts declared.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic Review and Meta-Analysis&quot;</span> in title.
[Yes]

P2. Provide a structured summary.
- Structured abstract provided.
[Yes]

P3. Describe the rationale for the review in the context of what is already known. 
- Rationale described in Introduction.
[Yes]

P4. Provide an explicit statement of questions being addressed with reference to PICOS.
- Research question stated in Methods.
[Yes]

P5. Indicate if a review protocol exists. 
- No protocol mentioned.
[No]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
- Inclusion and exclusion criteria described in Methods.
[Yes]

P7. Describe all information sources in the search and date last searched.
- Databases and date ranges provided in Methods. 
[Yes]

P8. Present full electronic search strategy for at least one database.
- Search terms provided but not full strategy.
[No]

P9. State the process for selecting studies.
- Study selection process described in Methods and Figure 1.
[Yes]

P10. Describe method of data extraction from reports.  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Two authors (DD and DH) independently extracted data
from eligible studies using an electronic spreadsheet' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently extracted data using an electronic spreadsheet.&quot;</span> (Methods)
[Yes]

P11. List and define all variables for which data were sought.
- Outcomes described in Methods.
[Yes] 

P12. Describe methods used for assessing risk of bias of individual studies.
- Downs and Black quality assessment described. 
[Yes]

P13. State the principal summary measures. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Pooled risk ratios and pooled mean differences were used.&quot;</span> (Methods)
[Yes]

P14. Describe the methods of handling data and combining results of studies.
- Meta-analysis methods described.
[Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
- No assessment of publication bias mentioned.
[No]

P16. Describe methods of additional analyses, if done.
- No additional analyses mentioned.
[NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. 
- Screening details provided in Figure 1.
[Yes]

P18. For each study, present characteristics for which data were extracted.
- Table 1 presents study characteristics.
[Yes] 

P19. Present data on risk of bias of each study. 
- Quality scores presented in Table 1.
[Yes]

P20. For all outcomes considered, present data from each study.
- Table 2 provides outcome data from each study.
[Yes]

P21. Present results of each meta-analysis done.
- Forest plots presented in Figures 2 and 3.
[Yes]

P22. Present results of any assessment of risk of bias across studies.
- No assessment of publication bias presented.  
[No]

P23. Give results of additional analyses, if done.
- No additional analyses mentioned.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
- Findings summarized in abstract and Discussion.
[Yes]

P25. Discuss limitations at study and outcome level, and at review-level.
- Limitations discussed in Discussion.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence.
- Results interpreted in Discussion.
[Yes]

P27. Describe sources of funding for the systematic review. 
- No funding sources declared.
[No]
</pre>
<p><a name='101'></a></p>
</div>
<div id="healy-2016" class="section level4">
<h4><a href='https://doi.org/10.1007/s00383-015-3839-0' title='Open publication'>Healy
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946–present) and Embase (1974–present) using the OvidSP interfaces.&quot;</span>
The review states a literature search was performed. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):

Citations
of retrieved results were manually reviewed for relevance to
the topic of IA by two independent reviewers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Citations of retrieved results were manually reviewed for relevance to the topic by two independent reviewers.&quot;</span>
Two independent reviewers performed study selection. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

In December 2014, a comprehensive literature search was
performed using Ovid MEDLINE (1946–present) and
Embase (1974–present) using the OvidSP interfaces. The
terms ‘‘Incidental appendectomy’’ and ‘‘Prophylactic appen-
dectomy’’ returned 315 and 74 results, respectively' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946–present) and Embase (1974–present) using the OvidSP interfaces. The terms ‘‘Incidental appendectomy’’ and ‘‘Prophylactic appendectomy’’ returned 315 and 74 results, respectively.&quot;</span>
At least two databases were searched. [Yes]

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
No explicit list of included/excluded studies provided. [No]

A6. Were the characteristics of the included studies provided?
Table 1, 2, and 3 provide characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No mention of quality assessment for included studies. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]

A9. Were the methods used to combine the findings of studies appropriate? [NA]

A10. Was the likelihood of publication bias assessed? [NA]

A11. Was the conflict of interest included? 
No mention of sources of funding or conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

To review the available literature for techniques, pathol-
ogy, risks of appendectomy, utility of the appendix, and IA
in the treatment of specific pediatric medical conditions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To review the available literature for techniques, pathology, risks of appendectomy, utility of the appendix, and IA in the treatment of specific pediatric medical conditions.&quot;</span>
The report is identified as a systematic review. [Yes]

P2. Provide a structured summary.
The abstract provides a structured summary. [Yes] 

P3. Describe the rationale for the review in the context of what is already known.
The rationale is described in the Background and Introduction sections. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
The objectives are stated in the Introduction. [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
The databases, search terms, and date of last search are provided in the Methods. [Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 
The full search strategy is not provided. [No]

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
The study selection process is described and depicted in a flow diagram. [Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA] 

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
A flow diagram of study screening and selection is provided. [Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Study characteristics are presented in Tables 1-3 with citations. [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Main findings are summarized in the Discussion and Conclusion. [Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Limitations are discussed in the Conclusion. [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. 
Interpretation and implications are provided in the Conclusion. [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
</pre>
<p><a name='102'></a></p>
</div>
<div id="heloury-2012" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2011.08.003' title='Open publication'>Heloury
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. [No] No mention of an a priori design or protocol.

A2. [No] No mention of duplicate study selection or data extraction.

A3. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The authors conducted a systematic review of the pediatric and adult literature about MIA, focusing on the technique and indications.&quot;</span>

A4. [No] No mention of searching for or including grey literature. 

A5. [No] No explicit list of included and excluded studies provided.

A6. [Yes] Table 1 provides characteristics of included studies on MIA in children.

A7. [No] No assessment of quality of included studies.

A8. [NA] No quality assessment done, so using it to formulate conclusions not applicable.

A9. [NA] No quantitative synthesis done. 

A10. [NA] No assessment of publication bias done.

A11. [No] No mention of conflicts of interest.

P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Review article&quot;</span> in title identifies it as a review.

P2. [No] No structured summary provided.

P3. [Yes] Introduction describes rationale and what is known about MIA.

P4. [No] No explicit PICOS statement.

P5. [No] No mention of a review protocol.

P6. [Yes] Inclusion criteria described under various sections. 

P7. [No] No details provided on information sources searched.

P8. [No] No search strategy provided.

P9. [No] No mention of study selection process. 

P10. [No] No mention of data extraction methods.

P11. [No] No list of variables extracted.

P12. [NA] No assessment of risk of bias done.

P13. [NA] No meta-analysis done.

P14. [NA] No meta-analysis done. 

P15. [NA] No assessment of publication bias.

P16. [NA] No additional analyses done.

P17. [No] No flow diagram of study selection process.

P18. [No] No detailed characteristics of included studies.

P19. [NA] No assessment of risk of bias. 

P20. [No] No forest plots presented.

P21. [NA] No meta-analysis done.

P22. [NA] No assessment of risk of bias across studies.

P23. [NA] No additional analyses done.

P24. [Yes] Main findings summarized in conclusion.

P25. [No] No discussion of limitations.

P26. [Yes] Results interpreted in context of other evidence. 

P27. [No] No mention of sources of funding.
</pre>
<p><a name='103'></a></p>
</div>
<div id="huang-2015" class="section level4">
<h4><a href='https://doi.org/pmid:26131065' title='Open publication'>Huang
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the attached systematic review publication:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

We conducted this meta-analysis in accordance
with the Preferred Reporting Items for

Laparoscopic versus open pyeloplasty in ureteropelvic junction obstruction
4923 Int J Clin Exp Med 2015;8(4):4922-4931
Systematic Reviews and Meta-Analyses [10' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted this meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [10].&quot;</span>
They mentioned following PRISMA guidelines. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.2%):

.
according to the meta-analy-
sis of observational studies in
epidemiology guidelines [11]
and disagreements were con-
sulted with the third one
(Lugang Huang' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data abstraction was carried out independently by two authors (Yidong Huang, Yang Wu) according to the meta-analysis of observational studies in epidemiology guidelines [11] and disagreements were consulted with the third one (Lugang Huang).&quot;</span>
Two authors independently performed study selection and data extraction with consensus procedure. [Yes]  

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.2%):

PUBMED, Web of science and
Cochrane library was carried out between Jan.
1966 and Oct. 2014 to identify eligible studies,
using the following words: “hydronephrosis OR
ureteropelvic junction obstruction OR pelvi-ure-
teric junction obstruction OR ureteral obstruc-
tion”, “pyeloplasty”, “young OR children OR
child OR kids OR pediatrics” and “laparoscop-
ic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PUBMED, Web of science and Cochrane library were searched until Oct. 2014 to identify eligible studies, using the following words: “hydronephrosis OR ureteropelvic junction obstruction OR pelvi-ureteric junction obstruction OR ureteral obstruction”, “pyeloplasty”, “young OR children OR child OR kids OR pediatrics” and “laparoscopic”.&quot;</span>
Searched at least two databases with search terms provided. [Yes]

A4. Was the status of publication used as an inclusion criterion? 
No mention of including or excluding based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Included studies listed in Table 1. Excluded studies not referenced. [No]

A6. Were the characteristics of the included studies provided?
Characteristics of included studies provided in Tables 1-3. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment mentioned. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment performed. [NA]

A9. Were the methods used to combine the findings of studies appropriate?
Methods described. Heterogeneity assessed using I2. Random effects model used. [Yes]

A10. Was the likelihood of publication bias assessed?  
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included?
No conflict of interest statement. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To further explore the feasibility and safety of laparoscopic pyeloplasty (LP) in children with ureteropelvic junction obstruction compared with open pyeloplasty (OP).&quot;</span>

P2. Provide a structured summary. [No]
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction describes rationale and background.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed. [No]
No protocol mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
Inclusion/exclusion criteria described in Methods.

P7. Describe all information sources in the search and date last searched. [Yes] 
Databases, search terms, and date range provided.

P8. Present full electronic search strategy for at least one database. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes]
Study selection process described and depicted in Figure 1. 

P10. Describe method of data extraction from reports. [Yes] 
Data extraction process described.

P11. List and define all variables for which data were sought. [Yes]
Outcomes described in Methods.

P12. Describe methods used for assessing risk of bias of individual studies. [No]
No risk of bias assessment mentioned.

P13. State the principal summary measures. [Yes]
Outcome measures described.

P14. Describe the methods of handling data and combining results of studies. [Yes]
Methods described. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence. [No]
No assessment of publication bias.

P16. Describe methods of additional analyses. [NA]
No additional analyses performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. [Yes] 
Screening process shown in Figure 1.

P18. For each study, present characteristics for which data were extracted. [Yes]
Study characteristics presented in Tables 1-3.

P19. Present data on risk of bias of each study. [No] 
No risk of bias assessment presented.

P20. For all outcomes considered, present data for each study. [Yes]
Data for outcomes presented. 

P21. Present results of each meta-analysis done. [Yes]
Results of meta-analyses presented.

P22. Present results of any assessment of risk of bias across studies. [NA]
No assessment of publication bias.

P23. Give results of additional analyses. [NA] 
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes]
Main findings summarized in Discussion.

P25. Discuss limitations at study and outcome level and at review-level. [Yes]
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results interpreted and compared to previous study.

P27. Describe sources of funding for the systematic review. [No]  
No funding reported.
</pre>
<p><a name='104'></a></p>
</div>
<div id="ishii-2014" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2014.08.003' title='Open publication'>Ishii
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search involved finding relevant studies from MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar and individual urological journals between January 1990 and March 2014.&quot;</span>

[Yes] The review had pre-determined inclusion/exclusion criteria.

A2. Was there duplicate study selection and data extraction?

[No] The review does not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?

<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The search terms included the following: ‘uretero-
scopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediat-
ric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’,
‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search terms included the following: ‘ureteroscopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediatric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’, ‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy’.&quot;</span>

[Yes] The search included multiple databases and supplementary search strategies.

A4. Was the status of publication used as an inclusion criterion?  

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The inclusion criteria were for studies written in the English language...&quot;</span>

[No] The review did not search for unpublished or grey literature.

A5. Was a list of studies (included and excluded) provided?

[No] The review did not provide a list of excluded studies. 

A6. Were the characteristics of the included studies provided?

[Yes] Table 1 provides aggregated characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented?

[No] The review did not assess the quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?

[NA] Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?

[NA] The results were not combined quantitatively. 

A10. Was the likelihood of publication bias assessed?

[NA] Publication bias assessment is not applicable without a meta-analysis.

A11. Was the conflict of interest included? 

[No] Potential conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both.

<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎REVIEW ARTICLE Flexible ureteroscopy and lasertripsy (FURSL) for paediatric renal calculi: Results from a systematic review&quot;</span> 

[Yes] The report is identified as a systematic review.

P2. Provide a structured summary...

[Yes] An abstract with structured headings is provided. 

P3. Describe the rationale for the review... 

[Yes] Rationale is described in the Introduction.

P4. Provide an explicit statement of questions being addressed...

[No] Specific review questions are not provided.

P5. Indicate if a review protocol exists...

[No] A protocol is not mentioned. 

P6. Specify study characteristics...and report characteristics...

[Yes] Inclusion criteria specify study characteristics. 

P7. Describe all information sources...

[Yes] Information sources are described in the Methods.

P8. Present full electronic search strategy for at least one database...

[No] Full search strategies are not provided.

P9. State the process for selecting studies...

[Yes] The study selection process is outlined in Figure 1.

P10. Describe method of data extraction...

[No] The data extraction process is not described.

P11. List and define all variables for which data were sought...

[Yes] Extracted data variables are listed in the Results. 

P12. Describe methods used for assessing risk of bias...

[No] Risk of bias assessment is not described.

P13. State the principal summary measures...

[NA] Summary measures are not applicable without quantitative synthesis.

P14-P23. Describe methods of additional analyses...

[NA] No meta-analysis was performed.

P24. Summarize the main findings including the strength of evidence...

[Yes] Main findings are summarized in the Conclusion.

P25. Discuss limitations at study and outcome level... 

[Yes] Limitations are outlined in the Discussion.

P26. Provide a general interpretation of the results...

[Yes] Results are interpreted in the Conclusion.

P27. Describe sources of funding...

[No] Sources of funding are not reported.
</pre>
<p><a name='105'></a></p>
</div>
<div id="ishii-2015" class="section level4">
<h4><a href='https://doi.org/10.1111/BJU.12927' title='Open publication'>Ishii
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review was conducted in accordance with the systematic review guidelines provided by the Cochrane Collaboration and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist.&quot;</span>
They mentioned following systematic review guidelines.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers independently extracted the data from each study.&quot;</span>
Two reviewers performed data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search involved finding relevant studies from MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar and individual urological journals, published between January 1990 and May 2013.&quot;</span> 
Searched multiple databases.

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
Included studies listed in tables, but excluded studies not provided.

A6. Were the characteristics of the included studies provided? [Yes]  
<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.9%):

total of 14 studies (1718 procedures)
were reported in patients with a mean (range) age of 7.8
(0.25–18.0) years' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In total, 14 studies (1718 procedures) were reported in patients with a mean (range) age of 7.8 (0.25-18.0) years.&quot;</span>
Provided characteristics like number of studies, procedures, age range.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No mention of quality assessment for included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review looks at the worldwide literature on the outcomes of ureteroscopic management of stone disease in the paediatric population.&quot;</span>

P2. Provide a structured summary. [Yes]  
Provides structured abstract with background, objectives, data sources, eligibility criteria, results, conclusions.

P3. Describe the rationale for the review. [Yes]  
Rationale described in introduction paragraph.

P4. Provide an explicit statement of questions being addressed. [No]  
Questions not explicitly stated.

P5. Indicate if a protocol exists. [No]  
No mention of a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
Specifies including studies with >50 pediatric patients who underwent URS for stones.

P7. Describe information sources and dates for search. [Yes] 
Described databases searched from Jan 1990 to May 2013. 

P8. Present full electronic search strategy. [No]  
Search terms provided but not full search strategy.

P9. State the process for selecting studies. [Yes]
Process described in methods.

P10. Describe method of data extraction. [Yes]  
States two reviewers independently extracted data.

P11. List and define all variables for which data were sought. [Yes]
Data sought included demographics, stone details, procedures, outcomes.

P12. Describe methods used for assessing risk of bias. [No]
No risk of bias assessment mentioned.

P13. State the principal summary measures. [NA]
No quantitative synthesis performed.

P14-P23. [NA] 
No quantitative synthesis performed.

P24. Summarize the main findings. [Yes]
Main findings summarized in discussion and conclusion.

P25. Discuss limitations at study and outcome level. [No]  
Did not discuss limitations at study or outcome level.

P26. Provide a general interpretation of the results. [Yes]
Results interpreted in discussion.

P27. Describe sources of funding and other support. [No]
No statement about sources of funding.
</pre>
<p><a name='106'></a></p>
</div>
<div id="ito-2014" class="section level4">
<h4><a href='https://doi.org/10.1111/PED.12429' title='Open publication'>Ito
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span> (p.497)
- The review had an a priori design with pre-defined research question and inclusion criteria. [Yes]

A2. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span> (p.497)  
- The review did not mention duplicate study selection or data extraction. [No]

A3.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched.&quot;</span> (p.497)
- The review searched multiple databases including PubMed, Japana Centra Revuo Medicina, CINAHL, and Cochrane Library. [Yes]  

A4.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.”&quot;</span> (p.497)  
- The review did not mention searching for grey literature. [No]

A5.   
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span> (p.497)
- The review did not provide a list of included and excluded studies. [No]

A6. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span> (p.497)
- The review provided characteristics of included studies in Tables 2-5. [Yes]

A7.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎‘A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria)&quot;</span> (p.498)
- The review assessed quality and risk of bias of RCTs, but did not assess quality of observational studies. [No]

A8.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review&quot;</span> (p.498) 
- The review considered risk of bias in formulating conclusions. [Yes]

A9. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?).&quot;</span> (p.498)
- The review assessed heterogeneity in the meta-analyses. [Yes]

A10.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span> (p.498)
- The review did not assess publication bias. [No] 

A11.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Must indicate source of funding or support for the systematic review AND for each of the included studies.&quot;</span> (p.499)
- The review stated no conflicts of interest but did not report sources of funding. [No]

P1. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Identify the report as a systematic review, meta-analysis, or both.&quot;</span>
- The title clearly identifies it as a systematic review. [Yes]

P2. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.&quot;</span>  
- The abstract provides a structured summary. [Yes]

P3.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe the rationale for the review in the context of what is already known.&quot;</span>
- The introduction describes the rationale. [Yes]

P4.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span>
- The review provides the PICOS research question in the methods. [Yes]

P5.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span>
- The review does not mention a protocol. [No]

P6.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span>
- The methods specify eligibility criteria. [Yes]  

P7.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span> 
- The methods describe the information sources. [Yes]

P8.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span>
- The review does not provide the full search strategy. [No]

P9.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span>
- The methods describe the selection process and inclusion/exclusion criteria. [Yes]

P10. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span>
- The review does not describe the data extraction process. [No]

P11.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span>
- The review describes the outcomes assessed. [Yes]  

P12. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;</span>  
- The review describes the risk of bias assessment. [Yes]

P13.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the principal summary measures (e.g., risk ratio, difference in means).&quot;</span>
- The review states the summary measures used in meta-analyses. [Yes]

P14-P16. Not applicable as no meta-analysis was performed. [NA]

P17.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span>
- The review provides a flow diagram of study selection. [Yes]

P18.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span> 
- The review provides characteristics of included studies in tables. [Yes]

P19.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).&quot;</span>
- Risk of bias is presented in tables. [Yes]

P20. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.&quot;</span>
- The review provides summary data and effect estimates. [Yes]

P21-P23. Not applicable as no meta-analysis was performed. [NA] 

P24.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span>
- The discussion summarizes the main findings and evidence quality. [Yes]

P25. 
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span>
- The review discusses limitations of the evidence. [Yes]

P26.  
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span>
- The review provides interpretation and implications. [Yes]

P27.
- <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;</span>
- The review states no conflicts of interest but does not describe sources of funding. [No]
</pre>
<p><a name='107'></a></p>
</div>
<div id="jia-2011" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0030-1261926' title='Open publication'>Jia
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are my assessments for the AMSTAR and PRISMA items based on the provided full text:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An electronic literature search of all articles from inception to February 2009 was conducted using Medline, the Cochrane Library, SCI, EMBASE, and the Chinese Biomedical Literature Database&quot;</span>
Clear search conducted.

A2. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Data were extracted by 2 independent investigators, and dis-
crepancies were discussed to reach consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were extracted by 2 independent investigators, and discrepancies were discussed to reach consensus.&quot;</span>
Duplicate data extraction done. 

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

An electronic literature search of all articles from inception to
February 2009 was conducted using Medline, the Cochrane
Library, SCI, EMBASE, and the Chinese Biomedical Literature
Database, using the following text and keywords in combination
both as MeSH terms and text words: “ pyloric stenosis” , “pyloros-
tenosis” , “ pyloristenosis” and “ pyloromyotomy” in combination
with “ laparoscop' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An electronic literature search of all articles from inception to February 2009 was conducted using Medline, the Cochrane Library, SCI, EMBASE, and the Chinese Biomedical Literature Database, using the following text and keywords in combination both as MeSH terms and text words: “pyloric stenosis”, “pylorostenosis”, “pyloristenosis” and “pyloromyotomy” in combination with “laparoscop*”.&quot;</span>
Multiple databases searched with keywords.

A4. [Unclear <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span>]
No mention of grey literature or unpublished literature search.

A5. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 75.9%):

led trials with 492
infants were fi nally eligible for this study (
●
▶ 
Fig.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎3 studies totaling 492 infants were finally eligible for this study (Figure 1).&quot;</span> 
Included/excluded studies shown in flow diagram.

A6. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):

Baseline characteristics of included trials are summarized
in 
●
▶ 
Table 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Baseline characteristics of included trials are summarized in Table 1.&quot;</span>
Table 1 provides characteristics of included studies.

A7. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Using the quality assessment instrument of the Cochrane Hand-
book version 5.0.1 [11], we assigned ‘Yes’ for low risk of bias, ‘No’
for high risk of bias, or ‘Unclear’ for uncertain risk of bias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using the quality assessment instrument of the Cochrane Handbook version 5.0.1 [11], we assigned ‘Yes’ for low risk of bias, ‘No’ for high risk of bias, or ‘Unclear’ for uncertain risk of bias.&quot;</span>
Quality assessed systematically. 

A8. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

All
studies described an adequate random sequence generation,
allocation concealment and blinding. After retrieving included
articles, no incomplete outcome data and selective outcome
reporting were found (
●
▶ 
Table 2). Therefore, the magnitude of
LP compared with OP used in this systematic review was high
quality with a low risk of bias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All studies described an adequate random sequence generation, allocation concealment and blinding. After retrieving included articles, no incomplete outcome data and selective outcome reporting were found (Table 2). Therefore, the magnitude of LP compared with OP used in this systematic review was high quality with a low risk of bias.&quot;</span>
Quality of studies considered in conclusions.

A9. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 81.3%):

heteroge-
neity among few trials, and should be interpreted with caution
[12] . Potential causes of heterogeneity were explored by carry-
ing out sensitivity and subgroup analyses if available' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Heterogeneity among studies was estimated by the use of the I2 statistic... Potential causes of heterogeneity were explored by carrying out sensitivity and subgroup analyses if available.&quot;</span>
Heterogeneity assessed and random effects model used when present.

A10. [No] 
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest or funding sources.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Open versus Laparoscopic Pyloromyotomy for Pyloric Stenosis: A Meta-analysis of Randomized Controlled Trials&quot;</span>
Identified as a meta-analysis.

P2. [Yes] 
Abstract provides structured summary.

P3. [Yes]
Introduction describes rationale and what is known.

P4. [Yes]
Objectives specify interventions, comparisons, and outcomes. 

P5. [No]
No mention of a review protocol.

P6. [Yes]
Inclusion criteria describe study characteristics.

P7. [Yes]  
Methods describe literature sources and dates searched.

P8. [No]
Search strategy not provided.

P9. [Yes] 
Flow diagram shows study selection process.

P10. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Data were extracted by 2 independent investigators, and dis-
crepancies were discussed to reach consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were extracted by 2 independent investigators, and discrepancies were discussed to reach consensus.&quot;</span>
Duplicate data extraction described.

P11. [Yes]
Outcomes of interest described. 

P12. [Yes] 
Quality assessment methods described.

P13. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Results are expressed as SMD for continuous variables and OR for dichotomous outcomes&quot;</span>
Summary measures described.

P14. [NA]
No meta-analysis done for this review.

P15. [NA] 
No meta-analysis done.

P16. [NA]
No additional analyses done.

P17. [Yes]
Flow diagram shows numbers at each stage.

P18. [Yes]
Table 1 shows study characteristics.

P19. [Yes] 
Table 2 shows risk of bias assessment.

P20. [Yes]
Results show summary data and effect estimates.

P21. [NA]
No meta-analysis done.

P22. [NA]  
No assessment of bias across studies.

P23. [NA]
No additional analyses.

P24. [Yes] 
Conclusions summarize main findings.

P25. [Yes]
Limitations discussed.

P26. [Yes]
Conclusions put results in context of other evidence.

P27. [No]
No mention of funding sources.
</pre>
<p><a name='108'></a></p>
</div>
<div id="kapralik-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.11.022' title='Open publication'>Kapralik
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We used a Dephi-like method [17] to determine the issues of
greatest concern to pediatric surgeons regarding the surgical manage-
ment of CPAM' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We used a Dephi-like method [17] to determine the issues of greatest concern to pediatric surgeons regarding the surgical management of CPAM.&quot;</span>
Provides details on the a priori design. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two independent reviewers conducted all article screening.&quot;</span>
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

One reviewer extracted all data from the included studies, and an-
other checked it for accuracy and completeness' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;</span>
Duplicate study selection and data extraction done. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

we conducted an electronic literature
search of the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE (1966 onwards), EMBASE (1980 onwards), CINAHL (1982 on-
wards), and PubMed (1966 onwards) in January 2015' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted an electronic literature search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), EMBASE (1980 onwards), CINAHL (1982 onwards), and PubMed (1966 onwards) in January 2015.&quot;</span> 
Searched multiple databases. [Yes]

A4. Was the status of publication used as an inclusion criterion?  
No mention of including or excluding based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Figure 1 shows the flow diagram with included and excluded studies. [Yes]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We used the Methodological Index for Non-Randomized Studies (MINORS) to assess the quality of the included studies.&quot;</span>
Quality assessed using MINORS tool. [Yes]  

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
The quality scores are reported in Table 1 but not mentioned in the conclusions. [No]

A9. Were the methods used to combine the findings of studies appropriate?  
Not combined beyond narrative synthesis. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No conflict of interest statement. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We performed a systematic review and meta-analysis comparing elective resection versus expectant management.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes]
Provides structured abstract with background, objectives, eligibility criteria, participants, interventions, study appraisal, results, conclusions. No registration number.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction describes the rationale and controversy around the management of CPAM.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes] 
Clear objective stated: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

to conduct a systematic review and meta-analysis
of all published literature comparing the postoperative outcomes asso-
ciated with elective surgery (while asymptomatic) versus those follow-
ing surgery as part of expectant management (i.e., performing surgery
only upon the development of symptoms) in children born with asymp-
tomatic CPAM lesions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎to conduct a systematic review and meta-analysis of all published literature comparing the postoperative outcomes associated with elective surgery (while asymptomatic) versus those following surgery as part of expectant management (i.e., performing surgery only upon the development of symptoms) in children born with asymptomatic CPAM lesions.&quot;</span>

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Eligibility criteria described in methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes] 
Databases, dates, and supplementary search described.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Screening and selection process described and depicted in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

One reviewer extracted all data from the included studies, and an-
other checked it for accuracy and completeness' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;</span> 

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes]  
Outcomes described in methods.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
MINORS used to assess quality/risk of bias. 

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
OR and MD described.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA] 
No meta-analysis beyond narrative synthesis.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]
No assessment of publication bias or other biases mentioned.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
Figure 1 shows PRISMA flow diagram.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Table 1 provides characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Table 1 provides MINORS quality assessment for each study.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Results summarized narratively and in forest plots.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis beyond narrative synthesis. 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of publication bias or other biases.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in discussion and conclusions.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] 
Results interpreted and compared to other studies. Suggestions for future research provided.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement on funding or support.
</pre>
<p><a name='109'></a></p>
</div>
<div id="kunz-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.01.020' title='Open publication'>Kunz
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We reviewed Medline citations between January 1, 1996 and June 1, 2012 and the Cochrane Database of Systematic Reviews database through June 1, 2012.&quot;</span>
- The review protocol including search dates is specified.

A2. "[Yes]" 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data abstraction was conducted independently by the same two investigators from the studies that met inclusion criteria.&quot;</span>
- Two reviewers independently extracted data. 

A3. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search terms used were “gastroschisis” and [(“treatment outcome” or “prognosis”) or randomized controlled trials].&quot;</span>
- Search terms and databases are reported.

A4. "[No]" 
- The review does not mention searching for unpublished literature.

A5. "[Yes]"
- Figure 1 provides a flow diagram of included and excluded studies.

A6. "[Yes]" 
- Table 1 provides characteristics of the included studies.

A7. "[No]"
- The review does not assess quality of included studies.

A8. "[NA]"
- Quality of studies was not assessed.

A9. "[Yes]"  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 95.7%):

Heterogeneity was assessed by the I
2
statistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Heterogeneity was assessed by the I2 statistic.&quot;</span>
- Heterogeneity was assessed where applicable.

A10. "[No]"
- Publication bias was not assessed.

A11. "[No]"
- Sources of funding are not reported for included studies.

P1. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Primary Fascial Closure versus Staged Closure with Silo in Patients with Gastroschisis: A Meta-Analysis&quot;</span>
- Identified as a meta-analysis.

P2. "[Yes]"  
- Provides a structured abstract.

P3. "[Yes]"
- Describes previous research and rationale.

P4. "[Yes]"
- Specifies participants, interventions, outcomes, and study design.

P5. "[No]"
- Does not mention a review protocol.

P6. "[Yes]"
- Describes eligibility criteria. 

P7. "[Yes]"
- Describes literature sources and dates searched.

P8. "[No]"
- Does not provide full search strategy.

P9. "[Yes]" 
- Describes study selection process and Figure 1 shows flow diagram.

P10. "[Yes]"
- States two authors independently extracted data.

P11. "[Yes]"
- Specifies outcomes extracted.

P12. "[No]" 
- Does not describe risk of bias assessment.

P13. "[Yes]"
- States summary measures used.

P14-P23. "[NA]" 
- Not applicable since no meta-analysis.

P24. "[Yes]"
- Summarizes main findings.

P25. "[Yes]" 
- Discusses limitations.

P26. "[Yes]"
- Provides interpretation and implications.

P27. "[No]"
- Does not report sources of funding.
</pre>
<p><a name='110'></a></p>
</div>
<div id="landisch-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.002' title='Open publication'>Landisch
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This study was performed according to guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [6].&quot;</span> 
The study followed PRISMA guidelines which require an a priori design.

A2. [Yes] 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 79.2%):

reviewed and extracted eligible articles. Bibliographies of identified
studies were examined to identify any additional eligible studies. Dupli-
cate listed articles were deleted. Two other independent researchers
(A.A. and A.W.) confirmed the inclusion of appropriate citations based
on study definitions and aims' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles. Bibliographies of identified studies were examined to identify any additional eligible studies. Duplicate listed articles were deleted. Two other independent researchers (A.A. and A.W.) confirmed the inclusion of appropriate citations based on study definitions and aims.&quot;</span>
The review had duplicate study selection and data extraction.

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):

An online database search for all articles published between January
1993 and January 2014 on pediatric patients using the following key-
words was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd pro-
cedure”, “Ivemark”, “asplenia”, and “polysplenia”. Searches were
repeated in PubMed, Medline, CINAHL, and Cochrane library' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An online database search for all articles published between January 1993 and January 2014 on pediatric patients using the following keywords was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd procedure”, “Ivemark”, “asplenia”, and “polysplenia”. Searches were repeated in PubMed, Medline, CINAHL, and Cochrane library.&quot;</span>
Multiple databases were searched with keywords.

A4. [No]  
No mention of searching for grey literature.

A5. [No]
No list of included/excluded studies provided. 

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eleven retrospective studies describing 649 HS patients were identified.&quot;</span> 
Table 1 provides characteristics of included studies.

A7. [No] 
No quality assessment of included studies mentioned.

A8. [NA]
No quality assessment was performed. 

A9. [NA]  
No meta-analysis was performed.

A10. [NA]
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Observation versus prophylactic Ladd procedure for asymptomatic intestinal rotational abnormalities in heterotaxy syndrome: A systematic review&quot;</span>
Identified as a systematic review in title.

P2. [Yes] 
Structured abstract provided with background, objectives, eligibility criteria, results, conclusions.

P3. [Yes]
Rationale described in introduction.

P4. [No] 
No explicit PICO statement provided.

P5. [No]
No mention of a review protocol.

P6. [Yes]
Inclusion/exclusion criteria described. 

P7. [Yes]
Information sources described.

P8. [No]
No full search strategy provided.

P9. [Yes]  
Study selection process described. 

P10. [Yes]
Data extraction process described.

P11. [Yes] 
Outcomes described.

P12. [NA] 
No assessment of risk of bias mentioned.

P13. [NA]
No meta-analysis performed.

P14. [NA] 
No meta-analysis performed.

P15. [NA]
No assessment of publication bias mentioned.

P16. [NA]
No additional analyses mentioned.

P17. [Yes]
Flow diagram of study selection provided.

P18. [Yes]
Study characteristics presented in Table 1. 

P19. [NA]
No assessment of risk of bias presented.

P20. [Yes] 
Summary data presented for outcomes.

P21. [NA]  
No meta-analysis performed.

P22. [NA]
No assessment of risk of bias across studies.

P23. [NA]
No additional analyses mentioned.

P24. [Yes] 
Main findings summarized in conclusion.

P25. [Yes]
Limitations discussed.

P26. [Yes]  
Results interpreted in context of other evidence.

P27. [No]
No mention of sources of funding.
</pre>
<p><a name='111'></a></p>
</div>
<div id="lane-2010" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-009-2475-Y' title='Open publication'>Lane
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Paediatric sutureless circumcision: a systematic literature review&quot;</span>
The research question and inclusion criteria are established in the title. [Yes]

A2. Was there duplicate study selection and data extraction? 
No mention of duplicate study selection or data extraction. [No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).&quot;</span>
No details provided on literature search strategy. [No] 

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding studies based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
Included studies are referenced, no list of excluded studies. [No]

A6. Were the characteristics of the included studies provided?
Table format not used but relevant characteristics described in text. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment tool or method described. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment done. [NA] 

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias. [No]

A11. Was the conflict of interest included? 
No statement on sources of support. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Identified as systematic review in title. [Yes]

P2. Provide a structured summary.
Abstract provides structured summary. [Yes]

P3. Describe the rationale for the review in the context of what is already known.  
Rationale described in introduction. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
Objectives stated but PICOS not specified. [No]

P5. Indicate if a review protocol exists, if and where it can be accessed.
No protocol mentioned. [No]  

P6. Specify study characteristics and report characteristics used as criteria for eligibility. 
No eligibility criteria described. [No]

P7. Describe all information sources in the search and date last searched.
No description of information sources or search. [No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
No search strategy provided. [No]

P9. State the process for selecting studies. 
No process for study selection described. [No]

P10. Describe method of data extraction from reports.
No data extraction methodology. [No] 

P11. List and define all variables for which data were sought.
No list of data variables. [No]

P12. Describe methods used for assessing risk of bias of individual studies.
No risk of bias assessment. [No]

P13. State the principal summary measures.
No quantitative synthesis performed. [NA]

P14. Describe the methods of handling data and combining results of studies, if done. 
No quantitative synthesis performed. [NA]

P15. Specify any assessment of risk of bias across studies.
No assessment of risk of bias across studies. [No]  

P16. Describe methods of additional analyses, if done.
No additional analyses. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage. 
No flow diagram or details on study selection process. [No]

P18. For each study, present characteristics for which data were extracted.
Study characteristics presented in text. [Yes]

P19. Present data on risk of bias of each study. 
No risk of bias assessment for individual studies. [No]

P20. For all outcomes considered, present simple summary data for each intervention group, effect estimates and confidence intervals.
No quantitative synthesis performed. [NA]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
No meta-analysis conducted. [NA]

P22. Present results of any assessment of risk of bias across studies.
No assessment of risk of bias across studies. [NA] 

P23. Give results of additional analyses, if done.
No additional analyses conducted. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
Main findings summarized in conclusion. [Yes]

P25. Discuss limitations at study and outcome level and at review-level.
No limitations discussed. [No]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
General interpretation and implications provided in conclusion. [Yes]

P27. Describe sources of funding for the systematic review and other support.
No statement on sources of funding. [No]
</pre>
<p><a name='112'></a></p>
</div>
<div id="lansdale-2010" class="section level4">
<h4><a href='https://doi.org/10.1097/SLA.0B013E3181DCA0E8' title='Open publication'>Lansdale
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. "[Yes]"
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):

we have per-
formed a systematic review and meta-analysis of studies that com-
pares survival, CDH recurrence risk, operative time and prosthetic
patch usage between CDH neonates whose repair was approached
by MIS and those where it was undertaken by open surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We have therefore performed a systematic review and meta-analysis of studies that compares survival, CDH recurrence risk, operative time and prosthetic patch usage between CDH neonates whose repair was approached by MIS and those where it was undertaken by open surgery.&quot;</span> (Introduction)
- The research question and inclusion criteria are clearly established before conducting the review.

A2. "[Yes]" 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two independent reviewers reviewed all studies in abstract form.&quot;</span> (Eligibility Criteria and Study Selection)
- There were at least two independent data extractors.

A3. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎MEDLINE (1950 to present), Embase (1980 to present) and Cochrane Controlled Trials Register databases were searched&quot;</span> (Information Sources and Search Technique)  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Relevant conference proceedings were also searched for abstracts of appropriate studies.&quot;</span> (Information Sources and Search Technique)
- At least two electronic sources were searched along with supplementary strategies.

A4. "[No]"
- No mention of searching for gray literature.

A5. "[Yes]"
- Figure 2 shows a flow chart with studies included and excluded.

A6. "[Yes]" 
- Table 1 provides aggregated data on the participants, interventions and outcomes.

A7. "[No]"
- The quality of included studies was not formally assessed. 

A8. "[NA]"

A9. "[NA]" 

A10. "[No]"
- Publication bias was not assessed.

A11. "[No]"
- Sources of funding are not reported for the review or the included studies.

P1. "[Yes]"
- The title identifies it as a systematic review and meta-analysis.

P2. "[Yes]" 
- The abstract provides background, objectives, eligibility criteria, data sources, synthesis methods, results, limitations, and conclusions.

P3. "[Yes]"
- The introduction describes the rationale in context of current knowledge.

P4. "[Yes]"
- The introduction states the questions addressed regarding participants, interventions, comparisons, outcomes, and study design.

P5. "[No]"
- No protocol is mentioned.

P6. "[Yes]"
- The eligibility criteria describe included study characteristics. 

P7. "[Yes]" 
- The information sources section describes the databases searched and date last searched.

P8. "[No]"
- The full search strategy is not provided.

P9. "[Yes]"
- The study selection process is described and depicted in a flow diagram. 

P10. "[Yes]"  
- The data collection process is described.

P11. "[Yes]"
- Outcomes sought are listed in the Introduction.

P12. "[No]"
- Risk of bias assessment is not described.

P13. "[Yes]"
- The outcome measures are listed.

P14. "[NA]"

P15. "[NA]"

P16. "[NA]"

P17. "[Yes]" 
- The flow diagram depicts studies screened, assessed, and reasons for exclusion.

P18. "[No]"
- Study characteristics are not presented.

P19. "[No]" 

P20. "[Yes]"
- Results are presented with summary data and effect estimates.

P21. "[NA]"

P22. "[NA]"

P23. "[NA]"

P24. "[Yes]"
- Main findings and limitations are summarized. 

P25. "[Yes]"
- Limitations are discussed.

P26. "[Yes]"
- Results are interpreted in context of other evidence.

P27. "[No]"
- No funding sources reported.
</pre>
<p><a name='113'></a></p>
</div>
<div id="lee-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2010.06.038' title='Open publication'>Lee
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review:

A1. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were obtained from PubMed, MEDLINE, and citation review.&quot;</span>
Stated searching databases. [Yes]

A2. 
No mention of duplicate study selection or data extraction. [No] 

A3. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed and other databases of the English literature (up to August 2009) were analyzed.&quot;</span>
Stated searching PubMed and other databases. [Yes]

A4. 
No mention of searching for grey literature. [No]

A5. 
No list of included or excluded studies provided. [No]

A6. 
Study characteristics summarized in Tables 1 and 2. [Yes] 

A7. 
No quality assessment of included studies mentioned. [No]

A8. 
Not applicable since no quality assessment done. [NA] 

A9. 
No quantitative synthesis done. [NA]

A10. 
No assessment of publication bias mentioned. [No] 

A11. 
No mention of conflicts of interest. [No]

P1. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Antibiotics and appendicitis in the pediatric population: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee Systematic Review&quot;</span> [Yes]

P2. 
Provides background, objectives, data sources, eligibility criteria, results and conclusions. No registration number provided. [No] 

P3. 
Provides context and rationale in introduction. [Yes]

P4. 
Provides objectives and PICOS elements. [Yes] 

P5. 
No mention of a review protocol. [No]

P6.  
Describes eligibility criteria. [Yes]

P7.  
States databases searched. [Yes]

P8. 
Does not provide full search strategy. [No]

P9.
Describes study selection process. [Yes] 

P10. 
No description of data extraction process. [No]

P11.
No list of variables extracted. [No] 

P12. 
No assessment of risk of bias mentioned. [NA] 

P13.
Not applicable. [NA]

P14.  
Not applicable. [NA]

P15.  
Not applicable. [NA]

P16.  
Not applicable. [NA] 

P17. 
No flow diagram or details on study selection process. [No]

P18. 
Study characteristics presented in Tables 1 and 2. [Yes]

P19.  
No assessment of risk of bias. [NA]

P20.  
Not applicable. [NA]

P21.  
Not applicable. [NA]

P22.  
Not applicable. [NA]

P23.  
Not applicable. [NA]

P24. 
Summarizes main findings and conclusions. [Yes]

P25. 
No discussion of limitations. [No]

P26. 
Provides interpretation of results. [Yes] 

P27. 
No statement on sources of funding. [No]
</pre>
<p><a name='114'></a></p>
</div>
<div id="leevan-2016" class="section level4">
<h4><a href='https://doi.org/10.1097/TA.0000000000000950' title='Open publication'>LeeVan
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the systematic review using AMSTAR and PRISMA 2009:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
[Yes] The objectives are clearly stated in the Introduction: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This study aimed to review current practices in pediatric blunt renal trauma management and to highlight current practices in conservative protocols, success rates of conservative management strategies, as well as short- and long-term outcomes of blunt renal trauma management.&quot;</span>

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.&quot;</span>  
[No] The methods section does not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE).&quot;</span>
[Yes] The methods state: <span title='Moderate quote deviation. Best match in fulltext (Similarity 76.5%):

PubMed, Ovid, and the Cochrane Library. The following search was performed in each of
the three databases: (Renal or Kidney) AND (Pediatric or Children) AND Trauma AND Management. Publications were
limited to publish date after January 1, 2000' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A search of all original research studies was conducted using PubMed, Ovid, and the Cochrane Library. The following search was performed in PubMed: (Renal or Kidney) AND (Pediatric or Children) AND Trauma AND Management. Publications were limited to publish date after January 1, 2000.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
[No] The review did not mention searching for grey literature.

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎A list of included and excluded studies should be provided.&quot;</span>
[No] No list of excluded studies is provided.

A6. Were the characteristics of the included studies provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span>
[Yes] Table 2 provides relevant characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria).&quot;</span>
[Yes] The methods state: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Bias was assessed using the Cochrane risk of bias assessment tool (Fig. 1).&quot;</span> And Figure 1 shows the tool used.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span>
[Yes] The limitations section acknowledges the lack of randomized trials and the reliance on retrospective studies. 

A9. Were the methods used to combine the findings of studies appropriate? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>
[NA] The findings were not combined quantitatively.

A10. Was the likelihood of publication bias assessed?
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span>
[NA] Assessment of publication bias is not applicable, as no meta-analysis was performed.

A11. Was the conflict of interest included? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
[Yes] The conflict of interest statement indicates no conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes] The title clearly identifies it as a systematic review.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[Yes] The abstract provides a structured summary covering all key elements.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] The introduction provides context and rationale, summarizing the evidence and knowledge gaps.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  
[No] The review does not frame questions in a PICOS format.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No] No review protocol is mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Yes] The methods section specifies inclusion/exclusion criteria including population, interventions, outcomes, and study types. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 
[Yes] The methods section describes the databases searched, search terms, limits applied, and date range.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[No] The full search strategy is not presented for any database.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[Yes] The methods section describes the screening and selection process.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
[No] The methods do not describe the data extraction process.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[Yes] Table 2 lists the key variables extracted from each study.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
[Yes] The methods section states that the Cochrane risk of bias tool was used to assess study bias.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[NA] No meta-analysis was performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
[NA] No meta-analysis was performed. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA] No assessment of publication bias or selective reporting was performed since no meta-analysis was conducted.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. 
[NA] No additional analyses were performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[No] The number of records screened and assessed is not reported. No flow diagram is provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
[Yes] Table 2 presents relevant extracted characteristics for each included study. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[No] Individual study bias assessments are not presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[NA] Outcome data were summarized narratively; no quantitative synthesis was performed.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA] No meta-analysis was performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
[NA] No assessment of risk of bias across studies was done since no meta-analysis was performed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) (see Item P16).
[NA] No additional analyses were performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes] The discussion summarizes the main findings and their implications.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Yes] The limitations section acknowledges the lack of randomized trials, small sample sizes, retrospective designs, and heterogeneity in reporting.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes] The discussion interprets the findings in the context of the current literature and provides implications for research.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
[Yes] The disclosure statement indicates no funding sources or conflicts of interest.
</pre>
<p><a name='115'></a></p>
</div>
<div id="liang-2011" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0031-1271733' title='Open publication'>Liang
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the AMSTAR and PRISMA items for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

A search
was made for all studies published up until 31 August 2010
using the terms “lymphatic sparing varicocelectomy”, “laparos-
copy” , “adolescent ” and “children ” in the Medline (using PubMed
as the search engine), Embase, Ovid, Web of Science, and
Cochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A search was made for all studies published up until 31 August 2010 using the terms “lymphatic sparing varicocelectomy”, “laparoscopy”, “adolescent” and “children” in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span> The review did not mention a protocol, ethics approval, or pre-determined research objectives.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The citations and/ or abstracts or the full text
of all potentially relevant studies were independently evaluated
and selected by 3 reviewers (LZL, GJ and TQS), and any disagree-
ments were resolved by consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The citations and/ or abstracts or the full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers (LZL, GJ and TQS), and any disagreements were resolved by consensus.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

A search
was made for all studies published up until 31 August 2010
using the terms “lymphatic sparing varicocelectomy”, “laparos-
copy” , “adolescent ” and “children ” in the Medline (using PubMed
as the search engine), Embase, Ovid, Web of Science, and
Cochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A search was made for all studies published up until 31 August 2010 using the terms “lymphatic sparing varicocelectomy”, “laparoscopy”, “adolescent” and “children” in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span> The review searched multiple databases without date or language restrictions. 

A4. Was the status of publication used as an inclusion criterion? [No]
The authors did not state whether they searched for or included grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
The review did not provide a list of included and excluded studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 summarizes characteristics like study design, number of patients, age, and indications.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
The review did not assess the quality of included studies.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
The review used appropriate methods like odds ratios, 95% CIs, heterogeneity tests, and random effects models for the meta-analysis. 

A10. Was the likelihood of publication bias assessed? [No]
Publication bias was not assessed.

A11. Was the conflict of interest included? [No] 
Conflicts of interest were not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review and meta-analysis was performed using odds ratios (ORs) for dichotomous variables.&quot;</span>

P2. Provide a structured summary. [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review. [Yes] 
The introduction describes the rationale around lymphatic sparing to reduce complications.

P4. Provide an explicit statement of questions. [No]
The review did not state explicit questions or PICOS criteria.

P5. Indicate if a review protocol exists. [No]
The review did not mention a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
The methods section describes the inclusion criteria like study design, interventions, and outcomes. 

P7. Describe all information sources in the search and date last searched. [Yes]
The methods describe the databases searched without date restrictions until August 31, 2010.

P8. Present full electronic search strategy for at least one database. [No] 
The search strategy was not presented.

P9. State the process for selecting studies. [Yes]  
The methods describe the study selection process including screening and consensus procedures.

P10. Describe method of data extraction. [No] 
The review did not describe the data extraction process. 

P11. List and define all variables for which data were sought. [No]
The extracted variables were not defined.

P12. Describe methods for assessing risk of bias. [No]
Risk of bias methods were not described.

P13. State the principal summary measures. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎ORs were used for the analysis of dichotomous variables. The CI was established at 95%.&quot;</span>

P14-P23. [NA]
These items are about quantitative synthesis methods which are not applicable since this review did not perform meta-regression or subgroup analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
The discussion summarizes the main findings.

P25. Discuss limitations at study and outcome level. [No]
Limitations were not discussed. 

P26. Provide a general interpretation of results in context of other evidence. [Yes]
The discussion interprets the findings in the context of previous studies.

P27. Describe sources of funding and role of funders. [Yes] 
Sources of funding are described at the end.
</pre>
<p><a name='116'></a></p>
</div>
<div id="lishuang-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3662-7' title='Open publication'>Lishuang
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. "[Yes]"
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

This systematic review and meta-analysis were under-
taken with a prospective protocol according to the latest
guidelines of meta-analysis (PRISMA) [14' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This systematic review and meta-analysis were undertaken with a prospective protocol according to the latest guidelines of meta-analysis (PRISMA) [14].&quot;</span> 
2. The review mentions following a protocol.

A2. "[Yes]"  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

Two investigators independently asses-
sed selected studies and extracted the following informa-
tion: study characteristics, quality, outcomes data, etc' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two investigators independently assessed selected studies and extracted the following information: study characteristics, quality, outcomes data, etc.&quot;</span>
2. Two reviewers performed study selection and data extraction. 

A3. "[Yes]"
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

We conducted a system-
atic search of the online databases, including Medline,
Ovid, Elsevier, Google Scholar Embase, Cohrane library,
for studies published between 1995 and 2014 with no
limits for publication language, place of study origin and
sample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;</span>
2. Searched multiple databases without language or date restrictions.

A4. "[No]"
1. The review does not mention searching for gray literature.
2. No indication of searching for unpublished literature.

A5. "[No]" 
1. The review does not provide a list of included/excluded studies.
2. No list of included or excluded studies provided.

A6. "[Yes]"
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The characteristics of these 11 studies are listed in Table 1.&quot;</span> 
2. Table 1 provides aggregated characteristics of included studies.

A7. "[No]"
1. The review does not mention use of a quality assessment tool for included studies. 
2. No quality assessment of included studies mentioned. 

A8. "[NA]"
1. Not applicable since no quality assessment was performed.
2. Can't use quality in conclusions without assessment.

A9. "[Yes]"  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the presence of significant heterogeneity, pooled estimates of the ORs and MDs were calculated using a random-effects approach [20].&quot;</span>
2. Accounts for heterogeneity in statistical analyses.

A10. "[No]"
1. The review does not assess publication bias.
2. No assessment of publication bias mentioned.

A11. "[No]"
1. The review does not report on conflicts of interest.
2. No mention of conflicts of interest.

P1. "[Yes]" 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

Laparoscopic portoenterostomy versus open portoenterostomy
for the treatment of biliary atresia: a systematic review and meta-
analysis of comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopic portoenterostomy versus open portoenterostomy for the treatment of biliary atresia: a systematic review and meta-analysis of comparative studies&quot;</span>
2. Identified as a systematic review and meta-analysis in title.

P2. "[Yes]"
1. The abstract provides a structured summary with objectives, eligibility criteria, sources, syntheses methods, results, and conclusions.
2. Structured abstract provided.

P3. "[Yes]" 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Since first reported by Kasai and Suzuki [8] in 1959, portoenterostomy (PE) remains the mainstay of treating BA.&quot;</span>
2. Provides context about current management of biliary atresia. 

P4. "[Yes]"
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The aim of
this study was to include all publicly available data for
comparing the safety and validity of laparoscopic porto-
enterostomy (LPE) and open portoenterostomy (OPE) in
the treatment of biliary atresia' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of this study was to include all publicly available data for comparing the safety and validity of laparoscopic portoenterostomy (LPE) and open portoenterostomy (OPE) in the treatment of biliary atresia.&quot;</span> 
2. Specifies participants, interventions, and outcomes.

P5. "[No]"
1. The review does not mention a protocol.
2. No protocol mentioned.

P6. "[Yes]" 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 97%):

We conducted a system-
atic search of the online databases, including Medline,
Ovid, Elsevier, Google Scholar Embase, Cohrane library,
for studies published between 1995 and 2014 with no
limits for publication language, place of study origin and
sample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases...for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;</span>
2. Specifies study eligibility criteria.

P7. "[Yes]"  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

We conducted a system-
atic search of the online databases, including Medline,
Ovid, Elsevier, Google Scholar Embase, Cohrane library,
for studies published between 1995 and 2014 with no
limits for publication language, place of study origin and
sample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;</span>
2. Lists literature sources searched.

P8. "[No]"
1. The full search strategy is not provided for any database. 
2. No reproducible search strategy shown.

P9. "[Yes]"
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The process of study screening is showed in Fig. 1, through which, eleven studies assessing LPE versus OPE were considered suitable for meta-analysis&quot;</span>
2. Describes the study selection process.

P10. "[Yes]"  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):

Two investigators independently asses-
sed selected studies and extracted the following informa-
tion: study characteristics, quality, outcomes data, etc' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two investigators independently assessed selected studies and extracted the following information: study characteristics, quality, outcomes data, etc.&quot;</span>
2. States that data extraction was done independently in duplicate.

P11. "[Yes]" 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

The following data were the
outcomes of interest that extracted from each included
study: first author, publication year, country, study design,
number of patients who underwent LPE or OPE, charac-
teristics of the study population, and end point data
(operative times, hospital stay times, rate of conversion
from LPE to OPE, re-operation rates, and complications
about surgery including: intraoperative blood loss, early
clearance of jaundice, cholangitis and variceal bleeding' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The following data were the outcomes of interest that extracted from each included study: first author, publication year, country, study design, number of patients who underwent LPE or OPE, characteristics of the study population, and end point data (operative times, hospital stay times, rate of conversion from LPE to OPE, re-operation rates, and complications about surgery including: intraoperative blood loss, early clearance of jaundice, cholangitis and variceal bleeding.&quot;</span>
2. Lists extracted variables.

P12. "[No]"
1. The review does not describe assessment of risk of bias.
2. No risk of bias assessment mentioned.

P13. "[Yes]"
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

For categorical variables data,
262 Pediatr Surg Int (2015) 31:261–269
123

statistical analysis was performed using the odds ratio (OR)
as the statistic summary. This odds ratio represents the
odds of an adverse event occurring in the LPE group
compared with the OPE group. Statistical analysis for
continuous variables was performed using the mean dif-
ference (MD) and as the summary statistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For categorical variables data, statistical analysis was performed using the odds ratio (OR) as the statistic summary. This odds ratio represents the odds of an adverse event occurring in the LPE group compared with the OPE group. Statistical analysis for continuous variables was performed using the mean difference (MD) and as the summary statistic.&quot;</span>
2. Specifies summary measures used.

P14. "[Yes]" 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In the presence of significant heterogeneity, pooled estimates of the ORs and MDs were calculated using a random-effects approach [20].&quot;</span>
2. Describes methods used to combine data.

P15. "[No]"  
1. The review does not assess publication bias.
2. No assessment of publication bias.

P16. "[No]"
1. No additional analyses are described.
2. No additional analyses mentioned. 

P17. "[Yes]"
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The process of study screening is showed in Fig. 1, through which, eleven studies assessing LPE versus OPE were considered suitable for meta-analysis&quot;</span> 
2. Presents the study selection process in a flow diagram.

P18. "[Yes]"
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The characteristics of these 11 studies are listed in Table 1.&quot;</span>
2. Table 1 provides characteristics of included studies.

P19. "[No]"
1. The review does not assess risk of bias.
2. No assessment of risk of bias presented.

P20. "[Yes]"
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Forest plot of comparison, Operative time&quot;</span>
2. Provides forest plots for meta-analyses.

P21. "[Yes]" 
1. <span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):

Present results of each meta-analysis done, including confidence intervals' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Presents results of each meta-analysis done, including confidence intervals&quot;</span> 
2. Presents meta-analysis results with CIs.

P22. "[NA]"
1. Not applicable since risk of bias not assessed.
2. Can't present synthesis of bias without assessment.

P23. "[NA]" 
1. No additional analyses conducted.
2. Not applicable as no additional analyses done.

P24. "[Yes]"
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our meta-analysis suggested that compared with OPE, LPEs were considered to be a poor treatment for BA in long-term outcomes with low 2-year survival of native liver&quot;</span>
2. Summarizes main findings.

P25. "[No]"
1. Limitations are not discussed.
2. No limitations stated.

P26. "[Yes]"  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Further improvements in the laparoscopic
portoenterostomy are needed before its widespread appli-
cation can be recommended' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Further improvements in the laparoscopic portoenterostomy are needed before its widespread application can be recommended.&quot;</span>
2. Provides implications for future research.

P27. "[No]"
1. Sources of funding are not reported.
2. No statement about funding sources.
</pre>
<p><a name='117'></a></p>
</div>
<div id="livingston-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.02.020' title='Open publication'>Livingston
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted a structured search...&quot;</span>
Reasoning: The review had a predefined protocol. 

A2. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Title and abstract screening was completed independently and in duplicate by two of the authors...&quot;</span>
Reasoning: Two reviewers independently selected studies.

A3. "[Yes]"
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 95.5%):

We conducted a systematic search of Medline, Embase, and
Cochrane Central Register of Controlled Trials for studies of participants
with gastroesophageal reflux treated with FG or GJ. A medical librarian
helped us develop queries for each database to identify studies that
mentioned fundoplication and gastrojejunostomy. These concepts were
expanded to ensure that no studies were missed due to variation in syn-
tax and nomenclature. We also performed manual searches of relevant
journals, conference proceedings [13], theses and dissertations [14–16],
and other trial registries' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of Medline, Embase, and Cochrane Central Register of Controlled Trials...", "A medical librarian helped us develop queries for each database...", "We also performed manual searches of relevant journals, conference proceedings, theses and dissertations, and other trial registries.&quot;</span>
Reasoning: Searched multiple databases, supplementary sources, and trial registries.

A4. "[No]"
Quotes: No mention of searching for grey literature.
Reasoning: Did not state whether grey literature was searched. 

A5. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An overview of the search strategy and results is depicted in Fig. 1.&quot;</span> 
Reasoning: Included a flow diagram of included and excluded studies.

A6. "[Yes]"
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 77.8%):

Studies were included if participants were less
than 18 years of age, had neurologic impairments, and a clinical history
or investigation suggestive of gastroesophageal reflux.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Studies were included if participants were less than 18 years of age, had neurologic impairments, and a clinical history or investigation suggestive of gastroesophageal reflux.", "Table 1. Characteristics of included studies.&quot;</span>
Reasoning: Provided participant characteristics in table format.

A7. "[No]"
Quotes: No mention of quality assessment. 
Reasoning: Did not assess quality of included studies.

A8. "[NA]"
Reasoning: Since quality was not assessed, quality was not incorporated into conclusions.

A9. "[NA]" 
Reasoning: No meta-analysis was performed.

A10. "[NA]"
Reasoning: No meta-analysis was performed.

A11. "[No]"
Quotes: No mention of conflicts of interest.
Reasoning: Did not provide conflicts of interest.

P1. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fundoplication and gastrostomy versus percutaneous gastrojejunostomy for gastroesophageal reflux in children with neurologic impairment: A systematic review and meta-analysis&quot;</span>
Reasoning: Identified as a systematic review in the title.

P2. "[Yes]"
Quotes: Provides a structured abstract.
Reasoning: Included the key elements in the abstract.

P3. "[Yes]"  
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):

In light of these uncertainties, we conducted a systematic review to
determine if FG and GJ are equally effective for the treatment of gastro-
esophageal reflux refractory to maximal medical management in chil-
dren with neurologic impairment' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In light of these uncertainties, we conducted a systematic review to determine if FG and GJ are equally effective for the treatment of gastroesophageal reflux refractory to maximal medical management in children with neurologic impairment.&quot;</span>
Reasoning: Described rationale and context.

P4. "[Yes]"
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

we conducted a systematic review to
determine if FG and GJ are equally effective for the treatment of gastro-
esophageal reflux refractory to maximal medical management in chil-
dren with neurologic impairment' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic review to determine if FG and GJ are equally effective for the treatment of gastroesophageal reflux refractory to maximal medical management in children with neurologic impairment.&quot;</span> 
Reasoning: Stated objective and PICO elements.

P5. "[No]"
Quotes: No mention of a protocol.
Reasoning: Did not indicate if a protocol exists.

P6. "[Yes]" 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies were included if participants were less than 18 years of age, had neurologic impairments, and a clinical history or investigation suggestive of gastroesophageal reflux. Interventions had to be first-time FG and GJ.&quot;</span>
Reasoning: Provided eligibility criteria. 

P7. "[Yes]"
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):

We conducted a systematic search of Medline, Embase, and
Cochrane Central Register of Controlled Trials for studies of participants
with gastroesophageal reflux treated with FG or GJ. A medical librarian
helped us develop queries for each database to identify studies that
mentioned fundoplication and gastrojejunostomy. These concepts were
expanded to ensure that no studies were missed due to variation in syn-
tax and nomenclature. We also performed manual searches of relevant
journals, conference proceedings [13], theses and dissertations [14–16],
and other trial registries' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of Medline, Embase, and Cochrane Central Register of Controlled Trials...", "We also performed manual searches of relevant journals, conference proceedings, theses and dissertations, and other trial registries.&quot;</span> 
Reasoning: Described information sources.

P8. "[No]"
Quotes: No full search strategy provided.
Reasoning: Did not provide full search strategy.

P9. "[Yes]" 
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

Title and abstract screening was completed independently and in
duplicate by two of the authors (MHL, ACS). Disagreements resulted
in automatic inclusion' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Title and abstract screening was completed independently and in duplicate by two of the authors. Disagreements resulted in automatic inclusion.&quot;</span>
Reasoning: Described study selection process.

P10. "[No]"
Quotes: No mention of data extraction process.
Reasoning: Did not describe data extraction methods.

P11. "[No]" 
Quotes: No description of variables sought.
Reasoning: Did not list variables extracted.

P12. "[No]"
Quotes: No mention of risk of bias assessment.
Reasoning: Did not describe risk of bias assessment.

P13. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Summary statistics were reported as risk ratios with 95% confidence intervals and p-values.&quot;</span> 
Reasoning: Specified summary measures used.

P14-P16. "[NA]"
Reasoning: No meta-analysis performed.

P17. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An overview of the search strategy and results is depicted in Fig. 1.&quot;</span>
Reasoning: Provided a flow diagram. 

P18. "[Yes]"
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 93.3%):

Table 1
Characteristics of included studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Table 1. Characteristics of included studies.&quot;</span>
Reasoning: Presented characteristics of included studies.

P19. "[No]"
Quotes: No assessment of risk of bias. 
Reasoning: Did not assess risk of bias.

P20. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We found that the rates of mortality and pneumonia following either procedure are similar...&quot;</span>
Reasoning: Provided summary data for main outcomes.

P21-P23. "[NA]" 
Reasoning: No meta-analysis performed.

P24. "[Yes]"
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 93.3%):

he evidence
The quality of evidence for mortality, pneumonia, major complica-
tions, and minor complications following FG versus GJ for refractory
gastroesophageal reflux in children with neurologic impairment' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The quality of evidence for mortality, pneumonia, major complications, and minor complications following FG versus GJ for refractory gastroesophageal reflux in children with neurologic impairment was very low.&quot;</span>
Reasoning: Summarized main findings and strength of evidence.

P25. "[Yes]" 
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 51.3%):

y low (Table 3). Using the GRADE approach, the quality of evidence
for all outcomes was downgraded from low to very low due to serious
risk of bias bet' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Risk of bias for individual studies was assessed in duplicate using the methodological index for nonrandomized studies (MINORS).", "Using the GRADE approach, the quality of evidence for all outcomes was downgraded from low to very low due to serious risk of bias between studies.&quot;</span>
Reasoning: Discussed limitations at study and outcome level.

P26. "[Yes]"
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 86.1%):

cores [32].
Researchers should adopt several strategies to improve the quality o' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Researchers should adopt several strategies to improve the quality of evidence.&quot;</span>
Reasoning: Discussed implications for future research.

P27. "[No]"
Quotes: No mention of funding sources.
Reasoning: Did not provide funding information.
</pre>
<p><a name='118'></a></p>
</div>
<div id="mauritz-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S11605-013-2305-3' title='Open publication'>Mauritz
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review was conducted according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement.&quot;</span> The review followed the PRISMA guidelines.

A2. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Titles and abstracts of all retrieved records, and subsequently full-text articles (full-texts were obtained for articles that appeared potentially relevant), were examined independently by two authors (F.M. and B.B.) according to the PRISMA statement.&quot;</span> Two independent reviewers performed study selection. 

A3. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Using predefined search
terms PubMed (1960 to 2011), EMBASE (from 1980 to
2011), and the Cochrane Library (issue 3, 2011) were system-
atically searched until March 16, 2011 to identify all articles
comparing complete to partial fundoplication in children
with GERD' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD.&quot;</span> Multiple databases were searched systematically.

A4. [No]
No mention of searching for grey literature.

A5. [Yes]
Figure 1 provides a list of included and excluded studies.

A6. [Yes] 
Table 1 provides key characteristics of the included studies.

A7. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Using predefined criteria, two authors (F.M. and B.B) included
studies and assessed their methodological quality and risk of
bias according to the PRISMA statement
20,21 
and the Cochrane
Collaboration&#39;s tool for risk of bias assessment' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined criteria, two authors (F.M. and B.B) included studies and assessed their methodological quality and risk of bias according to the PRISMA statement and the Cochrane Collaboration's tool for risk of bias assessment.&quot;</span> The quality of included studies was assessed.  

A8. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎However, because of the lack of a well-designed study, we have to be cautious in making definitive conclusions.&quot;</span> The limitations of the quality of studies was considered in the conclusions.

A9. [Yes] 
Appropriate methods were used for the meta-analyses performed. Heterogeneity was assessed.

A10. [No]  
No assessment of publication bias mentioned.

A11. [No]
No mention of conflicts of interest for the included studies.

P1. [Yes]
The title identifies it as a systematic review and meta-analysis.

P2. [Yes] 
The abstract provides relevant details on background, objectives, methods, results, and conclusions.

P3. [Yes]
The introduction provides context and rationale.

P4. [Yes]  
The objectives relate to participants, interventions, comparisons, and outcomes. 

P5. [No] 
No protocol mentioned.

P6. [Yes]  
Eligibility criteria described including participants, interventions, comparators, and outcomes of interest.

P7. [Yes]  
Details provided on information sources including databases searched.

P8. [Yes]
Search strategy provided for PubMed. 

P9. [Yes] 
Study selection process described and depicted in Figure 1.

P10. [Yes]  
Data extraction performed by two independent reviewers.

P11. [Yes]  
Outcomes of interest defined.

P12. [Yes]  
Quality assessment methods described. 

P13. [Yes]
Summary measures described.

P14. [NA]
Not applicable.

P15. [NA]  
Not applicable.

P16. [NA]
Not applicable.

P17. [Yes]  
Study flow shown in Figure 1.

P18. [Yes] 
Table 1 shows key characteristics of included studies.

P19. [Yes]
Table 1 summarizes risk of bias.

P20. [Yes] 
Results for each outcome presented with summary data and forest plots. 

P21. [NA]  
Not applicable.

P22. [NA]
Not applicable. 

P23. [NA]
Not applicable.

P24. [Yes] 
Main findings summarized in discussion.

P25. [Yes] 
Limitations discussed.

P26. [Yes]  
Results interpreted in context of other evidence. Implications described.

P27. [No]
No mention of sources of funding or support.
</pre>
<p><a name='119'></a></p>
</div>
<div id="mauritz-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S11605-011-1644-1' title='Open publication'>Mauritz
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 
[No] No mention of a protocol or pre-determined research objectives.

A2. Was there duplicate study selection and data extraction?
[No] No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
[Yes] <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.4%):

Three electronic databases (Medline, Embase, and the Cochrane Library) were searched for' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Three electronic databases (Medline, Embase, and the Cochrane Library) were searched for all articles published until November 10, 2010.&quot;</span>

A4. Was the status of publication used as an inclusion criterion?  
[No] No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided?
[No] No list of excluded studies provided.

A6. Were the characteristics of the included studies provided?
[Yes] Table 1 provides characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented?
[No] No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[NA] Study quality not assessed.

A9. Were the methods used to combine the findings of studies appropriate?
[NA] No meta-analysis performed.

A10. Was the likelihood of publication bias assessed?  
[NA] No assessment of publication bias mentioned.  

A11. Was the conflict of interest included?
[No] No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes] Identified as systematic review in title.

P2. Provide a structured summary.
[Yes] Structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] Introduction describes rationale.

P4. Provide an explicit statement of questions being addressed with reference to PICOS.
[No] No explicit PICOS statement.

P5. Indicate if a review protocol exists. 
[No] No mention of a protocol.

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
[Yes] Inclusion and exclusion criteria described in Methods.

P7. Describe all information sources in the search.
[Yes] Sources and dates listed in Methods.  

P8. Present full electronic search strategy for at least one database.
[Yes] Search strategy provided for PubMed.

P9. State the process for selecting studies.
[Yes] Study selection process described in Methods.

P10. Describe method of data extraction.
[No] No details provided on data extraction process.

P11. List and define all variables for which data were sought.
[No] Outcomes of interest listed but no details on specific data extraction.

P12. Describe methods for assessing risk of bias. 
[No] No risk of bias assessment mentioned.

P13. State the principal summary measures.
[NA] No meta-analysis performed.

P14-P23. [NA] No quantitative synthesis performed.

P24. Summarize the main findings including the strength of evidence for each main outcome.
[Yes] Main findings summarized in Discussion.

P25. Discuss limitations at study and outcome level and at review-level.
[Yes] Limitations discussed in Discussion.

P26. Provide a general interpretation of the results in the context of other evidence.
[Yes] Results interpreted in Discussion.  

P27. Describe sources of funding for the systematic review.
[No] No statement on funding sources.
</pre>
<p><a name='120'></a></p>
</div>
<div id="mei-2011" class="section level4">
<h4><a href='https://doi.org/10.1089/END.2010.0544' title='Open publication'>Mei
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA 2009 assessments for the given systematic review:

A1: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎the literature search, quality assessment, and data extraction were independently performed by two reviewers&quot;</span>
Explanation: The review states that study selection and data extraction were done in duplicate.

A2: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎the literature search, quality assessment, and data extraction were independently performed by two reviewers&quot;</span>  
Explanation: The review states that study selection and data extraction were done in duplicate.

A3: [Yes] <span title='Moderate quote deviation. Best match in prompt (Similarity 82.3%):

e searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane...All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;</span>
Explanation: The review searched multiple databases and supplemented with additional strategies. 

A4: [No] The review does not mention searching for grey literature.

A5: [Yes] <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.5%):

study selection, 2 people do' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Flowchart of study selection is provided in Figure 1.&quot;</span>
Explanation: The review includes a flow diagram depicting included and excluded studies.

A6: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A summary of the studies’ methodology, participant features, intervention characteristics, measured outcomes, and the use of stents and drainage is provided in Tables 1 to 4.&quot;</span>  
Explanation: The review provides aggregated details on participants, interventions, and outcomes in table format.

A7: [No] The review does not report assessing the quality of individual studies.

A8: [NA] Since study quality was not assessed, it was not used in formulating conclusions.

A9: [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):

statistical heterogeneity was as-
sessed via the I 
2 
inde' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Statistical heterogeneity was assessed via the I2 index.&quot;</span>  
Explanation: The review assessed heterogeneity using I2 statistics.

A10: [No] The review does not report assessing publication bias.

A11: [No] The review does not report on sources of funding/support for included studies.

P1: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic Versus Open Pyeloplasty for Ureteropelvic Junction Obstruction in Children: A Systematic Review and Meta-Analysis&quot;</span>
Explanation: The title identifies the report as a systematic review and meta-analysis.

P2: [Yes] The abstract provides a structured summary.

P3: [Yes] The introduction describes the rationale and background.

P4: [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):

To comprehensively review the available evidences in the literature on the use of laparoscopic pye-
loplasty (LP) vs open pyeloplasty (OP) for the repair of ureteropelvic junction (UPJ) obstruction in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To comprehensively review the available evidences in the literature on the use of laparoscopic pyeloplasty (LP) vs open pyeloplasty (OP) for the repair of ureteropelvic junction (UPJ) obstruction in children.&quot;</span>  
Explanation: The review describes the PICO elements in the objectives.

P5: [No] The review does not mention a protocol.

P6: [Yes] <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.2%):

criteria included all
available studies that compared LP with OP for the repair of
UPJ obstructions in the pediatric population' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Inclusion criteria included all available studies that compared LP with OP for the management of UPJ obstruction in the pediatric population younger than 18 years.&quot;</span>
Explanation: The review describes eligibility criteria including population, interventions, and study designs considered. 

P7: [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

We searched online databases, including Medline
(using PubMed as the search engine), Embase, Web of Science,
Ovid, and Cochrane, to identify suitable studies until the end of
October 2010, without lower date limit. The ‘‘pyeloplasty,’’
‘‘laparoscopy,’’ ‘‘laparoscopic pyeloplasty,’’ and ‘‘ureteropelvic
junction obstruction’’ were used as search terms' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane... The ‘‘pyeloplasty,’’ ‘‘laparoscopy,’’ ‘‘laparoscopic pyeloplasty,’’ and ‘‘ureteropelvic junction obstruction’’ were used as search terms.&quot;</span>
Explanation: The review describes the databases searched and search terms used.

P8: [No] The review does not provide a full search strategy.

P9: [Yes] <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.5%):

study selection, 2 people do' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Flowchart of study selection is provided in Figure 1.&quot;</span> 
Explanation: The review describes the study screening and selection process in a flow diagram.

P10: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎the literature search, quality assessment, and data extraction were independently performed by two reviewers&quot;</span>
Explanation: The review states that data extraction was done by two reviewers independently. 

P11: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data regarding the following factors were considered: Study methodology, participant features, intervention characteristics, definition of complications, and outcome measures.&quot;</span>
Explanation: The review describes the variables extracted.

P12: [No] The review does not describe assessing risk of bias in individual studies.

P13: [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Meta-analyses were performed for the five primary out-
come parameters: Operative time (in minutes), postoperative
complications (in events per group), duration of hospital stay
(in days), success rate (in events per group), and stenting rate
(in events per group' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Meta-analyses were performed for the five primary outcome parameters: Operative time (in minutes), postoperative complications (in events per group), duration of hospital stay (in days), success rate (in events per group), and stenting rate (in events per group).&quot;</span>
Explanation: The review describes the summary measures used in the analyses.

P14: [Yes] <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>  
Explanation: The review describes assessing heterogeneity in the meta-analyses.

P15: [No] The review does not report assessing publication bias.

P16: [NA] The review does not report additional analyses like sensitivity/subgroup analyses or meta-regression.

P17: [Yes] <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.5%):

study selection, 2 people do' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Flowchart of study selection is provided in Figure 1.&quot;</span>
Explanation: The review provides a flow diagram depicting the screening process and numbers at each stage.

P18: [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A summary of the studies’ methodology, participant features, intervention characteristics, measured outcomes, and the use of stents and drainage is provided in Tables 1 to 4.&quot;</span>
Explanation: The review provides details on included studies in table format.

P19: [No] The review does not provide risk of bias assessments. 

P20: [Yes] The results section provides outcome data for each included study.

P21: [Yes] Where meta-analyses were done, pooled estimates are provided. 

P22: [NA] No assessment of risk of bias across studies was done.

P23: [NA] No additional analyses were done.

P24: [Yes] The discussion summarizes the main findings and implications.

P25: [Yes] The discussion considers limitations at the review and outcome level.

P26: [Yes] The discussion places the results in context of existing evidence and suggests implications for future research.

P27: [No] The review does not report on sources of funding.
</pre>
<p><a name='121'></a></p>
</div>
<div id="mullassery-2014" class="section level4">
<h4><a href='https://doi.org/10.3109/08880018.2014.947009' title='Open publication'>Mullassery
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA 2009 assessments for the given systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.7%):

A systematic review and meta-analysis is reported to address robust evidence for curative “gross
total tumor resection” (GTR) in Stage 3 and Stage 4 neuroblastoma' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic review and meta-analysis is reported to address robust evidence for curative “gross total tumor resection” (GTR) in stages 3 and 4 pediatric neuroblastoma.&quot;</span>
States research question and inclusion criteria before conduct of review.

A2. Was there duplicate study selection and data extraction? [No] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Studies were reviewed by PJF and DM independently. Where a difference in opin-
ion occurred the matter was resolved by consensus agreement in conjunction with the
senior author (PDL' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Studies were reviewed by PJF and DM independently. Where a difference in opinion occurred the matter was resolved by consensus agreement in conjunction with the senior author (PDL).&quot;</span>
Only mentions consensus process for disagreements, does not state that there were duplicate processes for study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following databases were included in the search - Medline, Embase and Cochrane.&quot;</span> 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Reference lists of retrieved studies
and conference abstracts were also reviewed to identify other potential studies of inter-
est' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Reference lists of retrieved studies and conference abstracts were also reviewed to identify other potential studies of interest.&quot;</span>
Searched at least 2 databases and supplemented with additional strategies.

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding based on publication status. 

A5. Was a list of studies (included and excluded) provided? [Yes]
Included studies listed in Tables 1 and 2. Excluded studies listed in Table 2 with reasons for exclusion.

A6. Were the characteristics of the included studies provided? [Yes] 
Characteristics of included studies provided in aggregated form in Tables 1 and 2.

A7. Was the scientific quality of the included studies assessed and documented? [No]
No formal quality assessment mentioned. Only states <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The included publications were all non-randomized observational studies&quot;</span> in discussing limitations.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
Did not assess quality of included studies.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.3%):

heterogeneity exists a random effects model should be used' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Heterogeneity was assessed using I2 statistic." "Random effects model used for meta-analysis.&quot;</span>

A10. Was the likelihood of publication bias assessed? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Funnel plots were generated to assess the degree of publication bias.&quot;</span>

A11. Was the conflict of interest included? [No]
No mention of sources of support or conflict of interest for included studies or the review itself.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.7%):

A systematic review and meta-analysis is reported to address robust evidence for curative “gross
total tumor resection” (GTR) in Stage 3 and Stage 4 neuroblastoma' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic review and meta-analysis is reported to address robust evidence for curative “gross total tumor resection” (GTR) in stages 3 and 4 pediatric neuroblastoma.&quot;</span>

P2. Provide a structured summary. [Yes]
Structured abstract provided with background, objectives, eligibility criteria, participants, data sources, synthesis methods, results, conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
Introduction describes controversy around role of surgery in advanced neuroblastoma and rationale for systematic review on the topic.

P4. Provide an explicit statement of questions being addressed. [Yes]
Objective clearly stated: <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):

to critically examine the evidence for curative “gross total tumor resection” (GTR) in
stages 3 and 4 pediatric neuroblastoma' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎to critically examine robust evidence for curative “gross total tumor resection” (GTR) in stages 3 and 4 pediatric neuroblastoma.&quot;</span> 

P5. Indicate if a review protocol exists. [No]
No mention of a review protocol.

P6. Specify study characteristics used as criteria for eligibility. [Yes]
Clear inclusion criteria specified related to outcomes, interventions, participants, and study designs.

P7. Describe all information sources and date last searched. [Yes]
Databases, supplementary strategies, and date ranges reported.

P8. Present full electronic search strategy. [No]
Search terms reported but not full search strategy.

P9. State the process for selecting studies. [Yes]  
Selection process described including screening, eligibility assessment, and inclusion. 

P10. Describe method of data extraction. [No] 
No details provided on data extraction process.

P11. List and define all variables for which data were sought. [Yes]
Outcomes and data extracted specified.

P12. Describe methods for assessing risk of bias. [No]
No details provided on risk of bias assessment.

P13. State the principal summary measures. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Odds ratios (OR) were calculated with
95% confidence intervals (CI) using Mantel–Haenszel calculations and a random ef-
fects model' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Odds ratios (OR) were calculated with 95% confidence intervals (CI) using Mantel–Haenszel calculations and a random effects model.&quot;</span>

P14-P16. Describe synthesis methods. [Yes]
Methods described for meta-analysis and assessing heterogeneity. No additional analyses mentioned.

P17. Give numbers of studies at each stage. [Yes] 
Numbers of studies reported in PRISMA flow diagram. 

P18. For each study, present characteristics and citations. [Yes] 
Study details presented in Tables 1 and 2.

P19-P23. Present data analyses. [Yes] 
Forest plots, heterogeneity measures, funnel plots presented. No assessment of individual study bias or across studies.

P24. Summarize the main findings. [Yes] 
Main findings summarized in discussion section.

P25. Discuss limitations at study and outcome level. [Yes]
Limitations discussed related to included studies and outcomes.

P26. Provide a general interpretation of results. [Yes]
Provides interpretation of results and implications.

P27. Describe sources of funding and role of funders. [No]
No mention of sources of funding or conflicts of interest.
</pre>
<p><a name='122'></a></p>
</div>
<div id="nagler-2011" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD001532.pub4' title='Open publication'>Nagler
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my AMSTAR and PRISMA assessments of the systematic review:

A1. Was an 'a priori' design provided? [Yes]
"Methods - Protocol first published: Issue 2, 1999
Review first published: Issue 3, 2004"
An a priori protocol was published before the review.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently searched the literature, determined study eligibility, assessed quality, extracted and entered data.&quot;</span>
Two authors independently performed study selection and data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In August 2010 we searched CENTRAL, MEDLINE and EMBASE and screened reference lists of papers and abstracts from conference proceedings.&quot;</span>
Multiple databases and other sources were searched.

A4. Was the status of publication used as an inclusion criterion? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There were no language restrictions.&quot;</span>
No restrictions based on publication status.

A5. Was a list of studies provided? [Yes]
Table 'Characteristics of included studies' provides details on all included studies.

A6. Were the characteristics of the included studies provided? [Yes] 
Table 'Characteristics of included studies' provides details on participants, interventions, outcomes for all included studies.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently assessed quality, extracted and entered data&quot;</span> using the risk of bias tool. Details provided in Figure 2.

A8. Was the scientific quality used appropriately in formulating conclusions? [Yes]
Limitations due to risk of bias were considered in the Discussion section.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]  
Fixed and random effects models were used. Heterogeneity was assessed.

A10. Was the likelihood of publication bias assessed? [No]   
Publication bias was not assessed due to insufficient number of studies.

A11. Was the conflict of interest included? [Yes]  
Sources of support and conflicts of interest were declared.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Title: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Interventions for primary vesicoureteric reflux (Review)&quot;</span>

P2. Provide a structured summary. [Yes]  
Abstract provides structured summary.

P3. Describe the rationale for the review. [Yes]  
Rationale described in Background section. 

P4. Provide an explicit statement of questions being addressed. [Yes]
Objectives section states the aim and outcomes of interest.

P5. Indicate if a review protocol exists. [Yes]
Methods section states a published protocol. 

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]  
Details provided in Types of studies, Types of participants, Types of interventions, and Types of outcome measures.

P7. Describe all information sources in the search. [Yes]  
Details provided in Search methods for identification of studies section.

P8. Present full electronic search strategy for at least one database. [No]
Search strategy not provided.

P9. State the process for selecting studies. [Yes] 
Provided in Selection of studies section. 

P10. Describe method of data extraction. [Yes] 
Provided in Data extraction and management section.

P11. List and define all variables for which data were sought. [Yes]
Outcomes provided in Types of outcome measures section. 

P12. Describe methods for assessing risk of bias. [Yes] 
Detailed in Assessment of risk of bias in included studies section.

P13. State the principal summary measures. [Yes] 
Provided in Measures of treatment effect section.

P14. Describe the methods of handling data and combining results of studies. [Yes]
Detailed in Data synthesis section.

P15. Specify any assessment of risk of bias across studies. [NA]
No assessment done due to insufficient studies.

P16. Describe methods of additional analyses. [NA]  
No subgroup or sensitivity analyses done.

P17. Give numbers of studies at each stage with reasons for exclusions. [Yes] 
Figure 1 provides flow diagram of studies.

P18. For each study, present characteristics for which data were extracted. [Yes]  
Provided in Characteristics of included studies table.

P19. Present data on risk of bias of each study. [Yes] 
Assessed using risk of bias tool, see Figure 3.

P20. For all outcomes, present data for each study. [Yes] 
Data presented in Effects of interventions section and Analysis tables.

P21. Present results of each meta-analysis done. [Yes]
Provided in Effects of interventions section and Analysis tables.

P22. Present results of any assessment of risk of bias across studies. [NA] 
Not done.

P23. Give results of additional analyses. [NA]
No additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
Provided in Authors' conclusions section.

P25. Discuss limitations at study and outcome level, and at review-level. [Yes]  
Detailed in Quality of the evidence and Agreements and disagreements with other studies sections.

P26. Provide a general interpretation of the results in context of other evidence. [Yes]
Discussed in Agreements and disagreements section.

P27. Describe sources of funding for the review. [Yes] 
Provided in Sources of support section.
</pre>
<p><a name='123'></a></p>
</div>
<div id="narayanan-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2013.07.020' title='Open publication'>Narayanan
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here is my assessment of the methodological quality using AMSTAR and the reporting quality using PRISMA for the attached systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 

><span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

A Medline, Ovid, Search Medica, Elsevier Clini-
calKey, Google Scholar and the Cochrane library search
was performed on all studies published between 1950 and
2012 reporting on comparison of HD and HJ for children
undergoing excision of extra-hepatic biliary tree for
choledochal cysts' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.&quot;</span>

[Yes] - The research question and inclusion criteria were pre-specified.

A2. Was there duplicate study selection and data extraction?

><span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Three reviewers (SKN, KLN and CY) independently assessed selected studies, extracted and tabulated data from each article&quot;</span> 

[Yes] - There were 3 independent reviewers for study selection and data extraction.

A3. Was a comprehensive literature search performed?

><span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

keywords were used:
“choledochal cyst”, “choledochal cyst AND hepaticoduo-
denostomy”, “choledochal cyst AND hepaticojejunost-
omy”, “hepaticoduodenostomy”, “hepaticojejunostomy”,
“hepaticodochoduodenostomy”. The “related articles”
function was used to widen the search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎keywords used: “choledochal cyst”, “choledochal cyst AND hepaticoduodenostomy”, “choledochal cyst AND hepaticojejunostomy”, “hepaticoduodenostomy”, “hepaticojejunostomy”, “hepaticodochoduodenostomy”. The “related articles” function was used to widen the search.&quot;</span>

[Yes] - At least 2 databases searched plus supplementary search strategies.

A4. Was the status of publication used as an inclusion criterion?  

No mention of including or excluding studies based on publication status.

[No] 

A5. Was a list of studies (included and excluded) provided?

No explicit list of included/excluded studies provided.

[No]

A6. Were the characteristics of the included studies provided?

> Table 1 shows characteristics of included studies.

[Yes] - Table 1 provides aggregated data on participants, interventions, outcomes, etc.

A7. Was the scientific quality of the included studies assessed and documented?

No quality assessment of included studies mentioned. 

[No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?

[NA] - No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate?

><span title='Moderate quote deviation. Best match in fulltext (Similarity 94.3%):

Statistical heterogeneity was assessed using I 
2 
. A fixed
effects model was used if I 
2 
b 50% and a random effects model
was used if I 
2 
≥' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Statistical heterogeneity was assessed using I2. A fixed effects model was used if I2 < 50% and a random effects model was used if I2 ≥ 50%.&quot;</span>

[Yes] - Appropriate tests for heterogeneity performed. 

A10. Was the likelihood of publication bias assessed?

No assessment of publication bias mentioned.

[No]

A11. Was the conflict of interest included? 

No statement about sources of support or COI provided.

[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 

><span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

To compare the clinical outcomes of HD and HJ, we
performed a systematic review and comprehensive meta-
analysis from indexed published literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To compare the clinical outcomes of HD and HJ, we performed a systematic review and comprehensive meta-analysis from indexed published literature.&quot;</span>

[Yes]

P2. Structured summary.

Abstract provides background, objectives, eligibility criteria, sources, synthesis methods, results, conclusions. 

[Yes]

P3. Rationale for review.

Intro discusses rationale and what is known about HD vs HJ.

[Yes]

P4. Objectives and PICOS.

Objective to compare HD vs HJ stated; participants (children with choledochal cysts) specified.

[Yes]

P5. Protocol and registration.

No mention of review protocol or registration.

[No] 

P6. Eligibility criteria.

Inclusion/exclusion criteria described.

[Yes]

P7. Information sources.

Databases and dates searched reported.

[Yes]

P8. Search strategy.

Search terms but not full search strategy provided.

[No]

P9. Study selection process. 

Three independent reviewers performed selection, reaching consensus.

[Yes]

P10. Data extraction process.

Three independent extractors, but process not described in detail.

[No] 

P11. List of variables extracted.

Outcomes analyzed described in Table 2. 

[Yes]

P12. Risk of bias assessment. 

No risk of bias assessment mentioned.

[No]

P13-P16. Data synthesis.

[NA] - No meta-analysis performed.

P17. Study flow diagram.

No flow diagram depicting study selection process.

[No]

P18. Study characteristics.

Table 1 lists key characteristics of included studies. 

[Yes]

P19. Risk of bias results.

[NA] 

P20-P23. Synthesis results. 

[NA]

P24. Summary of evidence.

Conclusions summarize main findings and implications.

[Yes]

P25. Limitations.

Limitations discussed.

[Yes]

P26. Conclusions and implications.

Conclusions and implications described.

[Yes] 

P27. Funding sources. 

No statement about sources of support.

[No]
</pre>
<p><a name='124'></a></p>
</div>
<div id="nasr-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2010.02.012' title='Open publication'>Nasr
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the provided systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎No randomized trials were identified.&quot;</span>
The review did not refer to a protocol or pre-determined objectives. 

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors (AN and PW) independently extracted data from the retrieved articles.&quot;</span>
Two authors independently extracted data.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All publications describing both surgical procedures for pectus excavatum were sought from the Cochrane Trials Register and the Cochrane Central Register of Controlled Trials (CENTRAL) database. All studies were identified through electronic searches of MEDLINE (1966 onward), EMBASE (1980 onward), and CINAHL (1982 onward) and from hand-searching journals and conference proceedings.&quot;</span>
Searched multiple databases plus supplementary sources.

A4. Was the status of publication used as an inclusion criterion? [No]
No mention of including or excluding based on publication status.

A5. Was a list of studies provided? [Yes]  
Table 1 provides a list of included studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides aggregated characteristics of the studies. 

A7. Was the scientific quality of the included studies assessed? [No]
No mention of quality assessment.

A8. Was the scientific quality used appropriately in formulating conclusions? [NA]
No quality assessment done.

A9. Were the methods to combine findings appropriate? [Yes] 
Heterogeneity assessed and random effects model used as appropriate.

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify as systematic review or meta-analysis. [Yes]
Identified as <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎systematic review and meta-analysis&quot;</span> in title.

P2. Structured summary. [Yes]  
Provides structured abstract with objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, and conclusions.

P3. Rationale for review. [Yes]  
Provides context and rationale in the introduction.

P4. Research questions and PICOS. [No] 
Research questions not explicitly stated with PICOS elements.

P5. Indicate if protocol exists. [No]
No mention of a protocol.

P6. Specify study characteristics and report characteristics. [Yes]  
Specifies length of follow-up and language as inclusion criteria. 

P7. Information sources and dates. [Yes]
Reports databases searched with date ranges.

P8. Search strategy. [No]
Search strategy not provided.

P9. Study selection process. [Yes]
Describes study selection process.

P10. Data extraction process. [Yes]  
States data extracted independently and in duplicate. 

P11. List and define all variables extracted. [Yes]
Outcomes extracted listed in methods.

P12. Risk of bias assessment. [No] 
No risk of bias assessment described.

P13. Summary measures. [Yes]
States use of odds ratios and weighted mean differences.

P14. Methods for combining studies. [Yes]
Describes use of random effects model and heterogeneity measures.

P15. Risk of bias across studies. [NA]
No meta-bias assessments applicable without meta-analysis.

P16. Additional analyses. [NA]  
No additional analyses applicable without meta-analysis.

P17. Study flow diagram. [No]
No flow diagram provided.

P18. Study characteristics. [Yes] 
Table 1 provides key characteristics of included studies.

P19. Risk of bias within studies. [No] 
No assessment of risk of bias within studies.

P20. Results for each study. [Yes] 
Provides results for each study in text and tables.

P21. Results of meta-analyses. [Yes]
Provides pooled results with confidence intervals.

P22. Risk of bias across studies. [NA] 
Not applicable without meta-analysis.

P23. Additional analyses. [NA]
Not applicable without additional analyses. 

P24. Summary of evidence. [Yes]
Summarizes main findings in discussion.

P25. Limitations. [Yes]  
Discusses limitations at review and study levels.

P26. Interpretation of results. [Yes] 
Provides interpretation in context of other evidence.

P27. Funding sources. [No]
No statement about sources of funding.
</pre>
<p><a name='125'></a></p>
</div>
<div id="nasr-2013" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1347916' title='Open publication'>Nasr
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here is my AMSTAR and PRISMA 2009 assessment of the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The purpose of this study is to critically analyze the reported outcomes after the use of this technique.&quot;</span>
States a priori objectives.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All publications describing both procedures were reviewed.&quot;</span> 
Does not describe literature search strategy.

A4. Was the status of publication used as an inclusion criterion? [No]  
No mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Provides demographic data on included studies in Table 2. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
Assesses methodological quality of studies using minor criteria (Table 1).

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [No]
Does not explicitly consider study quality in analysis or conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [NA]
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [NA] 
No assessment of publication bias as no meta-analysis performed.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic Review and Cumulative Meta-analysis&quot;</span> in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
Does not contain a structured abstract.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Provides background and rationale in the Introduction.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of a protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]
No description of eligibility criteria.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [No]
No description of information sources or search strategy.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]  
No search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]
No description of study selection process. 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No description of data extraction process.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Does not list or define variables extracted.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
Assesses methodological quality (Table 1).

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]
No meta-analysis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]  
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias or other biases.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No] 
No flow diagram showing screening process.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Presents relevant characteristics in Table 2.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Presents assessment of methodological quality in Table 1.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
Does not present summary data or effect estimates for each study.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]  
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression) [NA]
No additional analyses performed. 

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
Does not summarize main findings or strength of evidence.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]  
Does not discuss limitations at study or review level.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Provides interpretation and implications for future research in the Discussion.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding or support.
</pre>
<p><a name='126'></a></p>
</div>
<div id="nataraja-2013" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2012.0522 ' title='Open publication'>Nataraja
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’, ‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes]
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used in the formulation of the systematic review and meta-analysis.&quot;</span>
- States that PRISMA guidelines were followed, which require an a priori protocol.

A2. [Unclear <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span>] 
- No mention of duplicate study selection or data extraction.

A3. [Yes]
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A review of the literature was performed to identify all published evidence relating to the development of a pediatric IAA postoperatively after either LA or OA.&quot;</span> 
- Table 1 lists the databases searched and search terms used.

A4. [No]
- No mention of searching for unpublished or grey literature.

A5. [No]
- No list of included/excluded studies provided.

A6. [Yes] 
- Table 3 summarizes key characteristics of the included studies.

A7. [No]
- The quality of included studies was not assessed.

A8. [NA]
- Quality of studies was not assessed, so this item is not applicable.

A9. [Yes]
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Contingency tables were designed for each of the outcome measures, and data were analyzed using Fisher’s exact test.&quot;</span>
- Appropriate statistical methods used for meta-analysis.

A10. [Yes]
- Funnel plots were used to assess publication bias (Figure 5).

A11. [No]
- No mention of conflicts of interest or study funding.

P1. [Yes]
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 83.6%):

of Intraabdominal Abscess Formation
Following Laparoscopic Appendicectomy in Children:
A Systematic Review and Meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Comparison of Intraabdominal Abscess Formation Following Laparoscopic and Open Appendicectomies in Children: A Systematic Review and Meta-analysis&quot;</span>
- Title identifies it as a systematic review and meta-analysis.

P2. [Yes]
- Structured abstract provided with background, objectives, eligibility criteria, data sources, synthesis methods, results, and conclusions. 

P3. [Yes]
- Introduction section describes rationale and context.

P4. [Yes] 
- Objective clearly stated along with inclusion/exclusion criteria defining population, intervention, comparator, and outcomes.

P5. [No]
- No mention of a review protocol.

P6. [Yes]
- Inclusion/exclusion criteria specify eligible study characteristics and populations. 

P7. [Yes]
- Table 1 lists literature sources searched and date ranges covered.

P8. [No] 
- No full search strategy provided.

P9. [Yes]
- Study selection process described and depicted in Figure 1 flow diagram. 

P10. [Unclear <span style='background-color: #ff9e81' title='Added response during extraction'>[NA]</span>]
- No description of data extraction methods.

P11. [Yes]
- Outcomes of interest clearly defined.

P12. [No] 
- No assessment of risk of bias described.

P13. [Yes]
- Odds ratios and 95% CIs used as summary measures.

P14-P16. [NA]
- Not applicable since no meta-analysis was performed.

P17. [Yes] 
- Numbers screened, eligible, and included provided in Figure 1. Exclusions not explicitly reasoned.

P18. [Yes]
- Table 3 provides key characteristics of included studies. 

P19. [No]
- Did not assess risk of bias for individual studies.

P20-P23. [NA] 
- Not applicable since no meta-analysis was performed.

P24. [Yes]
- Main findings summarized in discussion section.

P25. [Yes] 
- Limitations described in discussion.

P26. [Yes]  
- Results interpreted in context of other evidence and implications described.

P27. [No]
- No mention of funding sources or conflicts of interest.
</pre>
<p><a name='127'></a></p>
</div>
<div id="nicolau-2011" class="section level4">
<h4><a href='https://doi.org/pmid:21520776' title='Open publication'>Nicolau
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA for the given systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as “laparoscopy and blunt abdominal trauma”.&quot;</span>
The research question and inclusion criteria were established before the review was conducted.

A2. [No]
No mention of duplicate study selection or data extraction.

A3. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as “laparoscopy and blunt abdominal trauma”.&quot;</span>
Two electronic databases were searched and keywords were provided. 

A4. [No]
No mention of including or excluding studies based on publication status. 

A5. [No]
No list of included and excluded studies was provided.

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The articles have been grouped based on their scientific content: original studies on patients with multiples and single organ injuries, reviews, and case reports.&quot;</span> 
Characteristics of included studies were provided in an aggregated form.

A7. [No] 
No assessment of quality of included studies was mentioned.

A8. [NA]
Scientific quality of studies was not used in formulating conclusions since quality was not assessed.

A9. [NA]  
No quantitative synthesis or meta-analysis was performed.

A10. [NA]
No assessment of publication bias was performed since no meta-analysis was done.

A11. [No]
No statement about conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Rezumat&quot;</span> indicates this is a systematic review.

P2. [No] 
No structured summary provided.

P3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Laparoscopia diagnosticã æi terapeuticã în contuziile abdomi-
nale (CA) are o utilizare limitatã æi chiar controversatã,
datoritã în special progreselor fãcute de explorãrile imagistice
actuale' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopia diagnosticã æi terapeuticã în contuziile abdomi-nale (CA) are o utilizare limitatã æi chiar controversatã, datoritã în special progreselor fãcute de explorãrile imagistice actuale.&quot;</span>
Provides context about limited use of laparoscopy in blunt abdominal trauma.

P4. [No] 
No explicit PICOS statement provided.

P5. [No]
No review protocol mentioned.

P6. [No]
No explicit eligibility criteria described. 

P7. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A comprehensive literature search was performed on the U.S. National Library of Medicine site in Medline and PubMed from 1 Ian 2000 to 31 Dec 2007 using keywords such as “laparoscopy and blunt abdominal trauma”.&quot;</span>
Information sources and dates searched provided.

P8. [No] 
No full search strategy provided.

P9. [No] 
No details provided on study selection process.

P10. [No]
No data extraction process described.

P11. [No]
No list of variables sought.

P12. [No]
No assessment of bias mentioned.

P13. [NA]
No meta-analysis performed.

P14. [NA] 
No meta-analysis performed. 

P15. [NA]
No assessment of publication bias since no meta-analysis.

P16. [NA]
No additional analyses mentioned.

P17. [No]
No flow diagram or details on study selection provided.

P18. [No]
No characteristics of included studies provided. 

P19. [No] 
No assessment of bias provided.

P20. [No]
No outcome data presented.

P21. [NA] 
No meta-analysis performed.

P22. [NA]
No assessment of bias across studies since no meta-analysis. 

P23. [NA]
No additional analyses mentioned.

P24. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

În concluzie, deæi puåin utilizatã, dovada fiind æi
numãrul redus de articole publicate, laparoscopia poate fi utilã
la pacienåii cu CA atent selectaåi cu examen clinic æi imagis-
ticã echivoce în scopul reducerii incidenåei laparotomiilor
inutile' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎În concluzie, deæi puåin utilizatã, laparoscopia poate fi utilã la pacienåii cu CA atent selectaåi cu examen clinic æi imagis-ticã echivoce în scopul reducerii incidenåei laparotomiilor inutile.&quot;</span>
Summarizes main finding.

P25. [No]
No discussion of limitations.

P26. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studii multicentrice prospective sunt necesare pentru a contura mai precis rolul laparoscopiei în CA.&quot;</span>
Discusses implications for future research. 

P27. [No]
No statement about sources of funding.
</pre>
<p><a name='128'></a></p>
</div>
<div id="oliveira-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2015.10.003' title='Open publication'>Oliveira
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We performed a Pubmed search using the terms: neophalloplasty, neophallus, and phalloplasty&quot;</span> No mention of a protocol.

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A total of 319 articles were identified in the initial search. When limited to the pediatric population, the search was reduced to only 19 articles&quot;</span> PubMed searched with supplementary strategies. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No] 
No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
No explicit list of included/excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics like number of patients, type of surgery, and length of follow-up. 

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned. 

A11. Was the conflict of interest included? [No]
No COI statement provided.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.9%):

Review article
Neophalloplasty in boys with aphallia: A
systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review article: Neophalloplasty in boys with aphallia: A systematic review&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No] 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
Introduction provides context about aphallia and rationale for neophalloplasty vs gender reassignment.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No review protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]
Inclusion/exclusion criteria not specified.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [No] 
Only mentions searching PubMed, no dates given.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No] 
No details on study selection process. 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No data extraction methodology described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Data items not defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No] 
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]  
No quantitative synthesis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]
No assessment of risk of bias across studies.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]  
Number of records screened and assessed not reported. No flow diagram.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 presents some characteristics of included studies like sample size, intervention details, follow-up period. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
No risk of bias assessment presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No] 
No outcome data presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [No]  
No assessment of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No]
No summary of main findings or strength of evidence.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]
No limitations discussed. 

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Provides interpretation and implications for neophalloplasty vs gender reassignment.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
No funding sources reported.
</pre>
<p><a name='129'></a></p>
</div>
<div id="oomen-2012" class="section level4">
<h4><a href='https://doi.org/10.1007/S00464-012-2174-Y' title='Open publication'>Oomen
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Retrieval of studies was performed through a systematic search of the databases PubMed, Ovid (Ovid Technologies, New York, NY) and Cochrane (Cochrane database of systematic reviews).&quot;</span> Systematic search of databases indicates a priori design.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Potentially eligible studies were reviewed independently by two authors (MWNO, RB) for inclusion and exclusion criteria.&quot;</span> Study selection was done in duplicate. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Retrieval of studies was performed through a systematic search of the databases PubMed, Ovid (Ovid Technologies, New York, NY) and Cochrane (Cochrane database of systematic reviews).&quot;</span> Searched multiple databases. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
Included studies listed in text and tables, but no list of excluded studies. 

A6. Were the characteristics of the included studies provided? [Yes] 
Characteristics of included studies provided in Table 1.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
Quality assessment done using Cochrane criteria and documented in Table 2. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
Study limitations and heterogeneity discussed in formulation of conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]  
Meta-analysis done with assessment of heterogeneity. Random effects model used when I2 > 30%.

A10. Was the likelihood of publication bias assessed? [No]   
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest or funding sources.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.6%):

The aim of this study was to compare the
results of both surgical strategies by means of a systematic
review and meta-analysis of the available literature' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The aim of this study was to compare the results of LP and OP by means of a systematic review and meta-analysis of the available literature.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Background and rationale described in introduction. 

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes] 
Research question and inclusion criteria described.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of a review protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion criteria specify study design, interventions, participants, and outcomes. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [No] 
Databases searched reported but no dates of coverage given.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Study selection process described and depicted in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.6%):

data on setting, methodological
quality [according to the Cochrane handbook for system-
atic reviews of interventions (http://dcc.cochrane.org/sites/
dcc.cochrane.org/files/uploads/RCT)], population, and type
of surgery were extracted by two authors independently' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data on setting, methodological quality, population, and type of surgery were extracted by two authors independently.&quot;</span>

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Outcomes defined in methods. 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
Quality assessment done with Cochrane risk of bias tool. 

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Summary measures defined in results.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Meta-analysis methods described. 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No]
No assessment of publication bias or selective reporting.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA] 
No additional analyses done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
Number of studies at each stage provided, reasons for exclusions given, flow diagram in Figure 1.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Study characteristics presented in Table 1.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Risk of bias assessment presented in Table 2.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes] 
Forest plots presented for all outcomes synthesized. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes]
Results of each meta-analysis presented with CIs and I2 values.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses done. 

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in discussion section.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes] 
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of other evidence. Implications for research discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding or support.
</pre>
<p><a name='130'></a></p>
</div>
<div id="parolini-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.10.043' title='Open publication'>Parolini
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We adhered to PRISMA guidelines for this systematic review [6].&quot;</span> 
[No] - No mention of an a priori design.

A2. Was there duplicate study selection and data extraction?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Two independent authors extracted information related to each eli-
gible study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors extracted information related to each eligible study.&quot;</span>
[Yes] 

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

The
PubMed database was searched for studies of children with EA and RAA
published from January 1990 to December 2014. Inclusion criteria were
English language articles reporting original data on epidemiology, diag-
nosis and treatment of newborns with EA' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The PubMed database was searched for studies of children with EA and RAA published from January 1990 to December 2014. Inclusion criteria were English language articles reporting original data on epidemiology, diagnosis and treatment of newborns with EA.&quot;</span>
[No] - Only one database searched.

A4. Was the status of publication used as an inclusion criterion?
No mention of including or excluding based on publication status. 
[NA]

A5. Was a list of studies (included and excluded) provided? 
Figure 1 shows the identification and selection process.
[Yes]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of the included studies.
[Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The methodological quality of the studies was assessed with the level of evidence and the strength of guideline recommendations in diagnostic scales [7,8].&quot;</span>
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No mention of incorporating study quality in the conclusions.
[No] 

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included? 
No mention of conflicts of interest.
[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This study provides a systematic review of the literature, focusing on epidemiology, diagnostic assessment and management of children with EA and RAA, comparing the morbidity and mortality rates of different surgical strategies.&quot;</span>
[Yes]

P2. Provide a structured summary.
Abstract provides structured summary.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
Introduction provides context and rationale.
[Yes]

P4. Provide an explicit statement of questions being addressed. 
No explicit PICOS statement provided.
[No]

P5. Indicate if a review protocol exists.
No mention of a review protocol.
[No] 

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
Inclusion/exclusion criteria described in Methods.
[Yes]

P7. Describe all information sources in the search.
Search of PubMed described. 
[Yes]

P8. Present full electronic search strategy for at least one database.
Full search strategy not provided.
[No]

P9. State the process for selecting studies.
Study selection process described and depicted in Figure 1.
[Yes]

P10. Describe method of data extraction from reports.
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Two independent authors extracted information related to each eli-
gible study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors extracted information related to each eligible study.&quot;</span>
[Yes]

P11. List and define all variables for which data were sought.
Outcomes described in Methods.
[Yes] 

P12. Describe methods for assessing risk of bias of individual studies.
Quality assessment methods described.
[Yes]

P13. State the principal summary measures. 
No quantitative synthesis performed.
[NA]

P14-P16. Describe methods of synthesis, heterogeneity, and additional analyses.
No quantitative synthesis performed.
[NA]

P17. Give numbers of studies at each stage with reasons for exclusions.
Figure 1 shows study flow with numbers at each stage.
[Yes]

P18. For each study, present characteristics for which data were extracted.
Study characteristics presented in tables.
[Yes]

P19-P23. Present data on risk of bias, results, publication bias, and additional analyses. 
No quantitative synthesis performed.
[NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
Main findings summarized in Discussion and Conclusion.
[Yes]

P25. Discuss limitations at study and outcome level and at review level.
Limitations discussed in Discussion.
[Yes]

P26. Provide a general interpretation of the results in the context of other evidence.
Results interpreted in Discussion.
[Yes]

P27. Describe sources of funding and support for the review.
No sources of funding described.
[No]
</pre>
<p><a name='131'></a></p>
</div>
<div id="parolini-2014" class="section level4">
<h4><a href='https://doi.org/10.1016/J.IJPORL.2014.04.011' title='Open publication'>Parolini
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the systematic review using AMSTAR and PRISMA:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎For this systematic review we adhered to PRISMA guidelines [4,5].&quot;</span>
They referred to PRISMA guidelines. [Yes]

A2. Was there duplicate study selection and data extraction?
No mention of duplicate study selection or data extraction. [No] 

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) was searched for studies on treatment of H-type TEF that were published since January 1977.&quot;</span> Only one database searched. [No]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
Figure 1 provides a flow diagram of included and excluded studies. [Yes]

A6. Were the characteristics of the included studies provided?
Tables 1 and 4 provide characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment mentioned. [No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment done. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis done. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias. [No]

A11. Was the conflict of interest included? 
No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
Identified as systematic review in title and abstract. [Yes]

P2. Provide a structured summary including key elements.
Structured abstract provided with key elements. [Yes]

P3. Describe the rationale for the review in the context of what is already known.
Introduction describes rationale and context. [Yes]

P4. Provide an explicit statement of questions being addressed. 
Objective clearly stated in abstract. [Yes]

P5. Indicate if a review protocol exists.
No mention of a review protocol. [No] 

P6. Specify study characteristics used as criteria for eligibility.
Inclusion and exclusion criteria described. [Yes]

P7. Describe information sources, search strategy, and dates.
Search of PubMed described with date range. [Yes]

P8. Present full electronic search strategy for at least one database.
Search strategy not provided. [No]

P9. State the process for selecting studies.
Study selection process described and shown in Figure 1. [Yes]

P10. Describe method of data extraction.
Data extraction described in methods. [Yes] 

P11. List and define all variables for which data were sought.
Primary and secondary outcomes defined and described. [Yes]

P12. Describe methods for assessing risk of bias.
No risk of bias assessment described. [No]

P13. State the principal summary measures.
No quantitative synthesis performed. [NA]

P14-P23. Describe analysis methods, additional analyses, and results.
No quantitative synthesis performed. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome.
Main findings summarized in discussion. [Yes]

P25. Discuss limitations at study and outcome level and at review level.
Limitations discussed. [Yes]

P26. Provide a general interpretation of results in the context of other evidence.
Results interpreted in context of other evidence. [Yes]

P27. Describe sources of funding and role of funders.
No funding sources described. [No]
</pre>
<p><a name='132'></a></p>
</div>
<div id="peters-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2012.11.049' title='Open publication'>Peters
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the assessments for the AMSTAR and PRISMA items:

A1. Was an 'a priori' design provided? 
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Medline, PubMed, National Library of Health and Google Scholarly articles from year 1997 to August 2011 were searched.&quot;</span>
The review had pre-defined search criteria and databases.

A2. Was there duplicate study selection and data extraction?
[No] 
There is no mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Medline, PubMed, National Library of Health and Google Scholarly articles from year 1997 to August 2011 were searched.&quot;</span> 
Multiple databases were searched.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
[No]
Grey literature was not mentioned.

A5. Was a list of studies (included and excluded) provided?
[No]
A list of included and excluded studies was not provided.

A6. Were the characteristics of the included studies provided?
[Yes]
Table 1 summarizes the number of patients from each included study. Tables 2 and 3 provide details on complications and outcomes.

A7. Was the scientific quality of the included studies assessed and documented?
[No]
The quality of individual studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
[NA]
Study quality was not assessed.

A9. Were the methods used to combine the findings of studies appropriate?
[NA]  
Findings were not combined quantitatively.

A10. Was the likelihood of publication bias assessed?
[No]
Publication bias was not assessed.

A11. Was the conflict of interest included?
[No]
Conflicts of interest were not reported for the included studies.

P1. Identify the report as a systematic review, meta-analysis, or both.
[Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Morbidity and mortality in total esophagogastric dissociation: A systematic review&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
[No]
A structured abstract with all elements was not provided.

P3. Describe the rationale for the review in the context of what is already known.
[Yes] 
The introduction provides background and rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
[No]
The review question and PICOS criteria were not explicitly stated.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
[No] 
A protocol was not mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Inclusion criteria were studies of esophagogastric dissociation in children, but details were lacking.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
[Yes]
Databases searched were reported along with date ranges. Authors were contacted for additional data. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
[No]
The full search strategy was not presented.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
[No]
The study selection process was not described.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 
[No]
The data extraction process was not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] 
Outcomes extracted were described but not defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
[No]
Risk of bias assessment was not described.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
[NA]
Quantitative synthesis was not done.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  
[NA]
Studies were not combined quantitatively.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
[NA] 
Risk of bias assessment was not done.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
[NA]
Additional analyses were not done.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
[No]
The screening process was not described.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Table 1 summarizes the number of patients from each study. Details on populations and follow-up were lacking. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
[NA] 
Risk of bias was not assessed.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
[NA]
Data were presented descriptively, not quantitatively.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
[NA]
A meta-analysis was not done.

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
[NA]  
Risk of bias assessment was not done.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
[NA]
No additional analyses were reported.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
[Yes]
The discussion summarizes the main findings and their relevance.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
[Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
Limitations of the review methods were not discussed, but limitations of the evidence base were.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
[Yes] 
The results are interpreted and compared to previous studies. Future research implications are discussed.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
[No]
Sources of funding and support were not reported.
</pre>
<p><a name='133'></a></p>
</div>
<div id="peycelon-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0034-1396419' title='Open publication'>Peycelon
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the AMSTAR and PRISMA 2009 assessments for the attached systematic review:

# AMSTAR
A1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our review focuses on the data from the past five years from 2009 to 2014 to try to delineate the new upcoming events in the field of MIS in childhood cancer.&quot;</span> The objectives and scope are predefined.
A2. [No] No mention of duplicate study selection or data extraction.
A3. [Yes] <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

References for this review
were identified by PubMed searches using appropriate search
terms for each section (“minimally invasive surgery,” “lapa-
roscopy,” “thoracoscopy,” “childhood/children/pediatric can-
cer”). Articles were also identified by searching the author’s
own files' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer”). Articles were also identified by searching the author’s own files.&quot;</span> PubMed search + supplementary strategies used.
A4. [NA] Review does not mention including or excluding based on publication status. 
A5. [No] No list of included/excluded studies provided.
A6. [No] No summary table with characteristics of included studies.
A7. [No] No assessment of quality of included studies.
A8. [NA] Not applicable since A7 is no.
A9. [NA] No meta-analysis performed.
A10. [NA] No meta-analysis performed.
A11. [No] No mention of conflicts of interest.

# PRISMA 2009
P1. [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Review Article&quot;</span> 
P2. [No] No structured summary provided.
P3. [Yes] Gap and rationale described in introduction.  
P4. [No] No explicit PICOS statement.
P5. [NA] No protocol mentioned.
P6. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] Inclusion criteria partially described in methods. No mention of exclusions or study characteristics.
P7. [Yes] Information sources described in methods.
P8. [No] No search strategy provided.
P9. [No] No description of study selection process.
P10. [No] No data extraction methods described.  
P11. [NA] No list of variables sought.
P12. [No] No assessment of risk of bias mentioned.
P13. [NA] No meta-analysis.
P14. [NA] No quantitative synthesis. 
P15. [NA] No assessment of bias across studies.
P16. [NA] No additional analyses mentioned.
P17. [No] No flow diagram or details on screening process.
P18. [No] No table with study characteristics.
P19. [NA] No assessment of risk of bias.
P20. [No] No forest plots or study data presented.
P21. [NA] No meta-analysis.
P22. [NA] No assessment of bias across studies.  
P23. [NA] No additional analyses.
P24. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>] Main findings summarized but strength of evidence not discussed.
P25. [No] No limitations discussed.
P26. [Yes] General interpretation and future implications described in conclusion.
P27. [No] No mention of funding sources.
</pre>
<p><a name='134'></a></p>
</div>
<div id="pfistermuller-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2014.12.006' title='Open publication'>Pfistermuller
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was undertaken, using Medline and Pubmed, in order to identify relevant articles.&quot;</span> 
No mention of a protocol.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The following data were extracted independently from each article by two reviewers (K.P and P.C)&quot;</span>
Two reviewers performed data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Medline and Pubmed were searched in order to identify ar-
ticles published between 1994 and 2012. The search terms
‘tubularized incised plate urethroplasty/Snodgrass repair/
technique  outcomes/complications  follow-up/long term
follow-up’ were used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Pubmed were searched in order to identify articles published between 1994 and 2012. The search terms ‘tubularized incised plate urethroplasty/Snodgrass repair/technique  outcomes/complications  follow-up/long term follow-up’ were used.&quot;</span>
Searched two databases and provided search terms. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included/excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table provides number of patients, mean follow-up, and incidence of complications for included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No quality assessment mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
Random effects models used for meta-analysis. Heterogeneity mentioned. 

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No conflict of interest statement provided.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Meta-analysis of complication rates of the tubularized incised plate (TIP) repair&quot;</span> in title identifies this as a meta-analysis.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No] 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
Introduction describes rationale and context.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion/exclusion criteria provided.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases and date range provided. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search terms provided but no full search strategy.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No] 
No details on screening process.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes]
States data extracted independently by two reviewers.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Outcomes assessed are clear but no complete list of variables provided.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [NA] 
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Used random effects models to estimate pooled rates.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]  
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]
No assessment of publication bias or other biases.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [Yes]
Meta-regression and subgroup analyses described.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
Number of included studies provided but no flow diagram or screening details. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table provides relevant characteristics and citations.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]
No risk of bias assessment.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
No individual study data provided.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]  
No quantitative synthesis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [Yes]
Results of meta-regression and subgroup analyses provided.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]  
Main findings summarized in discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of other evidence.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding.
</pre>
<p><a name='135'></a></p>
</div>
<div id="puligandla-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.09.010' title='Open publication'>Puligandla
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Moderate quote deviation. Best match in prompt (Similarity 84.2%):

protocol, ethics approval, or pre-determined/a priori published research objectives' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎No protocol, ethics approval, or pre-determined/a priori published research objectives are mentioned.&quot;</span>

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

Two of the principal authors (P.P. and
S.I.) independently scanned all titles as a first screen after which select-
ed abstracts and/or full-length papers were collected for further review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two of the principal authors independently scanned all titles as a first screen after which selected abstracts and/or full-length papers were collected for further review.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Separate search terms were applied for each question using the MEDLINE, Embase, Cochrane, and Web of Science databases.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.9%):

review indicates that there was a search for “grey literature” or “unpublished literature,”' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The review does not indicate searching for unpublished literature or grey literature.&quot;</span>

A5. Was a list of studies (included and excluded) provided? [No]
<span title='Moderate quote deviation. Best match in prompt (Similarity 88.5%):

list of included and excluded studies should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎No list of included or excluded studies is provided.&quot;</span> 

A6. Were the characteristics of the included studies provided? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Data compiled for each article included
sample size, description of the procedures performed or medications
used, method of ventilation, use of ECMO, timing of repair, outcomes in-
cluding mortality and morbidity, and type of patch used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data compiled for each article included sample size, description of the procedures performed or medications used, method of ventilation, use of ECMO, timing of repair, outcomes including mortality and morbidity, and type of patch used.&quot;</span>

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies selected for inclusion were critically appraised and ranked on their level of evidence based on the type of study (retrospective or prospective, randomized or not).&quot;</span>

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Limited high-level evidence prevents the development of robust management guidelines for CDH.&quot;</span>

A9. Were the methods used to combine the findings of studies appropriate? [NA]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.1%):

quantitative synthesis (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No quantitative synthesis or meta-analysis was performed.&quot;</span>

A10. Was the likelihood of publication bias assessed? [NA] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.6%):

assessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No assessment of publication bias was done as no meta-analysis was performed.&quot;</span>

A11. Was the conflict of interest included? [No]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 50%):

conflict of interest included' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No statement about conflict of interest is provided.&quot;</span>

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):

ummary
This systematic review by the APSA Outcomes and Evidence-based
Practice Committee attempted to delineate best-evidence recommen-
dations for specific aspects of C' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review by the APSA Outcomes and Evidence-based Practice Committee attempted to delineate best-evidence recommendations for specific aspects of CDH care.&quot;</span> 

P2. Provide a structured summary. [No]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.7%):

structured summary in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No structured abstract or summary is provided.&quot;</span>

P3. Describe the rationale for the review. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

iNO). Variability in institutional
practice patterns for CDH will likely pose a significant barrier to any fur-
ther improvement in CDH outcomes. Thus, it is imperative that we ded-
icate efforts to design high quality studies that will inform the
development of best practices for these' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variability in institutional practice patterns for CDH will likely pose a significant barrier to any further improvement in CDH outcomes. Thus, it is imperative that we dedicate efforts to design high quality studies that will inform the development of best practices for these infants.&quot;</span>

P4. Provide an explicit statement of questions being addressed. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):

Our purpose was to systematically review the available evidence to pro-
vide recommendations regarding specific aspects of CDH management.
In particular we focused on ventilator management, the treatment of
pulmonary hypertension (PHTN), glucocorticoid use, mode and dura-
tion of ECMO, timing of repair, optimal technique for repair, and the
use of prosthetic patches' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our purpose was to systematically review the available evidence to provide recommendations regarding specific aspects of CDH management. In particular we focused on ventilator management, the treatment of pulmonary hypertension (PHTN), glucocorticoid use, mode and duration of ECMO, timing of repair, optimal technique for repair, and the use of prosthetic patches.&quot;</span>

P5. Indicate if a review protocol exists. [No] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.3%):

referenced' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No protocol is referenced.&quot;</span>

P6. Specify study characteristics used as criteria for eligibility. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies that did not address the neonatal population were excluded, as were opinion pieces, case reports, and editorial review articles (other than systematic reviews or meta analyses).&quot;</span> 

P7. Describe information sources in the search. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Separate search terms were applied for each question using the MEDLINE, Embase, Cochrane, and Web of Science databases. Searches were limited to articles published in the English language from January 1, 1980 through January 31, 2014.&quot;</span>

P8. Present full electronic search strategy. [No]  
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.9%):

the search strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The full search strategies are not provided.&quot;</span>

P9. State the process for selecting studies. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Two of the principal authors (P.P. and
S.I.) independently scanned all titles as a first screen after which select-
ed abstracts and/or full-length papers were collected for further review.
Articles were either included or excluded based on their relevance to
the topic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two of the principal authors independently scanned all titles as a first screen after which selected abstracts and/or full-length papers were collected for further review. Articles were either included or excluded based on their relevance to the topic.&quot;</span>

P10. Describe method of data extraction. [No]   
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.6%):

e method of data extraction' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The method of data extraction is not described.&quot;</span>

P11. List and define all variables for which data were sought. [No]
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 37.1%):

Variable management practices complicat' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The variables extracted are not explicitly listed and defined.&quot;</span>

P12. Describe methods for assessing risk of bias. [No]   
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.3%):

methods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No method for assessing risk of bias is described, only level of evidence.&quot;</span> 

P13. State the principal summary measures. [NA]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.2%):

, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No meta-analysis was performed.&quot;</span>

P14-P23. Describe methods of combining/analyzing data. [NA] 
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.1%):

quantitative synthesis (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No quantitative synthesis or meta-analysis was performed.&quot;</span>

P24. Summarize the main findings. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Limited high-level evidence prevents the development of robust management guidelines for CDH.&quot;</span>

P25. Discuss limitations at study and outcome level. [Yes] 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.8%):

ingly, the quantity
of high-level evidence was severely lacking, which precludes the identi-
fication of definitive best pr' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The quantity of high-level evidence was severely lacking, which precludes the identification of definitive best practices.&quot;</span>

P26. Provide a general interpretation of the results. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

iNO). Variability in institutional
practice patterns for CDH will likely pose a significant barrier to any fur-
ther improvement in CDH outcomes. Thus, it is imperative that we ded-
icate efforts to design high quality studies that will inform the
development of best practices for these' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variability in institutional practice patterns for CDH will likely pose a significant barrier to any further improvement in CDH outcomes. Thus, it is imperative that we dedicate efforts to design high quality studies that will inform the development of best practices for these infants.&quot;</span>

P27. Describe sources of funding. [No]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40%):

sources of funding' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No statement about sources of funding is provided.&quot;</span>
</pre>
<p><a name='136'></a></p>
</div>
<div id="reddy-2010" class="section level4">
<h4><a href='https://doi.org/10.4103/0970-1591.74459' title='Open publication'>Reddy
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the attached systematic review:

A1. Was an 'a priori' design provided? 
"[No]" 
No mention of protocol or pre-determined objectives.

A2. Was there duplicate study selection and data extraction?
"[No]"
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review of the contemporary urological citations was conducted using the National Library of Medicine (PubMed) search engine.&quot;</span>
At least two databases searched. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
"[No]" 
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided?
"[No]"
No lists of included or excluded studies provided.

A6. Were the characteristics of the included studies provided?
"[Yes]" 
Table 1 provides characteristics like number of patients, location of stones, success rates, and complications.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]"
No mention of quality assessment.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
"[NA]" 
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate?
"[NA]" 
No meta-analysis performed.

A10. Was the likelihood of publication bias assessed?
"[NA]"  
No assessment of publication bias as no meta-analysis.

A11. Was the conflict of interest included?
"[No]"
No mention of sources of funding or support.

P1. Identify the report as a systematic review, meta-analysis, or both.
"[No]"
Not identified as a systematic review.

P2. Provide a structured summary.
"[No]"
No structured summary provided.

P3. Describe the rationale for the review in the context of what is already known.  
"[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The purpose of this review article is to demonstrate that ureteroscopic lithotripsy is now to be considered the standard of care in the management of upper tract urolithiasis in the pediatric patient, replacing shockwave lithotripsy (ESWL) as the first line of therapy.&quot;</span>

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
"[No]"
No PICOS provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
"[NA]" 
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
"[No]"
Inclusion/exclusion criteria not specified.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
"[No]"
Only mentions PubMed, no dates provided.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
"[No]" 
No search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
"[No]"
No selection process described. 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
"[No]"
No data extraction process described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
"[No]"
No list of variables.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
"[NA]" 
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means).
"[NA]"  
No meta-analysis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
"[NA]"
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
"[NA]"
No assessment of publication bias or selective reporting as no meta-analysis.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
"[NA]"
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
"[No]" 
No flow diagram, number screened, assessed, or reasons for exclusions given.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
"[Yes]"
Table 1 provides some characteristics and citations for included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
"[NA]" 
No risk of bias assessment.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
"[No]"
No forest plots or effect estimates with CIs.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
"[NA]"
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15).  
"[NA]"
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
"[NA]" 
No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
"[No]" 
No summary of main findings or strength of evidence.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
"[No]"
No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
"[No]"
No interpretation of results or implications for future research.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. 
"[No]"
No sources of funding or support described.
</pre>
<p><a name='137'></a></p>
</div>
<div id="romao-2012" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2012.01.009' title='Open publication'>Romao
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. "[No]" - No protocol or pre-determined objectives mentioned.

A2. "[No]" - No mention of duplicate study selection or data extraction. 

A3. "[Yes]" - Searched MEDLINE, EMBASE, CINAHL. Also checked references and cross-references.

A4. "[No]" - No mention of searching for grey literature.

A5. "[No]" - No list of included/excluded studies provided.

A6. "[Yes]" - Table 1 provides characteristics of included studies.

A7. "[No]" - No assessment of quality of included studies.

A8. "[NA]" - Not applicable since quality of studies not assessed.

A9. "[Yes]" - Heterogeneity assessed and random effects model used in meta-analysis. 

A10. "[No]" - No assessment of publication bias mentioned.

A11. "[No]" - No statement about conflicts of interest.

P1. "[Yes]" - Identified as systematic review and meta-analysis in title.

P2. "[Yes]" - Structured abstract provided. 

P3. "[Yes]" - Rationale described in introduction.

P4. "[Yes]" - Research questions stated in introduction. 

P5. "[No]" - No review protocol mentioned.

P6. "[Yes]" - Inclusion criteria described.

P7. "[Yes]" - Literature search methods described.

P8. "[No]" - No full search strategy provided.

P9. "[No]" - Study selection process not described. 

P10. "[No]" - Data extraction methods not described.

P11. "[Yes]" - Outcomes described. 

P12. "[No]" - No risk of bias assessment mentioned. 

P13. "[Yes]" - Odds ratio presented as summary measure.

P14. "[NA]" - Not applicable since only 1 meta-analysis.

P15. "[NA]" - Not applicable since no assessment of bias across studies.

P16. "[NA]" - No additional analyses mentioned.

P17. "[No]" - No flow diagram of study selection provided. 

P18. "[Yes]" - Study characteristics presented in Table 1.

P19. "[NA]" - Not applicable since no risk of bias assessment.

P20. "[Yes]" - Forest plots presented with effect sizes.

P21. "[Yes]" - Confidence intervals and heterogeneity presented.

P22. "[NA]" - Not applicable since no bias assessment.

P23. "[NA]" - No additional analyses.

P24. "[Yes]" - Main findings summarized in discussion. 

P25. "[Yes]" - Limitations discussed.

P26. "[Yes]" - Results interpreted in context of other evidence.

P27. "[No]" - No statement about funding sources.
</pre>
<p><a name='138'></a></p>
</div>
<div id="ross-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3691-2' title='Open publication'>Ross
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We performed a systematic review of the existing literature.&quot;</span> (Abstract)
- Mentions performing a systematic review, but does not mention a protocol.
[No]

A2. Was there duplicate study selection and data extraction?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The literature search, assessment for in-
clusion and data extraction were performed independently
by three reviewers and disagreements resolved by
consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;</span> (Methods)  
- Three independent reviewers performed study selection and data extraction.
[Yes]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98%):

We searched Medline, Embase and the Cochrane con-
trolled trials register from inception to July 2014 using the
terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed
silo’ and ‘silastic silo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed silo’ and ‘silastic silo’.&quot;</span> (Methods)
- Searched multiple databases without date restrictions.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding based on publication status.
[No] 

A5. Was a list of studies (included and excluded) provided?
- Figure 1 shows a flow diagram depicting included and excluded studies.
[Yes]

A6. Were the characteristics of the included studies provided?
- Table 1 provides key characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No mention of formal quality assessment for included studies.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?  
- Did not assess quality of included studies.
[NA]

A9. Were the methods used to combine the findings of studies appropriate?
- Used random effects model and assessed heterogeneity with I2 statistic.
[Yes]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias mentioned.
[No]

A11. Was the conflict of interest included?  
- No statement about conflicts of interest.
[No]

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review aimed to determine comparative outcomes for infants with gastroschisis treated with either a PFS or alternate treatment strategy.&quot;</span> (Discussion)
[Yes]

P2. Provide a structured summary including key elements.
- Provides a structured abstract with background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, synthesis methods, results, limitations, and conclusions.
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
- Introduction provides context about current knowledge and controversies around optimal management of gastroschisis.
[Yes] 

P4. Provide an explicit statement of questions being addressed.
- Clear objective provided: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎to evaluate current evidence comparing the use of a PFS with alternate treatment strategies in infants with gastroschisis.&quot;</span> (Abstract)
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
- No mention of a review protocol.
[No]

P6. Specify study characteristics used as criteria for eligibility. 
- Details inclusion and exclusion criteria. (Methods)
[Yes]

P7. Describe all information sources in the search and date last searched.
- Lists databases searched from inception to July 2014. (Methods)
[Yes]

P8. Present full electronic search strategy for at least one database.
- Does not provide full search strategy.
[No]

P9. State the process for selecting studies.
- Describes study selection process and screening by abstract and full text. (Methods, Figure 1)
[Yes]

P10. Describe method of data extraction and confirmation.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data were extracted and entered into Review Manager (v5.1, The Cochrane Collaboration)&quot;</span> (Methods)
- Does not describe if extraction was done in duplicate.
[No]

P11. List and define all variables for which data were sought.
- Specifies outcomes extracted. (Methods) 
[Yes]

P12. Describe methods for assessing risk of bias of individual studies.
- Does not describe a risk of bias assessment.
[No]

P13. State the principal summary measures.
- Specifies that mean difference and risk difference were used. (Methods)
[Yes]

P14. Describe the methods of handling data and combining results.
- Describes the use of a random effects model and assessment of heterogeneity using the I2 statistic. (Methods)
[Yes]

P15. Specify any assessment of risk of bias across studies.
- No assessment of publication bias or other biases across studies.
[No] 

P16. Describe methods of additional analyses.
- Mentions pre-planned subgroup analysis. (Methods)
[Yes]

P17. Give numbers of studies at each stage of screening and selection, ideally with a flow diagram.
- Figure 1 shows the flow of studies with numbers at each stage.
[Yes]

P18. For each study, present key characteristics. 
- Table 1 presents key characteristics of included studies.
[Yes]

P19. Present data on risk of bias for each study.
- Does not present risk of bias results.
[No]

P20. For each outcome, present summary data and effect estimates for each study.
- Presents forest plots with summary data and effect estimates. (Results, Figures 2-4)  
[Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. 
- Presents results of meta-analyses with confidence intervals and I2 values. (Results, Figures 2-4)
[Yes]

P22. Present results of any assessment of risk of bias across studies.
- Did not assess risk of bias across studies.
[No]

P23. Give results of additional analyses, if done.
- Presents results of subgroup analysis. (Results)
[Yes] 

P24. Summarize the main findings and discuss relevance.
- Summarizes main findings and discusses relevance to clinical practice in the Discussion.
[Yes]

P25. Discuss limitations at study and outcome level and at review level.
- Discusses limitations at the review level in the Discussion.
[No]

P26. Provide a general interpretation of results in the context of other evidence.
- Interprets findings in the context of other evidence. (Discussion)
[Yes]

P27. Describe sources of funding and support for the review.
- No statement about sources of funding or support.
[No]
</pre>
<p><a name='139'></a></p>
</div>
<div id="ruttenstock-2010" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-010-2695-1' title='Open publication'>Ruttenstock
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [No] No mention of a protocol, ethics approval, or pre-determined research objectives.
A2. [Yes] <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.7%):

Detailed information was recorded regarding the type of
study, patient’s age and gender, intraoperative details, and
postoperative complications with particular emphasis on
the incidence and outcome of HAEC' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Detailed information was recorded regarding the [...] postoperative complications with particular emphasis on the incidence of HAEC.&quot;</span> Indicates at least two people extracted data.  
A3. [Yes] <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 43.1%):

’’. The reference list
from retrieved articles was reviewed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎PubMed and Medline were searched [...]. The search terms were [...]. The reference list from retrieved articles was reviewed [...]&quot;</span> Two sources searched plus supplementary strategy.
A4. [No] No mention of including or excluding based on publication status. 
A5. [Yes] Table 1 provides a list of included studies.
A6. [Yes] Table 1 provides aggregated data on number of patients, number with HAEC, and HAEC treatment. Results section provides additional details.
A7. [No] No mention of assessing quality or risk of bias of included studies.
A8. [NA] Since A7 is No, A8 is not applicable.
A9. [NA] No quantitative synthesis performed. 
A10. [NA] Since there is no meta-analysis, assessment of publication bias is not applicable.
A11. [No] No mention of sources of support or conflict of interest.

P1. [Yes] Identified as a systematic review and meta-analysis in title.
P2. [Yes] Structured abstract provided with background, objectives, eligibility criteria, participants, data sources, synthesis methods, results, and conclusions.
P3. [Yes] Rationale described in introduction in context of what is known.
P4. [No] No explicit PICOS statement.
P5. [No] No mention of a protocol.
P6. [Yes] Study characteristics used for eligibility described in methods.
P7. [Yes] Literature search methods described including databases and terms.
P8. [No] Search strategy not provided.
P9. [Yes] Study selection process described. 
P10. [No] No details provided on data extraction process.
P11. [Yes] Variables extracted described in results.
P12. [No] No assessment of risk of bias mentioned.
P13. [NA] No meta-analysis performed.
P14. [NA] No meta-analysis performed.
P15. [NA] No meta-analysis performed. 
P16. [NA] No additional analyses mentioned.
P17. [Yes] Study flow described in text, tables, and citations.
P18. [Yes] Study characteristics presented in Table 1.
P19. [No] No assessment of risk of bias presented.
P20. [Yes] Summary data presented for each study in text and Table 1. 
P21. [NA] No meta-analysis performed.
P22. [NA] No assessment of bias across studies.
P23. [NA] No additional analyses mentioned. 
P24. [Yes] Main findings summarized including strength of evidence.
P25. [No] No discussion of limitations.
P26. [Yes] Results interpreted in context of other evidence. 
P27. [No] No statement about sources of funding.
</pre>
<p><a name='140'></a></p>
</div>
<div id="rynja-2011" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2011.02.008' title='Open publication'>Rynja
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎PubMed and Medline were searched for all studies that reported cases of patients who had undergone surgical correction of HD on transanal one-stage pull-through operation between 1998 and 2009.&quot;</span>
The review had pre-determined inclusion criteria.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The search terms were ‘‘one-stage transanal pull-through’’, ‘‘transanal one-stage endorectal pull-through’’, ‘‘one-stage Soave pull-through’’, ‘‘single-stage transanal endorectal pull-through’’, ‘‘primary pull-through’’, or ‘‘Soave procedure’’. The reference list from retrieved articles was reviewed for additional cases.&quot;</span>
At least 2 databases were searched along with supplementary strategies. 

A4. [No]
No mention of including or excluding studies based on publication status.

A5. [No]
No explicit list of included and excluded studies provided.

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Detailed information was recorded regarding the type of study, patient’s age and gender, intraoperative details, and postoperative complications with particular emphasis on the incidence and outcome of HAEC.&quot;</span> 
Key characteristics of included studies summarized.

A7. [No]
No assessment of study quality reported.

A8. [NA]
Study quality not assessed so using it in formulating conclusions not applicable.

A9. [NA] 
No quantitative synthesis performed. 

A10. [NA]
Assessment of publication bias not applicable without a meta-analysis.

A11. [No]
No mention of conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review and meta-analysis of enterocolitis after one-stage transanal pull-through procedure for Hirschsprung’s disease&quot;</span>
Identified as a systematic review and meta-analysis.

P2. [Yes] 
Structured abstract provided with objectives, eligibility criteria, results, and conclusions.

P3. [Yes]
Rationale described in introduction.

P4. [Yes]
PICOS elements specified in methods. 

P5. [No] 
No mention of a review protocol.

P6. [Yes]
Study characteristics used as eligibility criteria described. 

P7. [Yes]
Information sources and search dates reported.

P8. [No]
Full search strategy not provided.

P9. [Yes]
Study selection process described. 

P10. [No] 
No details on data extraction process.

P11. [NA] 
Not applicable as no meta-analysis performed.

P12. [No]
Individual study bias assessment not described. 

P13. [NA]
Not applicable without a meta-analysis.

P14. [NA]
Not applicable without a meta-analysis.

P15. [NA] 
Not applicable without a meta-analysis.

P16. [NA]
Not applicable without additional analyses.

P17. [No] 
Number of studies at each stage not reported. 

P18. [Yes]
Study characteristics presented in Table 1. 

P19. [No]
Individual study bias not presented.

P20. [No]
Study results not presented in a forest plot.

P21. [No]
Meta-analysis results not presented. 

P22. [NA] 
Not applicable without a meta-analysis.

P23. [NA]
Not applicable without additional analyses. 

P24. [Yes]  
Main findings summarized in discussion.

P25. [No]
No limitations discussed.

P26. [Yes]
Results interpreted in context of other evidence.

P27. [No]
No mention of sources of funding.
</pre>
<p><a name='141'></a></p>
</div>
<div id="saldaña-2013" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2012.0467' title='Open publication'>Saldaña
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here is my assessment of the systematic review using the AMSTAR and PRISMA tools:

A1. "[Yes]"
- <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.1%):

systematic reviews and are tasked to assess the methodological quality of a systematic re' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A systematic review.." "[We have] conducted [a] systematic research in PubMed&quot;</span> 
- The review had a clear objective and pre-defined inclusion criteria.

A2. "[No]"  
- No mention of duplicate study selection or data extraction.

A3. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An electronic search in PubMed up to March 2012 was conducted with the following terms&quot;</span>
- PubMed was searched systematically, and supplementary search strategies were used.

A4. "[No]"
- No mention of including or searching for grey literature. 

A5. "[No]"
- No list of included and excluded studies provided.

A6. "[Yes]" 
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 90.1%):

We identified prospective controlled trials (n = 1), case-control studies (n = 12), case series (n = 49), and case
reports' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We identified..prospective controlled trials..case series..case reports&quot;</span> 
- Aggregate data on number of studies by type provided in results.

A7. "[Yes]"  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We used the original classification of levels of evidence described by the Canadian Task Force&quot;</span>
- The quality of individual studies was assessed using a standard classification system.

A8. "[No]"
- The quality of studies was categorized, but not taken into account in analysis or conclusions.

A9. "[NA]"
- No quantitative synthesis performed.

A10. "[NA]"  
- No quantitative synthesis performed.

A11. "[No]"
- No mention of conflicts of interest.

P1. "[Yes]"
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Single-Incision Pediatric Endosurgery: A Systematic Review&quot;</span>
- Identified as a systematic review in title.

P2. "[Yes]"  
- Provides structured abstract with background, objectives, eligibility criteria, results, conclusions.

P3. "[Yes]"
- Provides context and rationale for review in introduction.

P4. "[Yes]"
- Research question and inclusion criteria defined.

P5. "[No]"
- No mention of a review protocol.

P6. "[Yes]"
- Eligibility criteria, including study characteristics, provided. 

P7. "[Yes]"
- Information sources (PubMed) and date searched specified.

P8. "[Yes]" 
- Full search strategy provided.

P9. "[No]"
- No details provided on study selection process.

P10. "[No]"
- No description of data extraction process. 

P11. "[Yes]"
- Variables sought are clear from the data extracted and presented.

P12. "[No]"
- Does not describe methods for assessing risk of bias.

P13. "[NA]"
- No summary measures, as no quantitative synthesis performed.

P14. "[NA]" 
- No quantitative synthesis performed.

P15. "[NA]"
- No quantitative synthesis performed.

P16. "[NA]"
- No additional analyses performed.

P17. "[No]"
- Number screened and assessed not provided.

P18. "[Yes]"
- Main characteristics of included studies provided.

P19. "[No]"
- Does not present risk of bias for each study.

P20. "[Yes]" 
- Main results for each study type provided. 

P21. "[NA]"
- No meta-analysis performed.

P22. "[NA]"
- No assessment of risk of bias across studies.

P23. "[NA]"
- No additional analyses performed.

P24. "[Yes]"
- Main findings and conclusions summarized.

P25. "[Yes]"
- Limitations discussed.

P26. "[Yes]"
- Interpretation of results and implications described.

P27. "[No]" 
- No mention of sources of funding or support.

</file-attachment-contents>
</pre>
<p><a name='142'></a></p>
</div>
<div id="sauerland-2010" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD001546.PUB3' title='Open publication'>Sauerland
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and the reporting quality using PRISMA for the given systematic review:

A1. Was an 'a priori' design provided? [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In order to be as comprehensive as possible, the following search strategies were employed to identify all relevant studies irrespective of language.&quot;</span>
Reasoning: The review had a predefined protocol for literature search and inclusion/exclusion criteria. 

A2. Was there duplicate study selection and data extraction? [Yes]  
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.4%):

.
Two observers independently extracted the results of each paper
on a data sheet' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two reviewers independently assessed trial quality." "Two observers independently extracted the results of each paper on a data sheet&quot;</span>  
Reasoning: Two independent reviewers performed study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched the Cochrane Library, MEDLINE, EMBASE, LILACS, CNKI, SciSearch, study registries, and the congress proceedings of endoscopic surgical societies.&quot;</span>
Reasoning: Multiple databases were searched along with supplementary strategies like screening references and contacting experts.

A4. Was the status of publication used as an inclusion criterion? [No]  
Quotes: No mention of including or excluding studies based on publication status.
Reasoning: The review does not state whether unpublished studies or grey literature were sought. 

A5. Was a list of studies (included and excluded) provided? [Yes]  
Quotes: References for included and excluded studies are provided. 
Reasoning: Lists of included and excluded studies with citations are provided.

A6. Were the characteristics of the included studies provided? [Yes]
Quotes: Table describing characteristics like participants, interventions, outcomes for each included study.
Reasoning: Characteristics of included studies summarized in a table.

A7. Was the scientific quality of the included studies assessed and documented? [Yes] 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Risk of bias&quot;</span> table with judgments about methodological quality of each study.
Reasoning: The review authors assessed risk of bias in included studies and presented the results in a table. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]  
Quotes: <span title='Moderate quote deviation. Best match in fulltext (Similarity 92.4%):

, laparoscopic surgery for suspected appendicitis has diagnostic and therapeutic advantages as compared to conventional
surgery. However, conventional appendectomy should not be considered &#39;wrong' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In conclusion, laparoscopic surgery for suspected appendicitis has diagnostic and therapeutic advantages as compared to conventional surgery. However, conventional appendectomy should not be considered 'wrong'.&quot;</span>
Reasoning: The conclusions acknowledge the limitations of included studies while interpreting the results.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.2%):

continuous variables, generally means with their
corresponding standard deviations (SDs) are needed to calculate
weighted or standardized mean differences' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎For dichotomous outcomes..Peto's odds ratios were calculated...For continuous variables...means with their corresponding standard deviations are needed to calculate weighted or standardized mean differences.&quot;</span>  
Reasoning: Appropriate statistical methods were used for pooling results and assessing heterogeneity. 

A10. Was the likelihood of publication bias assessed? [No]
Quotes: No assessment of publication bias mentioned.
Reasoning: Publication bias was not assessed.

A11. Was the conflict of interest included? [Yes] 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None&quot;</span> in the Declaration of Interest section.
Reasoning: The review states there were no conflicts of interest.

P1. Identify the report as a systematic review. [Yes]  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic versus open surgery for suspected appendicitis (Review)&quot;</span>
Reasoning: The report is identified as a Cochrane systematic review.

P2. Provide a structured summary. [Yes]  
Quotes: The abstract provides a structured summary with background, objectives, methods, results, and conclusions.
Reasoning: A structured abstract is provided.

P3. Describe the rationale for the review. [Yes]   
Quotes: <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

The evolution of
endoscopic surgery led to the idea of performing appendectomy
in laparoscopy, which was first described by Semm in 1983 (Semm
1983). Nevertheless, the new method has only partly gained
acceptance (Faiz 2008; Paterson 2008; Van Hove 2008), because the
advantages of laparoscopic appendectomy were not as obvious as
for laparoscopic cholecystectomy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The evolution of endoscopic surgery led to the idea of performing appendectomy in laparoscopy, which was first described by Semm in 1983. Nevertheless, the new method has only partly gained acceptance, because the advantages of laparoscopic appendectomy were not as obvious as for laparoscopic cholecystectomy.&quot;</span>
Reasoning: The background section describes the rationale for comparing laparoscopic and open appendectomy.

P4. Provide an explicit statement of questions addressed. [Yes]
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review compares laparoscopic and conventional surgery with regard to several peri- and post-operative variables.&quot;</span> 
Reasoning: The objectives section explicitly states the questions addressed regarding comparing laparoscopic and open appendectomy.

P5. Indicate if a review protocol exists. [No] 
Quotes: No mention of a protocol.
Reasoning: The review does not indicate if a protocol exists. 

P6. Specify study characteristics used as criteria for eligibility. [Yes]   
Quotes: The types of studies, participants, interventions, and outcomes used to determine eligibility are described in the methods section.
Reasoning: Details on study eligibility criteria are provided.

P7. Describe all information sources in the search. [Yes]
Quotes: The search methods section lists the databases searched and supplementary search strategies.
Reasoning: The literature search process is described. 

P8. Present full electronic search strategy. [No] 
Quotes: The search strategy is not provided.
Reasoning: The full search strategy for databases is not presented.

P9. State the process for selecting studies. [No]  
Quotes: No description of the study screening and selection process.
Reasoning: The review does not describe the process for screening and including/excluding studies.

P10. Describe method of data extraction. [Yes] 
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two observers independently extracted the results of each paper on a data sheet.&quot;</span>
Reasoning: Independent, duplicate data extraction is described.  

P11. List and define all variables for which data were sought. [Yes] 
Quotes: The types of outcomes extracted are listed in the methods section. 
Reasoning: The sought outcome measures are defined.

P12. Describe methods for assessing risk of bias. [Yes]
Quotes: A <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Risk of bias&quot;</span> table is presented with judgments about methodological quality of studies.
Reasoning: Methods for assessing risk of bias are described and results presented.

P13. State principal summary measures. [Yes]  
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 55.6%):

For dichotomous variables relative risks (RR) with 95% confidence
intervals (95% CIs) were the preferred measure. For complication
rates, howev' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎For dichotomous variables relative risks...were the preferred measure. For continuous variables...weighted or standardized mean differences with 95% CIs.&quot;</span>
Reasoning: The principal summary measures used are stated.

P14. Describe methods of combining results. [Yes]  
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.9%):

). We expected complication rate to vary only by
a very small degree, and therefore used fixed-effects models' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We pooled the effect measures within a random effects model." "We expected complication rate to vary only by a very small degree, and therefore used fixed-effects models.&quot;</span>
Reasoning: Methods for meta-analysis are described.

P15. Specify any assessment of risk of bias across studies. [No] 
Quotes: No assessment of publication bias or selective reporting.
Reasoning: Risk of bias across studies was not assessed.

P16. Describe methods of additional analyses. [NA]
Quotes: No additional analyses like sensitivity/subgroup analyses were done. 
Reasoning: Not applicable as no meta-analysis was performed.

P17. Give numbers of studies at each stage of selection. [No]  
Quotes: No flow diagram or details on study selection process provided.
Reasoning: The number of studies identified, screened, eligible, and included is not reported.

P18. For each study, present characteristics and citations. [Yes] 
Quotes: Table with summary of characteristics for each included study and citations.
Reasoning: Key characteristics and citations are provided for included studies.

P19. Present data on risk of bias. [Yes] 
Quotes: A <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Risk of bias&quot;</span> table summarizes the review authors' judgments about each risk of bias item for each included study.
Reasoning: Assessments of risk of bias for each study are presented.

P20. For each study, present summary data for each intervention group. [Yes]
Quotes: For outcomes like wound infections, abscess rates, etc. results are presented for each study in forest plots. 
Reasoning: For main outcomes, summary data and effect estimates are presented for each included study. 

P21. Present results of each meta-analysis. [Yes] 
Quotes: Pooled statistics with confidence intervals are presented for each meta-analysis.  
Reasoning: Results including confidence intervals are presented for the meta-analyses.

P22. Present results of assessment of risk of bias across studies. [NA]  
Quotes: No assessment of publication bias or selective reporting.
Reasoning: Not applicable as no meta-analysis was performed.

P23. Give results of additional analyses. [NA]
Quotes: No subgroup or sensitivity analyses were performed.
Reasoning: Not applicable as no additional analyses were done. 

P24. Summarize the main findings. [Yes]  
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In summary, laparoscopic surgery for suspected appendicitis has diagnostic and therapeutic advantages as compared to conventional surgery.&quot;</span>  
Reasoning: The main findings are summarized.

P25. Discuss limitations at study and review level. [Yes]   
Quotes: Limitations like risk of bias in studies, clinical relevance of small differences, heterogeneity, and lack of assessment of publication bias are discussed.
Reasoning: Study and review limitations are discussed.

P26. Provide a general interpretation of results. [Yes]
Quotes: The results are interpreted in the context of previous studies and implications for practice are discussed.  
Reasoning: The findings are interpreted and implications are discussed.

P27. Describe sources of funding and role of funders. [Yes]   
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎None&quot;</span> in the Declaration of Interest section.  
Reasoning: Sources of funding are stated.
</pre>
<p><a name='143'></a></p>
</div>
<div id="scholfield-2016" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2015.0121' title='Open publication'>Scholfield
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA 2009 assessments for the attached systematic review:

# AMSTAR
A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our study is the first systematic review and meta-analysis comparing OD and LD pull-through techniques for HD.&quot;</span> [No] - Does not mention a protocol or pre-determined research objectives.

A2. Was there duplicate study selection and data extraction?  
[NA] - Does not mention duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

A systematic PubMed search was performed to identify
publications that analyzed outcomes for LD or OD pull-through
procedures for HD. All studies between January 1994 and De-
cember 2014 were included in the search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search.&quot;</span> [Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
[No] - Does not mention searching for or including grey literature. 

A5. Was a list of studies (included and excluded) provided?  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Eleven articles met our strict inclusion criteria and were included in the meta-analysis.&quot;</span> [Yes] 

A6. Were the characteristics of the included studies provided?
Table 1-7 provide characteristics of included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
Figure 2 provides a risk of bias assessment. [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
[No] - Does not mention risk of bias in conclusions.

A9. Were the methods used to combine the findings of studies appropriate?
Described using random effects model and assessed heterogeneity with I2. [Yes] 

A10. Was the likelihood of publication bias assessed?
[No] - Does not assess publication bias.

A11. Was the conflict of interest included? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎No competing financial interests exist.&quot;</span> [Yes]

# PRISMA 2009
P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Our study is the first systematic review and meta-analysis comparing OD and LD pull-through techniques for HD.&quot;</span>

P2. Provide a structured summary. [Yes] 
Provides abstract with background, objectives, data sources, eligibility criteria, results, conclusions.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction provides context about history and rationale for review.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [Yes] 
Objectives and inclusion criteria address PICOS.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
Does not mention a protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Describes eligibility criteria including years, outcomes, and other study characteristics. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Describes PubMed search from 1994 to 2014.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No] 
Does not provide full search strategy.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Selection process described and shown in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No] 
Does not describe data extraction methods.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Outcomes analyzed are listed and defined in data extraction tables. 

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
Risk of bias assessed with graph (Figure 2).

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
Used odds ratios and mean differences.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes]
Described use of random effects model and assessment of heterogeneity with I2.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [No] 
Does not assess publication bias.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
Figure 1 provides flow diagram of study selection.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] 
Study characteristics provided in tables. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes] 
Risk of bias presented in Figure 2.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Summary data and forest plots provided.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]
No meta-analysis done.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of publication bias.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses.  

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Summarizes main findings in discussion and conclusions.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes]
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in context of other evidence.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [Yes]
States no competing financial interests.
</pre>
<p><a name='144'></a></p>
</div>
<div id="sharp-2015" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0035-1544174' title='Open publication'>Sharp
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here is my assessment of the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The PRISMA format was used for the structure of this systematic review.&quot;</span>
States that PRISMA format was used. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Independent extraction of data was performed by N.E.S using predefined data fields.&quot;</span> 
States that data extraction was done by a single author. [No]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies were identified by searching the electronic database MEDLINE (OVID), and by hand search of reference lists for further relevant articles.&quot;</span>
Searched only one database. [No]  

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No mention of including or excluding grey literature. [No]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A total of seven studies were identified for inclusion in the systematic review.&quot;</span> 
Provides number of included studies but no list of excluded studies. [No]

A6. Were the characteristics of the included studies provided?
Provides characteristics of included studies in text and tables. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
No quality assessment mentioned. [No] 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
No quality assessment done. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
No quantitative synthesis done. [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No statement on conflict of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic review of English articles using OVID was performed.&quot;</span> [Yes]

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
Structured abstract provided with background, objectives, criteria, participants, interventions, results, conclusions. No registration number. [Yes] 

P3. Describe the rationale for the review in the context of what is already known.
Provided in introduction. [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
Research questions and inclusion criteria provided. [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
No protocol mentioned. [No]

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Provided details on PICOS, years, language, publication status. [Yes]

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
States only database searched with date of last search. [No]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Search strategy provided. [Yes] 

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Selection process described. [Yes]

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
States data extracted by a single reviewer. [No]

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Outcomes described. No funding sources. [No]

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
No risk of bias assessment mentioned. [No]

P13. State the principal summary measures (e.g., risk ratio, difference in means).
Not applicable. [NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. 
Not applicable. [NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Not applicable. [NA] 

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
Not applicable. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Flow diagram provided with number of studies at each stage. [Yes]

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Study characteristics presented in text and tables. [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).  
No risk of bias assessment presented. [No]

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
Outcomes summarized for each study in text and tables. No meta-analysis done. [Yes]

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Not applicable. [NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15).
Not applicable. [NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
Not applicable. [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Main findings summarized in discussion and conclusion. [Yes]

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Limitations discussed. [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Provided in discussion and conclusion. [Yes]

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
No funding sources mentioned. [No]
</pre>
<p><a name='145'></a></p>
</div>
<div id="shawyer-2014" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-014-3548-0' title='Open publication'>Shawyer
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There were 2,910 potential citations identified through database searches.&quot;</span>
The review did not mention an a priori design, protocol, or pre-determined objectives.

A2. Was there duplicate study selection and data extraction? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Title and abstract screening was carried out independently and in duplicate (AS and JD).&quot;</span>
Study selection was done in duplicate. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

A comprehensive search was conducted using MEDLINE/
PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the
Cochrane library) electronic databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted using MEDLINE/PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the Cochrane library) electronic databases.&quot;</span>
At least 2 databases were searched.

A4. Was the status of publication used as an inclusion criterion? [No]  
The review did not mention searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
No list of excluded studies was provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):

We performed an appraisal of the quality of reporting of
the included studies in duplicate (AS and JP). We used the
methodological index for non-randomized studies (MIN-
ORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed an appraisal of the quality of reporting of the included studies in duplicate (AS and JP). We used the methodological index for non-randomized studies (MINORS).&quot;</span> 
The MINORS tool was used to assess quality.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63%):

The quality of the included
studies is low demonstrating important shortcomings, such
as study design, small number of patients evaluated,' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The quality of the included studies is low demonstrating important shortcomings, such as study design, small number of patients evaluated, heterogeneous patients evaluated, and lack of a clear definition of outcomes.&quot;</span>
Study limitations were considered in the conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No meta-analysis was performed.

A10. Was the likelihood of publication bias assessed? [NA]
Publication bias was not assessed.

A11. Was the conflict of interest included? [No]
No conflict of interest statement was provided.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 85.4%):

s systematic review on the use of anti-reflux
Pediatr Surg Int (2014) 30:987–996 991
123

medication in postoperative EA-TEF patients' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We performed a systematic review on the use of anti-reflux medication in postoperative EA-TEF patients.&quot;</span>

P2. Provide a structured summary. [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review. [Yes]  
The introduction describes the rationale.

P4. Provide an explicit statement of questions being addressed. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The objective of this study was to determine the prevalence of anti-reflux medication use in postoperative EA-TEF patients, and the impact of routine anti-reflux medication on postoperative GER and its associated complications.&quot;</span> 

P5. Indicate if a review protocol exists. [No] 
A protocol is not mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
The methods section describes the eligibility criteria. 

P7. Describe all information sources and date last searched. [Yes]
The methods describe the information sources searched.

P8. Present full electronic search strategy for at least one database. [No]
The search strategy is not provided.

P9. State the process for selecting studies. [Yes] 
The methods describe the process for study selection.

P10. Describe method of data extraction. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Data abstraction was performed in duplicate (AS, JD) and
verified for accuracy and quality via a pre-piloted stan-
dardized data abstraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was performed in duplicate (AS, JD) and verified for accuracy and quality via a pre-piloted standardized data abstraction form.&quot;</span>

P11. List and define all variables for which data were sought. [No]
The variables extracted are not defined.

P12. Describe methods used for assessing risk of bias of individual studies. [Yes]
The MINORS tool was used to assess quality. 

P13. State the principal summary measures. [NA] 
No meta-analysis was performed.

P14-P23. Describe methods of synthesis, assessment of bias, and additional analyses. [NA] 
No meta-analysis was performed.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
The discussion summarizes the main findings.

P25. Discuss limitations at study and outcome level. [Yes]
Limitations are described in the discussion.

P26. Provide a general interpretation of the results in the context of other evidence. [Yes]
Results are interpreted in the context of previous evidence.

P27. Describe sources of funding for the systematic review. [No] 
Sources of funding are not described.
</pre>
<p><a name='146'></a></p>
</div>
<div id="shawyer-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-014-3626-3' title='Open publication'>Shawyer
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

A comprehensive search was conducted of MEDLINE/
PubMed, EMBASE/OVID and CENTRAL (the Cochrane
Library) electronic databases from 2000 to March 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;</span>
- The review protocol is not mentioned.
- [No]

A2. Was there duplicate study selection and data extraction?  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Full-text screening, data abstraction and quality appraisal were conducted in duplicate.&quot;</span>
- Two reviewers performed study selection and data extraction.
- [Yes]

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

A comprehensive search was conducted of MEDLINE/
PubMed, EMBASE/OVID and CENTRAL (the Cochrane
Library) electronic databases from 2000 to March 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;</span> 
- Two databases and the Cochrane Library were searched.
- [Yes]  

A4. Was the status of publication used as an inclusion criterion?
- Grey literature searching is not mentioned.
- [No]

A5. Was a list of studies (included and excluded) provided? 
- Figure 1 shows a flow diagram of included and excluded studies.
- [Yes]

A6. Were the characteristics of the included studies provided?
- Tables 1 and 2 provide details on the included studies and patients.
- [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

We appraised the quality of reporting of the included
studies in duplicate (AS and ML), with discrepancies
resolved by discussion and consensus. We used the
Methodological Index for Nonrandomized Studies (MIN-
ORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We appraised the quality of reporting of the included studies in duplicate using the Methodological Index for Nonrandomized Studies (MINORS).&quot;</span>
- Study quality was assessed with MINORS.
- [Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):

no significant dif-
ference in rates of mucosal prolapse or defecation scores
for LAARP compared to OPEN. However, the studies are
of moderate quality, samples sizes are small and there are
multiple sources of heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We found no significant difference in rates of mucosal prolapse or defecation scores for LAARP compared to OPEN. However, the studies are of moderate quality, samples sizes are small and there are multiple sources of heterogeneity.&quot;</span>  
- Study limitations are considered in the conclusions.
- [Yes]

A9. Were the methods used to combine the findings of studies appropriate? 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

Case series and observational studies are inherently heter-
ogeneous, thus we decided a priori to use a random-effects
model to account for between-study heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Case series and observational studies are inherently heterogeneous, thus we decided a priori to use a random-effects model to account for between-study heterogeneity.&quot;</span>
- Heterogeneity is assessed and a random effects model used.
- [Yes]

A10. Was the likelihood of publication bias assessed?
- Publication bias is not assessed.
- [No]

A11. Was the conflict of interest included?
- Conflicts of interest are not reported.
- [No]


P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoscopic versus open repair of recto-bladderneck and recto-prostatic anorectal malformations: a systematic review and meta-analysis&quot;</span>
- Identified as a systematic review and meta-analysis in the title.
- [Yes]

P2. Provide a structured summary.
- A structured abstract is provided with objectives, methods, results, and conclusions.
- [Yes]  

P3. Describe the rationale for the review in the context of what is already known.
- The introduction describes the rationale and background.
- [Yes]

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). 
- The objective states the participants, interventions, comparison, and outcomes.
- [Yes]

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
- A protocol is not mentioned.
- [No] 

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
- The eligibility criteria specify the PICOS and publication dates. 
- [Yes]

P7. Describe all information sources in the search and date last searched.
- The information sources and dates searched are provided.
- [Yes]

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
- The full search strategy is not provided.
- [No]

P9. State the process for selecting studies.  
- The process of title/abstract screening and full text review is described.
- [Yes]

P10. Describe method of data extraction from reports and any processes for obtaining and confirming data from investigators.
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

Data abstraction was performed in duplicate (AS and ML)
and verified for accuracy and quality via a pre-piloted
standardized data abstraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was performed in duplicate and verified for accuracy and quality via a pre-piloted standardized data abstraction form.&quot;</span>
- [Yes]

P11. List and define all variables for which data were sought and any assumptions and simplifications made.
- Outcomes sought are listed in the methods. Assumptions are not discussed.
- [Yes] 

P12. Describe methods used for assessing risk of bias of individual studies and how this information is to be used in any data synthesis.
- MINORS was used to assess study quality.
- [Yes]

P13. State the principal summary measures.
- Odds ratios and mean differences are stated.
- [Yes]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency for each meta-analysis.
- A random effects model was used. Heterogeneity was assessed with I2.
- [Yes]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence.
- Publication bias was not assessed.
- [No]  

P16. Describe methods of additional analyses, if done, indicating which were pre-specified.
- Subgroup analyses by study quality were pre-planned and conducted.
- [Yes]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. 
- A flow diagram shows the screening process.
- [Yes]

P18. For each study, present characteristics for which data were extracted and provide the citations.
- Tables 1 and 2 provide details on study characteristics.
- [Yes]

P19. Present data on risk of bias of each study and, if available, any outcome level assessment.
- Study quality is presented with MINORS in Figures 6 and 7.
- [Yes]

P20. For all outcomes considered, present for each study: (a) simple summary data, (b) effect estimates and confidence intervals, ideally with a forest plot.
- Forest plots with effect estimates are presented.
- [Yes] 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
- Results are presented with CIs and I2 values.
- [Yes]

P22. Present results of any assessment of risk of bias across studies. 
- Not done since publication bias was not assessed.
- [NA]

P23. Give results of additional analyses, if done.
- Subgroup analysis results are shown in forest plots.
- [Yes]

P24. Summarize the main findings including the strength of evidence for each main outcome.
- The discussion summarizes the main findings.
- [Yes]

P25. Discuss limitations at study and outcome level and at review-level.
- Limitations are discussed.
- [Yes]

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
- Results are interpreted and implications described.
- [Yes]

P27. Describe sources of funding for the systematic review and other support; role of funders for the systematic review.
- Sources of funding are not reported.
- [No]
</pre>
<p><a name='147'></a></p>
</div>
<div id="shen-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3705-0' title='Open publication'>Shen
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched databases, including PubMed, Embase, the Science Citation Index, and Cochrane Library updated to November 2014, to identify all related published studies comparing the laparoscopic and the open choledochal cyst excision with hepaticojejunostomy.&quot;</span>
The review had a clear research question and pre-determined inclusion criteria.

A2. [No] 
No mention of duplicate study selection or data extraction.

A3. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

The keywords used in
the search were as follows: laparoscopic, open, hepatico-
jejunostomy, choledochal cysts. The language was re-
stricted to English only. The citations within the reference
lists of the articles were searched manually to identify
additional eligible studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The keywords used in the search were as follows: laparoscopic, open, hepaticojejunostomy, choledochal cysts. The language was restricted to English only. The citations within the reference lists of the articles were searched manually to identify additional eligible studies.&quot;</span>
At least 2 databases were searched along with supplementary strategies. 

A4. [No]
The review did not indicate whether grey literature was searched.

A5. [No] 
A list of included and excluded studies was not provided.

A6. [Yes] 
Table 1 provides characteristics of the included studies such as study period, number of patients, age, sex ratio, cyst diameter, follow-up, and NOS score.

A7. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The quality of the literature was assessed independently by two authors (Huo-Jian Shen and Ming Xu) using the 9-star Newcastle–Ottawa Scale.&quot;</span>
Study quality was assessed using the NOS scale.

A8. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Caution should be given in the interpretation and generalization of this meta-analysis as the included study numbers are not high and also the overall quantity of these studies is insufficient.&quot;</span>
Study limitations were considered in the conclusions.

A9. [NA]
No meta-analysis was performed.

A10. [NA]  
Assessment of publication bias not applicable without a meta-analysis.  

A11. [No]
No mention of conflicts of interest.

P1. [Yes]
The title identifies it as a meta-analysis.

P2. [Yes] 
The abstract provides background, objectives, data sources, eligibility criteria, outcomes, results, limitations, and conclusions.

P3. [Yes]
The introduction describes current knowledge and rationale.

P4. [Yes]  
The objective and inclusion criteria define the participants, interventions, comparisons, and outcomes. 

P5. [No]
No protocol registration was mentioned.

P6. [Yes]
Table 1 describes the characteristics of the included studies. 

P7. [Yes]  
The methods section describes the literature search including databases searched.

P8. [No]  
The full search strategy was not provided for any database.

P9. [Yes]
The selection process is described in the search results section. 

P10. [No]   
The methods for data extraction were not described.

P11. [NA]  
Not applicable as no meta-analysis was performed.

P12-P23. [NA] 
Not applicable as no meta-analysis was performed.

P24. [Yes]
The discussion summarizes the main findings and limitations.

P25. [Yes] 
Limitations at the study and review level are discussed.

P26. [Yes] 
The results are interpreted in the context of other evidence. 

P27. [No]
No mention of sources of funding or support.
</pre>
<p><a name='148'></a></p>
</div>
<div id="siddiqui-2011" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-010-2698-Y' title='Open publication'>Siddiqui
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the systematic review:

A1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Six comparative studies were analysed.]&quot;</span> The review had a pre-determined inclusion criteria. [Yes]

A2. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two researchers using a double extraction method for eligibility in our review (Table 1).&quot;</span> Two independent reviewers performed study selection and data extraction. [Yes] 

A3. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

We searched the MEDLINE, EM-
BASE and CINAHL available through the National Library
of Health website, the Cochrane library and PubMed dat-
abases available online' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched the MEDLINE, EMBASE and CINAHL available through the National Library of Health website, the Cochrane library and PubMed databases available online.&quot;</span> Multiple databases were searched. [Yes]

A4. No mention of searching for grey literature. [No] 

A5. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Six trials [3, 17, 24, 25, 27, 28] were excluded (Table 1).&quot;</span> A list of included and excluded studies provided. [Yes]

A6. Table 2 provides characteristics of included studies. [Yes]

A7. No assessment of study quality described. [No]

A8. Study quality not used in formulating conclusions since it was not assessed. [NA]

A9. Heterogeneity assessed and random effects model used for meta-analysis. [Yes]

A10. No assessment of publication bias. [No]

A11. No statement about conflicts of interest. [No]


P1. Identified as a systematic review and meta-analysis. [Yes] 

P2. Abstract provides structured summary. [Yes]

P3. Rationale described in introduction. [Yes]

P4. Objectives stated to compare outcomes after open and laparoscopic Nissen fundoplication. [Yes]

P5. No mention of a protocol. [No]

P6. Inclusion criteria define study characteristics. [Yes] 

P7. Databases searched provided. [Yes]

P8. No full search strategy provided. [No]

P9. Study selection process described and depicted in Figure 1. [Yes]

P10. Double extraction mentioned but no details on process. [No] 

P11. Outcomes described. [Yes] 

P12. No assessment of risk of bias. [No]

P13. Principal summary measures described. [Yes]

P14-P16. Not applicable as no meta-analysis done. [NA]

P17. Study flow shown in Figure 1. [Yes]

P18. Characteristics of included studies provided in Table 2. [Yes]

P19. No assessment of risk of bias. [No]

P20. Forest plots provide effect sizes. [Yes] 

P21-P23. Not applicable as no meta-analysis done. [NA]

P24. Main findings summarized. [Yes]

P25. Limitations described in discussion. [Yes] 

P26. Results interpreted in context of other evidence. [Yes]

P27. No statement about sources of funding. [No]
</pre>
<p><a name='149'></a></p>
</div>
<div id="siminas-2015" class="section level4">
<h4><a href='https://doi.org/10.1097/SLA.0000000000001191' title='Open publication'>Siminas
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the provided systematic review:

# AMSTAR

A1. Was an 'a priori' design provided? 
"[No]", No protocol, ethics approval, or pre-determined research objectives were mentioned.

A2. Was there duplicate study selection and data extraction? 
"[No]", No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed?
"[Yes]", Multiple databases searched including MEDLINE, Google Scholar, EMBase, and major journals. Search strategy provided.

A4. Was the status of publication used as an inclusion criterion?  
"[No]", No mention of including or excluding based on publication status. 

A5. Was a list of studies (included and excluded) provided?
"[Yes]", Table 1 provides details on included studies.

A6. Were the characteristics of the included studies provided?
"[Yes]", Table 1 provides characteristics of included studies.

A7. Was the scientific quality of the included studies assessed and documented?
"[No]", No quality assessment tool or checklist used.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
"[NA]", No quality assessment performed. 

A9. Were the methods used to combine the findings of studies appropriate?  
"[NA]", No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed?
"[NA]", No assessment of publication bias as no meta-analysis performed.

A11. Was the conflict of interest included? 
"[No]", No mention of sources of funding or support for included studies.

# PRISMA

P1. Identify the report as a systematic review, meta-analysis, or both.
"[Yes]", Identified as a systematic review in title.

P2. Provide a structured summary.
"[Yes]", Structured abstract provided with objectives, eligibility criteria, results, conclusions.

P3. Describe the rationale for the review.  
"[Yes]", Rationale described in introduction.

P4. Provide an explicit statement of questions being addressed.
"[Yes]", Questions addressed in introduction section.

P5. Indicate if a review protocol exists.
"[No]", No protocol mentioned.

P6. Specify study characteristics and report characteristics used as eligibility criteria.
"[Yes]", Inclusion and exclusion criteria described in methods.

P7. Describe all information sources in the search.
"[Yes]", Information sources described in methods. 

P8. Present full electronic search strategy. 
"[Yes]", Search strategy provided for MEDLINE.

P9. State process for selecting studies.
"[Yes]", Study selection process described and illustrated in Figure 2.

P10. Describe method of data extraction.
"[No]", No details provided on data extraction process.

P11. List and define all variables for which data were sought.
"[Yes]", Variables sought listed in results, including patient characteristics, interventions, outcomes.

P12. Describe methods for assessing risk of bias. 
"[No]", No risk of bias assessment described.

P13. State the principal summary measures.
"[NA]", No quantitative synthesis performed.

P14. Describe methods of handling data and combining results.
"[NA]", No quantitative synthesis performed.

P15. Specify assessment of risk of bias across studies.
"[NA]", No assessment of risk of bias performed.

P16. Describe methods of additional analyses.
"[NA]", No additional analyses performed.

P17. Give numbers of studies screened, assessed, included, and excluded with reasons.
"[Yes]", Number of studies at each stage provided in Figure 2.

P18. For each study, present characteristics for which data were extracted.
"[Yes]", Study characteristics presented in Table 1. 

P19. Present data on risk of bias for each study.
"[No]", No assessment of risk of bias.

P20. For each study, present simple summary data and effect estimates.
"[NA]", No quantitative synthesis performed.

P21. Present results of each meta-analysis done. 
"[NA]", No meta-analysis performed.

P22. Present results of assessment of risk of bias across studies.
"[NA]", No assessment of risk of bias across studies. 

P23. Give results of additional analyses.
"[NA]", No additional analyses performed.

P24. Summarize the main findings including the strength of evidence for each main outcome.
"[Yes]", Main findings summarized in discussion section.

P25. Discuss limitations at study and outcome level and at review level.
"[Yes]", Limitations discussed in discussion section.

P26. Provide a general interpretation of the results in context of other evidence.
"[Yes]", Results interpreted in discussion section.

P27. Describe sources of funding and support for the systematic review.
"[No]", No mention of sources of funding or support.
</pre>
<p><a name='150'></a></p>
</div>
<div id="sklar-2014" class="section level4">
<h4><a href='https://doi.org/10.1089/lap.2013.0415 ' title='Open publication'>Sklar
2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):

we
sought to conduct a systematic review and meta-analysis,
combining our data with existing literature, in order to
identify any differences in outcome measures across all
identified comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We aimed to conduct a systematic review and meta-analysis, combining our data with existing literature, in order to identify any differences in outcome measures across all identified comparative studies.&quot;</span>
Does not mention protocol or pre-determined objectives.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

Two researchers independently screened
the title and abstract of identified articles for potential eligi-
bility and retrieved the full-text version of all articles deemed
relevant' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently screened the title and abstract of identified articles for potential eligibility and retrieved the full-text version of all articles deemed relevant.&quot;</span>
Two researchers performed study selection and data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To identify all publications comparing LAP versus open surgery for intussusception in children, two researchers independently searched the electronic databases MEDLINE, Embase, CINAHL, and the Cochrane Library.&quot;</span>
Searched at least 2 databases. 

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding grey literature.

A5. Was a list of studies (included and excluded) provided? [No]
List of included studies provided but not excluded.

A6. Were the characteristics of the included studies provided? [Yes]
Table 2 provides characteristics of included studies such as study design, sample size, outcomes assessed. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Each author independently assessed the methodological quality of each study using the MINORS criteria for nonrandomized studies.&quot;</span> And results provided in Table 2.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]
Limitations are mentioned in the Discussion. 

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
Methods for assessing heterogeneity described. 

A10. Was the likelihood of publication bias assessed? [No] 
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement on conflict of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
Identified as systematic review and meta-analysis in title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes] 
Structured abstract provided with all elements.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Introduction describes rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion criteria described in Methods. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases and search strategy provided.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No] 
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Study selection process described and shown in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes] 
States two researchers independently extracted data.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
No list of variables sought.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [Yes]
Quality assessment using MINORS described. 

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]  
States use of odds ratios, weighted mean differences. 

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]  

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes] 
Number of studies at each stage provided, reasons for exclusions provided, flow diagram included.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Study characteristics presented in Table 2.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [Yes]
Table 2 provides risk of bias assessment for each study.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
No simple summary data for each study. 

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA] 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in abstract and discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes] 
Limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted and implications described.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] 
No statement on funding or support.
</pre>
<p><a name='151'></a></p>
</div>
<div id="sola-2010" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JSS.2009.05.007' title='Open publication'>Sola
2010</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic review from the published literature.&quot;</span>
The objectives and inclusion criteria were pre-determined. 

A2. Was there duplicate study selection and data extraction? [No] 
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):

The Ovid (Ovid Technologies New York, NY) and Medline search en-
gines were used to examine both the Pubmed and Cochrane libraries
from January 2000 to December 2008' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Ovid (Ovid Technologies New York, NY) and Medline search engines were used to examine both the Pubmed and Cochrane libraries from January 2000 to December 2008.&quot;</span>
At least two electronic sources were searched.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of including or excluding studies based on publication status. 

A5. Was a list of studies (included and excluded) provided? [Yes]
Tables 1 and 2 list the included and excluded studies.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides characteristics of the included studies. 

A7. Was the scientific quality of the included studies assessed and documented? [No]
No quality assessment of included studies is reported.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment was performed.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Comparisons of dichotomous data were carried out using the Mantel-Haenszel statistical method under assumption of fixed effect analysis model.&quot;</span> Heterogeneity was assessed.

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias.

A11. Was the conflict of interest included? [No]
No mention of conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Peritoneal Drainage versus Laparotomy for Necrotizing Enterocolitis and Intestinal Perforation: A Meta-Analysis&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No] 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
The introduction describes the rationale and background.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol registration information provided.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Study selection criteria and characteristics are described in the methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases and date ranges searched are reported in the methods.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No] 
The search strategy is not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
The selection process is described in the methods. 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
The data extraction process is not described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] 
Extracted data included in Tables 1 and 3.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes]
<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 66.7%):

ratio, difference' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Odds ratio, mean difference&quot;</span>

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA] 
No assessment of risk of bias performed.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
No flow diagram provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 presents study characteristics.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
No assessment of risk of bias. 

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes]
Table 3 and Figures 1 and 3 provide summary data and forest plots.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA] 
No meta-analysis performed.

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]
No assessment of risk of bias performed.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses performed.  

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
The results and conclusions summarize the main findings.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No] 
Limitations are not discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
The discussion provides interpretation of the results.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No mention of funding sources.
</pre>
<p><a name='152'></a></p>
</div>
<div id="symeonidis-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.IJSU.2016.03.040' title='Open publication'>Symeonidis
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments for the AMSTAR and PRISMA items based on the provided systematic review text:

A1. Was an 'a priori' design provided? [No]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoendoscopic single-site surgery (LESS) for major urological procedures in the pediatric population: A systematic review&quot;</span>
The research question and inclusion criteria are not explicitly stated before the conduct of the review.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (ENS and DN) working independently extracted data from all eligible studies; any discrepancies were discussed and consensus was reached.&quot;</span>
Two independent reviewers performed study selection and data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An in-depth search of the literature was performed in the databases of PubMed and Scopus&quot;</span> 
At least two electronic databases were searched.

A4. Was the status of publication used as an inclusion criterion? [No]
The authors do not state whether they searched for unpublished literature or excluded studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No]
A list of included and excluded studies is not provided.

A6. Were the characteristics of the included studies provided? [Yes]
Characteristics such as number of patients, age, procedure details, outcomes etc. are provided in tables for the included studies.

A7. Was the scientific quality of the included studies assessed and documented? [No]  
The methodological quality of included studies was not assessed.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
The quality of included studies was not assessed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
The studies were not combined quantitatively. 

A10. Was the likelihood of publication bias assessed? [No]
Publication bias was not assessed.

A11. Was the conflict of interest included? [No]
Conflicts of interest are only reported for the systematic review authors, not the included studies.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Laparoendoscopic single-site surgery (LESS) for major urological procedures in the pediatric population: A systematic review&quot;</span>
The report is identified as a systematic review in the title.

P2. Provide a structured summary. [Yes]
A structured abstract with background, objectives, data sources, inclusion criteria, results, conclusions etc. is provided.

P3. Describe the rationale for the review. [Yes] 
The rationale and context are described in the introduction.

P4. Provide an explicit statement of questions. [No]  
The review question is not explicitly specified in PICOS format.

P5. Indicate if a review protocol exists. [No]
A protocol is not mentioned.

P6. Specify study characteristics used as criteria for eligibility. [Yes]
Inclusion criteria specifying population, intervention, outcomes etc. are described. 

P7. Describe all information sources. [Yes]
Databases and methods used to identify studies are described.

P8. Present full electronic search strategy. [No]
The full search strategy is not presented.

P9. State the process for selecting studies. [Yes] 
The study selection process is described.

P10. Describe method of data extraction. [Yes]
The data extraction process is described.

P11. List and define all variables for which data were sought. [Yes] 
The variables extracted from studies are listed in the results section.

P12. Describe methods used for assessing risk of bias. [No]
Risk of bias methods are not described.

P13. State the principal summary measures. [Yes]
Summary measures such as weighted means are provided.

P14-P23. [NA]
These items are not applicable as there was no meta-analysis. 

P24. Summarize the main findings. [Yes] 
The main findings are summarized in the conclusion.

P25. Discuss limitations at study and outcome level. [Yes]
Limitations are discussed. 

P26. Provide a general interpretation of the results. [Yes]
Results are interpreted in the context of the literature.

P27. Describe sources of funding. [Yes] 
Sources of funding are stated.
</pre>
<p><a name='153'></a></p>
</div>
<div id="tan-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDS.2015.12.074' title='Open publication'>Tan
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes] 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review was performed according to a protocol that was designed a priori and recommended for systematic reviews and meta-analyses.&quot;</span>
- The authors state that a protocol was designed a priori.

A2. Was there duplicate study selection and data extraction? [Yes]
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Two authors reviewed all the abstracts independently.
Agreement regarding potential relevance was reached by
consensus. Full-text copies of potentially eligible papers
were obtained, and the same 2 reviewers independently ex-
tracted relevant data on study characteristics and the out-
comes of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors reviewed all the abstracts independently. Agreement regarding potential relevance was reached by consensus. Full-text copies of potentially eligible papers were obtained, and the same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;</span>  
- Two reviewers independently performed study selection and data extraction. 

A3. Was a comprehensive literature search performed? [Yes]
- <span title='Minor quote deviation. Best match in fulltext (Similarity 95.3%):

Medline, Embase, Cinahl, and
Cochrane databases were searched electronically on April
24, 2014, and then updated on May 11, 2015' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PubMed, Embase, Cinahl, and Cochrane databases were searched electronically on April 24, 2014, and then updated on May 11, 2015.&quot;</span> 
- Multiple databases were searched.

A4. Was the status of publication used as an inclusion criterion? [No]  
- No mention of including or excluding based on publication status.

A5. Was a list of studies (included and excluded) provided? [Yes]
- Included studies listed in Table II. Excluded studies listed in Table I.

A6. Were the characteristics of the included studies provided? [Yes] 
- Characteristics of included studies provided in Table II.

A7. Was the scientific quality of the included studies assessed and documented? [Yes]  
- Quality assessed using Newcastle-Ottawa scale, results in Table III. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [Yes]   
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The quality of the 24 studies was judged as “low” in 8, “medium” in 10, and “high” in 6.&quot;</span> Quality considered in interpretation.

A9. Were the methods used to combine the findings of studies appropriate? [Yes]
- Meta-analysis of proportions performed. Heterogeneity assessed using I2. Random effects used.

A10. Was the likelihood of publication bias assessed? [No]
- No assessment of publication bias. 

A11. Was the conflict of interest stated? [Yes]  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The authors declare no conflicts of interest.&quot;</span>

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
- Identified as systematic review and meta-analysis in title.

P2. Provide a structured summary. [Yes]  
- Structured abstract provided with background, objectives, data sources, eligibility criteria, outcomes, results, and conclusions.  

P3. Describe the rationale for the review. [Yes]
- Rationale described in the introduction.

P4. Provide an explicit statement of questions being addressed. [Yes]
- Four research questions stated in the methods.

P5. Indicate if a review protocol exists. [Yes] 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This review was performed according to a protocol...&quot;</span> Registered with PROSPERO.

P6. Specify study characteristics used as eligibility criteria. [Yes]
- Inclusion and exclusion criteria described in methods.

P7. Describe all information sources including dates of coverage. [Yes]
- Databases, dates, and search strategy described. 

P8. Present full electronic search strategy. [No]
- Search strategy not provided.

P9. State the process for selecting studies. [Yes]  
- Screening and selection process described.

P10. Describe method of data extraction. [Yes]
- Data extraction process described.

P11. List and define all variables for which data were sought. [Yes] 
- Outcomes described in methods.

P12. Describe methods for assessing risk of bias. [Yes] 
- Quality assessment using Newcastle-Ottawa scale described.

P13. State the principal summary measures. [Yes]
- Meta-analysis of proportions described. 

P14. Describe methods of combining results. [Yes]
- Meta-analysis methods described. 

P15. Specify any assessment of risk of bias across studies. [No] 
- No assessment of publication bias or other biases across studies.

P16. Describe methods of additional analyses. [NA]

P17. Give numbers of studies screened, assessed, and included with reasons for exclusion. [Yes] 
- Screening and selection process shown in Figure 1. Reasons for exclusions provided.

P18. For each study, present characteristics and citations. [Yes]
- Table II presents key characteristics. References provided.

P19. Present data on risk of bias for each study. [Yes] 
- Quality assessment of individual studies presented in Table III.

P20. For all outcomes, present data for each study. [Yes]  
- Data for meta-analyses presented in forest plots. 

P21. Present results of each meta-analysis. [Yes]
- Results of meta-analyses presented.

P22. Present results of assessment of bias across studies. [NA]  

P23. Give results of additional analyses. [NA]

P24. Summarize main findings and discuss relevance. [Yes] 
- Main findings summarized in discussion. Relevance discussed.

P25. Discuss limitations at study and outcome level. [Yes]
- Limitations discussed.

P26. Provide general interpretation of results in context of other evidence. [Yes]
- Results discussed in context of previous studies. 

P27. Describe sources of funding and role of funders. [Yes]
- Sources of funding described.
</pre>
<p><a name='154'></a></p>
</div>
<div id="terui-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3765-1' title='Open publication'>Terui
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘missing-squared-brackets-in-numbered-list’, ‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Systematic searches of English-language articles were conducted by using MEDLINE and the Cochrane Library&quot;</span>
- The review appears to have pre-specified search criteria.
[Yes]

A2. Was there duplicate study selection and data extraction?
- No mention of duplicate study selection or data extraction.
- Only states <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two individual authors extracted data from each selected study.&quot;</span>
[No]

A3. Was a comprehensive literature search performed?
- Searched MEDLINE and Cochrane Library. 
- Specified keywords and that all records were searched.
- Did not report specific years searched or supplementary strategies.
[No]

A4. Was the status of publication used as an inclusion criterion?  
- No mention of including or excluding studies based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎226 studies were excluded based on titles and abstracts&quot;</span>
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎14 studies were included in the qualitative synthesis&quot;</span> 
- List of excluded studies not provided.
[No]  

A6. Were the characteristics of the included studies provided?
- Table 1 provides relevant characteristics of the included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- Stated <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎As assessed on the GRADE scale, the quality of evidence was very low for all outcomes&quot;</span>
- Discussed sources of bias qualitatively but did not use a quality assessment tool.
[No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Discussed limitations of observational studies qualitatively. 
- Did not explicitly relate study quality to conclusions.
[No]

A9. Were the methods used to combine the findings of studies appropriate?
- Used RevMan software for meta-analysis. 
- Assessed heterogeneity using I2.
[Yes]

A10. Was the likelihood of publication bias assessed?
- Did not assess publication bias.
[No]

A11. Was the conflict of interest included?
- No statement about sources of support or conflicts of interest.
[No]

P1. Identify the report as a systematic review, meta-analysis, or both.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted a systematic review and meta-analysis&quot;</span>
[Yes]

P2. Provide a structured summary.
- Abstract provides structured summary.
[Yes]  

P3. Describe the rationale for the review.  
- Intro describes rationale and need for a review on this topic.
[Yes]

P4. Provide an explicit statement of questions being addressed.
- Objective clearly specified in abstract and intro.
[Yes]

P5. Indicate if a review protocol exists.
- No mention of a protocol.
[No]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
- Inclusion criteria specify population, interventions, study design. 
[Yes]

P7. Describe all information sources in the search and date last searched.
- Specified databases searched but not date ranges.
[No]

P8. Present full electronic search strategy for at least one database. 
- Did not provide full search strategy.
[No] 

P9. State the process for selecting studies.
- PRISMA flow diagram depicts study selection process.
[Yes]

P10. Describe method of data extraction.
- States <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two individual authors extracted data&quot;</span> but no other details.
[No]

P11. List and define all variables for which data were sought.
- Listed data extracted in Methods.
[Yes]

P12. Describe methods used for assessing risk of bias of individual studies.
- Discussed limitations qualitatively but did not describe a formal risk of bias assessment. 
[No]

P13. State the principal summary measures.
- Stated that RRs and 95% CIs were calculated.
[Yes]

P14-P23. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> (no meta-analysis performed)

P24. Summarize the main findings including the strength of evidence for each main outcome.
- Conclusions summarize findings and quality of evidence.
[Yes]

P25. Discuss limitations at study and outcome level.
- Discussed study limitations in detail.
[Yes]  

P26. Provide a general interpretation of the results in the context of other evidence.
- Discussed findings in context of previous reviews.
[Yes]

P27. Describe sources of funding for the systematic review. 
- No statement about sources of funding.
[No]
</pre>
<p><a name='155'></a></p>
</div>
<div id="thomson-2015" class="section level4">
<h4><a href='https://doi.org/10.1136/BMJOPEN-2014-006063' title='Open publication'>Thomson
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the provided systematic review:

# AMSTAR
A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A study protocol outlining the search strategy, outcomes, and methods of data extraction and statistical analysis was designed and prospectively registered with the Prospero database (CRD42013005698).&quot;</span>
States that a protocol was registered prospectively. 

A2. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Titles and abstracts of potentially relevant papers were screened by two independent authors (DT and BA). The full texts of all identified studies were assessed against the criteria in table 1 by the two independent authors (DT and BA), and study reference lists were hand searched for potentially relevant studies.&quot;</span> 
States that study selection and data extraction were done by two independent authors.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched all publications from 1 January 1998 to 1 January 2014 from EMBASE, MEDLINE and Cochrane library databases using the search strategy detailed in online supplementary appendix I.&quot;</span> 
Searched two databases along with supplementary searching.

A4. [No]
No mention of searching for unpublished literature or grey literature.

A5. [Yes]  
Figure 1 shows a flow chart with included and excluded studies.

A6. [Yes] 
Table 2 provides characteristics of the included studies.

A7. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Two independent authors (DT and BA) assessed study
quality using the Newcastle-Ottawa Scale for case–
control and cohort studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors (DT and BA) assessed study quality using the Newcastle-Ottawa Scale for case–control and cohort studies.&quot;</span> Quality assessed with Newcastle-Ottawa scale.

A8. [No] 
Study quality not incorporated into conclusions.

A9. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.1%):

Random-effects models
were used when there was significant' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Random-effects models were used when there was significant heterogeneity.&quot;</span> Heterogeneity assessed and random effects used when present.

A10. [No]  
No assessment of publication bias mentioned.

A11. [No]
No statement about conflicts of interest.

# PRISMA
P1. [Yes] 
Title identifies as a systematic review and meta-analysis. 

P2. [Yes]
Provides structured abstract with objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, and conclusions.

P3. [Yes]
Introduction describes rationale and what is known.

P4. [Yes] 
Objectives specify participants, interventions, comparisons, and outcomes. 

P5. [Yes]
Mentions protocol registration with PROSPERO registry number.

P6. [Yes]
Methods specify inclusion/exclusion criteria and characteristics used.

P7. [Yes]  
Methods describe literature sources searched - databases, dates, keywords.

P8. [No] 
Search strategy not provided for any database.

P9. [Yes]  
Process of study screening and selection described and flow diagram provided.

P10. [Yes]
States that data extraction done independently and in duplicate. 

P11. [Yes] 
Outcomes sought described in methods.

P12. [Yes]  
Study quality assessed with Newcastle-Ottawa scale.

P13. [Yes]
States summary measures used - mean difference, ORs.

P14. [NA] 
No meta-analysis performed.

P15. [NA]
No assessment of publication bias mentioned.

P16. [NA]
No additional analyses mentioned. 

P17. [Yes]
Flow diagram shows studies screened, excluded, and reasons.

P18. [Yes] 
Table 2 shows characteristics of included studies. 

P19. [Yes]  
Study quality assessed and limitations described.

P20. [Yes] 
Results present summary data and effect estimates with confidence intervals.

P21. [NA]
No meta-analysis performed.

P22. [NA] 
No assessment of publication bias.

P23. [NA]  
No additional analyses mentioned.

P24. [Yes]
Main findings summarized in discussion.

P25. [Yes]
Limitations discussed.

P26. [Yes] 
Results interpreted in context of other evidence.

P27. [Yes]
Funding sources stated.
</pre>
<p><a name='156'></a></p>
</div>
<div id="thyoka-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S00247-013-2693-2' title='Open publication'>Thyoka
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality and reporting quality of the systematic review using AMSTAR and PRISMA 2009 tools:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We decided, a priori, to limit our review to studies that reported outcomes of balloon dilatation (both endoscopically and under fluoroscopic control) of anastomotic strictures secondary to surgical repair of oesophageal atresia in children.&quot;</span>
Explicitly states an a priori decision to limit inclusion criteria. [Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two reviewers (M.T. and A.T.) independently abstracted data from all studies onto a predefined data collection form. Any discrepancies were resolved by consensus.&quot;</span>
States two independent reviewers performed study selection and data extraction with consensus procedure. [Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched the standard databases (January, 1960–May, 2012): MEDLINE, EMBASE and Cochrane Library Controlled Trials Register (CENTRAL) using the MeSH Terms...&quot;</span>
Searched at least 2 databases along with supplementary search strategies. [Yes]

A4. Was the status of publication used as an inclusion criterion? 
No mention of including or excluding studies based on publication status. [No] 

A5. Was a list of studies (included and excluded) provided?
Included studies listed in Table 1. Excluded studies not listed but exclusion reasons described in Figure 1. [Yes]

A6. Were the characteristics of the included studies provided?
Table 1 provides characteristics of included studies. [Yes] 

A7. Was the scientific quality of the included studies assessed and documented?
No mention of formal quality assessment of included studies. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]

A9. Were the methods used to combine the findings of studies appropriate? [NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias mentioned. [No]

A11. Was the conflict of interest included? 
No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Here we review the current evidence of the outcomes of balloon dilatation of anastomotic strictures secondary to surgical repair of oesophageal atresia.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]
Introduction describes background and rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] 
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No mention of protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion criteria described in Methods section. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes]
Databases, years, and supplementary sources described.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Screening and selection process described and depicted in Figure 1.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes] 
States data extracted independently by two reviewers onto predefined forms.  

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
Outcomes of interest not explicitly defined.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA] 

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes]
Figure 1 provides flow diagram of screening and selection process. 

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 provides key characteristics of included studies.

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
No risk of bias assessment presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [No]
No forest plots presented.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [NA]

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in Discussion section.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]
Limitations of included studies not discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] 
Results interpreted in Discussion section.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of support.
</pre>
<p><a name='157'></a></p>
</div>
<div id="van-dalen-2015" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD008403.pub3' title='Open publication'>van
Dalen 2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the given systematic review:

A1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched CENTRAL (The Cochrane Library 2014, Issue 1), MEDLINE/PubMed (from 1966 to February 2014) and EMBASE/Ovid (from 1980 to February 2014) to identify relevant studies.&quot;</span>
- The review had an a priori design with predefined research questions and inclusion criteria.
[Yes]

A2.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors performed the study selection independently.&quot;</span>
- Two authors independently selected studies for inclusion. 
[Yes]

A3.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched CENTRAL (The Cochrane Library 2014, Issue 1), MEDLINE/PubMed (from 1966 to February 2014) and EMBASE/Ovid (from 1980 to February 2014) to identify relevant studies.&quot;</span> 
- At least two electronic databases were searched.
[Yes]

A4.  
- No mention of searching for grey literature.
- The review did not state whether grey literature was searched.
[No]

A5.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We assessed eight full text studies for eligibility and all of these studies were excluded from the review because they were not RCTs or CCTs.&quot;</span>
- A list of included and excluded studies was provided.
[Yes]

A6.  
- No studies were included.
[NA]

A7.  
- No studies were included.
[NA] 

A8.  
- No studies were included.
[NA]

A9. 
- No quantitative synthesis was performed.
[NA]

A10.  
- No assessment of publication bias was mentioned.
[No]

A11. 
- No funding sources were reported for the review or the individual studies. 
[No]

P1. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children&quot;</span>
- The title identifies it as a systematic review.
[Yes] 

P2. 
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 91.4%):

C T
Background
Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Abstract. Background. Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases.&quot;</span>
- A structured summary is provided.
[Yes]

P3. 
- <span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):

Background
Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Background. Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases.&quot;</span>  
- The rationale for the review is described.
[Yes]

P4.  
- <span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):

To ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intra-
abdominal or intra-thoracic neoplasms in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intra-abdominal or intra-thoracic neoplasms in children.&quot;</span>
- Review questions are stated.
[Yes]

P5.  
- No protocol mentioned.
[No] 

P6.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Studies that compared MIS (e.g. laparoscopy or thoracoscopy) to open surgery (e.g. laparotomy or thoracotomy) were considered for inclusion.&quot;</span>
- Eligibility criteria are described.
[Yes]

P7. 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched the following electronic databases: CENTRAL (The Cochrane Library 2014, Issue 1), MEDLINE/PubMed (from 1966 to 18 February 2014) and EMBASE/Ovid (from 1980 to 18 February 2014).&quot;</span>
- Information sources are described.
[Yes]

P8.  
- Search strategies for the databases are provided in the appendix.
[Yes]

P9.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors independently screened titles and abstracts to identify studies meeting the inclusion criteria.&quot;</span> 
- Study selection process is described.
[Yes] 

P10. 
- No details on data extraction methods.
[No]

P11.  
- Outcomes of interest are listed under <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Types of outcome measures&quot;</span>.
[Yes]

P12.  
- No risk of bias assessment done since no studies were included.
[NA]

P13. 
- Not applicable since no meta-analysis was done.
[NA]

P14. 
- Not applicable since no meta-analysis was done.
[NA]

P15.
- Not applicable since no meta-analysis was done.  
[NA]

P16.
- Not applicable since no meta-analysis was done.
[NA] 

P17.  
- The study flow diagram shows the screening process. 
[Yes]

P18.
- No studies were included.
[NA]

P19. 
- No studies were included.
[NA]

P20.  
- No studies were included.
[NA]

P21.
- Not applicable since no meta-analysis was done.
[NA]

P22. 
- Not applicable since no meta-analysis was done.
[NA]

P23.
- Not applicable since no meta-analysis was done.
[NA]

P24.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Thus there is insufficient evidence to allow any definitive conclusions regarding the use of MIS in these patients.&quot;</span>
- Main findings are summarized.
[Yes]

P25.  
- Limitations are discussed in the Discussion section.
[Yes]

P26.  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The role of MIS for paediatric solid tumours therefore remains a challenge and has yet to be defined.&quot;</span>
- Overall interpretation is provided.
[Yes]

P27.  
- No funding reported.
[No]
</pre>
<p><a name='158'></a></p>
</div>
<div id="vanden-berg-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.UROLONC.2015.07.003' title='Open publication'>Vanden
Berg 2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the attached systematic review:

A1. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Google Scholar, and Scopus electronic databases for studies published between 1980 and 2014 based on Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [19].&quot;</span>
States that research question and inclusion criteria were pre-determined based on PRISMA guidelines.

A2. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The 2 reviewers, R.N.W.V. and E.N.B. independently reviewed all study abstracts in duplicate with disagreements resolved by the senior author (J.C.R.). Full-text articles appearing to meet selection criteria were reviewed, and study data was abstracted in the same manner.&quot;</span>
States that two independent reviewers performed study selection and data extraction with consensus procedure.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Google Scholar, and Scopus electronic databases for studies published between 1980 and 2014 based on Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [19].&quot;</span> 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The exact search strategy for each data-
base is detailed in Appendix 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The exact search strategy for each database is detailed in Appendix 1.&quot;</span>
Searched at least two databases, reported years and databases used, provided search strategy. 

A4. [No]
No mention of including or excluding studies based on publication status.

A5. [No] 
Does not provide a list of included and excluded studies.

A6. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In total, 4,022 patients were included. Of these, 1,632 children (41%) were male patients. Reported ages ranged from o1 month to 18 years. Bilateral tumors were present in 1,153 (29%) patients, including at least 4 metachronous contralateral tumors.&quot;</span>
Provides aggregated data on characteristics of included studies.

A7. [No] 
Does not mention assessing quality of included studies.

A8. [NA]
Did not assess quality of included studies.

A9. [NA]  
Did not conduct meta-analysis. 

A10. [NA]
Did not assess publication bias.

A11. [No]
Does not report on conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Nephron-sparing surgery for Wilms tumor: A systematic review&quot;</span> 
Identified as systematic review in title.

P2. [Yes]
Provides structured abstract with background, objectives, data sources, eligibility criteria, results, limitations, and conclusions.

P3. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎In contrast to adult renal malignancies, children with WT often present with very large tumors relative to the size of the normal renal parenchyma and relative to the child as well. Modern management of bilateral WT incorporates neoadjuvant chemotherapy along with NSS as first-line treatment [7–9].&quot;</span>
Describes rationale and context.

P4. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Specifically, the aims of this study are to assess the reported outcomes of NSS and to compare these with the current gold-standard surgical treatment of WT, RN.&quot;</span>
Provides objectives addressing participants, interventions, comparisons, and outcomes. 

P5. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Before the formal literature search, the protocol was prospectively registered at the international registry of systematic reviews, PROSPERO (registration number CRD42015016420).&quot;</span> 
States protocol was registered and provides registration number.

P6. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We included English-language studies of children (aged 18 y or younger) diagnosed with WT that compared the outcomes or effects of NSS vs. RN.&quot;</span>
Specifies eligibility criteria including population, language, interventions, and outcomes.

P7. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Google Scholar, and Scopus electronic databases for studies published between 1980 and 2014.&quot;</span>
Lists databases searched with date ranges.

P8. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The exact search strategy for each data-
base is detailed in Appendix 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The exact search strategy for each database is detailed in Appendix 1.&quot;</span>
Provides full search strategy.

P9. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The 2 reviewers, R.N.W.V. and E.N.B. independently reviewed all study abstracts in duplicate with disagreements resolved by the senior author (J.C.R.). Full-text articles appearing to meet selection criteria were reviewed, and study data was abstracted in the same manner.&quot;</span>
Describes process of screening, eligibility assessment, and inclusion.

P10. [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The 2 reviewers, R.N.W.V. and E.N.B. independently reviewed all study abstracts in duplicate with disagreements resolved by the senior author (J.C.R.). Full-text articles appearing to meet selection criteria were reviewed, and study data was abstracted in the same manner.&quot;</span>
States that data extraction was done independently and in duplicate. 

P11. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

Patient cohort
In total, 4,022 patients were included. Of these, 1,632
children (41%) were male patients. Reported ages ranged
from o1 month to 18 years. Bilateral tumors were present
in 1,153 (29%) patients, including at least 4 metachronous
contralateral tumors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patient cohort: In total, 4,022 patients were included. Of these, 1,632 children (41%) were male patients. Reported ages ranged from o1 month to 18 years. Bilateral tumors were present in 1,153 (29%) patients, including at least 4 metachronous contralateral tumors.&quot;</span> 
Lists variables extracted.

P12. [No] 
Does not describe methods for assessing risk of bias.

P13. [NA] 
Did not conduct meta-analysis.

P14. [NA]
Did not conduct meta-analysis. 

P15. [NA]
Did not assess publication bias.

P16. [NA]
Did not conduct additional analyses.

P17. [Yes]
Provides PRISMA flow diagram detailing records identified, screened, eligible, and included. 

P18. [No]
Does not provide detailed characteristics for each included study.

P19. [No]
Does not assess risk of bias for individual studies.

P20. [No] 
Does not present summary data and effect estimates for each study.

P21. [NA]  
Did not conduct meta-analysis.

P22. [NA]
Did not assess risk of bias across studies.

P23. [NA]
Did not conduct additional analyses.

P24. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Nevertheless, most current studies of patients with RN and NSS appear to show similar tumor rupture, recurrence, ESRD, and overall survival outcomes between the 2 techniques.&quot;</span>
Summarizes main findings.

P25. [Yes]  
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎However, these comparisons are limited by inherent biases in the design and reporting of most included studies.&quot;</span>
Discusses limitations at study level.

P26. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎There are significant opportunities for future research on the use of NSS in children with WT, including issues related to surgical quality, optimal technique, timing and duration of chemotherapy, and variation in the use of NSS among centers.&quot;</span>
Discusses implications for future research.

P27. [No]
Does not describe sources of funding.
</pre>
<p><a name='159'></a></p>
</div>
<div id="van-den-hondel-2014" class="section level4">
<h4><a href='https://doi.org/10.1055/S-0033-1351663' title='Open publication'>van
den Hondel 2014</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the methodological quality with AMSTAR and reporting quality with PRISMA for the attached systematic review:

A1. Was an 'a priori' design provided? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systematic literature search was conducted in the PubMed, Embase, and Web of Science databases with the help of an experienced librarian.&quot;</span> This indicates that a protocol with pre-determined inclusion/exclusion criteria was established before conducting the review.

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two investigators (D.H. and C.S.) independently screened titles and abstracts of retrieved citations, retrieved full texts of eligible articles, and selected relevant articles matching the selection criteria described below.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):

A systematic literature search was conducted in the PubMed,
Embase, and Web of Science databases with the help of an
experienced librarian. The general search terms were the
same for the three databases, which are as follows: anorectal
malformations, Hirschsprung disease, colostomy, and chil-
dren' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic literature search was conducted in the PubMed, Embase, and Web of Science databases with the help of an experienced librarian. The general search terms were the same for the three databases, which are as follows: anorectal malformations, Hirschsprung disease, colostomy, and children.&quot;</span> At least two databases were searched along with supplementary strategies.

A4. Was the status of publication used as an inclusion criterion? [No]
The review does not mention searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [Yes] 
Included studies are listed in Table 3. Excluded studies are referenced in the flow diagram (Fig. 1).

A6. Were the characteristics of the included studies provided? [Yes]
Study characteristics such as study design, sample size, follow-up, outcomes, etc. are provided in Tables 3-5. 

A7. Was the scientific quality of the included studies assessed and documented? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

Methodological quality was assessed with the checklist pro-
posed by Downs and Black,
5 
with a maximum score of 32 for
the optimal study quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Methodological quality was assessed with the checklist proposed by Downs and Black, with a maximum score of 32 for the optimal study quality.&quot;</span> Quality scores are provided in Table 3.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [No]  
The quality assessment does not seem to be incorporated in interpreting the results.

A9. Were the methods used to combine the findings of studies appropriate? [NA]
No meta-analysis was performed.

A10. Was the likelihood of publication bias assessed? [NA]  
Publication bias assessment is not applicable since no meta-analysis was performed.

A11. Was the conflict of interest included? [No]
Conflicts of interest are not reported.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
"A retrospective case study of children with an anorectal
malformation who received a colostomy, born between January 1990 and July 2012. Furthermore, a systematic literature search on colostomies in neonates with an anorectal malformation or Hirschsprung disease."

P2. Provide a structured summary. [Yes]
A structured abstract with objectives, data sources, study eligibility criteria, participants, interventions, study appraisal, results, and conclusions is provided. 

P3. Describe the rationale for the review. [Yes] 
The rationale is described in the Introduction.

P4. Provide an explicit statement of questions being addressed. [No]
The review does not provide explicit PICOS criteria.

P5. Indicate if a review protocol exists. [No]
A protocol is not mentioned.

P6. Specify study characteristics and report characteristics used as criteria for eligibility. [Yes]
Inclusion and exclusion criteria are described in the Methods.

P7. Describe all information sources in the search. [Yes]
Information sources are described in the Methods.

P8. Present full electronic search strategy. [No]
The search strategy is not provided in sufficient detail to be reproducible.

P9. State the process for selecting studies. [Yes]  
The process for screening and study selection is described in the Methods and illustrated in a flow diagram.

P10. Describe method of data extraction. [Yes]  
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):

two investigators selected the articles independently,
extracted literature data, and recorded them in purpose-
designed forms' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two investigators selected the articles independently, extracted literature data, and recorded them in purpose-designed forms.&quot;</span>

P11. List and define all variables for which data were sought. [Yes]
Outcomes extracted are described in the Methods.

P12. Describe methods for assessing risk of bias. [Yes]
The use of the Downs and Black checklist to assess quality is described. 

P13. State the principal summary measures. [NA]
Not applicable as no meta-analysis was performed.

P14-P16. Describe methods of synthesis, heterogeneity assessment, and additional analyses. [NA] 
Not applicable as no meta-analysis was performed.

P17. Give numbers of studies screened, assessed for eligibility, and included, with reasons for exclusion. [Yes]
A flow diagram detailing study selection is provided.

P18. For each study, present characteristics for which data were extracted. [Yes] 
Study characteristics are presented in Tables 3-5.

P19. Present data on risk of bias. [Yes]
Quality scores are provided in Table 3.

P20. For each study, present simple summary data and effect estimates. [Yes]
Study data are summarized in Tables 4 and 5. 

P21-P23. Present synthesis results, bias assessment, and additional analyses. [NA]
Not applicable as no meta-analysis was performed.

P24. Summarize the main findings including the strength of evidence for each main outcome. [Yes] 
Main findings are summarized in the Discussion.

P25. Discuss limitations at study and outcome level and at review-level. [Yes]
Limitations are discussed in the Discussion.

P26. Provide a general interpretation of results in the context of other evidence. [Yes]
Results are interpreted in the context of previous evidence in the Discussion.

P27. Describe sources of funding and role of funders. [No]
Sources of funding are not reported.

In summary, this systematic review adequately addressed most of the assessed methodological and reporting quality items with some limitations related to protocol registration, search strategy, consideration of bias, and funding.
</pre>
<p><a name='160'></a></p>
</div>
<div id="vernon-roberts-2013" class="section level4">
<h4><a href='https://doi.org/10.1002/14651858.CD006151.pub3 ' title='Open publication'>Vernon-Roberts
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[We sought to include randomised controlled trials that recruited children up to the age of 18 years with neurological impairments and GOR who were undergoing gastrostomy tube insertion.]&quot;</span> 
The research question and inclusion criteria were established before conducting the review.
[Yes]

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The review authors worked independently to select trials; none were identified.&quot;</span>
There were at least two independent data extractors.
[Yes]

A3. Was a comprehensive literature search performed?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We searched the following databases on 23 March 2012: the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, EMBASE, CINAHL, LILACS and ISI Web of Science.&quot;</span>
At least two electronic databases were searched along with supplementary strategies like checking references and contacting experts.
[Yes]

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
No direct mention of including or excluding based on publication status. 
[No]

A5. Was a list of studies (included and excluded) provided?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Figure 1 shows a study flow diagram including the number of identified reports, duplicates and discarded studies.&quot;</span>
A flow diagram depicting the screening process was provided.
[Yes]

A6. Were the characteristics of the included studies provided?
No studies were included.
[NA]

A7. Was the scientific quality of the included studies assessed and documented?
No studies were included. 
[NA]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
No studies were included.
[NA] 

A9. Were the methods used to combine the findings of studies appropriate?
No quantitative synthesis was performed.
[NA]

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias was done.
[No]

A11. Was the conflict of interest included? 
Conflicts of interest for the review authors were reported.
[Yes]

P1. Identify the report as a systematic review, meta-analysis, or both.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Fundoplication versus postoperative medication for gastro-oesophageal reflux in children with neurological impairment undergoing gastrostomy (Review)&quot;</span>
The report is identified as a systematic review.
[Yes]

P2. Provide a structured summary.
A structured abstract with background, objectives, methods, results, authors' conclusions is provided. 
[Yes]

P3. Describe the rationale for the review in the context of what is already known.
The background section describes the rationale and context for the review.
[Yes] 

P4. Provide an explicit statement of questions being addressed. 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To compare the effectiveness of antireflux surgery and antireflux medications for children with neurological impairment and GOR who are undergoing placement of a gastrostomy feeding tube.&quot;</span>
The objective clearly states the question being addressed regarding population, interventions, comparisons.
[Yes]

P5. Indicate if a review protocol exists and provide registration information.
No protocol registration information is provided.
[No]

P6. Specify study characteristics used as criteria for eligibility.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We sought to include randomised controlled trials that recruited children up to the age of 18 years with neurological impairments and GOR who were undergoing gastrostomy tube insertion.&quot;</span> 
Study eligibility criteria are described.
[Yes]

P7. Describe information sources and date last searched.
The information sources and dates searched are described.
[Yes]

P8. Present full electronic search strategy for at least one database. 
The search strategies for multiple databases are provided in the appendix.
[Yes]

P9. State the process for selecting studies.
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The review authors worked independently to select trials; none were identified.&quot;</span>
The study selection process is described.
[Yes]

P10. Describe method of data extraction from reports.
<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):

Data extraction forms will be designed to include study design, participant characteristics, study
setting, intervention type and outcomes. Data will be extracted independently by two review au-
thors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data extraction forms will be designed to include study design, participant characteristics, study setting, intervention type and outcomes. Data will be extracted independently by two review authors.&quot;</span>
The planned data extraction process is described.
[Yes]

P11. List and define all variables for which data were sought.
The primary and secondary outcomes are listed and defined in the methods section. 
[Yes]

P12. Describe methods used for assessing risk of bias. 
The planned risk of bias assessment using The Cochrane Collaboration's tool is described.
[Yes]

P13. State the principal summary measures.
No summary measures were calculated since no studies were included.
[NA]

P14-P23. Describe data synthesis, assessment of bias, and additional analyses.
No data synthesis, assessment of bias across studies, or additional analyses were performed since no studies were included.
[NA]

P24. Summarize the main findings including the strength of evidence.
The main findings and implications are summarized in the authors' conclusions.
[Yes]

P25. Discuss limitations at study and outcome level.
The lack of evidence and limitations are discussed.
[Yes]

P26. Provide a general interpretation of the results in context of other evidence.
The results are interpreted in the context of the lack of evidence on this topic.
[Yes]

P27. Describe sources of funding and role of funders.
Sources of funding and conflicts of interest are described.
[Yes]
</pre>
<p><a name='161'></a></p>
</div>
<div id="wang-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-013-3335-3' title='Open publication'>Wang
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the provided systematic review:

A1. Was an 'a priori' design provided? [No] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The eligibility determination, quality assessment and data extraction for each study were conducted independently by two of the authors (FRW and YHX) and conflicts were resolved by a third author (HJZ).&quot;</span> There is no mention of a protocol.

A2. Was there duplicate study selection and data extraction? [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The eligibility determination, quality assessment and data extraction for each study were conducted independently by two of the authors (FRW and YHX) and conflicts were resolved by a third author (HJZ).&quot;</span>

A3. Was a comprehensive literature search performed? [Yes] <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The systematic search of the literature was performed using the electronic databases of PubMed (1950–), Embase (1988–) and Cochrane databases.&quot;</span> And search terms are provided.

A4. Was the status of publication used as an inclusion criterion? [No] There is no mention of including or excluding studies based on publication status.

A5. Was a list of studies (included and excluded) provided? [No] A list of included studies is provided in Tables 1 and 2, but no list of excluded studies. 

A6. Were the characteristics of the included studies provided? [Yes] Characteristics are provided in Tables 1 and 2.

A7. Was the scientific quality of the included studies assessed and documented? [No] No formal quality assessment is reported. 

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA] Since quality was not assessed, it was not used in formulating conclusions.

A9. Were the methods used to combine the findings of studies appropriate? [Yes] Random-effects models were used for meta-analyses due to heterogeneity. 

A10. Was the likelihood of publication bias assessed? [Yes] Funnel plots were constructed to assess publication bias.

A11. Was the conflict of interest included? [No] No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes] Identified as a systematic review and meta-analysis in the title.

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [Yes] The abstract provides this information.

P3. Describe the rationale for the review in the context of what is already known. [Yes] The introduction provides background and rationale.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No] No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No] No mention of a protocol.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes] Inclusion criteria are specified in the methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes] Databases, search terms, and date last searched are provided. 

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [Yes] Full search strategies for 3 databases are provided in the appendix.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes] The process is described in the methods. 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [Yes] Data extraction process is described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [Yes] Outcomes extracted are listed.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No] No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [Yes] Odds ratios and weighted mean differences used.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [Yes] Use of random effects models and tests for heterogeneity described.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [Yes] Publication bias assessed with funnel plots.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [Yes] Subgroup analyses are described.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes] A flow diagram of study selection is provided.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes] Study characteristics are provided in Tables 1 and 2. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA] No risk of bias assessment.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [Yes] Outcomes data are presented in Tables 2 and forest plots.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency. [Yes] Meta-analysis results are presented with CIs and heterogeneity measures. 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [Yes] Subgroup analysis results are presented.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes] Main findings are summarized in the discussion.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes] Limitations are discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes] Results are interpreted and implications described.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No] No statement about sources of funding.
</pre>
<p><a name='162'></a></p>
</div>
<div id="wayne-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3676-1' title='Open publication'>Wayne
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL from inception to September 2014.&quot;</span>
An a priori design is provided as they specify searching major databases from inception to September 2014.

A2. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Two reviewers independently assessed each included
study and compared the scores for each item on the ap-
plicable quality assessment tool to reach a consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two reviewers independently assessed each included study and compared the scores for each item on the applicable quality assessment tool to reach a consensus.&quot;</span>
Duplicate study selection and data extraction was done with two independent reviewers and a consensus procedure.

A3. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and CINAHL from inception to September 2014.&quot;</span> 
<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.4%):

We used the following search terms: ‘‘Cryp-
torchidism’’ AND ‘‘Intra-abdominal’’ OR ‘‘Abdomen/ab-
dominal cavity/inguinal canal/groin' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We used the following search terms: “Cryptorchidism” AND “Intra-abdominal” OR “Abdomen/abdominal cavity/inguinal canal/groin.”&quot;</span>
A comprehensive literature search was performed using at least two electronic sources. 

A4. [No]
No mention of including or excluding studies based on publication status.

A5. [No] 
No list of included and excluded studies is provided.

A6. [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):

We summarized the results, with an
emphasis on higher-quality evidence; we considered SRs to
be the highest quality evidence, followed by RCTs, and
non-randomized studies [21], taking the results of our
quality assessment into consideration' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We summarized the results, with an emphasis on higher-quality evidence; we considered SRs to be the highest quality evidence, followed by RCTs, and non-randomized studies, taking the results of our quality assessment into consideration.&quot;</span>
Study characteristics are summarized in the text, with a focus on study design.

A7. [Yes]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.2%):

and quality assessed each
relevant study using AMSTAR for systematic reviews
(SRs), Cochrane ‘Risk of bias’ tool for randomized con-
trolled trials (RCTs), and MINORS for non-randomized
studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We used AMSTAR to assess the quality of all relevant systematic reviews (SRs)...the Cochrane ‘Risk of bias’ tool for randomized controlled trials (RCTs)...and MINORS for non-randomized studies.&quot;</span> 
The scientific quality of included studies was assessed using validated tools. 

A8. [Yes] 
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):

To miti-
gate the potential bias related to the inclusion of non-ran-
domized studies, we took into consideration each study’s
quality assessment results when drawing conclusions and
making recommendations' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To mitigate the potential bias related to the inclusion of non-randomized studies, we took into consideration each study’s quality assessment results when drawing conclusions and making recommendations.&quot;</span>
The quality assessments were taken into account when formulating conclusions.

A9. [NA]
No meta-analysis was performed.

A10. [No] 
No assessment of publication bias is mentioned.

A11. [No]
No mention of conflicts of interest.

P1. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎What is the ideal surgical approach for intra-abdominal testes? a systematic review&quot;</span>
Identified as a systematic review in the title.

P2. [Yes]
The abstract provides relevant details on background, objectives, eligibility criteria, data sources, study selection/appraisal/synthesis, results, limitations, and conclusions. 

P3. [Yes] 
The introduction describes the rationale and context around surgical management of cryptorchidism and controversy regarding intra-abdominal testes.

P4. [Yes]
The objective specifies the population (males with intra-abdominal testes), interventions (surgical repair techniques), outcomes (orchiopexy success, atrophy, complications). 

P5. [No] 
No mention of a review protocol.

P6. [Yes]
Eligibility criteria are described including population, language, and exclusion of editorials/case studies. Rationale is provided.

P7. [Yes]  
Information sources are described including databases searched and date ranges. 

P8. [No]
The full search strategy is not provided for any database.

P9. [Yes]
The screening process is described including number of studies at each stage and reasons for exclusions.

P10. [Yes] 
Data extraction by one reviewer and checking by a second reviewer is described.

P11. [Yes] 
Outcomes of interest are defined relating to orchiopexy success, atrophy, and complications.

P12. [Yes]
Risk of bias was assessed for each study design using validated tools. 

P13. [NA] 
No meta-analysis performed.

P14. [NA]
No meta-analysis performed. 

P15. [NA]
No meta-analysis performed.

P16. [NA]  
No additional analyses mentioned.

P17. [Yes]
Screening results are presented in a flow diagram with number of studies at each stage.

P18. [Yes] 
Study details are presented in a table including key characteristics. 

P19. [Yes]
Risk of bias results are presented in the table.

P20. [NA] 
No meta-analysis performed.

P21. [NA]
No meta-analysis performed. 

P22. [NA]  
No assessment of bias across studies.

P23. [NA]
No additional analyses mentioned.

P24. [Yes]  
Main findings and conclusions are summarized, considering relevance to clinicians.

P25. [Yes]
Limitations are described including lack of RCTs.

P26. [Yes]
Results are interpreted in context of other evidence and implications for future research are described.

P27. [No]
No mention of sources of funding or support.
</pre>
<p><a name='163'></a></p>
</div>
<div id="weih-2012" class="section level4">
<h4><a href='https://doi.org/10.1007/S00423-011-0874-8' title='Open publication'>Weih
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘wrong-response-partial-unclear-etc’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the attached systematic review:

A1. Was an 'a priori' design provided? [No]
No mention of a protocol, ethics approval, or pre-determined research objectives.

A2. Was there duplicate study selection and data extraction? [No]
No mention of duplicate study selection or data extraction.

A3. Was a comprehensive literature search performed? [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎An analysis of Medline-published therapeutic options in the treatment of SBS was performed.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No] 
No mention of searching for unpublished literature.

A5. Was a list of studies (included and excluded) provided? [No]
No list of included or excluded studies provided.

A6. Were the characteristics of the included studies provided? [No]
No table or description of study characteristics provided. 

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [NA]
No assessment of publication bias mentioned.

A11. Was the conflict of interest included? [No]
No statement about sources of support or conflict of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎A systemic review of Medline-cited studies dealing with current practice and future perspectives in the treatment of short bowel in children was performed.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No]
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes] 
The introduction provides context about short bowel syndrome and current challenges in treatment.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement provided.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [No]  
No details on eligibility criteria provided.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Partial <span style='background-color: #ff9e81' title='Added response during extraction'>[Yes]</span>]
States that Medline was searched but no dates or supplementary searches mentioned.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
No search strategy provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [No]  
No details on study selection process. 

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]
No data extraction methods described.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
No list of data sought.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [No]
No risk of bias assessment described.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]
No quantitative synthesis performed.

P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]
No quantitative synthesis performed.

P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA]  
No assessment of risk of bias mentioned.

P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [NA]
No additional analyses mentioned.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [No]
No flow diagram, number of studies screened, assessed, or reasons for exclusions given.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [No] 
No table of study characteristics. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [No]
No risk of bias assessment presented.

P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [NA]  
No quantitative synthesis performed.

P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency (e.g., I2) for each meta-analysis. [NA]
No meta-analysis performed. 

P22. Present results of any assessment of risk of bias across studies (see Item P15). [NA] 
No assessment of risk of bias across studies.

P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). [NA]
No additional analyses mentioned.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [No] 
No summary of main findings or strength of evidence.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [No]  
No limitations discussed.

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
The discussion provides context and implications for future research.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding or support.
</pre>
<p><a name='164'></a></p>
</div>
<div id="wenk-2015" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2015.08.056' title='Open publication'>Wenk
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the assessments of the methodological quality (AMSTAR) and reporting quality (PRISMA) of the systematic review:

A1. Was an 'a priori' design provided? [Yes]
- <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.7%):

search strategy for at least one database, including any limits used, such that it could be repeated.
P9. State the process for selecting studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Search strategies for MEDLINE, EMBASE and Cochrane were designed to capture all relevant studies.&quot;</span> (p.2148)  
- The search was designed before conducting the review.

A2. Was there duplicate study selection and data extraction? [No]  
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data from selected studies were extracted by two authors (RNV and KW).&quot;</span> (p.2148)
- Only 2 authors performed selection and extraction.

A3. Was a comprehensive literature search performed? [Yes]  
- Electronic searches of MEDLINE, EMBASE, and Cochrane were performed. (p.2152)
- Supplementary search of reference lists was done.  

A4. Was the status of publication used as an inclusion criterion? [No]
- No mention of including or excluding based on publication status.

A5. Was a list of studies provided? [Yes]  
- Table 1 lists characteristics of included studies. (p.2149) 
- Appendix 2, Table A1 lists excluded studies with reasons. (p.2152)

A6. Were the characteristics of the included studies provided? [Yes]
- Table 1 provides characteristics of participants, interventions, outcomes. (p.2149)

A7. Was the scientific quality of the included studies assessed? [No] 
- No mention of quality assessment of included studies.

A8. Was the scientific quality used appropriately in formulating conclusions? [NA]
- Since quality was not assessed (A7), this is not applicable.  

A9. Were the methods used to combine studies appropriate? [Yes]  
- Heterogeneity was assessed and random effects model used when present. (p.2148, 2149)

A10. Was publication bias assessed? [No]
- No assessment of publication bias mentioned. 

A11. Was the conflict of interest included? [No]  
- No statement about conflicts of interest or sources of support.

P1. Identify as systematic review or meta-analysis. [Yes]  
- Identified as meta-analysis in title. (p.2147)

P2. Structured summary. [Yes]  
- Provides structured abstract with objectives, eligibility criteria, results, conclusions. (p.2147)

P3. Rationale for review. [Yes]  
- Discusses rationale and aim in introduction. (p.2148)

P4. Research questions and PICO. [Yes]   
- Specifies participants, outcomes clearly. (p.2148)

P5. Indicate if protocol exists. [No]   
- No mention of protocol.

P6. Specify study characteristics and eligibility criteria. [Yes]
- Specifies inclusion and exclusion criteria. (p.2148)

P7. Information sources and dates. [Yes]
- Reports databases, dates, supplementary sources. (p.2152) 

P8. Present full search strategy. [Yes] 
- Provides full search strategies for databases. (p.2152)

P9. Study selection process. [Yes] 
- States that 2 authors performed selection. (p.2148) 

P10. Data extraction process. [Yes]   
- States 2 authors performed extraction. (p.2148)

P11. List and define all variables collected. [Yes] 
- Outcomes and subgroups clearly defined. (p.2148)

P12. Risk of bias assessment. [No]
- No risk of bias assessment mentioned.

P13. Summary measures. [Yes]
- Specifies use of odds ratios. (p.2148)

P14. Synthesis methods. [Yes]  
- Describes use of fixed and random effects models. (p.2148)

P15. Risk of bias across studies. [No] 
- No assessment of publication bias or selective reporting.

P16. Additional analyses. [NA]
- No additional analyses like meta-regression done.

P17. Study flow diagram. [No]  
- No flow diagram provided.

P18. Study characteristics. [Yes] 
- Table 1 reports key characteristics of included studies. (p.2149)

P19. Risk of bias for individual studies. [No] 
- No assessment of risk of bias. 

P20. Study level data and effect sizes. [Yes]  
- Forest plots provide data and effect sizes. (Figs. 1-6) 

P21. Results of meta-analyses. [Yes]   
- Where applicable, meta-analysis results provided. (Figs. 1-6)

P22. Risk of bias across studies. [No]
- No assessment of risk of bias across studies.

P23. Additional analyses. [NA]  
- No additional analyses performed.

P24. Summary of evidence. [Yes]
- Conclusions summarize main findings and evidence. (p.2154)

P25. Limitations at study and review level. [Yes]  
- Discusses limitations of included studies and review process. (p.2153)

P26. Interpretation of results. [Yes] 
- Discusses results in context of other evidence. (p.2153-2154) 

P27. Source of funding. [No]
- No statement about sources of funding.
</pre>
<p><a name='165'></a></p>
</div>
<div id="wilkinson-2012" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPUROL.2010.11.008' title='Open publication'>Wilkinson
2012</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We report the findings of a systematic review of the postoperative complication rates following distal hypospadias surgery using these two techniques.&quot;</span> 
A priori design stated.

A2. "[No]"  
Two authors performed the review but no mention of duplicate study selection or extraction.

A3. "[Yes]"
<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

The Medline (1990eDec 2009), Embase (1990eDec 2009) and
Cochrane databases were searched using the single search
term ‘hypospadias’ to ensure the broadest capture of rele-
vant papers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term ‘hypospadias’ to ensure the broadest capture of relevant papers.&quot;</span>
Comprehensive search performed.

A4. "[No]"
No mention of searching for grey literature. 

A5. "[No]"  
No list of included/excluded studies provided.

A6. "[Yes]" 
Table 1 provides aggregated characteristics of included studies.

A7. "[No]"   
No quality assessment of included studies mentioned.

A8. "[NA]"
No quality assessment performed so using it in formulating conclusions not applicable.

A9. "[NA]"
No quantitative synthesis performed. 

A10. "[NA]"  
No assessment of publication bias as no meta-analysis.

A11. "[No]"
No mention of conflicts of interest.

P1. "[Yes]"
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Review of Mathieu and TIP repair outcomes&quot;</span>
Identified as systematic review in title.

P2. "[No]"
No structured summary provided.

P3. "[Yes]"  
Rationale described in introduction.

P4. "[No]"
No explicit PICO statement provided.

P5. "[No]"
No mention of review protocol.

P6. "[Yes]"
Study characteristics for inclusion described. 

P7. "[Yes]" 
Information sources described.

P8. "[No]"  
No full search strategy provided.

P9. "[Yes]" 
Study selection process described.

P10. "[No]"
No data extraction process described. 

P11. "[Yes]"
Outcomes sought described.

P12. "[No]"
No risk of bias assessment described.

P13. "[Yes]"
Summary measures of fistula rates and stenoses rates provided.

P14. "[NA]" 
No meta-analysis performed.

P15. "[NA]"
No assessment of risk of bias across studies as no meta-analysis.  

P16. "[NA]" 
No additional analyses described.

P17. "[No]"
No flow diagram of study selection provided.

P18. "[Yes]"
Study characteristics presented in Table 1. 

P19. "[No]"
No assessment of risk of bias for individual studies.

P20. "[Yes]" 
Outcome data for each study presented in Table 1.

P21. "[NA]"  
No meta-analysis performed.

P22. "[NA]"
No assessment of risk of bias across studies as no meta-analysis.

P23. "[NA]"
No additional analyses described. 

P24. "[Yes]" 
Main findings summarized in discussion and conclusion.

P25. "[Yes]" 
Limitations discussed.

P26. "[Yes]"
Results interpreted in context of other evidence.

P27. "[No]"
No mention of sources of funding.
</pre>
<p><a name='166'></a></p>
</div>
<div id="wright-2013" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JURO.2013.02.3234' title='Open publication'>Wright
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here is my assessment of the methodological quality using AMSTAR and reporting quality using PRISMA 2009 for the attached systematic review:

A1. Was an 'a priori' design provided? 
<span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎[The research question and inclusion criteria should be established before the conduct of the review.]&quot;</span> [No]
The review does not mention an a priori protocol.

A2. Was there duplicate study selection and data extraction?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Data extraction was completed in duplicate and reviewed for accuracy and quality.]&quot;</span> [Yes]
The review states that data extraction was done in duplicate. 

A3. Was a comprehensive literature search performed?
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):

Our search yielded 288 citations, of which 11 (622 patients) met
inclusion criteria and were incorporated into the systematic review. Most
series were retrospective observational studies of moderate or low method-
ological quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Our search yielded 288 citations, of which 11...met inclusion criteria and were incorporated into the systematic review. Most series were retrospective observational studies of moderate or low methodological quality.]&quot;</span> [Yes]
The review searched multiple databases and other sources.

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[A gray literature search of conference abstracts was also performed.]&quot;</span> [Yes] 
The review searched conference abstracts as a source of grey literature.

A5. Was a list of studies (included and excluded) provided?
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):

Full text
review and application of eligibility criteria led to ex-
clusion of 17 studies, leaving 11 for inclusion in our
systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Full text review and application of eligibility criteria led to exclusion of 17 studies, leaving 11 for inclusion in our systematic review.]&quot;</span> [Yes]
The review provides details on included and excluded studies after full text review. 

A6. Were the characteristics of the included studies provided? 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎[Data on the primary outcome are outlined in table 2.]&quot;</span> [Yes]
Table 2 provides characteristics of the included studies.

A7. Was the scientific quality of the included studies assessed and documented??
<span title='Minor quote deviation. Best match in fulltext (Similarity 96.1%):

Critical appraisal of the included studies was carried out
by 2 independent reviewers using a quality assessment
instrument adopted from Elyas et al,
14 
modified to fit the
objectives of this study (see Appendix). All discrepancies
were resolved through third-party review of the method-
ology' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Critical appraisal of the included studies was carried out by 2 independent reviewers using a quality assessment instrument...All discrepancies were resolved through third-party review of the methodology.]&quot;</span> [Yes]
A quality assessment was performed and reported in the results.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):

To most accurately esti-
mate the true complication rate, we excluded scar-
ring from our analysis, as it was not reported in the
other included studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[To most accurately estimate the true complication rate, we excluded scarring from our analysis, as it was not reported in the other included studies.]&quot;</span> [Yes]
The quality assessment guided analysis decisions.

A9. Were the methods used to combine the findings of studies appropriate?
<span title='Minor quote deviation. Best match in fulltext (Similarity 95.8%):

Heterogeneity between
studies was tested using the Cochran chi-square Q test
with a p value set at 0.1 and quantified using the I 
2
statistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Heterogeneity between studies was tested using the Cochran chi-square Q test with a p value set at 0.1 and quantified using the I2 statistic.]&quot;</span> [Yes]
Appropriate statistical methods were used to assess heterogeneity before meta-analysis.

A10. Was the likelihood of publication bias assessed?
No assessment of publication bias is mentioned. [No]

A11. Was the conflict of interest included?
No statement on conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This systematic review and meta-analysis highlights...&quot;</span>

P2. Provide a structured summary... [Yes]
The abstract provides a structured summary.

P3. Describe the rationale for the review... [Yes] 
The introduction describes the rationale and background.

P4. Provide an explicit statement of questions being addressed... [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):

We hypoth-
esized that PHS would improve surgical outcomes in
patients with hypospadias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We hypothesized that PHS would improve surgical outcomes in patients with hypospadias.&quot;</span> 

P5. Indicate if a review protocol exists... [No]
A protocol is not mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
The eligibility criteria are described in the Methods.

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes] 
The literature search strategy is described in the Methods.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
The full search strategy for databases is not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
The study selection process is described and depicted in a flow diagram.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate)... [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Data extraction was completed in duplicate and reviewed for accuracy and quality.&quot;</span>

P11. List and define all variables for which data were sought... [Yes] 
Extracted data are described in the Methods.

P12-P23. [NA] No risk of bias assessment, meta-analysis, or additional analyses.

P24. Summarize the main findings including the strength of evidence for each main outcome... [Yes] 
The findings are summarized in the Conclusions.

P25. Discuss limitations at study and outcome level... [Yes]
Limitations are discussed throughout and in the Conclusions.

P26. Provide a general interpretation of the results in the context of other evidence... [Yes]
The Conclusions section provides an interpretation and implications.

P27. Describe sources of funding for the systematic review... [No]
No statement on sources of funding.
</pre>
<p><a name='167'></a></p>
</div>
<div id="yang-2011" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2011.04.001' title='Open publication'>Yang
2011</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the assessments for the AMSTAR and PRISMA items based on the attached full text:

A1. Was an 'a priori' design provided?
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 81.7%):

The aim of this review was to critique the current literature to
determine the efficacy of LH.
Meth' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The aim of this review was to critique the current literature to determine the efficacy of LH in the repair of PIH.&quot;</span>
- The objective is clearly stated in the introduction. [Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The citations, abstracts, or full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers (YCL, ZHY, and TQS), and any disagreements were resolved by consensus.&quot;</span>
- Study selection was performed by 3 independent reviewers. [Yes]  

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

All published studies until July 30, 2010, were
searched with the terms laparoscopy, laparoscopic her-
niorrhaphy, pediatric inguinal hernia, and open hernior-
rhaphy from Medline (using PubMed as the search
engine), Embase, Ovid, Web of Science, and Cochrane
databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All published studies until July 30, 2010, were searched with the terms laparoscopy, laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy from Medline, Embase, Ovid, Web of Science, and Cochrane databases.&quot;</span>
- Multiple databases were searched. [Yes]

A4. Was the status of publication used as an inclusion criterion? 
- No mention of including or excluding studies based on publication status. [No]

A5. Was a list of studies (included and excluded) provided?
- No list of excluded studies is provided. [No] 

A6. Were the characteristics of the included studies provided?
- Table 1 provides summary characteristics of the included studies. [Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- No assessment of study quality is reported. [No]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- Study quality was not assessed. [NA]

A9. Were the methods used to combine the findings of studies appropriate?  
- Statistical heterogeneity assessed using I2. Random effects model used for I2 > 50%. [Yes]

A10. Was the likelihood of publication bias assessed?
- No assessment of publication bias. [No]

A11. Was the conflict of interest included?
- No statement about conflicts of interest. [No]

P1. Identify the report as a systematic review, meta-analysis, or both. 
- <span title='Moderate quote deviation. Best match in fulltext (Similarity 93.9%):

in this systemic review and meta-
analysis, we demonstrated that' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In this systemic review and meta-analysis, we demonstrated that...&quot;</span> [Yes]

P2. Provide a structured summary.
- Abstract provides structured summary. [Yes]

P3. Describe the rationale for the review.  
- Rationale described in the introduction. [Yes]

P4. Provide an explicit statement of questions being addressed.
- Objective clearly stated in introduction. [Yes]

P5. Indicate if a review protocol exists.
- No mention of a review protocol. [No]

P6. Specify study characteristics and report characteristics used as criteria for eligibility.
- Inclusion and exclusion criteria described in Methods. [Yes]

P7. Describe all information sources in the search.
- Information sources described in Methods. [Yes]

P8. Present full electronic search strategy. 
- No full search strategy provided. [No]

P9. State the process for selecting studies.
- Study selection process described in Methods. [Yes]  

P10. Describe method of data extraction.
- Data extraction described in Methods. [Yes]

P11. List and define all variables for which data were sought.
- Outcome measures described in Methods. [Yes]

P12. Describe methods for assessing risk of bias. 
- No assessment of risk of bias. [No]

P13. State the principal summary measures.
- Use of ORs and WMDs described in Methods. [Yes]

P14-P16. Describe methods of synthesis, assessment of consistency, and additional analyses.
- Meta-analysis methods described. No additional analyses. [Yes] 

P17. Give numbers of studies at each stage.  
- Number of studies at each stage shown in flow diagram. [Yes]

P18. Present study characteristics.
- Study characteristics presented in Table 1. [Yes]

P19. Present risk of bias assessments.
- No risk of bias assessment presented. [No] 

P20. Present summary data and effect estimates for each study.
- Summary data and effect estimates presented in forest plots. [Yes]

P21. Present results of each meta-analysis. 
- Meta-analysis results presented in text and forest plots. [Yes]

P22-P23. Present assessment of risk of bias across studies and results of additional analyses. 
- Not applicable as these were not performed. [NA]

P24. Summarize the main findings.
- Main findings summarized in Discussion. [Yes]

P25. Discuss limitations at study and outcome level.
- Limitations discussed in Discussion. [Yes]

P26. Provide general interpretation of results.
- Results interpreted in context of other evidence. [Yes]

P27. Describe sources of funding and role of funders.
- Sources of funding described in Acknowledgements. [Yes]
</pre>
<p><a name='168'></a></p>
</div>
<div id="yang-2013" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-013-3345-1' title='Open publication'>Yang
2013</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the AMSTAR and PRISMA assessments for the given systematic review:

A1. Was an 'a priori' design provided? [No]
<span title='Moderate quote deviation. Best match in fulltext (Similarity 77.2%):

A systematic literature search was performed to identify
articles that reported the children and infants with POI' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic literature search was performed to identify articles that reported the children and infants with POI since 1990 in English-language.&quot;</span>
No mention of a protocol or pre-determined objectives. 

A2. Was there duplicate study selection and data extraction? [Yes] 
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All identified articles were independently assessed by three authors.&quot;</span>

A3. Was a comprehensive literature search performed? [Yes]
<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):

MEDLINE electronic
database was searched in April 2013 using key words
‘‘postoperative intussusception’’. References lists of iden-
tified articles were screened for additional publications of
interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MEDLINE electronic database was searched in April 2013 using key words ‘postoperative intussusception’." "References lists of identified articles were screened for additional publications of interest.&quot;</span>

A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? [No]
No mention of searching for grey literature.

A5. Was a list of studies (included and excluded) provided? [No] 
No list of excluded studies provided.

A6. Were the characteristics of the included studies provided? [Yes]
Table 1 provides details on the included studies such as number of patients, gender, age, procedures, etc.

A7. Was the scientific quality of the included studies assessed and documented? [No] 
No quality assessment of included studies mentioned.

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? [NA]
No quality assessment performed.

A9. Were the methods used to combine the findings of studies appropriate? [NA]  
No quantitative synthesis performed.

A10. Was the likelihood of publication bias assessed? [No]
No assessment of publication bias mentioned. 

A11. Was the conflict of interest included? [No]
No statement about conflicts of interest.

P1. Identify the report as a systematic review, meta-analysis, or both. [Yes]
<span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎To review the clinical features of POI, we performed this study based on the systematic review of the published literature.&quot;</span>

P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. [No] 
No structured abstract provided.

P3. Describe the rationale for the review in the context of what is already known. [Yes]  
Rationale described in the introduction section.

P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). [No]
No explicit PICOS statement.

P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. [No]
No protocol mentioned.

P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. [Yes]
Inclusion and exclusion criteria described in Methods section. 

P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. [Yes] 
Database and date of search reported.

P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. [No]
Search strategy not provided.

P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [Yes]
Study selection process described and flow diagram provided.

P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. [No]  
No details provided on data extraction process.

P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. [No]
No list of variables sought.

P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. [NA] 
No risk of bias assessment.

P13. State the principal summary measures (e.g., risk ratio, difference in means). [NA]
No meta-analysis performed.

P14-P16. [NA]
No meta-analysis performed.

P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. [Yes] 
Flow diagram provided with number of studies at each stage.

P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. [Yes]
Table 1 provides details on each included study. 

P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12). [NA]  
No risk of bias assessment performed.

P20-P23. [NA] 
No meta-analysis performed.

P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [Yes]
Main findings summarized in the Discussion section.

P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). [Yes] 
Limitations discussed. 

P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research. [Yes]
Results interpreted in the Discussion section.

P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [No]
No statement about sources of funding.
</pre>
<p><a name='169'></a></p>
</div>
<div id="youssef-2016" class="section level4">
<h4><a href='https://doi.org/10.1016/J.JPEDSURG.2016.02.010' title='Open publication'>Youssef
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘missing-squared-brackets-in-numbered-list’, ‘unsolicited-ranges’</i>
<pre>
Here are my responses for assessing the methodological quality with AMSTAR and reporting quality with PRISMA 2009 for the given systematic review:

A1. Was an 'a priori' design provided? 
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎The protocol of this review was prospectively published in the PROSPERO registry (CRD42015016745) [13].&quot;</span>
- The protocol was registered before conducting the review.
[Yes]

A2. Was there duplicate study selection and data extraction?
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All of the resulting titles were twice inspected independently.&quot;</span>
- Two reviewers independently screened titles.
[Yes]  

A3. Was a comprehensive literature search performed?
- <span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):

Papers with pertinent titles
were systematically identified by searching the following sources: AMED,
PubMed, MEDLINE, Cochrane, EMBASE, Africa-wide information, Biosys,
Global Health, LLAOS, and Web of Science in November 2014 with no
date or language restrictions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Papers were systematically identified by searching the following sources: AMED, PubMed, MEDLINE, Cochrane, EMBASE, Africa-wide information, Biosys, Global Health, LLAOS, and Web of Science in November 2014 with no date or language restrictions.&quot;</span> 
- Searched multiple databases without restrictions.
[Yes]

A4. Was the status of publication used as an inclusion criterion?
- No mention of including or excluding based on publication status.
[No]

A5. Was a list of studies (included and excluded) provided?
- Included studies listed in Table 1. Excluded studies not referenced.
[No] 

A6. Were the characteristics of the included studies provided? 
- Table 1 provides characteristics of included studies.
[Yes]

A7. Was the scientific quality of the included studies assessed and documented?
- Used Newcastle-Ottawa scale, results in Table 2.  
[Yes]

A8. Was the scientific quality of the included studies used appropriately in formulating conclusions?
- No explicit mention of study quality in conclusions.
[No]

A9. Were the methods used to combine the findings of studies appropriate?  
- Used random effects model due to differences in study contexts. Assessed heterogeneity (e.g. I2).
[Yes]

A10. Was the likelihood of publication bias assessed?  
- Assessed with funnel plot for mortality outcome.
[Yes]

A11. Was the conflict of interest included?
- No mention of sources of funding or support.
[No]

P1. Identify as systematic review or meta-analysis.
- <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎This meta-analysis supports recent publications...&quot;</span>
[Yes]

P2. Provide structured summary.
- Abstract provides structured summary.
[Yes]

P3. Describe rationale for review. 
- Intro describes rationale and what is known.
[Yes]

P4. Provide explicit questions with PICOS.
- Questions not explicitly stated with PICOS.
[No]

P5. Indicate if protocol exists and provide registration.
- Mentions protocol published in PROSPERO with registration number. 
[Yes]

P6. Specify eligibility criteria with rationale.
- Eligibility criteria described in methods with PICOS and rationale.
[Yes] 

P7. Describe information sources and dates.
- Databases searched described. Date of search provided.
[Yes]

P8. Present full search strategy. 
- Full search strategy included for PubMed.
[Yes]

P9. State process of study selection.
- Study selection process described and depicted in flow diagram.
[Yes]

P10. Describe data extraction process. 
- No details provided on data extraction process.
[No] 

P11. List and define variables extracted.
- Outcomes described but no mention of other variables.
[No]

P12. Describe risk of bias assessment. 
- Used Newcastle-Ottawa scale but no details at outcome level.
[No]

P13. State summary measures.
- Summary measures like OR, MD described. 
[Yes]

P14-P23. <span style='background-color: #ffe9e2' title='Added squared brackets during extraction'>[NA]</span> (no meta-analysis)

P24. Summarize main findings.
- Conclusions summarize main findings.
[Yes]

P25. Discuss limitations at study and outcome level. 
- Limitations of included studies discussed.
[Yes]

P26. Provide general interpretation of results.
- Results interpreted in context of other evidence.
[Yes]

P27. Describe sources of funding. 
- No sources of funding reported.
[No]
</pre>
<p><a name='171'></a></p>
</div>
<div id="zhao-2015" class="section level4">
<h4><a href='https://doi.org/10.1007/S00383-015-3680-5' title='Open publication'>Zhao
2015</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<pre>
Here are my assessments of the methodological quality using AMSTAR and reporting quality using PRISMA for the attached systematic review:

A1. "[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
Reasoning: The review had predefined research objectives.

A2. "[Yes]"
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.5%):

Two authors independently extracted data from the list of
the included studies, and a third reviewer was required for
a final decision in the case of any discrepancies' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place."  "Two authors independently extracted data from the list of the included studies, and a third reviewer was required for a final decision in the case of any discrepancies.&quot;</span>
Reasoning: There were two independent data extractors and a process for resolving discrepancies.

A3. "[Yes]" 
Quotes: <span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.7%):

ods
Search strategy
An electronic search was performed using EMBASE,
PubMed, MEDLINE from 2000 to 2014' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎At least two electronic sources should be searched." "An electronic search was performed using EMBASE, PubMed, MEDLINE from 2000 to 2014.&quot;</span> 
Reasoning: Searched three electronic databases.

A4. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The authors should state that they searched for reports regardless of their publication type.&quot;</span>
Reasoning: Did not mention searching for grey literature.

A5. "[Yes]" 
Quotes: <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 62%):

A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A list of included and excluded studies should be provided." "References, reviews and meta-analyses were then scanned for additional articles.&quot;</span>
Reasoning: Provided references for included and excluded studies.

A6. "[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes.&quot;</span> 
Reasoning: Provided Table 1 with characteristics of included studies.

A7. "[No]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria).&quot;</span>
Reasoning: Did not assess methodological quality of individual studies.

A8. "[No]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.&quot;</span>
Reasoning: Did not assess quality of individual studies.

A9. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2).&quot;</span>  
Reasoning: Assessed heterogeneity using I2. 

A10. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken).&quot;</span>
Reasoning: Did not assess publication bias.

A11. "[No]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.&quot;</span>
Reasoning: Did not report sources of funding.

P1. "[Yes]"
Quotes: <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Single-incision versus conventional laparoscopic appendicectomy in children: a systematic review and meta-analysis&quot;</span>
Reasoning: Identified as systematic review and meta-analysis.

P2. "[Yes]" 
Quotes: <span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70.3%):

Provide a structured summary' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Abstract provides structured summary.&quot;</span>
Reasoning: Structured abstract provided.

P3. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe the rationale for the review in the context of what is already known.&quot;</span>
Reasoning: Provided background and rationale.

P4. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).&quot;</span>
Reasoning: Research objectives stated. 

P5. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.&quot;</span>
Reasoning: No protocol mentioned.

P6. "[Yes]"  
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.&quot;</span>
Reasoning: Provided inclusion/exclusion criteria.

P7. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.&quot;</span>
Reasoning: Described literature search including databases and years searched.

P8. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.&quot;</span>
Reasoning: Did not provide full search strategy.

P9. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).&quot;</span> 
Reasoning: Described study selection process.

P10. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.&quot;</span>
Reasoning: Described process of independent dual data extraction.

P11. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.&quot;</span>
Reasoning: Listed outcomes extracted.

P12. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.&quot;</span>
Reasoning: Did not assess risk of bias.

P13. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎State the principal summary measures (e.g., risk ratio, difference in means).&quot;</span>
Reasoning: Provided summary measures.

P14. "[NA]"
Reasoning: No meta-analysis performed.

P15. "[NA]" 
Reasoning: No assessment of risk of bias across studies without meta-analysis.

P16. "[NA]"
Reasoning: No additional analyses.

P17. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.&quot;</span>
Reasoning: Provided flow diagram of study selection.

P18. "[Yes]" 
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.&quot;</span>
Reasoning: Presented characteristics of included studies in Table 1.

P19. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).&quot;</span>
Reasoning: Did not assess risk of bias.

P20. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.&quot;</span>
Reasoning: Presented outcome data and forest plots.

P21. "[NA]"
Reasoning: No meta-analysis performed. 

P22. "[NA]"
Reasoning: No assessment of bias across studies without meta-analysis.

P23. "[NA]"
Reasoning: No additional analyses.

P24. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).&quot;</span>
Reasoning: Provided summary of main findings.

P25. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).&quot;</span>
Reasoning: Discussed limitations.

P26. "[Yes]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Provide a general interpretation of the results in the context of other evidence, and implications for future research.&quot;</span>
Reasoning: Provided interpretation and implications.

P27. "[No]"
Quotes: <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.&quot;</span>
Reasoning: No funding sources reported.
</pre>
<p><a name='172'></a></p>
</div>
<div id="zhu-2016" class="section level4">
<h4><a href='https://doi.org/10.1007/S10029-015-1423-0' title='Open publication'>Zhu
2016</a></h4>
<table style="margin: 0; width: 100%">
<caption>
PRISMA
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P1. Identify the report as a systematic review, meta-analysis, or both.">
P1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.">
P2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P3. Describe the rationale for the review in the context of what is already known.">
P3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).">
P4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.">
P5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.">
P6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.">
P7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.">
P8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).">
P9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.">
P10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.">
P11</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.">
P12</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P13. State the principal summary measures (e.g., risk ratio, difference in means).">
P13</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.">
P14</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<table style="margin: 0; width: 100%; border-top: 0">
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).">
P15</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.">
P16</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.">
P17</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.">
P18</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).">
P19</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.">
P20</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.">
P21</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P22. Present results of any assessment of risk of bias across studies (see Item P15).">
P22</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).">
P23</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).">
P24</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).">
P25</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.">
P26</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.">
P27</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<br>
<table style="margin: 0; width: 100%">
<caption>
AMSTAR
</caption>
<thead>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A1. Was an &#39;a priori&#39; design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”">
A1</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.">
A2</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).">
A3</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.">
A4</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”">
A5</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul &quot;Follow-up poorly reported in general&quot;">
A6</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A7. Was the scientific quality of the included studies assessed and documented? &#39;A priori&#39; methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).">
A7</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.">
A8</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.">
A9</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.">
A10</span>
</th>
<th style="text-align:left;">
<span style="border-bottom: 1px dashed black"
title="A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..">
A11</span>
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
Human Consensus
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
0
</td>
</tr>
<tr>
<td style="text-align:left;">
LLM
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
NA
</td>
<td style="text-align:left;">
1
</td>
<td style="text-align:left;">
0
</td>
<td style="text-align:left;">
1
</td>
</tr>
</tbody>
</table>
<p><br><span style="padding: 8px 0; color: #999">LLM response</span></p>
<i>Minor score formatting issues fixed during extraction:
‘unsolicited-ranges’</i>
<pre>
Here are the assessments for the 11 AMSTAR questions and 27 PRISMA items:

A1. 
1. <span title='Perfect quote from prompt (Similarity 100%).' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: transparent'>&quot;‎The research question and inclusion criteria should be established before the conduct of the review.&quot;</span>
2. The review had pre-determined research objectives.
[Yes]

A2. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Two authors (Zhu and Wu) independently performed an electronic database search to identify studies that met the eligibility criteria.&quot;</span>
2. There were 2 independent reviewers for study selection.  
[Yes]

A3.  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We performed a literature search of the PubMed data-
base (National Library of Medicine, Bethesda, MD, USA)
that covered the period from 1966 to December 2013. The
search conducted for Embase and the Cochrane Central
Register of Controlled Trials was restricted to English-
language literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a literature search of the PubMed database (National Library of Medicine, Bethesda, MD, USA) that covered the period from 1966 to December 2013. The search conducted for Embase and the Cochrane Central Register of Controlled Trials was restricted to English-language literature.&quot;</span>
2. Multiple databases were searched.
[Yes]

A4.
[NA] 

A5. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Figure 1 shows details of study identification, inclusion and exclusion.&quot;</span> 
2. A list of excluded studies was provided.
[Yes]

A6. 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Table 1 shows the detail informa-
tion of all the trials' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Table 1 shows the detail information of all the trials.&quot;</span>
2. Characteristics of included studies were provided in a table.
[Yes]

A7. 
[No]

A8.  
[NA]

A9. 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):

The previous two sets of
pooled data both showed good homogeneity among the
involved trials. Thus, fixed models were applied for anal-
ysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The previous two sets of pooled data both showed good homogeneity among the involved trials. Thus, fixed models were applied for analysis.&quot;</span>
2. Heterogeneity was assessed and fixed effect model used when appropriate.
[Yes]  

A10. 
[No] 

A11. 
1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 80.6%):

Conflict of interest YZ declare' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Conflict of interest: None declared.&quot;</span>
2. Conflicts of interest were reported.
[Yes]

P1. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Minimally invasive surgery for congenital diaphragmatic hernia: a meta-analysis&quot;</span>
2. Identified as a meta-analysis.
[Yes]

P2. 
1. <span title='Moderate quote deviation. Best match in prompt (Similarity 78%):

e: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Abstract provides background, objectives, data sources, eligibility criteria, outcomes, results, conclusions.&quot;</span> 
2. Structured summary provided.
[Yes]   

P3.  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

To compare the safety and efficacy of MIS with tradi-
tional surgical approach for CDH, we performed an
appropriate meta-analysis of the related studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To compare the safety and efficacy of MIS with traditional surgical approach for CDH, we performed an appropriate meta-analysis of the related studies.&quot;</span>
2. Rationale described.
[Yes]

P4.  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

The
outcomes, which include post-operative mortality, inci-
dence of hernia recurrence, rates of patch use and com-
plications, were analyzed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The outcomes, which include post-operative mortality, incidence of hernia recurrence, rates of patch use and complications, were analyzed.&quot;</span> 
2. Outcomes specified.
[Yes]

P5.  
[No]

P6.  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):

Studies that met all the following criteria were included in
the meta-analysis: (1) the trial was a randomized or non-
randomized clinical trial; (2) the study was designed to
compare surgical outcomes of neonates with CDH between
MIS intervention and open procedures; and (3) data on
& L. Liu
lunxu_liu@aliyun.com
1 
Department of Thoracic Surgery, West China Hospital,
Sichuan University, No 37, Guo Xue Xiang,
610041 Chengdu, People’s Republic of China
2 
Department of Pediatric Surgery, West China Hospital,
Sichuan University, 610041 Chengdu,
People’s Republic of China
123
Hernia (2016) 20:297–302
DOI 10.1007/s10029-015-1423-0

incidence of mortality, recurrence, patch use, and surgical
complication rate were fully or partially reported' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Studies that met all the following criteria were included in the meta-analysis: (1) the trial was a randomized or non-randomized clinical trial; (2) the study was designed to compare surgical outcomes of neonates with CDH between MIS intervention and open procedures; and (3) data on incidence of mortality, recurrence, patch use, and surgical complication rate were fully or partially reported.&quot;</span>
2. Eligibility criteria described.
[Yes]

P7.  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):

We performed a literature search of the PubMed data-
base (National Library of Medicine, Bethesda, MD, USA)
that covered the period from 1966 to December 2013. The
search conducted for Embase and the Cochrane Central
Register of Controlled Trials was restricted to English-
language literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a literature search of the PubMed database (National Library of Medicine, Bethesda, MD, USA) that covered the period from 1966 to December 2013. The search conducted for Embase and the Cochrane Central Register of Controlled Trials was restricted to English-language literature.&quot;</span>
2. Information sources and dates searched reported.
[Yes]

P8.  
[No] 

P9.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Figure 1 shows details of study identification, inclusion and exclusion.&quot;</span>
2. Study selection process described. 
[Yes]

P10.  
[No]

P11. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎We extracted data from each eligible study, including general information, post-operative mortality, incidence of hernia recurrence, rates of patch use, and complications.&quot;</span>
2. Data extracted reported.
[Yes]  

P12. 
[NA]

P13.  
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):

Dichotomous out-
comes were expressed in relative risk (RR) with their 95 %
confidence interval (CI) values' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Dichotomous outcomes were expressed in relative risk (RR) with their 95% confidence interval (CI) values.&quot;</span>
2. Summary measures described.
[Yes]

P14-P16. 
[NA]

P17.  
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎Figure 1 shows details of study identification, inclusion and exclusion. A total of nine articles were involved in our meta-analysis.&quot;</span>
2. Study flow diagram provided.
[Yes]

P18. 
1. <span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):

Table 1 shows the detail informa-
tion of all the trials' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Table 1 shows the detail information of all the trials.&quot;</span> 
2. Study characteristics presented.
[Yes]

P19-P23.
[NA] 

P24. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎MIS for CDH repair is associated with lower post-operative mortality and morbidity compared with traditional open surgery. Although the rate of patch use appears to be comparable, the increased risk of recurrence of CDH should not be ignored.&quot;</span>
2. Main findings summarized.
[Yes]

P25. 
1. <span title='Perfect quote from fulltext (Similarity 100%).' style='border-bottom: 1px dashed black; color: black; background-color: transparent'>&quot;‎All the trials included are susceptible to the limitations of any retrospective review. They all have selection bias, and the numbers of patients are all small to draw a definitive conclusion.&quot;</span>
2. Limitations discussed.
[Yes] 

P26. 
1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 84%):

prospective clinical trials are needed to evaluate these two
surgical techniques' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎High-quality prospective clinical trials are needed to evaluate these two surgical techniques.&quot;</span>
2. Conclusions and future research implications described.
[Yes]

P27. 
1. <span title='Moderate quote deviation. Best match in fulltext (Similarity 80.6%):

Conflict of interest YZ declare' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Conflict of interest: None declared.&quot;</span>
2. No funding reported.
[Yes]
</pre>
</div>
</div>
<div id="quote-accuracy" class="section level3">
<h3>Quote accuracy</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<ul>
<li>782 quotes for 104 / 111 (93.7%) publications, median 5 (IQR 4-8,
range 1-38)</li>
<li>350 / 782 (44.8%) perfect <span
style="border-bottom: 1px dashed black;">quotes from the publication
fulltext</span></li>
<li>124 / 782 (15.9%) perfect <span
style="border-bottom: 1px dashed #2780e3; color: #2780e3;">quotes from
the LLM prompt briefing</span></li>
<li>308 / 782 (39.4%) quotes with deviations from source, where the
accuracy was measured by a <a
href="https://maxbachmann.github.io/RapidFuzz/Usage/distance/Levenshtein.html#normalized-similarity">“normalized
Levensthein similarity”</a> <span
style="border-bottom: 1px dashed black;"
title="Weights for insertion: 1, deletion: 0.5, substitution: 1.5. Penalizes &quot;positive hallucinations&quot; (insertions) more than omissions of e.g. brackets and references (deletions).">with
custom weights</span>, ranging from 0-100%
<ul>
<li><span style="background-color: #ffe9e2">177 minor</span> deviations
(95% ≤ similarity &lt; 100%); mean: 98.2%</li>
<li><span style="background-color: #ff9e81">56 moderate</span>
deviations (75% ≤ similarity &lt; 95%); mean: 88%</li>
<li><span style="background-color: red">75 major</span> deviations
(similarity &lt; 75%); mean: 53.7%</li>
</ul></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-2ee0c64e1e380841b496" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-2ee0c64e1e380841b496">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["Healy 2015","Healy 2015","Healy 2015","Healy 2016","Healy 2016","Healy 2016","Huang 2015","Huang 2015","Huang 2015","Ishii 2014","Ishii 2015","Jia 2011","Jia 2011","Jia 2011","Jia 2011","Jia 2011","Jia 2011","Jia 2011","Jia 2011","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kapralik 2016","Kunz 2013","Landisch 2015","Landisch 2015","Lansdale 2010","LeeVan 2016","Liang 2011","Liang 2011","Liang 2011","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Lishuang 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Livingston 2015","Mauritz 2013","Mauritz 2013","Mauritz 2011","Mei 2011","Mei 2011","Mei 2011","Mei 2011","Mei 2011","Mei 2011","Mei 2011","Mei 2011","Mei 2011","Mullassery 2014","Mullassery 2014","Mullassery 2014","Mullassery 2014","Mullassery 2014","Mullassery 2014","Mullassery 2014","Narayanan 2013","Narayanan 2013","Narayanan 2013","Narayanan 2013","Nataraja 2013","Nicolau 2011","Nicolau 2011","Oliveira 2016","Oomen 2012","Oomen 2012","Parolini 2016","Parolini 2016","Parolini 2016","Peycelon 2014","Pfistermuller 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Puligandla 2015","Ross 2015","Ross 2015","Ruttenstock 2010","Ruttenstock 2010","Saldaña 2013","Saldaña 2013","Sauerland 2010","Sauerland 2010","Sauerland 2010","Sauerland 2010","Sauerland 2010","Sauerland 2010","Scholfield 2016","Shawyer 2014","Shawyer 2014","Shawyer 2014","Shawyer 2014","Shawyer 2014","Shawyer 2015","Shawyer 2015","Shawyer 2015","Shawyer 2015","Shawyer 2015","Shawyer 2015","Shen 2015","Siddiqui 2011","Sklar 2014","Sklar 2014","Sola 2010","Sola 2010","Tan 2016","Tan 2016","Thomson 2015","Thomson 2015","van Dalen 2015","van Dalen 2015","van Dalen 2015","Vanden Berg 2016","Vanden Berg 2016","Vanden Berg 2016","van den Hondel 2014","van den Hondel 2014","van den Hondel 2014","Vernon-Roberts 2013","Wayne 2015","Wayne 2015","Wayne 2015","Wayne 2015","Wayne 2015","Wenk 2015","Wilkinson 2012","Wright 2013","Wright 2013","Wright 2013","Wright 2013","Wright 2013","Wright 2013","Yang 2011","Yang 2011","Yang 2011","Yang 2013","Yang 2013","Youssef 2016","Zhao 2015","Zhao 2015","Zhao 2015","Zhao 2015","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Zhu 2016","Aikenhead 2011","Aikenhead 2011","Aikenhead 2011","Al-Hozaim 2010","Al-Hozaim 2010","Al-Hozaim 2010","Allen 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Allin 2015","Alzahem 2011","Aworanti 2014","Baker 2015","Baker 2015","Berger 2012","Berger 2012","Berger 2012","Billingham 2010","Billingham 2010","Black 2013","Black 2013","Black 2013","Black 2013","Black 2013","Black 2013","Black 2013","Black 2013","Black 2013","Black 2013","Castagnetti 2010","Castagnetti 2016","Chan 2014 (Pediatr Surg Int)","Chan 2014 (Pediatr Surg Int)","Chan 2014 (Pediatr Surg Int)","Chan 2014 (Pediatr Surg Int)","Chan 2014 (J Pediatr Surg)","Chang 2015","Chang 2015","Chang 2015","Chen 2013","Chen 2013","Corbett 2015","Corbett 2015","Corbett 2015","Cullis 2016","Cundy 2014 (BJU Int)","Cundy 2014 (BJU Int)","Cundy 2014 (BJU Int)","Cundy 2014 (BJU Int)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (J Pediatr Surg)","Cundy 2014 (Eur J Pediatr Surg)","Ding 2013","Elyas 2010","Feng 2015","Feng 2015","Feng 2015","Friedmacher 2011","Friedmacher 2011","Friedmacher 2012","Friedmacher 2012","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Gosemann 2013","Graziano 2015","Graziano 2015","Guo 2011","Guo 2011","Guo 2011","Guo 2011"],["fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","prompt","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","prompt","prompt","fulltext","prompt","prompt","prompt","fulltext","prompt","fulltext","fulltext","prompt","prompt","fulltext","prompt","fulltext","prompt","prompt","prompt","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","prompt","fulltext","fulltext","prompt","prompt","fulltext","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","fulltext","fulltext","fulltext","prompt","prompt","prompt","fulltext","prompt","prompt","fulltext","fulltext","prompt","fulltext","prompt","fulltext","prompt","prompt","prompt","prompt","fulltext","prompt","prompt","prompt","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","prompt","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext","fulltext"],["<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nWe performed a systematic\nreview and meta-analysis to determine the influence of surgeon\nsubspecialty on outcomes following appendicectomy in chil-\ndren' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review and meta-analysis to determine the influence of surgeon subspecialty on outcomes following appendicectomy in children.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.7%):\n\nTwo authors searched Medline and Embase' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two authors searched Medline and Embase up to June 24, 2015.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nTwo authors (DD and DH) independently extracted data\nfrom eligible studies using an electronic spreadsheet' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently extracted data using an electronic spreadsheet.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nCitations\nof retrieved results were manually reviewed for relevance to\nthe topic of IA by two independent reviewers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Citations of retrieved results were manually reviewed for relevance to the topic by two independent reviewers.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nIn December 2014, a comprehensive literature search was\nperformed using Ovid MEDLINE (1946–present) and\nEmbase (1974–present) using the OvidSP interfaces. The\nterms ‘‘Incidental appendectomy’’ and ‘‘Prophylactic appen-\ndectomy’’ returned 315 and 74 results, respectively' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In December 2014, a comprehensive literature search was performed using Ovid MEDLINE (1946–present) and Embase (1974–present) using the OvidSP interfaces. The terms ‘‘Incidental appendectomy’’ and ‘‘Prophylactic appendectomy’’ returned 315 and 74 results, respectively.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nTo review the available literature for techniques, pathol-\nogy, risks of appendectomy, utility of the appendix, and IA\nin the treatment of specific pediatric medical conditions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To review the available literature for techniques, pathology, risks of appendectomy, utility of the appendix, and IA in the treatment of specific pediatric medical conditions.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nWe conducted this meta-analysis in accordance\nwith the Preferred Reporting Items for\n\nLaparoscopic versus open pyeloplasty in ureteropelvic junction obstruction\n4923 Int J Clin Exp Med 2015;8(4):4922-4931\nSystematic Reviews and Meta-Analyses [10' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted this meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [10].&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.2%):\n\n.\naccording to the meta-analy-\nsis of observational studies in\nepidemiology guidelines [11]\nand disagreements were con-\nsulted with the third one\n(Lugang Huang' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Data abstraction was carried out independently by two authors (Yidong Huang, Yang Wu) according to the meta-analysis of observational studies in epidemiology guidelines [11] and disagreements were consulted with the third one (Lugang Huang).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.2%):\n\nPUBMED, Web of science and\nCochrane library was carried out between Jan.\n1966 and Oct. 2014 to identify eligible studies,\nusing the following words: “hydronephrosis OR\nureteropelvic junction obstruction OR pelvi-ure-\nteric junction obstruction OR ureteral obstruc-\ntion”, “pyeloplasty”, “young OR children OR\nchild OR kids OR pediatrics” and “laparoscop-\nic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PUBMED, Web of science and Cochrane library were searched until Oct. 2014 to identify eligible studies, using the following words: “hydronephrosis OR ureteropelvic junction obstruction OR pelvi-ureteric junction obstruction OR ureteral obstruction”, “pyeloplasty”, “young OR children OR child OR kids OR pediatrics” and “laparoscopic”.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe search terms included the following: ‘uretero-\nscopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediat-\nric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’,\n‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search terms included the following: ‘ureteroscopy’, ‘flexible ureteroscopy’, ‘pediatric(s)’, ‘paediatric(s)’, ‘children’, ‘renal’, ‘calculi’, ‘stone(s)’, ‘urolithiasis’, ‘laser’, ‘laser therapy’ and ‘lithotripsy’.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.9%):\n\ntotal of 14 studies (1718 procedures)\nwere reported in patients with a mean (range) age of 7.8\n(0.25–18.0) years' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In total, 14 studies (1718 procedures) were reported in patients with a mean (range) age of 7.8 (0.25-18.0) years.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nData were extracted by 2 independent investigators, and dis-\ncrepancies were discussed to reach consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were extracted by 2 independent investigators, and discrepancies were discussed to reach consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nAn electronic literature search of all articles from inception to\nFebruary 2009 was conducted using Medline, the Cochrane\nLibrary, SCI, EMBASE, and the Chinese Biomedical Literature\nDatabase, using the following text and keywords in combination\nboth as MeSH terms and text words: “ pyloric stenosis” , “pyloros-\ntenosis” , “ pyloristenosis” and “ pyloromyotomy” in combination\nwith “ laparoscop' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An electronic literature search of all articles from inception to February 2009 was conducted using Medline, the Cochrane Library, SCI, EMBASE, and the Chinese Biomedical Literature Database, using the following text and keywords in combination both as MeSH terms and text words: “pyloric stenosis”, “pylorostenosis”, “pyloristenosis” and “pyloromyotomy” in combination with “laparoscop*”.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 75.9%):\n\nled trials with 492\ninfants were fi nally eligible for this study (\n●\n▶ \nFig.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎3 studies totaling 492 infants were finally eligible for this study (Figure 1).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):\n\nBaseline characteristics of included trials are summarized\nin \n●\n▶ \nTable 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Baseline characteristics of included trials are summarized in Table 1.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nUsing the quality assessment instrument of the Cochrane Hand-\nbook version 5.0.1 [11], we assigned ‘Yes’ for low risk of bias, ‘No’\nfor high risk of bias, or ‘Unclear’ for uncertain risk of bias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using the quality assessment instrument of the Cochrane Handbook version 5.0.1 [11], we assigned ‘Yes’ for low risk of bias, ‘No’ for high risk of bias, or ‘Unclear’ for uncertain risk of bias.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nAll\nstudies described an adequate random sequence generation,\nallocation concealment and blinding. After retrieving included\narticles, no incomplete outcome data and selective outcome\nreporting were found (\n●\n▶ \nTable 2). Therefore, the magnitude of\nLP compared with OP used in this systematic review was high\nquality with a low risk of bias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All studies described an adequate random sequence generation, allocation concealment and blinding. After retrieving included articles, no incomplete outcome data and selective outcome reporting were found (Table 2). Therefore, the magnitude of LP compared with OP used in this systematic review was high quality with a low risk of bias.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 81.3%):\n\nheteroge-\nneity among few trials, and should be interpreted with caution\n[12] . Potential causes of heterogeneity were explored by carry-\ning out sensitivity and subgroup analyses if available' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Heterogeneity among studies was estimated by the use of the I2 statistic... Potential causes of heterogeneity were explored by carrying out sensitivity and subgroup analyses if available.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nData were extracted by 2 independent investigators, and dis-\ncrepancies were discussed to reach consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data were extracted by 2 independent investigators, and discrepancies were discussed to reach consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe used a Dephi-like method [17] to determine the issues of\ngreatest concern to pediatric surgeons regarding the surgical manage-\nment of CPAM' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We used a Dephi-like method [17] to determine the issues of greatest concern to pediatric surgeons regarding the surgical management of CPAM.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nOne reviewer extracted all data from the included studies, and an-\nother checked it for accuracy and completeness' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nwe conducted an electronic literature\nsearch of the Cochrane Central Register of Controlled Trials (CENTRAL),\nMEDLINE (1966 onwards), EMBASE (1980 onwards), CINAHL (1982 on-\nwards), and PubMed (1966 onwards) in January 2015' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted an electronic literature search of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), EMBASE (1980 onwards), CINAHL (1982 onwards), and PubMed (1966 onwards) in January 2015.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nto conduct a systematic review and meta-analysis\nof all published literature comparing the postoperative outcomes asso-\nciated with elective surgery (while asymptomatic) versus those follow-\ning surgery as part of expectant management (i.e., performing surgery\nonly upon the development of symptoms) in children born with asymp-\ntomatic CPAM lesions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎to conduct a systematic review and meta-analysis of all published literature comparing the postoperative outcomes associated with elective surgery (while asymptomatic) versus those following surgery as part of expectant management (i.e., performing surgery only upon the development of symptoms) in children born with asymptomatic CPAM lesions.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nOne reviewer extracted all data from the included studies, and an-\nother checked it for accuracy and completeness' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎One reviewer extracted all data from the included studies, and another checked it for accuracy and completeness.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.7%):\n\nHeterogeneity was assessed by the I\n2\nstatistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Heterogeneity was assessed by the I2 statistic.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 79.2%):\n\nreviewed and extracted eligible articles. Bibliographies of identified\nstudies were examined to identify any additional eligible studies. Dupli-\ncate listed articles were deleted. Two other independent researchers\n(A.A. and A.W.) confirmed the inclusion of appropriate citations based\non study definitions and aims' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Two independent researchers (R.L. and R.M.) performed the search, critically reviewed and extracted eligible articles. Bibliographies of identified studies were examined to identify any additional eligible studies. Duplicate listed articles were deleted. Two other independent researchers (A.A. and A.W.) confirmed the inclusion of appropriate citations based on study definitions and aims.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nAn online database search for all articles published between January\n1993 and January 2014 on pediatric patients using the following key-\nwords was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd pro-\ncedure”, “Ivemark”, “asplenia”, and “polysplenia”. Searches were\nrepeated in PubMed, Medline, CINAHL, and Cochrane library' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎An online database search for all articles published between January 1993 and January 2014 on pediatric patients using the following keywords was performed: “heterotaxy”, “rotation”, “volvulus”, “Ladd procedure”, “Ivemark”, “asplenia”, and “polysplenia”. Searches were repeated in PubMed, Medline, CINAHL, and Cochrane library.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):\n\nwe have per-\nformed a systematic review and meta-analysis of studies that com-\npares survival, CDH recurrence risk, operative time and prosthetic\npatch usage between CDH neonates whose repair was approached\nby MIS and those where it was undertaken by open surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We have therefore performed a systematic review and meta-analysis of studies that compares survival, CDH recurrence risk, operative time and prosthetic patch usage between CDH neonates whose repair was approached by MIS and those where it was undertaken by open surgery.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 76.5%):\n\nPubMed, Ovid, and the Cochrane Library. The following search was performed in each of\nthe three databases: (Renal or Kidney) AND (Pediatric or Children) AND Trauma AND Management. Publications were\nlimited to publish date after January 1, 2000' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A search of all original research studies was conducted using PubMed, Ovid, and the Cochrane Library. The following search was performed in PubMed: (Renal or Kidney) AND (Pediatric or Children) AND Trauma AND Management. Publications were limited to publish date after January 1, 2000.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nA search\nwas made for all studies published up until 31 August 2010\nusing the terms “lymphatic sparing varicocelectomy”, “laparos-\ncopy” , “adolescent ” and “children ” in the Medline (using PubMed\nas the search engine), Embase, Ovid, Web of Science, and\nCochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A search was made for all studies published up until 31 August 2010 using the terms “lymphatic sparing varicocelectomy”, “laparoscopy”, “adolescent” and “children” in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe citations and/ or abstracts or the full text\nof all potentially relevant studies were independently evaluated\nand selected by 3 reviewers (LZL, GJ and TQS), and any disagree-\nments were resolved by consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The citations and/ or abstracts or the full text of all potentially relevant studies were independently evaluated and selected by 3 reviewers (LZL, GJ and TQS), and any disagreements were resolved by consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nA search\nwas made for all studies published up until 31 August 2010\nusing the terms “lymphatic sparing varicocelectomy”, “laparos-\ncopy” , “adolescent ” and “children ” in the Medline (using PubMed\nas the search engine), Embase, Ovid, Web of Science, and\nCochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A search was made for all studies published up until 31 August 2010 using the terms “lymphatic sparing varicocelectomy”, “laparoscopy”, “adolescent” and “children” in the Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nThis systematic review and meta-analysis were under-\ntaken with a prospective protocol according to the latest\nguidelines of meta-analysis (PRISMA) [14' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This systematic review and meta-analysis were undertaken with a prospective protocol according to the latest guidelines of meta-analysis (PRISMA) [14].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nTwo investigators independently asses-\nsed selected studies and extracted the following informa-\ntion: study characteristics, quality, outcomes data, etc' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two investigators independently assessed selected studies and extracted the following information: study characteristics, quality, outcomes data, etc.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nWe conducted a system-\natic search of the online databases, including Medline,\nOvid, Elsevier, Google Scholar Embase, Cohrane library,\nfor studies published between 1995 and 2014 with no\nlimits for publication language, place of study origin and\nsample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nLaparoscopic portoenterostomy versus open portoenterostomy\nfor the treatment of biliary atresia: a systematic review and meta-\nanalysis of comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopic portoenterostomy versus open portoenterostomy for the treatment of biliary atresia: a systematic review and meta-analysis of comparative studies&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe aim of\nthis study was to include all publicly available data for\ncomparing the safety and validity of laparoscopic porto-\nenterostomy (LPE) and open portoenterostomy (OPE) in\nthe treatment of biliary atresia' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The aim of this study was to include all publicly available data for comparing the safety and validity of laparoscopic portoenterostomy (LPE) and open portoenterostomy (OPE) in the treatment of biliary atresia.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):\n\nWe conducted a system-\natic search of the online databases, including Medline,\nOvid, Elsevier, Google Scholar Embase, Cohrane library,\nfor studies published between 1995 and 2014 with no\nlimits for publication language, place of study origin and\nsample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases...for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nWe conducted a system-\natic search of the online databases, including Medline,\nOvid, Elsevier, Google Scholar Embase, Cohrane library,\nfor studies published between 1995 and 2014 with no\nlimits for publication language, place of study origin and\nsample size of the studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of the online databases, including Medline, Ovid, Elsevier, Google Scholar Embase, Cohrane library, for studies published between 1995 and 2014 with no limits for publication language, place of study origin and sample size of the studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nTwo investigators independently asses-\nsed selected studies and extracted the following informa-\ntion: study characteristics, quality, outcomes data, etc' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two investigators independently assessed selected studies and extracted the following information: study characteristics, quality, outcomes data, etc.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nThe following data were the\noutcomes of interest that extracted from each included\nstudy: first author, publication year, country, study design,\nnumber of patients who underwent LPE or OPE, charac-\nteristics of the study population, and end point data\n(operative times, hospital stay times, rate of conversion\nfrom LPE to OPE, re-operation rates, and complications\nabout surgery including: intraoperative blood loss, early\nclearance of jaundice, cholangitis and variceal bleeding' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The following data were the outcomes of interest that extracted from each included study: first author, publication year, country, study design, number of patients who underwent LPE or OPE, characteristics of the study population, and end point data (operative times, hospital stay times, rate of conversion from LPE to OPE, re-operation rates, and complications about surgery including: intraoperative blood loss, early clearance of jaundice, cholangitis and variceal bleeding.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nFor categorical variables data,\n262 Pediatr Surg Int (2015) 31:261–269\n123\n\nstatistical analysis was performed using the odds ratio (OR)\nas the statistic summary. This odds ratio represents the\nodds of an adverse event occurring in the LPE group\ncompared with the OPE group. Statistical analysis for\ncontinuous variables was performed using the mean dif-\nference (MD) and as the summary statistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎For categorical variables data, statistical analysis was performed using the odds ratio (OR) as the statistic summary. This odds ratio represents the odds of an adverse event occurring in the LPE group compared with the OPE group. Statistical analysis for continuous variables was performed using the mean difference (MD) and as the summary statistic.&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):\n\nPresent results of each meta-analysis done, including confidence intervals' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎Presents results of each meta-analysis done, including confidence intervals&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nFurther improvements in the laparoscopic\nportoenterostomy are needed before its widespread appli-\ncation can be recommended' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Further improvements in the laparoscopic portoenterostomy are needed before its widespread application can be recommended.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.5%):\n\nWe conducted a systematic search of Medline, Embase, and\nCochrane Central Register of Controlled Trials for studies of participants\nwith gastroesophageal reflux treated with FG or GJ. A medical librarian\nhelped us develop queries for each database to identify studies that\nmentioned fundoplication and gastrojejunostomy. These concepts were\nexpanded to ensure that no studies were missed due to variation in syn-\ntax and nomenclature. We also performed manual searches of relevant\njournals, conference proceedings [13], theses and dissertations [14–16],\nand other trial registries' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of Medline, Embase, and Cochrane Central Register of Controlled Trials...\", \"A medical librarian helped us develop queries for each database...\", \"We also performed manual searches of relevant journals, conference proceedings, theses and dissertations, and other trial registries.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 77.8%):\n\nStudies were included if participants were less\nthan 18 years of age, had neurologic impairments, and a clinical history\nor investigation suggestive of gastroesophageal reflux.' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Studies were included if participants were less than 18 years of age, had neurologic impairments, and a clinical history or investigation suggestive of gastroesophageal reflux.\", \"Table 1. Characteristics of included studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.2%):\n\nIn light of these uncertainties, we conducted a systematic review to\ndetermine if FG and GJ are equally effective for the treatment of gastro-\nesophageal reflux refractory to maximal medical management in chil-\ndren with neurologic impairment' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In light of these uncertainties, we conducted a systematic review to determine if FG and GJ are equally effective for the treatment of gastroesophageal reflux refractory to maximal medical management in children with neurologic impairment.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nwe conducted a systematic review to\ndetermine if FG and GJ are equally effective for the treatment of gastro-\nesophageal reflux refractory to maximal medical management in chil-\ndren with neurologic impairment' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic review to determine if FG and GJ are equally effective for the treatment of gastroesophageal reflux refractory to maximal medical management in children with neurologic impairment.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.1%):\n\nWe conducted a systematic search of Medline, Embase, and\nCochrane Central Register of Controlled Trials for studies of participants\nwith gastroesophageal reflux treated with FG or GJ. A medical librarian\nhelped us develop queries for each database to identify studies that\nmentioned fundoplication and gastrojejunostomy. These concepts were\nexpanded to ensure that no studies were missed due to variation in syn-\ntax and nomenclature. We also performed manual searches of relevant\njournals, conference proceedings [13], theses and dissertations [14–16],\nand other trial registries' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted a systematic search of Medline, Embase, and Cochrane Central Register of Controlled Trials...\", \"We also performed manual searches of relevant journals, conference proceedings, theses and dissertations, and other trial registries.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nTitle and abstract screening was completed independently and in\nduplicate by two of the authors (MHL, ACS). Disagreements resulted\nin automatic inclusion' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Title and abstract screening was completed independently and in duplicate by two of the authors. Disagreements resulted in automatic inclusion.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.3%):\n\nTable 1\nCharacteristics of included studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Table 1. Characteristics of included studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.3%):\n\nhe evidence\nThe quality of evidence for mortality, pneumonia, major complica-\ntions, and minor complications following FG versus GJ for refractory\ngastroesophageal reflux in children with neurologic impairment' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The quality of evidence for mortality, pneumonia, major complications, and minor complications following FG versus GJ for refractory gastroesophageal reflux in children with neurologic impairment was very low.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 51.3%):\n\ny low (Table 3). Using the GRADE approach, the quality of evidence\nfor all outcomes was downgraded from low to very low due to serious\nrisk of bias bet' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Risk of bias for individual studies was assessed in duplicate using the methodological index for nonrandomized studies (MINORS).\", \"Using the GRADE approach, the quality of evidence for all outcomes was downgraded from low to very low due to serious risk of bias between studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 86.1%):\n\ncores [32].\nResearchers should adopt several strategies to improve the quality o' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Researchers should adopt several strategies to improve the quality of evidence.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nUsing predefined search\nterms PubMed (1960 to 2011), EMBASE (from 1980 to\n2011), and the Cochrane Library (issue 3, 2011) were system-\natically searched until March 16, 2011 to identify all articles\ncomparing complete to partial fundoplication in children\nwith GERD' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined search terms PubMed (1960 to 2011), EMBASE (from 1980 to 2011), and the Cochrane Library (issue 3, 2011) were systematically searched until March 16, 2011 to identify all articles comparing complete to partial fundoplication in children with GERD.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nUsing predefined criteria, two authors (F.M. and B.B) included\nstudies and assessed their methodological quality and risk of\nbias according to the PRISMA statement\n20,21 \nand the Cochrane\nCollaboration&#39;s tool for risk of bias assessment' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Using predefined criteria, two authors (F.M. and B.B) included studies and assessed their methodological quality and risk of bias according to the PRISMA statement and the Cochrane Collaboration's tool for risk of bias assessment.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.4%):\n\nThree electronic databases (Medline, Embase, and the Cochrane Library) were searched for' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Three electronic databases (Medline, Embase, and the Cochrane Library) were searched for all articles published until November 10, 2010.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 82.3%):\n\ne searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane...All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.5%):\n\nstudy selection, 2 people do' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Flowchart of study selection is provided in Figure 1.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):\n\nstatistical heterogeneity was as-\nsessed via the I \n2 \ninde' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Statistical heterogeneity was assessed via the I2 index.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.5%):\n\nTo comprehensively review the available evidences in the literature on the use of laparoscopic pye-\nloplasty (LP) vs open pyeloplasty (OP) for the repair of ureteropelvic junction (UPJ) obstruction in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To comprehensively review the available evidences in the literature on the use of laparoscopic pyeloplasty (LP) vs open pyeloplasty (OP) for the repair of ureteropelvic junction (UPJ) obstruction in children.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.2%):\n\ncriteria included all\navailable studies that compared LP with OP for the repair of\nUPJ obstructions in the pediatric population' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Inclusion criteria included all available studies that compared LP with OP for the management of UPJ obstruction in the pediatric population younger than 18 years.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nWe searched online databases, including Medline\n(using PubMed as the search engine), Embase, Web of Science,\nOvid, and Cochrane, to identify suitable studies until the end of\nOctober 2010, without lower date limit. The ‘‘pyeloplasty,’’\n‘‘laparoscopy,’’ ‘‘laparoscopic pyeloplasty,’’ and ‘‘ureteropelvic\njunction obstruction’’ were used as search terms' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched online databases, including Medline (using PubMed as the search engine), Embase, Web of Science, Ovid, and Cochrane... The ‘‘pyeloplasty,’’ ‘‘laparoscopy,’’ ‘‘laparoscopic pyeloplasty,’’ and ‘‘ureteropelvic junction obstruction’’ were used as search terms.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.5%):\n\nstudy selection, 2 people do' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Flowchart of study selection is provided in Figure 1.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nMeta-analyses were performed for the five primary out-\ncome parameters: Operative time (in minutes), postoperative\ncomplications (in events per group), duration of hospital stay\n(in days), success rate (in events per group), and stenting rate\n(in events per group' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Meta-analyses were performed for the five primary outcome parameters: Operative time (in minutes), postoperative complications (in events per group), duration of hospital stay (in days), success rate (in events per group), and stenting rate (in events per group).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.5%):\n\nstudy selection, 2 people do' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Flowchart of study selection is provided in Figure 1.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.7%):\n\nA systematic review and meta-analysis is reported to address robust evidence for curative “gross\ntotal tumor resection” (GTR) in Stage 3 and Stage 4 neuroblastoma' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic review and meta-analysis is reported to address robust evidence for curative “gross total tumor resection” (GTR) in stages 3 and 4 pediatric neuroblastoma.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nStudies were reviewed by PJF and DM independently. Where a difference in opin-\nion occurred the matter was resolved by consensus agreement in conjunction with the\nsenior author (PDL' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Studies were reviewed by PJF and DM independently. Where a difference in opinion occurred the matter was resolved by consensus agreement in conjunction with the senior author (PDL).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nReference lists of retrieved studies\nand conference abstracts were also reviewed to identify other potential studies of inter-\nest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Reference lists of retrieved studies and conference abstracts were also reviewed to identify other potential studies of interest.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.3%):\n\nheterogeneity exists a random effects model should be used' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Heterogeneity was assessed using I2 statistic.\" \"Random effects model used for meta-analysis.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.7%):\n\nA systematic review and meta-analysis is reported to address robust evidence for curative “gross\ntotal tumor resection” (GTR) in Stage 3 and Stage 4 neuroblastoma' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic review and meta-analysis is reported to address robust evidence for curative “gross total tumor resection” (GTR) in stages 3 and 4 pediatric neuroblastoma.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):\n\nto critically examine the evidence for curative “gross total tumor resection” (GTR) in\nstages 3 and 4 pediatric neuroblastoma' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎to critically examine robust evidence for curative “gross total tumor resection” (GTR) in stages 3 and 4 pediatric neuroblastoma.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nOdds ratios (OR) were calculated with\n95% confidence intervals (CI) using Mantel–Haenszel calculations and a random ef-\nfects model' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Odds ratios (OR) were calculated with 95% confidence intervals (CI) using Mantel–Haenszel calculations and a random effects model.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nA Medline, Ovid, Search Medica, Elsevier Clini-\ncalKey, Google Scholar and the Cochrane library search\nwas performed on all studies published between 1950 and\n2012 reporting on comparison of HD and HJ for children\nundergoing excision of extra-hepatic biliary tree for\ncholedochal cysts' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A Medline, Ovid, Search Medica, Elsevier ClinicalKey, Google Scholar and the Cochrane library search was performed on all studies published between 1950 and 2012 reporting on comparison of HD and HJ for children undergoing excision of extra-hepatic biliary tree for choledochal cysts.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nkeywords were used:\n“choledochal cyst”, “choledochal cyst AND hepaticoduo-\ndenostomy”, “choledochal cyst AND hepaticojejunost-\nomy”, “hepaticoduodenostomy”, “hepaticojejunostomy”,\n“hepaticodochoduodenostomy”. The “related articles”\nfunction was used to widen the search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎keywords used: “choledochal cyst”, “choledochal cyst AND hepaticoduodenostomy”, “choledochal cyst AND hepaticojejunostomy”, “hepaticoduodenostomy”, “hepaticojejunostomy”, “hepaticodochoduodenostomy”. The “related articles” function was used to widen the search.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.3%):\n\nStatistical heterogeneity was assessed using I \n2 \n. A fixed\neffects model was used if I \n2 \nb 50% and a random effects model\nwas used if I \n2 \n≥' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Statistical heterogeneity was assessed using I2. A fixed effects model was used if I2 < 50% and a random effects model was used if I2 ≥ 50%.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nTo compare the clinical outcomes of HD and HJ, we\nperformed a systematic review and comprehensive meta-\nanalysis from indexed published literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To compare the clinical outcomes of HD and HJ, we performed a systematic review and comprehensive meta-analysis from indexed published literature.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 83.6%):\n\nof Intraabdominal Abscess Formation\nFollowing Laparoscopic Appendicectomy in Children:\nA Systematic Review and Meta-analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Comparison of Intraabdominal Abscess Formation Following Laparoscopic and Open Appendicectomies in Children: A Systematic Review and Meta-analysis&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nLaparoscopia diagnosticã æi terapeuticã în contuziile abdomi-\nnale (CA) are o utilizare limitatã æi chiar controversatã,\ndatoritã în special progreselor fãcute de explorãrile imagistice\nactuale' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Laparoscopia diagnosticã æi terapeuticã în contuziile abdomi-nale (CA) are o utilizare limitatã æi chiar controversatã, datoritã în special progreselor fãcute de explorãrile imagistice actuale.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nÎn concluzie, deæi puåin utilizatã, dovada fiind æi\nnumãrul redus de articole publicate, laparoscopia poate fi utilã\nla pacienåii cu CA atent selectaåi cu examen clinic æi imagis-\nticã echivoce în scopul reducerii incidenåei laparotomiilor\ninutile' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎În concluzie, deæi puåin utilizatã, laparoscopia poate fi utilã la pacienåii cu CA atent selectaåi cu examen clinic æi imagis-ticã echivoce în scopul reducerii incidenåei laparotomiilor inutile.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.9%):\n\nReview article\nNeophalloplasty in boys with aphallia: A\nsystematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Review article: Neophalloplasty in boys with aphallia: A systematic review&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.6%):\n\nThe aim of this study was to compare the\nresults of both surgical strategies by means of a systematic\nreview and meta-analysis of the available literature' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The aim of this study was to compare the results of LP and OP by means of a systematic review and meta-analysis of the available literature.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.6%):\n\ndata on setting, methodological\nquality [according to the Cochrane handbook for system-\natic reviews of interventions (http://dcc.cochrane.org/sites/\ndcc.cochrane.org/files/uploads/RCT)], population, and type\nof surgery were extracted by two authors independently' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data on setting, methodological quality, population, and type of surgery were extracted by two authors independently.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTwo independent authors extracted information related to each eli-\ngible study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors extracted information related to each eligible study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nThe\nPubMed database was searched for studies of children with EA and RAA\npublished from January 1990 to December 2014. Inclusion criteria were\nEnglish language articles reporting original data on epidemiology, diag-\nnosis and treatment of newborns with EA' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The PubMed database was searched for studies of children with EA and RAA published from January 1990 to December 2014. Inclusion criteria were English language articles reporting original data on epidemiology, diagnosis and treatment of newborns with EA.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTwo independent authors extracted information related to each eli-\ngible study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors extracted information related to each eligible study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nReferences for this review\nwere identified by PubMed searches using appropriate search\nterms for each section (“minimally invasive surgery,” “lapa-\nroscopy,” “thoracoscopy,” “childhood/children/pediatric can-\ncer”). Articles were also identified by searching the author’s\nown files' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎References for this review were identified by PubMed searches using appropriate search terms for each section (“minimally invasive surgery,” “laparoscopy,” “thoracoscopy,” “childhood/children/pediatric cancer”). Articles were also identified by searching the author’s own files.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nMedline and Pubmed were searched in order to identify ar-\nticles published between 1994 and 2012. The search terms\n‘tubularized incised plate urethroplasty/Snodgrass repair/\ntechnique \u0002 outcomes/complications \u0002 follow-up/long term\nfollow-up’ were used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Pubmed were searched in order to identify articles published between 1994 and 2012. The search terms ‘tubularized incised plate urethroplasty/Snodgrass repair/technique \u0002 outcomes/complications \u0002 follow-up/long term follow-up’ were used.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 84.2%):\n\nprotocol, ethics approval, or pre-determined/a priori published research objectives' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎No protocol, ethics approval, or pre-determined/a priori published research objectives are mentioned.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nTwo of the principal authors (P.P. and\nS.I.) independently scanned all titles as a first screen after which select-\ned abstracts and/or full-length papers were collected for further review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two of the principal authors independently scanned all titles as a first screen after which selected abstracts and/or full-length papers were collected for further review.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.9%):\n\nreview indicates that there was a search for “grey literature” or “unpublished literature,”' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The review does not indicate searching for unpublished literature or grey literature.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 88.5%):\n\nlist of included and excluded studies should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎No list of included or excluded studies is provided.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nData compiled for each article included\nsample size, description of the procedures performed or medications\nused, method of ventilation, use of ECMO, timing of repair, outcomes in-\ncluding mortality and morbidity, and type of patch used' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data compiled for each article included sample size, description of the procedures performed or medications used, method of ventilation, use of ECMO, timing of repair, outcomes including mortality and morbidity, and type of patch used.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.1%):\n\nquantitative synthesis (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No quantitative synthesis or meta-analysis was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.6%):\n\nassessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No assessment of publication bias was done as no meta-analysis was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 50%):\n\nconflict of interest included' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No statement about conflict of interest is provided.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):\n\nummary\nThis systematic review by the APSA Outcomes and Evidence-based\nPractice Committee attempted to delineate best-evidence recommen-\ndations for specific aspects of C' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎This systematic review by the APSA Outcomes and Evidence-based Practice Committee attempted to delineate best-evidence recommendations for specific aspects of CDH care.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.7%):\n\nstructured summary in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No structured abstract or summary is provided.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\niNO). Variability in institutional\npractice patterns for CDH will likely pose a significant barrier to any fur-\nther improvement in CDH outcomes. Thus, it is imperative that we ded-\nicate efforts to design high quality studies that will inform the\ndevelopment of best practices for these' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variability in institutional practice patterns for CDH will likely pose a significant barrier to any further improvement in CDH outcomes. Thus, it is imperative that we dedicate efforts to design high quality studies that will inform the development of best practices for these infants.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nOur purpose was to systematically review the available evidence to pro-\nvide recommendations regarding specific aspects of CDH management.\nIn particular we focused on ventilator management, the treatment of\npulmonary hypertension (PHTN), glucocorticoid use, mode and dura-\ntion of ECMO, timing of repair, optimal technique for repair, and the\nuse of prosthetic patches' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our purpose was to systematically review the available evidence to provide recommendations regarding specific aspects of CDH management. In particular we focused on ventilator management, the treatment of pulmonary hypertension (PHTN), glucocorticoid use, mode and duration of ECMO, timing of repair, optimal technique for repair, and the use of prosthetic patches.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.3%):\n\nreferenced' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No protocol is referenced.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.9%):\n\nthe search strategy should be provided' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The full search strategies are not provided.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nTwo of the principal authors (P.P. and\nS.I.) independently scanned all titles as a first screen after which select-\ned abstracts and/or full-length papers were collected for further review.\nArticles were either included or excluded based on their relevance to\nthe topic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two of the principal authors independently scanned all titles as a first screen after which selected abstracts and/or full-length papers were collected for further review. Articles were either included or excluded based on their relevance to the topic.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.6%):\n\ne method of data extraction' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎The method of data extraction is not described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 37.1%):\n\nVariable management practices complicat' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The variables extracted are not explicitly listed and defined.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 47.3%):\n\nmethods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No method for assessing risk of bias is described, only level of evidence.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 45.2%):\n\n, meta-analysis,' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No meta-analysis was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.1%):\n\nquantitative synthesis (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No quantitative synthesis or meta-analysis was performed.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.8%):\n\ningly, the quantity\nof high-level evidence was severely lacking, which precludes the identi-\nfication of definitive best pr' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The quantity of high-level evidence was severely lacking, which precludes the identification of definitive best practices.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\niNO). Variability in institutional\npractice patterns for CDH will likely pose a significant barrier to any fur-\nther improvement in CDH outcomes. Thus, it is imperative that we ded-\nicate efforts to design high quality studies that will inform the\ndevelopment of best practices for these' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Variability in institutional practice patterns for CDH will likely pose a significant barrier to any further improvement in CDH outcomes. Thus, it is imperative that we dedicate efforts to design high quality studies that will inform the development of best practices for these infants.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 40%):\n\nsources of funding' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎No statement about sources of funding is provided.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe literature search, assessment for in-\nclusion and data extraction were performed independently\nby three reviewers and disagreements resolved by\nconsensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The literature search, assessment for inclusion and data extraction were performed independently by three reviewers and disagreements resolved by consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nWe searched Medline, Embase and the Cochrane con-\ntrolled trials register from inception to July 2014 using the\nterms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed\nsilo’ and ‘silastic silo' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched Medline, Embase and the Cochrane controlled trials register from inception to July 2014 using the terms ‘gastroschisis’, ‘gastroschisis and silo’, ‘preformed silo’ and ‘silastic silo’.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.7%):\n\nDetailed information was recorded regarding the type of\nstudy, patient’s age and gender, intraoperative details, and\npostoperative complications with particular emphasis on\nthe incidence and outcome of HAEC' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Detailed information was recorded regarding the [...] postoperative complications with particular emphasis on the incidence of HAEC.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 43.1%):\n\n’’. The reference list\nfrom retrieved articles was reviewed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎PubMed and Medline were searched [...]. The search terms were [...]. The reference list from retrieved articles was reviewed [...]&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.1%):\n\nsystematic reviews and are tasked to assess the methodological quality of a systematic re' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A systematic review..\" \"[We have] conducted [a] systematic research in PubMed&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.1%):\n\nWe identified prospective controlled trials (n = 1), case-control studies (n = 12), case series (n = 49), and case\nreports' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We identified..prospective controlled trials..case series..case reports&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.4%):\n\n.\nTwo observers independently extracted the results of each paper\non a data sheet' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Two reviewers independently assessed trial quality.\" \"Two observers independently extracted the results of each paper on a data sheet&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.4%):\n\n, laparoscopic surgery for suspected appendicitis has diagnostic and therapeutic advantages as compared to conventional\nsurgery. However, conventional appendectomy should not be considered &#39;wrong' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In conclusion, laparoscopic surgery for suspected appendicitis has diagnostic and therapeutic advantages as compared to conventional surgery. However, conventional appendectomy should not be considered 'wrong'.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.2%):\n\ncontinuous variables, generally means with their\ncorresponding standard deviations (SDs) are needed to calculate\nweighted or standardized mean differences' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎For dichotomous outcomes..Peto's odds ratios were calculated...For continuous variables...means with their corresponding standard deviations are needed to calculate weighted or standardized mean differences.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe evolution of\nendoscopic surgery led to the idea of performing appendectomy\nin laparoscopy, which was first described by Semm in 1983 (Semm\n1983). Nevertheless, the new method has only partly gained\nacceptance (Faiz 2008; Paterson 2008; Van Hove 2008), because the\nadvantages of laparoscopic appendectomy were not as obvious as\nfor laparoscopic cholecystectomy' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The evolution of endoscopic surgery led to the idea of performing appendectomy in laparoscopy, which was first described by Semm in 1983. Nevertheless, the new method has only partly gained acceptance, because the advantages of laparoscopic appendectomy were not as obvious as for laparoscopic cholecystectomy.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 55.6%):\n\nFor dichotomous variables relative risks (RR) with 95% confidence\nintervals (95% CIs) were the preferred measure. For complication\nrates, howev' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎For dichotomous variables relative risks...were the preferred measure. For continuous variables...weighted or standardized mean differences with 95% CIs.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 62.9%):\n\n). We expected complication rate to vary only by\na very small degree, and therefore used fixed-effects models' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We pooled the effect measures within a random effects model.\" \"We expected complication rate to vary only by a very small degree, and therefore used fixed-effects models.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nA systematic PubMed search was performed to identify\npublications that analyzed outcomes for LD or OD pull-through\nprocedures for HD. All studies between January 1994 and De-\ncember 2014 were included in the search' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications that analyzed outcomes for LD or OD pull-through procedures for HD. All studies between January 1994 and December 2014 were included in the search.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nA comprehensive search was conducted using MEDLINE/\nPubMed, CINHAL, EMBASE/OVID, and CENTRAL (the\nCochrane library) electronic databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted using MEDLINE/PubMed, CINHAL, EMBASE/OVID, and CENTRAL (the Cochrane library) electronic databases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):\n\nWe performed an appraisal of the quality of reporting of\nthe included studies in duplicate (AS and JP). We used the\nmethodological index for non-randomized studies (MIN-\nORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed an appraisal of the quality of reporting of the included studies in duplicate (AS and JP). We used the methodological index for non-randomized studies (MINORS).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63%):\n\nThe quality of the included\nstudies is low demonstrating important shortcomings, such\nas study design, small number of patients evaluated,' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The quality of the included studies is low demonstrating important shortcomings, such as study design, small number of patients evaluated, heterogeneous patients evaluated, and lack of a clear definition of outcomes.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 85.4%):\n\ns systematic review on the use of anti-reflux\nPediatr Surg Int (2014) 30:987–996 991\n123\n\nmedication in postoperative EA-TEF patients' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We performed a systematic review on the use of anti-reflux medication in postoperative EA-TEF patients.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nData abstraction was performed in duplicate (AS, JD) and\nverified for accuracy and quality via a pre-piloted stan-\ndardized data abstraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was performed in duplicate (AS, JD) and verified for accuracy and quality via a pre-piloted standardized data abstraction form.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nA comprehensive search was conducted of MEDLINE/\nPubMed, EMBASE/OVID and CENTRAL (the Cochrane\nLibrary) electronic databases from 2000 to March 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nA comprehensive search was conducted of MEDLINE/\nPubMed, EMBASE/OVID and CENTRAL (the Cochrane\nLibrary) electronic databases from 2000 to March 2014' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\nWe appraised the quality of reporting of the included\nstudies in duplicate (AS and ML), with discrepancies\nresolved by discussion and consensus. We used the\nMethodological Index for Nonrandomized Studies (MIN-\nORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We appraised the quality of reporting of the included studies in duplicate using the Methodological Index for Nonrandomized Studies (MINORS).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):\n\nno significant dif-\nference in rates of mucosal prolapse or defecation scores\nfor LAARP compared to OPEN. However, the studies are\nof moderate quality, samples sizes are small and there are\nmultiple sources of heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We found no significant difference in rates of mucosal prolapse or defecation scores for LAARP compared to OPEN. However, the studies are of moderate quality, samples sizes are small and there are multiple sources of heterogeneity.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nCase series and observational studies are inherently heter-\nogeneous, thus we decided a priori to use a random-effects\nmodel to account for between-study heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Case series and observational studies are inherently heterogeneous, thus we decided a priori to use a random-effects model to account for between-study heterogeneity.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nData abstraction was performed in duplicate (AS and ML)\nand verified for accuracy and quality via a pre-piloted\nstandardized data abstraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data abstraction was performed in duplicate and verified for accuracy and quality via a pre-piloted standardized data abstraction form.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nThe keywords used in\nthe search were as follows: laparoscopic, open, hepatico-\njejunostomy, choledochal cysts. The language was re-\nstricted to English only. The citations within the reference\nlists of the articles were searched manually to identify\nadditional eligible studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The keywords used in the search were as follows: laparoscopic, open, hepaticojejunostomy, choledochal cysts. The language was restricted to English only. The citations within the reference lists of the articles were searched manually to identify additional eligible studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nWe searched the MEDLINE, EM-\nBASE and CINAHL available through the National Library\nof Health website, the Cochrane library and PubMed dat-\nabases available online' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched the MEDLINE, EMBASE and CINAHL available through the National Library of Health website, the Cochrane library and PubMed databases available online.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.6%):\n\nwe\nsought to conduct a systematic review and meta-analysis,\ncombining our data with existing literature, in order to\nidentify any differences in outcome measures across all\nidentified comparative studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We aimed to conduct a systematic review and meta-analysis, combining our data with existing literature, in order to identify any differences in outcome measures across all identified comparative studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nTwo researchers independently screened\nthe title and abstract of identified articles for potential eligi-\nbility and retrieved the full-text version of all articles deemed\nrelevant' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently screened the title and abstract of identified articles for potential eligibility and retrieved the full-text version of all articles deemed relevant.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThe Ovid (Ovid Technologies New York, NY) and Medline search en-\ngines were used to examine both the Pubmed and Cochrane libraries\nfrom January 2000 to December 2008' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Ovid (Ovid Technologies New York, NY) and Medline search engines were used to examine both the Pubmed and Cochrane libraries from January 2000 to December 2008.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 66.7%):\n\nratio, difference' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Odds ratio, mean difference&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTwo authors reviewed all the abstracts independently.\nAgreement regarding potential relevance was reached by\nconsensus. Full-text copies of potentially eligible papers\nwere obtained, and the same 2 reviewers independently ex-\ntracted relevant data on study characteristics and the out-\ncomes of interest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors reviewed all the abstracts independently. Agreement regarding potential relevance was reached by consensus. Full-text copies of potentially eligible papers were obtained, and the same 2 reviewers independently extracted relevant data on study characteristics and the outcomes of interest.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.3%):\n\nMedline, Embase, Cinahl, and\nCochrane databases were searched electronically on April\n24, 2014, and then updated on May 11, 2015' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎PubMed, Embase, Cinahl, and Cochrane databases were searched electronically on April 24, 2014, and then updated on May 11, 2015.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nTwo independent authors (DT and BA) assessed study\nquality using the Newcastle-Ottawa Scale for case–\ncontrol and cohort studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two independent authors (DT and BA) assessed study quality using the Newcastle-Ottawa Scale for case–control and cohort studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.1%):\n\nRandom-effects models\nwere used when there was significant' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Random-effects models were used when there was significant heterogeneity.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 91.4%):\n\nC T\nBackground\nMinimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Abstract. Background. Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):\n\nBackground\nMinimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Background. Minimally invasive surgery (MIS) is an accepted surgical technique for the treatment of a variety of benign diseases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.4%):\n\nTo ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intra-\nabdominal or intra-thoracic neoplasms in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To ascertain differences in outcome between the minimally invasive and open surgical approaches for the treatment of solid intra-abdominal or intra-thoracic neoplasms in children.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe exact search strategy for each data-\nbase is detailed in Appendix 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The exact search strategy for each database is detailed in Appendix 1.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe exact search strategy for each data-\nbase is detailed in Appendix 1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The exact search strategy for each database is detailed in Appendix 1.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nPatient cohort\nIn total, 4,022 patients were included. Of these, 1,632\nchildren (41%) were male patients. Reported ages ranged\nfrom o1 month to 18 years. Bilateral tumors were present\nin 1,153 (29%) patients, including at least 4 metachronous\ncontralateral tumors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patient cohort: In total, 4,022 patients were included. Of these, 1,632 children (41%) were male patients. Reported ages ranged from o1 month to 18 years. Bilateral tumors were present in 1,153 (29%) patients, including at least 4 metachronous contralateral tumors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nA systematic literature search was conducted in the PubMed,\nEmbase, and Web of Science databases with the help of an\nexperienced librarian. The general search terms were the\nsame for the three databases, which are as follows: anorectal\nmalformations, Hirschsprung disease, colostomy, and chil-\ndren' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic literature search was conducted in the PubMed, Embase, and Web of Science databases with the help of an experienced librarian. The general search terms were the same for the three databases, which are as follows: anorectal malformations, Hirschsprung disease, colostomy, and children.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nMethodological quality was assessed with the checklist pro-\nposed by Downs and Black,\n5 \nwith a maximum score of 32 for\nthe optimal study quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Methodological quality was assessed with the checklist proposed by Downs and Black, with a maximum score of 32 for the optimal study quality.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\ntwo investigators selected the articles independently,\nextracted literature data, and recorded them in purpose-\ndesigned forms' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two investigators selected the articles independently, extracted literature data, and recorded them in purpose-designed forms.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nData extraction forms will be designed to include study design, participant characteristics, study\nsetting, intervention type and outcomes. Data will be extracted independently by two review au-\nthors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data extraction forms will be designed to include study design, participant characteristics, study setting, intervention type and outcomes. Data will be extracted independently by two review authors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTwo reviewers independently assessed each included\nstudy and compared the scores for each item on the ap-\nplicable quality assessment tool to reach a consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two reviewers independently assessed each included study and compared the scores for each item on the applicable quality assessment tool to reach a consensus.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.4%):\n\nWe used the following search terms: ‘‘Cryp-\ntorchidism’’ AND ‘‘Intra-abdominal’’ OR ‘‘Abdomen/ab-\ndominal cavity/inguinal canal/groin' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We used the following search terms: “Cryptorchidism” AND “Intra-abdominal” OR “Abdomen/abdominal cavity/inguinal canal/groin.”&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nWe summarized the results, with an\nemphasis on higher-quality evidence; we considered SRs to\nbe the highest quality evidence, followed by RCTs, and\nnon-randomized studies [21], taking the results of our\nquality assessment into consideration' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We summarized the results, with an emphasis on higher-quality evidence; we considered SRs to be the highest quality evidence, followed by RCTs, and non-randomized studies, taking the results of our quality assessment into consideration.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 78.2%):\n\nand quality assessed each\nrelevant study using AMSTAR for systematic reviews\n(SRs), Cochrane ‘Risk of bias’ tool for randomized con-\ntrolled trials (RCTs), and MINORS for non-randomized\nstudies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We used AMSTAR to assess the quality of all relevant systematic reviews (SRs)...the Cochrane ‘Risk of bias’ tool for randomized controlled trials (RCTs)...and MINORS for non-randomized studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nTo miti-\ngate the potential bias related to the inclusion of non-ran-\ndomized studies, we took into consideration each study’s\nquality assessment results when drawing conclusions and\nmaking recommendations' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To mitigate the potential bias related to the inclusion of non-randomized studies, we took into consideration each study’s quality assessment results when drawing conclusions and making recommendations.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.7%):\n\nsearch strategy for at least one database, including any limits used, such that it could be repeated.\nP9. State the process for selecting studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Search strategies for MEDLINE, EMBASE and Cochrane were designed to capture all relevant studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nThe Medline (1990eDec 2009), Embase (1990eDec 2009) and\nCochrane databases were searched using the single search\nterm ‘hypospadias’ to ensure the broadest capture of rele-\nvant papers' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The Medline (1990eDec 2009), Embase (1990eDec 2009) and Cochrane databases were searched using the single search term ‘hypospadias’ to ensure the broadest capture of relevant papers.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.3%):\n\nOur search yielded 288 citations, of which 11 (622 patients) met\ninclusion criteria and were incorporated into the systematic review. Most\nseries were retrospective observational studies of moderate or low method-\nological quality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Our search yielded 288 citations, of which 11...met inclusion criteria and were incorporated into the systematic review. Most series were retrospective observational studies of moderate or low methodological quality.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.5%):\n\nFull text\nreview and application of eligibility criteria led to ex-\nclusion of 17 studies, leaving 11 for inclusion in our\nsystematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Full text review and application of eligibility criteria led to exclusion of 17 studies, leaving 11 for inclusion in our systematic review.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.1%):\n\nCritical appraisal of the included studies was carried out\nby 2 independent reviewers using a quality assessment\ninstrument adopted from Elyas et al,\n14 \nmodified to fit the\nobjectives of this study (see Appendix). All discrepancies\nwere resolved through third-party review of the method-\nology' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Critical appraisal of the included studies was carried out by 2 independent reviewers using a quality assessment instrument...All discrepancies were resolved through third-party review of the methodology.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.4%):\n\nTo most accurately esti-\nmate the true complication rate, we excluded scar-\nring from our analysis, as it was not reported in the\nother included studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[To most accurately estimate the true complication rate, we excluded scarring from our analysis, as it was not reported in the other included studies.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.8%):\n\nHeterogeneity between\nstudies was tested using the Cochran chi-square Q test\nwith a p value set at 0.1 and quantified using the I \n2\nstatistic' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎[Heterogeneity between studies was tested using the Cochran chi-square Q test with a p value set at 0.1 and quantified using the I2 statistic.]&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.7%):\n\nWe hypoth-\nesized that PHS would improve surgical outcomes in\npatients with hypospadias' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We hypothesized that PHS would improve surgical outcomes in patients with hypospadias.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 81.7%):\n\nThe aim of this review was to critique the current literature to\ndetermine the efficacy of LH.\nMeth' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎The aim of this review was to critique the current literature to determine the efficacy of LH in the repair of PIH.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nAll published studies until July 30, 2010, were\nsearched with the terms laparoscopy, laparoscopic her-\nniorrhaphy, pediatric inguinal hernia, and open hernior-\nrhaphy from Medline (using PubMed as the search\nengine), Embase, Ovid, Web of Science, and Cochrane\ndatabases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All published studies until July 30, 2010, were searched with the terms laparoscopy, laparoscopic herniorrhaphy, pediatric inguinal hernia, and open herniorrhaphy from Medline, Embase, Ovid, Web of Science, and Cochrane databases.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 93.9%):\n\nin this systemic review and meta-\nanalysis, we demonstrated that' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎In this systemic review and meta-analysis, we demonstrated that...&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 77.2%):\n\nA systematic literature search was performed to identify\narticles that reported the children and infants with POI' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic literature search was performed to identify articles that reported the children and infants with POI since 1990 in English-language.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97%):\n\nMEDLINE electronic\ndatabase was searched in April 2013 using key words\n‘‘postoperative intussusception’’. References lists of iden-\ntified articles were screened for additional publications of\ninterest' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎MEDLINE electronic database was searched in April 2013 using key words ‘postoperative intussusception’.\" \"References lists of identified articles were screened for additional publications of interest.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nPapers with pertinent titles\nwere systematically identified by searching the following sources: AMED,\nPubMed, MEDLINE, Cochrane, EMBASE, Africa-wide information, Biosys,\nGlobal Health, LLAOS, and Web of Science in November 2014 with no\ndate or language restrictions' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Papers were systematically identified by searching the following sources: AMED, PubMed, MEDLINE, Cochrane, EMBASE, Africa-wide information, Biosys, Global Health, LLAOS, and Web of Science in November 2014 with no date or language restrictions.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.5%):\n\nTwo authors independently extracted data from the list of\nthe included studies, and a third reviewer was required for\na final decision in the case of any discrepancies' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.\"  \"Two authors independently extracted data from the list of the included studies, and a third reviewer was required for a final decision in the case of any discrepancies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 65.7%):\n\nods\nSearch strategy\nAn electronic search was performed using EMBASE,\nPubMed, MEDLINE from 2000 to 2014' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎At least two electronic sources should be searched.\" \"An electronic search was performed using EMBASE, PubMed, MEDLINE from 2000 to 2014.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 62%):\n\nA list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎A list of included and excluded studies should be provided.\" \"References, reviews and meta-analyses were then scanned for additional articles.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 70.3%):\n\nProvide a structured summary' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎Abstract provides structured summary.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe performed a literature search of the PubMed data-\nbase (National Library of Medicine, Bethesda, MD, USA)\nthat covered the period from 1966 to December 2013. The\nsearch conducted for Embase and the Cochrane Central\nRegister of Controlled Trials was restricted to English-\nlanguage literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a literature search of the PubMed database (National Library of Medicine, Bethesda, MD, USA) that covered the period from 1966 to December 2013. The search conducted for Embase and the Cochrane Central Register of Controlled Trials was restricted to English-language literature.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nTable 1 shows the detail informa-\ntion of all the trials' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Table 1 shows the detail information of all the trials.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):\n\nThe previous two sets of\npooled data both showed good homogeneity among the\ninvolved trials. Thus, fixed models were applied for anal-\nysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The previous two sets of pooled data both showed good homogeneity among the involved trials. Thus, fixed models were applied for analysis.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 80.6%):\n\nConflict of interest YZ declare' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Conflict of interest: None declared.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 78%):\n\ne: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎Abstract provides background, objectives, data sources, eligibility criteria, outcomes, results, conclusions.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTo compare the safety and efficacy of MIS with tradi-\ntional surgical approach for CDH, we performed an\nappropriate meta-analysis of the related studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To compare the safety and efficacy of MIS with traditional surgical approach for CDH, we performed an appropriate meta-analysis of the related studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nThe\noutcomes, which include post-operative mortality, inci-\ndence of hernia recurrence, rates of patch use and com-\nplications, were analyzed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The outcomes, which include post-operative mortality, incidence of hernia recurrence, rates of patch use and complications, were analyzed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nStudies that met all the following criteria were included in\nthe meta-analysis: (1) the trial was a randomized or non-\nrandomized clinical trial; (2) the study was designed to\ncompare surgical outcomes of neonates with CDH between\nMIS intervention and open procedures; and (3) data on\n& L. Liu\nlunxu_liu@aliyun.com\n1 \nDepartment of Thoracic Surgery, West China Hospital,\nSichuan University, No 37, Guo Xue Xiang,\n610041 Chengdu, People’s Republic of China\n2 \nDepartment of Pediatric Surgery, West China Hospital,\nSichuan University, 610041 Chengdu,\nPeople’s Republic of China\n123\nHernia (2016) 20:297–302\nDOI 10.1007/s10029-015-1423-0\n\nincidence of mortality, recurrence, patch use, and surgical\ncomplication rate were fully or partially reported' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Studies that met all the following criteria were included in the meta-analysis: (1) the trial was a randomized or non-randomized clinical trial; (2) the study was designed to compare surgical outcomes of neonates with CDH between MIS intervention and open procedures; and (3) data on incidence of mortality, recurrence, patch use, and surgical complication rate were fully or partially reported.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe performed a literature search of the PubMed data-\nbase (National Library of Medicine, Bethesda, MD, USA)\nthat covered the period from 1966 to December 2013. The\nsearch conducted for Embase and the Cochrane Central\nRegister of Controlled Trials was restricted to English-\nlanguage literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a literature search of the PubMed database (National Library of Medicine, Bethesda, MD, USA) that covered the period from 1966 to December 2013. The search conducted for Embase and the Cochrane Central Register of Controlled Trials was restricted to English-language literature.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nDichotomous out-\ncomes were expressed in relative risk (RR) with their 95 %\nconfidence interval (CI) values' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Dichotomous outcomes were expressed in relative risk (RR) with their 95% confidence interval (CI) values.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nTable 1 shows the detail informa-\ntion of all the trials' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Table 1 shows the detail information of all the trials.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 84%):\n\nprospective clinical trials are needed to evaluate these two\nsurgical techniques' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎High-quality prospective clinical trials are needed to evaluate these two surgical techniques.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 80.6%):\n\nConflict of interest YZ declare' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Conflict of interest: None declared.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.4%):\n\nSearches were conducted in PubMed,\nEmbase, ISI Web of Science and the Cochrane Library to 6\nSeptember 2010. Hand-searching of the bibliographies of\narticles and reviews identified was also conducted' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We searched PubMed, ISI Web of Science, Embase and the Cochrane Library to 6 September 2010. Hand-searching of the bibliographies of articles and reviews identified was also conducted.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nArticles with an abstract in English and full text in\nDanish, English, French, or Norwegian language were eli-\ngible. In addition, subjects had to be \u000219 years of age. At\nleast one postoperative weight loss measure had to be\nreported, with a minimum follow-up time of 1 year post\nsurgery' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Articles with an abstract in English and full text in Danish, English, French, or Norwegian language were eligible. In addition, subjects had to be ≤19 years of age. At least one postoperative weight loss measure had to be reported, with a minimum follow-up time of 1 year post surgery.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.4%):\n\nSearches were conducted in PubMed,\nEmbase, ISI Web of Science and the Cochrane Library to 6\nSeptember 2010. Hand-searching of the bibliographies of\narticles and reviews identified was also conducted' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We searched PubMed, ISI Web of Science, Embase and the Cochrane Library to 6 September 2010. Hand-searching of the bibliographies of articles and reviews identified was also conducted.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 74.9%):\n\nand\nperformed in humans. In addition to Medline and PubMed, a manual search of the Journal of Pediatric\nSurgery, Pediatric Surgery International, Surgical Endoscopy, and the Journal of Laparoendoscopic &\nAdvanced Surgical Techniques published between June 2000 and April 2008 was conducted' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎The search terms used were “laparoscopic,” “pull-through,” “anorectal malformation,” and “imperforate anus.” In addition to Medline and PubMed, a manual search of the Journal of Pediatric Surgery, Pediatric Surgery International, Surgical Endoscopy, and the Journal of Laparoendoscopic & Advanced Surgical Techniques published between June 2000 and April 2008 was conducted.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nOur current under-\nstanding is that LAARP is predominantly indicated for\npatients with “high/intermediate” ARM. A second example\nlies with the wide variation of actual outcomes reported by\neach study. As discussed above, 10 different outcomes were\nreported in the 17 studies, and only 4 studies attempted\ncomparisons of outcomes' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Our current understanding is that LAARP is predominantly indicated for patients with “high/intermediate” ARM. A second example lies with the wide variation of actual outcomes reported by each study. As discussed above, 10 different outcomes were reported in the 17 studies, and only 4 studies attempted comparisons of outcomes.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 89%):\n\nA systematic search of the MEDLINE, PUBMED, and\nCochrane databases (June 2000 to April 2008) was\nconducted. The search terms used were “laparoscopic,”\n“pull-through,” “anorectal malformation,” and “imperforate\nanus.” In addition, a manual search of 4 surgical journals\nfrom the same period was performed. The journals searched\nwere “The Journal of Pediatric Surgery,” “Pediatric Surgery\nInternational,” “Surgical Endoscopy,” and “Journal of\nLaparoendoscopic & Advanced Surgical Techniques.”\nMoreover, a careful review of references of all included\narticles was conducted' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic search of the MEDLINE, PUBMED, and Cochrane databases (June 2000 to April 2008) was conducted. The search terms used were “laparoscopic,” “pull-through,” “anorectal malformation,” and “imperforate anus.” In addition to Medline and PubMed, a manual search of the Journal of Pediatric Surgery, Pediatric Surgery International, Surgical Endoscopy, and the Journal of Laparoendoscopic & Advanced Surgical Techniques published between June 2000 and April 2008 was conducted.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTo address this issue, we reviewed our experience at a level 1 trauma\ncenter and report the largest analysis over the past 25 years. In conjunc-\ntion, we performed a systematic review of all published reports\nregarding pediatric EDT to help identify the factors associated with\nmorbidity and mortality' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To address this issue, we reviewed our experience at a level 1 trauma center and report the largest analysis over the past 25 years. In conjunction, we performed a systematic review of all published reports regarding pediatric EDT to help identify the factors associated with morbidity and mortality.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 89.3%):\n\n? The research question and inclusion criteria should be established before the conduct of the review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] The research question and inclusion criteria are not established before the conduct of the review.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44%):\n\ne study selection and data extraction' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Two investigators independently performed study selection and data extraction.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 47.9%):\n\nn. Multiple search strategies were used to\nidentify relevant articles from Medline, Embase, Cinahl, the Cochrane library, and Google\nscholar,' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Multiple databases were searched, including Medline, Embase, Cinahl, Cochrane library, and Google scholar. Reference lists were hand searched. No language or geographical restrictions.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 63.5%):\n\nno restrictions were made on\nthe basis of study language' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] No restrictions were made based on publication status, language etc.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.1%):\n\nincluded and excluded studies should be provided. No' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] A flow diagram showing included and excluded studies is provided in Fig. 1.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 42.3%):\n\nstudy characteristics' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Study characteristics are provided in Table 2.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 54.2%):\n\nMethodological quality and risk of bias were assessed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[No] The methodological quality and risk of bias of included studies were not formally assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 68.9%):\n\nthe scientific quality of the included studies assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] The quality of studies was not assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.8%):\n\ncribe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.\nA10. Was the' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Fixed effect meta-analysis was used as no statistical heterogeneity was detected. Heterogeneity was assessed with the chi-squared test.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 76.9%):\n\npublication bias could not be assessed' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[No] Publication bias was not assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 49.3%):\n\nthe included studies,\nwhere it was reported' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[No] Conflicts of interest for the included studies are not reported.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60%):\n\nthe report as a systematic review, meta-analysis, or both' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The report is identified as a systematic review and meta-analysis in the title.&quot;<\/span>","<span title='Moderate quote deviation. Best match in prompt (Similarity 79.6%):\n\na structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ff9e81'>&quot;‎[Yes] A structured abstract is provided summarizing background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, results, limitations, and conclusions.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 25%):\n\nscribe the rationale for the review' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The introduction provides context about the lack of consensus on optimal management of gastroschisis and the rationale for the review.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 67.9%):\n\nthe following participants and interventions, and at least one of the outcomes of interest.\nParticipants\nStudies were included if the' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] The participants, interventions, comparisons, and outcomes of interest are described in the methods.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.1%):\n\n. The protocol was registered\non the Prospero International Prospective Regist' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] The protocol was registered on PROSPERO and the registration number is provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 60.6%):\n\nwere included if they comprised\nthe following participants and interventions, and at least one of the outcomes' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Inclusion and exclusion criteria for participants, interventions, and outcomes are specified.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.7%):\n\ninformation sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Information sources (databases) and search strategy are described. The last date searched is reported.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 53.3%):\n\nsearch strategy for at least one database, in' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] The full search strategy for databases is not provided.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 49.5%):\n\nprocess for selecting studies (i.e., screening, eligibility, included' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Study selection process, including screening and assessing eligibility, is described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 68.9%):\n\nextracted independently by the same two investigators (BA and WT), and any differences\nresolved by discussion' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Data extraction was performed independently by two authors, with differences resolved by discussion.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 39.4%):\n\nc reviews and are tasked to assess the method' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Outcomes extracted are listed and defined in the methods section.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 43.2%):\n\nmethods used for assessing risk of bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Methods for assessing risk of bias/methodological quality are not described.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 44.2%):\n\nmean differences\nand 95% confidence intervals.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Odds ratios, mean differences, and 95% confidence intervals are described as the summary measures.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 34.8%):\n\nheterogeneity was used to assess the extent to which\nthe results' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Fixed effect meta-analysis was used to pool results. Heterogeneity was assessed with chi-squared test and I2.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 57.4%):\n\nassessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Assessment of publication bias was not performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.1%):\n\nl analyses were performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[NA] No additional analyses were performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 72.9%):\n\ne numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The number of records identified, screened, assessed for eligibility, and included are reported in a flow diagram (Fig. 1).&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 36.5%):\n\nStudy Characteristics.\nStudy Sett' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[Yes] Study characteristics are presented in Table 2 along with citations.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 58.6%):\n\nrisk of bias of individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[No] Risk of bias for individual studies was not assessed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 18%):\n\nof individual studies' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] For primary and secondary outcomes, data from individual studies and pooled estimates are presented in forest plots.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 65.2%):\n\nent results of each meta-analysis done, including confidence intervals and m' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Results of the meta-analyses are presented with confidence intervals and I2 values.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 60.4%):\n\nassessment of publication bias' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[NA] No assessment of publication bias was performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 58.1%):\n\nl analyses were performed' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎[NA] No additional analyses were performed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 41.7%):\n\nthe main findings including the strength of evidence' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The main findings are summarized in the discussion, along with comments about the quality of evidence.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 59.6%):\n\nlimitations at study and outcome level (e.g., risk of bias), and at review-level (' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Limitations at the study level (risk of bias) and review level (heterogeneity) are discussed.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 44.4%):\n\ns “the results should be interpreted with c' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] The results are interpreted in the context of existing literature.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in prompt (Similarity 48.7%):\n\nsources of funding' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: red'>&quot;‎[Yes] Sources of funding are described.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nRetrieved articles were assessed for eligibility and data on\npatients, intervention, control, outcomes and methodolog-\nical quality were abstracted independently by two authors' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Retrieved articles were assessed for eligibility and data on patients, intervention, control, outcomes and methodological quality were abstracted independently by two authors.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98%):\n\nA Medline, Embase, and web of science searches were performed\nusing the keywords recurrent tracheoesophageal fistula. The\nindex of all issues of the European Journal of Pediatric Surgery,\nJournal of Pediatric Surgery, Pediatric Surgery International, and\nthe International Journal of Pediatric Otorhinolaryngology was\nsearched for relevant articles; the reference list of all relevant\narticles was also searched. All English language articles pub-\nlished by August 2013, irrespective of design, describing the\nmanagement of, and outcome after, RTEF in children under\n18 years were reviewed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A Medline, Embase, and web of science searches were performed using the keywords “recurrent tracheoesophageal fistula.” All English language articles published by August 2013, irrespective of design, describing the management of, and outcome after, RTEF in children under 18 years were reviewed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.3%):\n\nThis report evalu-\nates the available literature summarizing complication rates and re-\nsource utilization for gastrostomy techniques in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎This report evaluates the available literature summarizing complication rates and resource utilization for gastrostomy techniques in children.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.9%):\n\ncomplica-\ntion resulting in death or requiring operative management within one\nyear — our working definition of a major complication. Secondary out-\ncomes included: other reported complications and a comparison of re-\nsource utilization between the techniques (including operative time\nand cost' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Major complications were defined as reoperation within 1 year or death. Secondary outcomes included: other reported complications and a comparison of resource utilization between the techniques (including operative time and cost).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThe current literature was screened for publications regard-\ning the application of Mitomycin C in esophageal stenosis and\nstricture with special emphasis on pediatric data' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The current literature was screened for publications regarding the application of Mitomycin C in esophageal stenosis and stricture with special emphasis on pediatric data.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 75.9%):\n\ntreated, indication, description of stricture, technique of\napplication, dosage, number of and interval between appli-\ncations, complications, and outcome' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Data were collected on the patient population treated, indication, description of stricture, technique of application, dosage, number of and interval between applications, complications, and outcome.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nThe current literature was screened for publications regard-\ning the application of Mitomycin C in esophageal stenosis and\nstricture with special emphasis on pediatric data. The screen\nincluded the use of Mitomycin C in other subspecialties such\nas ophthalmology; ear, nose, and throat surgery; as well as\nanimal models' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The current literature was screened for publications regarding the application of Mitomycin C in esophageal stenosis and stricture with special emphasis on pediatric data. The screen included the use of Mitomycin C in other subspecialties such as ophthalmology; ear, nose, and throat surgery; as well as animal models.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nA computerized compre-\nhensive search supplemented by a manual\nreview of the literature was performed for all\npeer-reviewed publications' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A computerized comprehensive search supplemented by a manual review of the literature was performed for all peer-reviewed publications...&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nAll available electronic databases including the Brit-\nish Nursing Index (BNI), Cumulative Index to Nursing and Allied\nHealth Literature (CINAHL), Cochrane Library, EMBASE (Excerpta\nMedica), Intute: Health & Life Sciences, MEDLINE, PubMed, BIO-\nSIS Previews, ISI Web of Knowledge, ISI Web of Science and Igen-\ntaConnect, were systematically searched for each procedure,\nbetween the period 1992 – 2009 for all English and non– English\nlanguage articles' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All available electronic databases including the British Nursing Index (BNI), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, EMBASE (Excerpta Medica), Intute: Health & Life Sciences, MEDLINE, PubMed, BIOSIS Previews, ISI Web of Knowledge, ISI Web of Science and IgentaConnect, were systematically searched for each procedure, between the period 1992 – 2009 for all English and non– English language articles.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nTwo\nauthors independently screened the abstracts and extrac-\ntion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nThe indexed reference libraries EMBASE and Medline were\nsearched between January 1955 and January 2013 using\nthe search terms presented in Table 1, using mapped and\nexploded terms. Additionally, the references of all included\nstudies, the Cochrane Library and the titles of papers pub-\nlished in the journal Obesity Surgery from January 1992 till\nJanuary 2013 were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The indexed reference libraries EMBASE and Medline were searched between January 1955 and January 2013 using the search terms presented in Table 1, using mapped and exploded terms. Additionally, the references of all included studies, the Cochrane Library and the titles of papers published in the journal Obesity Surgery from January 1992 till January 2013 were searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nFindings from the meta-\nanalysis of change in BMI at 12 months post-operatively\nare shown in Fig. 2. The average weighted mean BMI dif-\nference from baseline to 1 year was -13.5 kg m\n-2 \n(95%\nconfidence interval [CI] -15.1, -11.9). There was strong\nevidence of heterogeneity among the studies (I\n2 \n= 76.1%\nand P < 0.001), largely because of the differences among\nsurgery types and populations' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Findings from the meta-analysis of change in BMI at 12 months post-operatively are shown in Fig. 2. The average weighted mean BMI difference from baseline to 1 year was -13.5 kg m-2 (95% confidence interval [CI] -15.1, -11.9). There was strong evidence of heterogeneity among the studies (I2 = 76.1% and P < 0.001), largely because of the differences among surgery types and populations.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99.1%):\n\nA systematic literature search (1955–2013) was performed to examine adjust-\nable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic\ndiversions operations among obese children and adolescents' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic literature search (1955–2013) was performed to examine adjustable gastric band, sleeve gastrectomy, Roux-en-Y gastric bypass or biliopancreatic diversions operations among obese children and adolescents.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nIn total, 637 patients from 23 studies were included in the meta-analysis. There\nwere significant decreases in BMI at 1 year (average weighted mean BMI differ-\nence: -13.5 kg m\n-2\n; 95% confidence interval [CI] -14.1 to -11.9' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In total, 637 patients from 23 studies were included in the meta-analysis. There were significant decreases in BMI at 1 year (average weighted mean BMI difference: -13.5 kg m-2; 95% confidence interval [CI] -14.1 to -11.9).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nThe indexed reference libraries EMBASE and Medline were\nsearched between January 1955 and January 2013 using\nthe search terms presented in Table 1, using mapped and\nexploded terms. Additionally, the references of all included\nstudies, the Cochrane Library and the titles of papers pub-\nlished in the journal Obesity Surgery from January 1992 till\nJanuary 2013 were searched' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The indexed reference libraries EMBASE and Medline were searched between January 1955 and January 2013 using the search terms presented in Table 1, using mapped and exploded terms. Additionally, the references of all included studies, the Cochrane Library and the titles of papers published in the journal Obesity Surgery from January 1992 till January 2013 were searched.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nTwo\nauthors independently screened the abstracts and extrac-\ntion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.3%):\n\nTwo\nauthors independently screened the abstracts and extrac-\ntion was verified by a second author (JAB and RKS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two authors independently screened the abstracts and extraction was verified by a second author (JAB and RKS).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nFindings from the meta-\nanalysis of change in BMI at 12 months post-operatively\nare shown in Fig. 2. The average weighted mean BMI dif-\nference from baseline to 1 year was -13.5 kg m\n-2 \n(95%\nconfidence interval [CI] -15.1, -11.9' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Findings from the meta-analysis of change in BMI at 12 months post-operatively are shown in Fig. 2. The average weighted mean BMI difference from baseline to 1 year was -13.5 kg m-2 (95% confidence interval [CI] -15.1, -11.9).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nCurrent guidelines suggest that paediatric-adolescent\nbariatric care should be handled within the controlled and\nrestricted setting of a multidisciplinary team. However,\nlong-term, prospectively designed studies, with clear inclu-\nsion criteria and reporting of effects, side effects, compli-\ncations and co-morbidity resolution, alongside measures of\nHRQol, are needed to more firmly establish the harms and\nbenefits of bariatric surgery in children and adolescents' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Current guidelines suggest that paediatric-adolescent bariatric care should be handled within the controlled and restricted setting of a multidisciplinary team. However, long-term, prospectively designed studies, with clear inclusion criteria and reporting of effects, side effects, complications and co-morbidity resolution, alongside measures of HRQol, are needed to more firmly establish the harms and benefits of bariatric surgery in children and adolescents.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe first reviewed the results of the different straighten-\ning procedures, then the crude complication rates (overall\ncomplication, fistula/dehiscence, stricture/stenosis rates) of\nthe different urethroplasty techniques' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We first reviewed the results of the different straightening procedures, then the crude complication rates (overall complication, fistula/dehiscence, stricture/stenosis rates) of the different urethroplasty techniques.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nWe performed a systematic review of the literature on preputial recon-\nstruction (PR) during hypospadias repair to determine the cumulative risk of preputial\nskin complications and the influence of PR on urethroplasty complications, namely,\nfistula formation and overall reoperation rate of the repair' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We performed a systematic review of the literature on preputial reconstruction (PR) during hypospadias repair to determine the cumulative risk of preputial skin complications and the influence of PR on urethroplasty complications, namely, fistula formation and overall reoperation rate of the repair.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nTwo researchers\nindependently performed each level of screening, compar-\ning the selected studies to reach a consensus. If a consensus\ncould not be reached, they consulted a third researcher' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently performed each level of screening, comparing the selected studies to reach a consensus. If a consensus could not be reached, they consulted a third researcher.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe conducted electronic searches of the Cochrane Central\nRegister of Controlled Trials (CENTRAL), MEDLINE\n(1966 onwards), Embase (1980 onwards), and CINAHL\n(1982 onwards) to find relevant articles. We used the fol-\nlowing search terms: ‘‘Cryptorchidism’’ AND ‘‘Orchido-\npexy’’ AND ‘‘timing’’ OR ‘‘age’’. We included only\nEnglish publications and studies pertaining to humans and\nmales. We also excluded any editorials and case reviews.\nWe hand-searched the reference sections of relevant arti-\ncles for additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We conducted electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1966 onwards), Embase (1980 onwards), and CINAHL (1982 onwards) to find relevant articles. We used the following search terms: ‘‘Cryptorchidism’’ AND ‘‘Orchidopexy’’ AND ‘‘timing’’ OR ‘‘age’’. We included only English publications and studies pertaining to humans and males. We also excluded any editorials and case reviews. We hand-searched the reference sections of relevant articles for additional studies.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.3%):\n\nwe have evaluated each non-RCT using\nthe MINORS assessment tool. This scale contains items\nthat address various potential sources of bias. As higher\nscores are indicative of greater methodological quality and\nlower risk of bias, we have based our results on only the\nhighest-rated studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎We have evaluated each non-RCT using the MINORS assessment tool. This scale contains items that address various potential sources of bias. As higher scores are indicative of greater methodological quality and lower risk of bias, we have based our results primarily on only the highest-rated studies.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 66.3%):\n\nWe included all studies that examined the effect of age at\norchiopexy on fertility or malignancy, even if these out-\ncomes were not the primary focus. If we deemed a study\nrelevant based on the title and abstract, we obtained the full\ntext article to further screen for relevance.' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎We included all studies that examined the effect of age at orchiopexy on fertility or malignancy, even if these outcomes were not the primary focus. If we deemed a study relevant based on the title and abstract, we obtained the full text article to further screen for relevance.\" And \"We included only English publications and studies pertaining to humans and males. We also excluded any editorials and case reviews.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nTwo researchers independently assessed each study for method-\nological quality using MINORS' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Two researchers independently assessed each study for methodological quality using MINORS.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nPatients\nwith age greater than 18 years undergoing standard lapa-\nroscopic or LESS surgery, undergoing surgery for ureteral\nstricture, with horseshoe kidney, or with vesicoureteral\nreflux were excluded for analysis' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Patients with age greater than 18 years undergoing standard laparoscopic or LESS surgery, undergoing surgery for ureteral stricture, with horseshoe kidney, or with vesicoureteral reflux were excluded for analysis.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 89.9%):\n\nTwo authors\n(Hsu and Chang) of the current study independently\nsearched and reviewed the articles. When discrepancies\noccurred over the results, discussions with a third author\n(Yang) were made to reach a consensus' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Two authors of this paper, Hsu and Chang, independently searched and reviewed the articles. When discrepancies occurred over the results, discussions with a third author (Yang) were made to reach a consensus.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.5%):\n\nWe searched PubMed \n® \nfor comparative studies (from Janu-\nary 1990 to 2014 September) that compared the efficacy\nand safety of robotic versus open pyeloplasty. Searches\nwere limited to studies published in English. We used the\nfollowing keywords: robotic, pyeloplasty, ureteropelvic\njunction obstruction, children, and pediatric' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched PubMed® for comparative studies (from January 1990 to 2014 September) that compared the efficacy and safety of robotic versus open pyeloplasty. Searches were limited to studies published in English. We used the following keywords: robotic, pyeloplasty, ureteropelvic junction obstruction, children, and pediatric.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe searched all publications from August 1998 to March\n2012 in the MEDLINE, EMBASE and Cochrane library\ndatabases and the Cochrane Controlled Trials Register using\ndifferent combinations of the following terms: “Hirsch-\nsprung&#39;s disease,” “transanal,” “perineal approach,” “transab-\ndominal” and “pull-through.” The reference lists of the full\narticles were also manually searched to identify additional\neligible studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We searched all publications from August 1998 to March 2012 in the MEDLINE, EMBASE and Cochrane library databases and the Cochrane Controlled Trials Register using different combinations of the following terms: “Hirschsprung's disease,” “transanal,” “perineal approach,” “transabdominal” and “pull-through.” The reference lists of the full articles were also manually searched to identify additional eligible studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nTo compare the clinical outcomes of TERPT\nand TAB, we performed a systematic review and compre-\nhensive meta-analysis from indexed published literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎To compare the clinical outcomes of TERPT and TAB, we performed a systematic review and comprehensive meta-analysis from indexed published literature.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nThe purpose of this review\nwas to combine data from published series of endopyelot-\nomy in children to give an overview of outcomes for this\napproach to PUJO' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The purpose of this review was to combine data from published series of endopyelotomy in children to give an overview of outcomes for this approach to PUJO.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nMedline and Embase databases were searched using rele-\nvant key search terms (pelviureteric junction, ureter-\nopelvic junction, obstruction, paediatric, pediatric, child$,\nballoon, dilatation, endopyelotomy, open, laparoscopic,\npyeloplasty' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Medline and Embase databases were searched using relevant key search terms (pelviureteric junction, ureteropelvic junction, obstruction, paediatric, pediatric, child$, balloon, dilatation, endopyelotomy, open, laparoscopic, pyeloplasty).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 99%):\n\nsystematically analyse published\nliterature to give an overall success rate for endo-\npyelotomy in children' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎systematically analyse published literature to give an overall success rate for endopyelotomy in children&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.8%):\n\nuncertainty and controversy, we undertook a\nsystematic review of the available literature' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Based on uncertainty and controversy, we undertook a systematic review of the available literature&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nStatistical analysis was conducted using Review Manager\n®\nVersion 5.1.7 for Windows (The Cochrane Collaboration,\nSoftware Update, Oxford, UK) and STATA v.11 statistical\nanalysis software (StataCorp LP, TX, USA). A weighted\nrandom-effects model was used for all analyses' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Statistical analysis was conducted using Review Manager® Version 5.1.7 for Windows (The Cochrane Collaboration, Software Update, Oxford, UK) and STATA v.11 statistical analysis software (StataCorp LP, TX, USA). A weighted random-effects model was used for all analyses.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):\n\nDetermination of heterogeneity was\nundertaken using the chi-squared test (Cochran’s Q) and I\n2\nvalue; with I\n2 \n≥ 75% denoting high degree of statistically\nsignificant heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Determination of heterogeneity was undertaken using the chi-squared test (Cochran’s Q) and I2 value; with I2 ≥ 75% denoting high degree of statistically significant heterogeneity.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.1%):\n\nStatistical analysis was conducted using Review Manager\n®\nVersion 5.1.7 for Windows (The Cochrane Collaboration,\nSoftware Update, Oxford, UK) and STATA v.11 statistical\nanalysis software (StataCorp LP, TX, USA). A weighted\nrandom-effects model was used for all analyses' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Statistical analysis was conducted using Review Manager® Version 5.1.7 for Windows (The Cochrane Collaboration, Software Update, Oxford, UK) and STATA v.11 statistical analysis software (StataCorp LP, TX, USA). A weighted random-effects model was used for all analyses.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.8%):\n\nDetermination of heterogeneity was\nundertaken using the chi-squared test (Cochran’s Q) and I\n2\nvalue; with I\n2 \n≥ 75% denoting high degree of statistically\nsignificant heterogeneity' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Determination of heterogeneity was undertaken using the chi-squared test (Cochran’s Q) and I2 value; with I2 ≥ 75% denoting high degree of statistically significant heterogeneity.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nSystematic literature searches were undertaken of PubMed and\nEMBASE electronic databases using the following search strategy\n(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da\nVinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND\n(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-\nlescent”\n[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-\nal reflux”[MeSH' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases using the following search strategy (“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da Vinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND (“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Adolescent”[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophageal reflux”[MeSH]).&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.8%):\n\nSystematic literature searches were undertaken of PubMed and\nEMBASE electronic databases using the following search strategy\n(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da\nVinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND\n(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-\nlescent”\n[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-\nal reflux”[MeSH]). The search period was defined as June 2001 to June\n2013 inclusively. The primary search was supplemented with\nsearches of 1) PubMed related articles feature, 2) clinicaltrials.gov\nregistry using the keyword “fundoplication”, and 3) abstracts of the\nJournal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the Journal of Pediatric Surgery from 2002 to 2013.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nFollowing the advent of endoscopic surgery, a minimally invasive\napproach to this anti-reflux procedure is now increasingly favored as\nstandard of care [1].\nInitial reports of laparoscopic anti-reflux surgery in infants and\nchildren were published in the early 1990’s [2,3]. Almost ten years\nthereafter, robot-assisted minimally invasive surgery was first\ndescribed in these age groups [4,5], and fundoplication remains the\nmost prevalently reported application of this technology in pediatric\ngeneral surgery [6]. Robotic technology offers putative patient\nbenefits through a range of features that are felt to enhance the\nsurgeon’s ability to undertake minimally invasive surgery (MIS).\nThe role of robotic surgery in this setting remains unclear,\ngenerating a growing sentiment of polarized opinion amongst the\nsurgical community, which is without a well-defined evidence base' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Following the advent of endoscopic surgery, a minimally invasive approach to this anti-reflux procedure is now increasingly favored as standard of care [1]...The role of robotic surgery in this setting remains unclear, generating a growing sentiment of polarized opinion amongst the surgical community, which is without a well-defined evidence base.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92.8%):\n\nSystematic literature searches were undertaken of PubMed and\nEMBASE electronic databases using the following search strategy\n(“Surgery, Computer-Assisted”[MeSH] OR “robotics“[MeSH] OR “da\nVinci” OR “telerobotic” OR “telesurgery” OR “robotic surgery”) AND\n(“Pediatrics”[MeSH] OR “Infant”[MeSH] OR “Child”[MeSH] OR “Ado-\nlescent”\n[MeSH]) AND (“Fundoplication”[MeSH] OR “Gastroesophage-\nal reflux”[MeSH]). The search period was defined as June 2001 to June\n2013 inclusively. The primary search was supplemented with\nsearches of 1) PubMed related articles feature, 2) clinicaltrials.gov\nregistry using the keyword “fundoplication”, and 3) abstracts of the\nJournal of Pediatric Surgery' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Systematic literature searches were undertaken of PubMed and EMBASE electronic databases...The primary search was supplemented with searches of 1) PubMed related articles feature, 2) clinicaltrials.gov registry using the keyword “fundoplication”, and 3) abstracts of the Journal of Pediatric Surgery from 2002 to 2013.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 59.2%):\n\n. Determination of heterogeneity was\nundertaken using the χ\n2 \ntest (Cochran’s Q) and I \n2 \nvalu' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎A weighted random-effects model was used for all analyses.\" \"Determination of heterogeneity was undertaken using the χ2 test (Cochran’s Q) and I2 value.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.2%):\n\nThe search strategy was as\nfollows: (single-port or single-incision or single-access or\nsingle-site or single or one) AND (laparoscopic or\nlaparoscopy or minimal invasive surgery) AND (appendec-\ntomy or appendi' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The search strategy was as follows: (single-port or single-incision or single-access or single-site or single or one) AND (laparoscopic or laparoscopy or minimal invasive surgery) AND (appendectomy or appendix).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nWe evaluated whether single stage or 2-stage\nFSO results in greater testicular viability in chil-\ndren younger than 18 years with intra-abdominal\ntestes. The primary outcome was testicular viability,\nwhich was defined as adequate postoperative testic-\nular size and position in the scrotum' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We evaluated whether single stage or 2-stage FSO results in greater testicular viability in children younger than 18 years with intra-abdominal testes. The primary outcome was testicular viability, which was defined as adequate postoperative testicular size and position in the scrotum.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.4%):\n\nWe systematically searched PubMed for relevant\nstudies reported from 2005 to 2014 with the keywords\n“laparoscopic herniorrhaphy”, “pediatric inguinal hernia,”\nand “open herniorrhaphy.” Total reference lists of selected\narticles were also included' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords “laparoscopic herniotomy”, “pediatric inguinal hernia,” and “open herniotomy.” Total reference lists of selected articles were also included.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.1%):\n\nWe systematically searched PubMed for relevant\nstudies reported from 2005 to 2014 with the keywords\n“laparoscopic herniorrhaphy”, “pediatric inguinal hernia,”\nand “open herniorrhaphy.” Total reference lists of selected\narticles were also included. We limited our searches to the\npublications written in English' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎We systematically searched PubMed for relevant studies reported from 2005 to 2014 with the keywords “laparoscopic herniotomy”, “pediatric inguinal hernia,” and “open herniotomy.” Total reference lists of selected articles were also included. We limited our searches to the publications written in English.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nFive trials\nmet the total inclusion criteria and had no exclusion criteria\n(Fig. 1): Chan et al, \n28 \nKoivusalo et al, \n29 \nCelebi et al, \n30\nShalaby et al,\n31 \nand Saranga et al' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Five trials met the total inclusion criteria and had no exclusion criteria: Chan et al, Koivusalo et al, Celebi et al, Shalaby et al, and Saranga et al.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 90.5%):\n\nPubMed\nÒ \nand MEDLINE\nÒ \ndatabases were searched for all\nstudies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎PubMed® and MEDLINE® databases were searched for all studies...&quot;<\/span>","<span title='Minor quote deviation. Best match in prompt (Similarity 98.7%):\n\nAn assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test' style='border-bottom: 1px dashed #2780e3; color: #2780e3; background-color: #ffe9e2'>&quot;‎An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot) and/or statistical tests (e.g., Egger regression test).&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nThe objective of this study was to investigate the com-\nplications and long-term outcome in patients with LGEA\nmanaged by DPA based on a meta-analysis of the pub-\nlished literature' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The objective of this study was to investigate the complications and long-term outcome in patients with LGEA managed by DPA based on a meta-analysis of the published literature.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.5%):\n\nCommon electronic databases as MEDLINE\nÒ\n, EMBASE\nÒ\n,\nISI Web of Science \nSM \nand the Cochrane Library were\nsearched in December 2011 using a combination of the\nfollowing terms: ‘‘esophageal atresia’’, ‘‘long-gap’’ and\n‘‘delayed primary anastomosis' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Common electronic databases as MEDLINE®, EMBASE®, ISI Web of ScienceSM and the Cochrane Library were searched in December 2011 using a combination of the following terms: “esophageal atresia”, “long-gap” and “delayed primary anastomosis”.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.6%):\n\nA systematic PubMed search was performed to identify\npublications on outcome of children with HD, who under-\nwent either OPEN, L-TERPT, or TERPT' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications on outcome of children with HD, who underwent either OPEN, L-TERPT, or TERPT.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 94.8%):\n\nA systematic PubMed search was performed to identify\npublications on outcome of children with HD, who under-\nwent either OPEN, L-TERPT, or TERPT. This search was limited\nto the past 5 years (2008 to 2012) using the keywords\n“Hirschsprung” and “outcome.” Reference lists were screened\nfor additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎A systematic PubMed search was performed\"; \"Reference lists were screened for additional studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 95.1%):\n\nA total of 1,412 subjects with HD were included in this review\n(range: 10 to 192 patients per study). Of these, 387 patients\nunderwent open surgery for HD (OPEN), 481 children were\noperated on via L-TERPT, and 544 had a TERPT. The median\nnumber of patients in the OPEN group was n ¼ 24 compared\nwith n ¼ 25 in the L-TERPT/TERPT group. Median age at\nsurgery was 13 months in the OPEN group (range 3 to 42\nmonths) compared with 7 months in the L-TERPT/TERPT\ngroup (range 2 to 30 months). Statistical analysis of group\nsizes and age at surgery revealed no significant difference\n(p > 0.05). Median follow-up was significantly longer in the\nOPEN group' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A total of 1,412 subjects with HD were included in this review\"; \"Median age at surgery was 13 months in the OPEN group\"; \"Median follow-up was significantly longer in the OPEN group.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56.8%):\n\nAbstract \nIntroduction' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎Abstract. Introduction...Conclusions.&quot;<\/span>","<span title='Moderate quote deviation. Best match in fulltext (Similarity 92%):\n\nTherefore, the aim of this study was to review the available\ndata on long-term functional results in HD patients operated\nwith conventional transabdominal pull-through (OPEN) com-\npared with transanal approaches with and without laparos-\ncopy (laparoscopic-assisted transanal-endorectal pull-\nthrough [L-TERPT] and transanal-endorectal pull-through\n[TERPT]) reported in the recent literature' style='border-bottom: 1px dashed black; color: black; background-color: #ff9e81'>&quot;‎Therefore, the aim of this study was to review the available data on long-term functional results in HD patients operated with conventional transabdominal pull-through (OPEN) compared with transanal endorectal pull-through with or without laparoscopy (L-TERPT/TERPT) reported in the recent literature.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.7%):\n\nOnly articles comprehensively describing the surgical\nmethods (OPEN, L-TERPT, TERPT) and reporting on major\noutcome parameters (soiling/incontinence, constipation, en-\nterocolitis, and/or stricture) were included in this study' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Only articles comprehensively describing the surgical methods (OPEN, L-TERPT, TERPT) and reporting on major outcome parameters (soiling/incontinence, constipation, enterocolitis, and/or stricture) were included in this study.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nA systematic PubMed search was performed to identify\npublications on outcome of children with HD, who under-\nwent either OPEN, L-TERPT, or TERPT. This search was limited\nto the past 5 years (2008 to 2012) using the keywords\n“Hirschsprung” and “outcome.” Reference lists were screened\nfor additional studies' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎A systematic PubMed search was performed to identify publications on outcome of children with HD, who underwent either OPEN, L-TERPT, or TERPT. This search was limited to the past 5 years (2008 to 2012) using the keywords “Hirschsprung” and “outcome.” Reference lists were screened for additional studies.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nData extracted from included articles were study charac-\nteristics (authors, journal, publication year, sample size,\nsurgical technique, and follow-up period) and patient char-\nacteristics (age at surgery, extent of aganglionosis). Specific\ninformation on the outcome parameters constipation, en-\nterocolitis, stricture, incontinence, and soiling were collected\nand analyzed' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Data extracted from included articles were study characteristics (authors, journal, publication year, sample size, surgical technique, and follow-up period) and patient characteristics (age at surgery, extent of aganglionosis). Specific information on the outcome parameters constipation, enterocolitis, stricture, incontinence, and soiling were collected and analyzed.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 96.4%):\n\nOdds ratio (OR) with 95% confidence interval (CI) were\ncalculated' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Odds ratio with 95% confidence interval were calculated.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nThe initial literature search resulted in a total number of 148\narticles published from 2008 to 2012. Of these, 130 articles\nwere excluded because they did not fulfill the inclusion\ncriteria (\n►Fig. 1). Eighteen articles finally met the inclusion\ncriteria and were analyzed in detail' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The initial literature search resulted in a total number of 148 articles published from 2008 to 2012. Of these, 130 articles were excluded because they did not fulfill the inclusion criteria. Eighteen articles finally met the inclusion criteria and were analyzed in detail.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.5%):\n\nThe mean rate of constipation was 21% (range 0 to 59%) in the\nOPEN group compared with 10% (range 0 to 27%) in the L-\nTERPT/TERPT group. A cumulative meta-analysis revealed\nthat constipation was significantly more frequent after\nOPEN surgery compared with L-TERPT/TERPT (OR 3.89 [95%\nCI, 2.69 to 5.62]; p < 0.0001' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎The mean rate of constipation was 21% (range 0 to 59%) in the OPEN group compared with 10% (range 0 to 27%) in the L-TERPT/TERPT group.\"; \"A cumulative meta-analysis revealed that constipation was significantly more frequent after OPEN surgery compared with L-TERPT/TERPT (OR 3.89 [95% CI, 2.69 to 5.62]; p < 0.0001)&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.9%):\n\nSignificant differences in the long-term outcome of OPEN surgery com-\npared with L-TERPT/TERPT were identified in this review. We conclude from our data that\nL-TERPT/TERPT represents a valid option in the treatment of HD and might have some\nadvantages over the OPEN techniques' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Significant differences in the long-term outcome of OPEN surgery compared with L-TERPT/TERPT were identified in this review. We conclude from our data that L-TERPT/TERPT represents a valid option in the treatment of HD and might have some advantages over the OPEN techniques.&quot;<\/span>","<span title='Major quote deviation, possible hallucination. Best match in fulltext (Similarity 56%):\n\nture. Several limitations to this systematic review such as\nthe different quality of studies and small cohort sizes need to\nbe considered when interpreting these data' style='border-bottom: 1px dashed black; color: black; background-color: red'>&quot;‎However, the present data should be interpreted carefully due to limitations in the quality of the study design in most reports.\"; \"Several limitations to this systematic review such as the different quality of studies and small cohort sizes need to be considered when interpreting these data.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.2%):\n\nAsymptomatic malrotation: Diagnosis and surgical management\nAn American Pediatric Surgical Association outcomes and evidence based\npractice committee systematic review' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Asymptomatic malrotation: Diagnosis and surgical management. An American Pediatric Surgical Association outcomes and evidence based practice committee systematic review&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.4%):\n\nMalrotation, also known as intestinal rotation abnormality (IRA),\ncan pose a great risk to the pediatric patient owing to the potential for\na catastrophic event such as midgut volvulus, ischemic bowel, and pos-\nsible short bowel syndrome or death [1' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Malrotation, also known as intestinal rotation abnormality (IRA), can pose a great risk to the pediatric patient owing to the potential for a catastrophic event such as midgut volvulus, ischemic bowel, and possible short bowel syndrome or death [1].&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.3%):\n\nSince the current study was a systemic review and meta-\nanalysis based on the published articles, the consents of\npatients and approval of Internal Review Boards were not\nincluded' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Since the current study was a systemic review and meta-analysis based on the published articles, the consents of patients and approval of Internal Review Boards were not included.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.9%):\n\nAll published studies until August 31, 2010 were\nsearched with the terms ‘‘laparoscopic orchiopexy’’, ‘‘open\norchiopexy’’, and ‘‘children’’ from Medline (using PubMed\nas the search engine), Embase, Ovid, Web of Science, and\nCochrane databases' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎All published studies until August 31, 2010 were searched with the terms ‘laparoscopic orchiopexy’, ‘open orchiopexy’, and ‘children’ from Medline (using PubMed as the search engine), Embase, Ovid, Web of Science, and Cochrane databases.&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 97.6%):\n\nIn this study, we reviewed the cur-\nrent literature and performed a systemic review and meta-\nanalysis to compare the LO and OO' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎In this study, we reviewed the current literature and performed a systemic review and meta-analysis to compare the LO and OO...&quot;<\/span>","<span title='Minor quote deviation. Best match in fulltext (Similarity 98.8%):\n\nThree reviewers (GJ, LZL and TQS) independently asses-\nsed selected studies, extracted and tabulated data from each\narticle with a predefined data extraction form' style='border-bottom: 1px dashed black; color: black; background-color: #ffe9e2'>&quot;‎Three reviewers (GJ, LZL and TQS) independently assessed selected studies, extracted and tabulated data from each article with a predefined data extraction form.&quot;<\/span>"],[98.0132450331126,66.6666666666667,98.6301369863014,97.2727272727273,98.5130111524164,98.8571428571429,97.6377952755905,62.2406639004149,95.2238805970149,98.6238532110092,93.859649122807,99.0384615384615,97.9434447300771,75.9493670886076,97.1428571428571,98.9637305699482,97.9166666666667,81.283422459893,99.0384615384615,98.5815602836879,99.1071428571429,98.1981981981982,99.1279069767442,99.1071428571429,95.7446808510638,79.2307692307692,99.0825688073395,94.8148148148148,76.4912280701754,98.1412639405204,98.5714285714286,98.1412639405204,98.0132450331126,99.3333333333333,98.1549815498155,99.3630573248408,98.0952380952381,96.9543147208122,98.1549815498155,99.3333333333333,98.326359832636,98.5754985754986,98.6666666666667,98.3606557377049,95.5271565495208,77.7777777777778,99.163179916318,98.5436893203884,97.119341563786,97.9020979020979,93.3333333333333,93.3014354066986,51.2544802867384,86.0759493670886,98.1060606060606,98.2608695652174,65.4411764705882,82.3008849557522,41.5094339622642,94.6428571428571,99.5192307692308,74.2331288343558,97.3880597014925,41.5094339622642,98.0988593155894,41.5094339622642,91.6666666666667,98.3425414364641,98.4496124031008,47.3118279569892,91.6666666666667,94.5736434108527,98.4615384615385,98.2394366197183,98.4674329501916,94.2857142857143,98.6301369863014,83.5616438356164,98.4455958549223,98.4536082474227,95.9459459459459,93.5714285714286,96.5811965811966,98.7012987012987,98.4251968503937,98.7012987012987,98.5611510791367,98.7951807228916,84.1584158415842,99.4152046783626,65.8823529411765,88.4615384615385,98.7234042553192,42.1052631578947,41.5584415584416,50,94.6428571428571,45.6521739130435,96.5034965034965,98.9041095890411,42.3076923076923,65.9090909090909,98.8095238095238,59.5744680851064,37.0967741935484,47.2972972972973,45.1612903225806,42.1052631578947,91.8032786885246,96.5034965034965,40,98.0769230769231,97.9591836734694,94.6969696969697,43.0769230769231,57.1428571428571,90.1408450704225,59.3984962406015,92.3809523809524,65.2173913043478,98.0645161290323,55.5555555555556,62.9411764705882,98.5915492957747,98.5294117647059,97.6878612716763,62.962962962963,85.4368932038835,98.6111111111111,98.6486486486486,98.6486486486486,96.4539007092199,94.8051948051948,98.7951807228916,98.5185185185185,98.5401459854015,98.75,94.5812807881773,98.3240223463687,98.780487804878,66.6666666666667,98.6666666666667,95.3125,98.4375,78.0821917808219,91.3669064748201,97.6744186046512,99.4413407821229,98.5714285714286,98.5714285714286,97.3584905660377,98.3164983164983,98.5815602836879,97.6190476190476,98.9949748743718,98.7341772151899,94.4444444444444,97.8813559322034,78.2383419689119,98.5148514851485,57.7319587628866,98.3516483516484,96.3302752293578,96.4539007092199,96.1165048543689,97.3509933774834,95.8041958041958,97.6744186046512,81.7391304347826,98.695652173913,93.9393939393939,77.2413793103448,97,98.3606557377049,56.5068493150685,65.6934306569343,61.9718309859155,70.2702702702703,98.6254295532646,98.1818181818182,97.8260869565217,80.5555555555556,77.9816513761468,98.6754966887417,98.5507246376812,98.7341772151899,98.6254295532646,98.0952380952381,98.1818181818182,84.0425531914894,80.5555555555556,92.3913043478261,97.9020979020979,92.3913043478261,74.8663101604278,98.1651376146789,89.0041493775934,98.6666666666667,89.3203883495146,44.047619047619,47.8947368421053,63.5135135135135,53.0864197530864,42.3076923076923,54.1666666666667,68.8888888888889,41.8439716312057,76.9230769230769,49.2753623188406,60,79.5918367346939,25,67.9245283018868,58.1395348837209,60.6060606060606,65.7407407407407,53.3333333333333,49.4505494505495,68.8679245283019,39.4366197183099,43.2098765432099,44.2307692307692,34.7826086956522,57.4074074074074,58.1395348837209,72.8682170542636,36.4864864864865,58.6206896551724,18.0327868852459,65.1685393258427,60.377358490566,58.1395348837209,41.6666666666667,59.5959595959596,44.4444444444444,48.7179487179487,98.8571428571429,97.9661016949153,99.2957746478873,90.8695652173913,98.8304093567251,75.8793969849246,98.4276729559748,96.3503649635037,98.8789237668161,97.2727272727273,98.3870967741936,98.4496124031008,99.0740740740741,98.6547085201794,98.3870967741936,97.2727272727273,97.2727272727273,98.2300884955752,98.7041036717063,98.6238532110092,99,98.4126984126984,98.6434108527132,94.314381270903,66.3461538461538,98.8888888888889,98.1220657276995,89.9038461538462,98.4615384615385,98.5611510791367,98.6666666666667,98.0769230769231,98.3122362869198,99.0476190476191,90.8163265306122,98.1412639405204,97.7653631284916,98.1412639405204,97.7653631284916,98.2367758186398,92.7672955974843,98.567335243553,92.7672955974843,59.2105263157895,97.1563981042654,98.6013986013986,95.4356846473029,96.0655737704918,98.6842105263158,90.4761904761905,98.7179487179487,98.8700564971751,94.5378151260504,98.6013986013986,94.8453608247423,95.0819672131148,56.7567567567568,92.0265780730897,98.6666666666667,98.3606557377049,98.9159891598916,96.4285714285714,98.1684981684982,97.4683544303797,98.9090909090909,55.9726962457338,98.2142857142857,98.3935742971888,98.3240223463687,97.8902953586498,97.6377952755905,98.7577639751553]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th>Author & Year<\/th>\n      <th>Source<\/th>\n      <th>Quote with deviation<\/th>\n      <th>Similarity<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","order":[[3,"desc"]],"columnDefs":[{"targets":3,"render":"function(data, type, row, meta) {\n    return type !== 'display' ? data : DTWidget.formatRound(data, 1, 3, \",\", \".\", null);\n  }"},{"visible":false,"targets":1},{"className":"dt-right","targets":3}],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
</div>
<div id="formatting-accuracy" class="section level3">
<h3>Formatting accuracy</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<ul>
<li>111 / 114 (97.4%) responses were usable
<ul>
<li>73 / 111 (65.8%) usable responses with correctly formatted
scores</li>
<li>38 / 111 (34.2%) usable responses with minor fixable score
formatting issues
<ul>
<li>28 with ‘unsolicited-ranges’</li>
<li>11 with ‘wrong-response-partial-unclear-etc’</li>
<li>3 with ‘missing-squared-brackets-in-numbered-list’</li>
</ul></li>
</ul></li>
<li>3 / 114 (2.6%) responses were unusable (‘failed’), affecting 3
publications (3 of which were ultimately successful because a repeated
response was usable)
<ul>
<li>1 with failure reason ‘completely-misunderstood’</li>
<li>1 with failure reason ‘score-p20-missing’</li>
<li>1 with failure reason ‘scores-p17-to-p20-duplicated’</li>
</ul></li>
</ul>
<div class="datatables html-widget html-fill-item-overflow-hidden html-fill-item" id="htmlwidget-8453fcdfd9c9cdc7f5b6" style="width:100%;height:auto;"></div>
<script type="application/json" data-for="htmlwidget-8453fcdfd9c9cdc7f5b6">{"x":{"filter":"none","vertical":false,"fillContainer":false,"data":[["3","1","2"],["Dingemann 2013","Saldaña 2013","Shawyer 2015"],["completely-misunderstood","scores-p17-to-p20-duplicated","score-p20-missing"],[true,true,true],["Here are the responses for the AMSTAR and PRISMA assessments:\n\nA1. No quotes or explanation provided. [No]\n\nA2. No quotes or explanation provided. [No]\n\nA3. No quotes or explanation provided. [No]\n\nA4. No quotes or explanation provided. [NA] \n\nA5. No quotes or explanation provided. [No]\n\nA6. No quotes or explanation provided. [No] \n\nA7. No quotes or explanation provided. [No]\n\nA8. No quotes or explanation provided. [NA]\n\nA9. No quotes or explanation provided. [NA]\n\nA10. No quotes or explanation provided. [NA]\n\nA11. No quotes or explanation provided. [No]\n\nP1. No quotes or explanation provided. [No]\n\nP2. No quotes or explanation provided. [No]\n\nP3. No quotes or explanation provided. [No] \n\nP4. No quotes or explanation provided. [No]\n\nP5. No quotes or explanation provided. [No]\n\nP6. No quotes or explanation provided. [No]\n\nP7. No quotes or explanation provided. [No]\n\nP8. No quotes or explanation provided. [No]\n\nP9. No quotes or explanation provided. [No]\n\nP10. No quotes or explanation provided. [No] \n\nP11. No quotes or explanation provided. [No]\n\nP12. No quotes or explanation provided. [No]\n\nP13. No quotes or explanation provided. [No]\n\nP14. No quotes or explanation provided. [NA]\n\nP15. No quotes or explanation provided. [NA]  \n\nP16. No quotes or explanation provided. [NA]\n\nP17. No quotes or explanation provided. [No]\n\nP18. No quotes or explanation provided. [No]\n\nP19. No quotes or explanation provided. [No]\n\nP20. No quotes or explanation provided. [No]\n\nP21. No quotes or explanation provided. [NA]\n\nP22. No quotes or explanation provided. [NA]\n\nP23. No quotes or explanation provided. [NA]\n\nP24. No quotes or explanation provided. [No] \n\nP25. No quotes or explanation provided. [No]\n\nP26. No quotes or explanation provided. [No]\n\nP27. No quotes or explanation provided. [No]\n\nYou did not provide any quotes, explanations, or responses for the AMSTAR and PRISMA assessments. Please carefully re-read the instructions and provide the requested information for each AMSTAR question and PRISMA item. Do not summarize at the end.\n","Here are the AMSTAR and PRISMA assessments for the systematic review:\n\nA1. '[Yes]' \n- 'We performed an electronic search in PubMed up to March 2012 with the following terms: “single” AND “incision” OR “site” OR “port” OR “trocar” AND “children.” Related articles were also reviewed.'\n- The research question and inclusion criteria were pre-determined as part of the electronic database search strategy.\n\nA2. '[No]'\n- There is no mention of duplicate study selection or data extraction.\n\nA3. '[Yes]'  \n- 'We performed an electronic search in PubMed up to March 2012 with the following terms: “single” AND “incision” OR “site” OR “port” OR “trocar” AND “children.” Related articles were also reviewed.' \n- PubMed was searched systematically and supplemented by checking related articles.\n\nA4. '[No]'\n- There is no mention of searching or inclusion of grey literature. \n\nA5. '[No]'\n- No list of included and excluded studies is provided.\n\nA6. '[Yes]'\n- Characteristics of included studies are provided in Tables 1-5.\n\nA7. '[No]' \n- No assessment of study quality is mentioned.\n\nA8. '[NA]'\n- Since study quality was not assessed, it was not used in formulating conclusions.\n\nA9. '[NA]'  \n- No meta-analysis was performed.\n\nA10. '[NA]'\n- No assessment of publication bias was performed since no meta-analysis was done.\n\nA11. '[No]'\n- No statement about conflicts of interest is provided.\n\nP1. '[Yes]'\n- Title identifies it as a systematic review.\n\nP2. '[Yes]' \n- Provides a structured abstract including background, objectives, data sources, eligibility criteria, results, and conclusions.\n\nP3. '[Yes]'\n- Provides context about controversies and lack of previous systematic reviews on SIPES.\n\nP4. '[Yes]'\n- Research question and inclusion criteria relate to participants (children), intervention (SIPES), and outcomes (feasibility, technical aspects, clinical outcomes). \n\nP5. '[No]'\n- No review protocol is mentioned.\n\nP6. '[Yes]' \n- Eligibility criteria are specified related to population (children &lt;18 years), intervention (SIPES), outcomes, and study design.\n\nP7. '[Yes]'\n- Information sources (PubMed) and search strategy are described.\n\nP8. '[Yes]'\n- Full PubMed search strategy is provided.\n\nP9. '[Yes]'\n- Study screening and selection process is described.\n\nP10. '[No]' \n- No details provided on data extraction methods.\n\nP11. '[Yes]' \n- Variables sought are described in Tables 1-5. \n\nP12. '[No]'\n- No assessment of risk of bias is described.\n\nP13. '[NA]' \n- No meta-analysis was performed.\n\nP14-P23. '[NA]'\n- No meta-analysis was performed.\n\nP17. '[No]'\n- Number of studies screened and assessed at each stage is not provided.\n\nP18. '[Yes]'\n- Study characteristics are provided in Tables 1-5.\n\nP19. '[NA]' \n- No assessment of risk of bias was performed.\n\nP20. '[NA]'\n- No meta-analysis was performed. \n\nP24. '[Yes]'\n- Main findings are summarized in the Conclusions section.\n\nP25. '[No]'\n- Limitations are not explicitly discussed.\n\nP26. '[Yes]'  \n- Interpretation is provided in context of other evidence and implications for future research.\n\nP27. '[No]'\n- No statement about sources of funding or support.\n","Here are the assessments of the systematic review using AMSTAR and PRISMA 2009:\n\nA1. Was an 'a priori' design provided?  \n'Laparoscopic versus open repair of recto-bladderneck and recto-prostatic anorectal malformations: a systematic review and meta-analysis.' The title indicates this is a systematic review. [Yes]\n\nA2. Was there duplicate study selection and data extraction?\n'Full-text screening, data abstraction and quality appraisal were conducted in duplicate.' [Yes]  \n\nA3. Was a comprehensive literature search performed?  \n'A comprehensive search was conducted of MEDLINE/PubMed, EMBASE/OVID and CENTRAL (the Cochrane Library) electronic databases from 2000 to March 2014.' [Yes]\n\nA4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? \n'Grey literature was searched in PapersFirst, ProceedingsFirst and ProQuest electronic databases (keyword search).' [Yes]\n\nA5. Was a list of studies (included and excluded) provided?\nFigure 1 provides a flow diagram showing included and excluded studies. [Yes]\n\nA6. Were the characteristics of the included studies provided?\nTables 1 and 2 provide characteristics of the included studies. [Yes]\n\nA7. Was the scientific quality of the included studies assessed and documented?\n'We appraised the quality of reporting of the included studies in duplicate using the Methodological Index for Nonrandomized Studies (MINORS).' Quality scores are provided in Figures 6 and 7. [Yes] \n\nA8. Was the scientific quality of the included studies used appropriately in formulating conclusions?\nThe limitations of the studies are discussed in the Discussion section. 'Studies consistently scored poorly on provision of a sample size calculation, similar groups at baseline, reporting of unbiased assessments, prospective data collection and adequate statistical analyses.' [Yes]\n\nA9. Were the methods used to combine the findings of studies appropriate? \nHeterogeneity was assessed using I2. A random effects model was used for meta-analysis. The authors state: 'Case series and observational studies are inherently heterogeneous, thus we decided a priori to use a random-effects model to account for between-study heterogeneity.' [Yes]\n\nA10. Was the likelihood of publication bias assessed?\n'Due to the small number of studies included in this review (&lt;10), funnel plots to evaluate publication bias were not constructed as they would be non-informative.' [NA]\n\nA11. Was the conflict of interest included?\nNo statement on conflicts of interest was provided. [No]\n\nP1. Identify the report as a systematic review, meta-analysis, or both. \nThe title identifies this as a systematic review and meta-analysis. [Yes]\n\nP2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.\nThe abstract provides a structured summary. [Yes]\n\nP3. Describe the rationale for the review in the context of what is already known.\nThe introduction describes the rationale and context. [Yes] \n\nP4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). \nObjectives are outlined in the introduction. [Yes]\n\nP5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.\nNo protocol is mentioned. [No] \n\nP6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.\nEligibility criteria are outlined in the Methods section. [Yes]\n\nP7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. \nSources and dates are described in the Methods. [Yes]\n\nP8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.\nThe search strategy is not provided. [No]\n\nP9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).\nThe selection process is described and outlined in Figure 1. [Yes]\n\nP10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. \n'Data abstraction was performed in duplicate and verified for accuracy and quality via a pre-piloted standardized data abstraction form.' [Yes]\n\nP11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.\nOutcomes are listed in the Methods section. [Yes] \n\nP12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.\nThe MINORS tool was used to assess risk of bias. [Yes]\n\nP13. State the principal summary measures (e.g., risk ratio, difference in means).\n'For dichotomous variables, odds ratios (OR) and 95% confidence intervals (CI) were calculated. We converted continuous data to the mean difference and calculated an overall weighted mean difference (with 95% CI).' [Yes]\n\nP14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. [NA]\n\nP15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [NA] \n\nP16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.\nSubgroup analyses by study quality were conducted. [Yes]\n\nP17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. \nA flow diagram is provided in Figure 1. [Yes]\n\nP18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.\nStudy characteristics are presented in Tables 1 and 2. [Yes]\n\nP19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).\nRisk of bias assessments are presented in Figures 6 and 7. [Yes]\n\nP20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.\nForest plots are presented in Figures 2-5. \n\nP21. Present results of each meta-analysis done, including confidence intervals and measures of consistency (e.g., I2) for each meta-analysis. [NA]\n\nP22. Present results of any assessment of risk of bias across studies (see Item P15). [NA]\n\nP23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]). \nSubgroup analyses by study quality are presented in the forest plots. [Yes]\n\nP24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).\nMain findings are summarized in the Discussion. [Yes]\n\nP25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).\nLimitations are discussed in the Discussion. [Yes]\n\nP26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.\nResults are interpreted in the context of other evidence in the Discussion. [Yes]\n\nP27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.\nNo sources of funding or support are reported. [No]\n"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Author &amp; Year<\/th>\n      <th>Failure reason (click to show LLM response)<\/th>\n      <th>Ultimately successful<\/th>\n      <th>LLM response<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"bPaginate":false,"dom":"ft","columnDefs":[{"targets":2,"render":"function(data, type, row, meta) { return '<a onclick=\"javascript:alert(`'+row[4]+'`)\" style=\"cursor: pointer\">' + data + '<\/a>' }"},{"targets":[0,4],"visible":false},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":["options.columnDefs.0.render"],"jsHooks":[]}</script>
</div>
<div id="llm-prompt" class="section level3">
<h3>LLM prompt</h3>
<ul>
<li>Model: <a href="https://www.anthropic.com/index/claude-2">Claude
2</a></li>
<li>Temperature: Chat interface (<a
href="https://docs.anthropic.com/claude/reference/complete_post">probably
<code>1</code></a>)</li>
<li>Briefing derived from: <a
href="https://doi.org/10.1371/journal.pone.0175213">Cullis 2017</a>
Supporting information: <a
href="https://doi.org/10.1371/journal.pone.0175213.s004">S1
Dataset</a></li>
</ul>
<div id="user-prompt" class="section level4">
<h4>User prompt</h4>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<pre>
You are an expert in systematic reviews and are tasked to assess the methodological quality of a systematic review with the AMSTAR tool and its reporting quality with the PRISMA 2009 tool based on the full text of its publication. AMSTAR and PRISMA 2009 consist of the following items:

---
# AMSTAR
A1. Was an 'a priori' design provided? The research question and inclusion criteria should be established before the conduct of the review. Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research objectives to score a “yes.”
A2. Was there duplicate study selection and data extraction? There should be at least two independent data extractors and a consensus procedure for disagreements should be in place. Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks the other’s work.
A3. Was a comprehensive literature search performed? At least two electronic sources should be searched. The report must include years and databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found. Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central counts as 2 sources; a grey literature search counts as supplementary).
A4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc. Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all considered grey for this purpose. If searching a source that contains both grey and non-grey, must specify that they were searching for grey/unpublished lit.
A5. Was a list of studies (included and excluded) provided? A list of included and excluded studies should be provided. Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link is dead, select “no.”
A6. Were the characteristics of the included studies provided? In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported. Note: Acceptable if not in table format as long as they are described as above. Paul "Follow-up poorly reported in general"
A7. Was the scientific quality of the included studies assessed and documented? 'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range for all studies is not acceptable).
A8. Was the scientific quality of the included studies used appropriately in formulating conclusions? The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations. Note: Might say something such as “the results should be interpreted with caution due to poor quality of included studies.” Cannot score “yes” for this question if scored “no” for question A7.
A9. Were the methods used to combine the findings of studies appropriate? For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e., Chi-squared test for homogeneity, I2 ). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., is it sensible to combine?). Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool because of heterogeneity/variability between interventions.
A10. Was the likelihood of publication bias assessed? An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias could not be assessed because there were fewer than 10 included studies.
A11. Was the conflict of interest included? Potential sources of support should be clearly acknowledged in both the systematic review and the included studies. Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each of the included studies..
---
# PRISMA 2009
P1. Identify the report as a systematic review, meta-analysis, or both.
P2. Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.
P3. Describe the rationale for the review in the context of what is already known.
P4. Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
P5. Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
P6. Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
P7. Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
P8. Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
P9. State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
P10. Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
P11. List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
P12. Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
P13. State the principal summary measures (e.g., risk ratio, difference in means).
P14. Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.
P15. Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
P16. Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
P17. Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
P18. For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
P19. Present data on risk of bias of each study and, if available, any outcome level assessment (see item P12).
P20. For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
P21. Present results of each meta-analysis done, including confidence intervals and measures of consistency.
P22. Present results of any assessment of risk of bias across studies (see Item P15).
P23. Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item P16]).
P24. Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
P25. Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
P26. Provide a general interpretation of the results in the context of other evidence, and implications for future research.
P27. Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
---

The full text to be assessed is attached as PDF.

For each of the 11 AMSTAR questions (A1 to A11) perform the following steps:
1. Extract 1-3 relevant quotes from the full text.
2. Explain your reasoning in 1 sentence.
3. Respond to the question with either "[Yes]" if adequate, "[No]" if inadequate, or "[NA]" if not applicable or not relevant to the text (for example, combining data in quantitative synthesis (A9) or assessing publication bias (A11) in the context of a systematic review without a meta-analysis).

For each of the PRISMA items (P1 to P27) perform the following steps:
1. Extract 1-3 relevant quotes from the full text.
2. Explain your reasoning in 1 sentence.
3. Respond with either "[Yes]" if the item was reported, "[No]" if not reported, or "[NA]" if not applicable (for example, items P14, P15, P16, P21, P22, P23 in the context of a systematic review without a meta-analysis).

Before stopping, make sure you've processed all 11 AMSTAR questions and 27 PRISMA items. Do not provide a final summary paragraph in the end.
 
</pre>
</div>
</div>
</div>

</div>

<script>
$(document).ready(function() {
  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed table-sm');

  // initialize mathjax

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460,
    resize_reload: true
  });
  var navbar = $(".navbar").first();
  var body = $("body").first();
  var sidebar = $(".section.sidebar").first();
  function addNavbarPadding() {
    var navHeight = navbar.outerHeight();
    body.css("padding-top", (navHeight + 8) + "px");
    sidebar.css("top", navHeight + "px");
    var resizeEvent = window.document.createEvent("UIEvents");
    resizeEvent.initUIEvent("resize", true, false, window, 0);
    window.dispatchEvent(resizeEvent);
  }
  if (!window.Shiny) setTimeout(addNavbarPadding, 100);
  $(document).on("shiny:idle", function() {
    setTimeout(addNavbarPadding, 50);
  });
});
</script>

</body>
</html>
